    <sentence id="DDI-DrugBank.d244.s0" text="Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.">
        <entity id="DDI-DrugBank.d244.s0.e0" charOffset="138-152"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d244.s0.e1" charOffset="161-170"
            type="drug" text="gentamicin"/>
        <entity id="DDI-DrugBank.d244.s0.e2" charOffset="173-180"
            type="drug" text="amikacin"/>
        <entity id="DDI-DrugBank.d244.s0.e3" charOffset="184-197"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d244.s0.e4" charOffset="200-211"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d244.s0.e5" charOffset="214-244"
            type="group" text="non-steroidal anti-inflammatory"/>
        <entity id="DDI-DrugBank.d244.s0.e6" charOffset="259-267"
            type="drug" text="ibuprofen"/>
        <entity id="DDI-DrugBank.d244.s0.e7" charOffset="271-280"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d244.s0.e8" charOffset="283-292"
            type="drug" text="vancomycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d244.s1" text="Do not start or stop any medicine without doctor or pharmacist approval."/>
    <sentence id="DDI-DrugBank.d226.s0" text="Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.">
        <entity id="DDI-DrugBank.d226.s0.e0" charOffset="12-20"
            type="brand" text="Adenocard"/>
        <entity id="DDI-DrugBank.d226.s0.e1" charOffset="23-31"
            type="drug" text="adenosine"/>
        <entity id="DDI-DrugBank.d226.s0.e2" charOffset="121-129"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d226.s0.e3" charOffset="132-162"
            type="group" text="beta-adrenergic blocking agents"/>
        <entity id="DDI-DrugBank.d226.s0.e4" charOffset="165-195"
            type="group" text="calcium channel blocking agents"/>
        <entity id="DDI-DrugBank.d226.s0.e5" charOffset="202-241"
            type="group" text="angiotensin converting enzyme inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d226.s1" text="Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.">
        <entity id="DDI-DrugBank.d226.s1.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d226.s1.e1" charOffset="12-20"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d226.s1.e2" charOffset="100-108"
            type="brand" text="Adenocard"/>
        <ddi id="DDI-DrugBank.d226.s1.d0" e1="DDI-DrugBank.d226.s1.e0"
            e2="DDI-DrugBank.d226.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d226.s1.d1" e1="DDI-DrugBank.d226.s1.e1"
            e2="DDI-DrugBank.d226.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d226.s2" text="Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenocard should be used with caution in the presence of these agents.">
        <entity id="DDI-DrugBank.d226.s2.e0" charOffset="105-113"
            type="brand" text="Adenocard"/>
    </sentence>
    <sentence id="DDI-DrugBank.d226.s3" text="The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.">
        <entity id="DDI-DrugBank.d226.s3.e0" charOffset="11-19"
            type="brand" text="Adenocard"/>
        <entity id="DDI-DrugBank.d226.s3.e1" charOffset="43-51"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d226.s3.d0" e1="DDI-DrugBank.d226.s3.e0"
            e2="DDI-DrugBank.d226.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d226.s4" text="The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.">
        <entity id="DDI-DrugBank.d226.s4.e0" charOffset="15-23"
            type="drug" text="adenosine"/>
        <entity id="DDI-DrugBank.d226.s4.e1" charOffset="44-58"
            type="group" text="methylxanthines"/>
        <entity id="DDI-DrugBank.d226.s4.e2" charOffset="68-75"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d226.s4.e3" charOffset="81-92"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d226.s4.d0" e1="DDI-DrugBank.d226.s4.e0"
            e2="DDI-DrugBank.d226.s4.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d226.s4.d1" e1="DDI-DrugBank.d226.s4.e0"
            e2="DDI-DrugBank.d226.s4.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d226.s4.d2" e1="DDI-DrugBank.d226.s4.e0"
            e2="DDI-DrugBank.d226.s4.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d226.s5" text="In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.">
        <entity id="DDI-DrugBank.d226.s5.e0" charOffset="25-39"
            type="group" text="methylxanthines"/>
        <entity id="DDI-DrugBank.d226.s5.e1" charOffset="58-66"
            type="drug" text="adenosine"/>
        <entity id="DDI-DrugBank.d226.s5.e2" charOffset="87-95"
            type="drug" text="adenosine"/>
        <ddi id="DDI-DrugBank.d226.s5.d0" e1="DDI-DrugBank.d226.s5.e0"
            e2="DDI-DrugBank.d226.s5.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d226.s5.d1" e1="DDI-DrugBank.d226.s5.e0"
            e2="DDI-DrugBank.d226.s5.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d226.s6" text="Adenosine effects are potentiated by dipyridamole.">
        <entity id="DDI-DrugBank.d226.s6.e0" charOffset="0-8"
            type="drug" text="Adenosine"/>
        <entity id="DDI-DrugBank.d226.s6.e1" charOffset="37-48"
            type="drug" text="dipyridamole"/>
        <ddi id="DDI-DrugBank.d226.s6.d0" e1="DDI-DrugBank.d226.s6.e0"
            e2="DDI-DrugBank.d226.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d226.s7" text="Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.">
        <entity id="DDI-DrugBank.d226.s7.e0" charOffset="23-31"
            type="drug" text="adenosine"/>
        <entity id="DDI-DrugBank.d226.s7.e1" charOffset="69-80"
            type="drug" text="dipyridamole"/>
        <ddi id="DDI-DrugBank.d226.s7.d0" e1="DDI-DrugBank.d226.s7.e0"
            e2="DDI-DrugBank.d226.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d226.s8" text="Carbamazepine has been reported to increase the degree of heart block produced by other agents.">
        <entity id="DDI-DrugBank.d226.s8.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d226.s9" text="As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.">
        <entity id="DDI-DrugBank.d226.s9.e0" charOffset="25-33"
            type="drug" text="adenosine"/>
        <entity id="DDI-DrugBank.d226.s9.e1" charOffset="148-160"
            type="drug" text="carbamazepine"/>
        <ddi id="DDI-DrugBank.d226.s9.d0" e1="DDI-DrugBank.d226.s9.e0"
            e2="DDI-DrugBank.d226.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d449.s0" text="Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended.">
        <entity id="DDI-DrugBank.d449.s0.e0" charOffset="23-39"
            type="group" text="antifungal agents"/>
        <entity id="DDI-DrugBank.d449.s0.e1" charOffset="49-60"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d449.s0.e2" charOffset="65-76"
            type="drug" text="itraconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d449.s1" text="Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).">
        <entity id="DDI-DrugBank.d449.s1.e0" charOffset="0-9"
            type="drug" text="Nafazodone"/>
        <entity id="DDI-DrugBank.d449.s1.e1" charOffset="12-22"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d449.s1.e2" charOffset="25-34"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d449.s1.e3" charOffset="46-50"
            type="brand" text="Xanax"/>
        <ddi id="DDI-DrugBank.d449.s1.d0" e1="DDI-DrugBank.d449.s1.e0"
            e2="DDI-DrugBank.d449.s1.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d449.s1.d1" e1="DDI-DrugBank.d449.s1.e1"
            e2="DDI-DrugBank.d449.s1.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d449.s1.d2" e1="DDI-DrugBank.d449.s1.e2"
            e2="DDI-DrugBank.d449.s1.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d449.s2" text="Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).">
        <entity id="DDI-DrugBank.d449.s2.e0" charOffset="0-9"
            type="drug" text="Fluoxetine"/>
        <entity id="DDI-DrugBank.d449.s2.e1" charOffset="12-14"
            type="group" text="OCs"/>
        <entity id="DDI-DrugBank.d449.s2.e2" charOffset="17-26"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d449.s2.e3" charOffset="29-37"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d449.s2.e4" charOffset="40-60"
            type="group" text="macrolide antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d164.s0" text="No drug interaction studies were performed."/>
    <sentence id="DDI-DrugBank.d164.s1" text="No in vitro metabolism studies were performed."/>
    <sentence id="DDI-DrugBank.d321.s0" text="Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.">
        <entity id="DDI-DrugBank.d321.s0.e0" charOffset="0-12"
            type="drug" text="Dexamethasone"/>
        <entity id="DDI-DrugBank.d321.s0.e1" charOffset="53-73"
            type="drug" text="albendazole sulfoxide"/>
        <entity id="DDI-DrugBank.d321.s0.e2" charOffset="107-119"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d321.s0.e3" charOffset="158-168"
            type="drug" text="albendazole"/>
        <ddi id="DDI-DrugBank.d321.s0.d0" e1="DDI-DrugBank.d321.s0.e2"
            e2="DDI-DrugBank.d321.s0.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d321.s1" text="Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.">
        <entity id="DDI-DrugBank.d321.s1.e0" charOffset="0-11"
            type="drug" text="Praziquantel"/>
        <entity id="DDI-DrugBank.d321.s1.e1" charOffset="32-43"
            type="drug" text="praziquantel"/>
        <entity id="DDI-DrugBank.d321.s1.e2" charOffset="128-148"
            type="drug" text="albendazole sulfoxide"/>
        <entity id="DDI-DrugBank.d321.s1.e3" charOffset="245-255"
            type="drug" text="albendazole"/>
        <ddi id="DDI-DrugBank.d321.s1.d0" e1="DDI-DrugBank.d321.s1.e1"
            e2="DDI-DrugBank.d321.s1.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d321.s2" text="Mean T max and mean plasma elimination half-life of albendazole sulfoxide were unchanged.">
        <entity id="DDI-DrugBank.d321.s2.e0" charOffset="52-72"
            type="drug" text="albendazole sulfoxide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d321.s3" text="The pharmacokinetics of praziquantel were unchanged following coadministration with albendazole (400 mg).">
        <entity id="DDI-DrugBank.d321.s3.e0" charOffset="24-35"
            type="drug" text="praziquantel"/>
        <entity id="DDI-DrugBank.d321.s3.e1" charOffset="84-94"
            type="drug" text="albendazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d321.s4" text="Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).">
        <entity id="DDI-DrugBank.d321.s4.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d321.s4.e1" charOffset="12-32"
            type="drug" text="Albendazole sulfoxide"/>
        <entity id="DDI-DrugBank.d321.s4.e2" charOffset="142-151"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d321.s4.e3" charOffset="188-198"
            type="drug" text="albendazole"/>
        <ddi id="DDI-DrugBank.d321.s4.d0" e1="DDI-DrugBank.d321.s4.e1"
            e2="DDI-DrugBank.d321.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d321.s5" text="Albendazole sulfoxide plasma concentrations were unchanged 4 hours after dosing.">
        <entity id="DDI-DrugBank.d321.s5.e0" charOffset="0-20"
            type="drug" text="Albendazole sulfoxide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d321.s6" text="Theophylline: The pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.">
        <entity id="DDI-DrugBank.d321.s6.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d321.s6.e1" charOffset="38-49"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d321.s6.e2" charOffset="52-64"
            type="drug" text="aminophylline"/>
        <entity id="DDI-DrugBank.d321.s6.e3" charOffset="148-158"
            type="drug" text="albendazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d102.s0" text="No information provided"/>
    <sentence id="DDI-DrugBank.d114.s0" text="PROLEUKIN may affect central nervous function.">
        <entity id="DDI-DrugBank.d114.s0.e0" charOffset="0-8"
            type="brand" text="PROLEUKIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s1" text="Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, sedatives, tranquilizers).">
        <entity id="DDI-DrugBank.d114.s1.e0" charOffset="76-93"
            type="group" text="psychotropic drugs"/>
        <entity id="DDI-DrugBank.d114.s1.e1" charOffset="102-110"
            type="group" text="narcotics"/>
        <entity id="DDI-DrugBank.d114.s1.e2" charOffset="113-122"
            type="group" text="analgesics"/>
        <entity id="DDI-DrugBank.d114.s1.e3" charOffset="125-135"
            type="group" text="antiemetics"/>
        <entity id="DDI-DrugBank.d114.s1.e4" charOffset="138-146"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d114.s1.e5" charOffset="149-161"
            type="group" text="tranquilizers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s2" text="Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.">
        <entity id="DDI-DrugBank.d114.s2.e0" charOffset="65-79"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d114.s2.e1" charOffset="82-93"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d114.s2.e2" charOffset="115-123"
            type="group" text="cytotoxic"/>
        <entity id="DDI-DrugBank.d114.s2.e3" charOffset="159-169"
            type="drug" text="doxorubicin"/>
        <entity id="DDI-DrugBank.d114.s2.e4" charOffset="194-205"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d114.s2.e5" charOffset="208-219"
            type="drug" text="asparaginase"/>
        <entity id="DDI-DrugBank.d114.s2.e6" charOffset="235-243"
            type="brand" text="PROLEUKIN"/>
        <ddi id="DDI-DrugBank.d114.s2.d0" e1="DDI-DrugBank.d114.s2.e0"
            e2="DDI-DrugBank.d114.s2.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d114.s2.d1" e1="DDI-DrugBank.d114.s2.e1"
            e2="DDI-DrugBank.d114.s2.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d114.s2.d2" e1="DDI-DrugBank.d114.s2.e2"
            e2="DDI-DrugBank.d114.s2.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d114.s2.d3" e1="DDI-DrugBank.d114.s2.e3"
            e2="DDI-DrugBank.d114.s2.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d114.s2.d4" e1="DDI-DrugBank.d114.s2.e4"
            e2="DDI-DrugBank.d114.s2.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d114.s2.d5" e1="DDI-DrugBank.d114.s2.e5"
            e2="DDI-DrugBank.d114.s2.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s3" text="The safety and efficacy of PROLEUKIN in combination with any antineoplastic agents have not been established.">
        <entity id="DDI-DrugBank.d114.s3.e0" charOffset="27-35"
            type="brand" text="PROLEUKIN"/>
        <entity id="DDI-DrugBank.d114.s3.e1" charOffset="61-81"
            type="group" text="antineoplastic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s4" text="In addition, reduced kidney and liver function secondary to PROLEUKIN treatment may delay elimination of concomitant medications and increase the risk of adverse events from those drugs.">
        <entity id="DDI-DrugBank.d114.s4.e0" charOffset="60-68"
            type="brand" text="PROLEUKIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s5" text="Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.">
        <entity id="DDI-DrugBank.d114.s5.e0" charOffset="121-129"
            type="brand" text="PROLEUKIN"/>
        <entity id="DDI-DrugBank.d114.s5.e1" charOffset="135-155"
            type="group" text="antineoplastic agents"/>
        <entity id="DDI-DrugBank.d114.s5.e2" charOffset="172-182"
            type="drug" text="dacarbazine"/>
        <entity id="DDI-DrugBank.d114.s5.e3" charOffset="185-196"
            type="drug" text="cis-platinum"/>
        <entity id="DDI-DrugBank.d114.s5.e4" charOffset="199-207"
            type="drug" text="tamoxifen"/>
        <entity id="DDI-DrugBank.d114.s5.e5" charOffset="213-227"
            type="drug" text="interferon-alfa"/>
        <ddi id="DDI-DrugBank.d114.s5.d0" e1="DDI-DrugBank.d114.s5.e0"
            e2="DDI-DrugBank.d114.s5.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d114.s5.d1" e1="DDI-DrugBank.d114.s5.e0"
            e2="DDI-DrugBank.d114.s5.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d114.s5.d2" e1="DDI-DrugBank.d114.s5.e0"
            e2="DDI-DrugBank.d114.s5.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d114.s5.d3" e1="DDI-DrugBank.d114.s5.e0"
            e2="DDI-DrugBank.d114.s5.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d114.s5.d4" e1="DDI-DrugBank.d114.s5.e0"
            e2="DDI-DrugBank.d114.s5.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s6" text="These reactions consisted of erythema, pruritus, and hypotension and occurred within hours of administration of chemotherapy."/>
    <sentence id="DDI-DrugBank.d114.s7" text="These events required medical intervention in some patients."/>
    <sentence id="DDI-DrugBank.d114.s8" text="Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.">
        <entity id="DDI-DrugBank.d114.s8.e0" charOffset="161-169"
            type="brand" text="PROLEUKIN"/>
        <entity id="DDI-DrugBank.d114.s8.e1" charOffset="175-189"
            type="drug" text="interferon-alfa"/>
        <ddi id="DDI-DrugBank.d114.s8.d0" e1="DDI-DrugBank.d114.s8.e0"
            e2="DDI-DrugBank.d114.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s9" text="Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.">
        <entity id="DDI-DrugBank.d114.s9.e0" charOffset="140-154"
            type="drug" text="interferon-alfa"/>
        <entity id="DDI-DrugBank.d114.s9.e1" charOffset="160-168"
            type="brand" text="PROLEUKIN"/>
        <ddi id="DDI-DrugBank.d114.s9.d0" e1="DDI-DrugBank.d114.s9.e0"
            e2="DDI-DrugBank.d114.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s10" text="Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.">
        <entity id="DDI-DrugBank.d114.s10.e0" charOffset="9-23"
            type="group" text="glucocorticoids"/>
        <entity id="DDI-DrugBank.d114.s10.e1" charOffset="51-59"
            type="brand" text="PROLEUKIN"/>
        <entity id="DDI-DrugBank.d114.s10.e2" charOffset="212-220"
            type="brand" text="PROLEUKIN"/>
        <entity id="DDI-DrugBank.d114.s10.e3" charOffset="264-272"
            type="brand" text="PROLEUKIN"/>
        <entity id="DDI-DrugBank.d114.s10.e4" charOffset="305-317"
            type="group" text="Beta-blockers"/>
        <entity id="DDI-DrugBank.d114.s10.e5" charOffset="329-345"
            type="group" text="antihypertensives"/>
        <entity id="DDI-DrugBank.d114.s10.e6" charOffset="388-396"
            type="brand" text="PROLEUKIN"/>
        <ddi id="DDI-DrugBank.d114.s10.d0" e1="DDI-DrugBank.d114.s10.e0"
            e2="DDI-DrugBank.d114.s10.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d114.s10.d1" e1="DDI-DrugBank.d114.s10.e4"
            e2="DDI-DrugBank.d114.s10.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d114.s10.d2" e1="DDI-DrugBank.d114.s10.e5"
            e2="DDI-DrugBank.d114.s10.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s11" text="Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.">
        <entity id="DDI-DrugBank.d114.s11.e0" charOffset="29-52"
            type="group" text="Iodinated Contrast Media"/>
        <entity id="DDI-DrugBank.d114.s11.e1" charOffset="154-166"
            type="drug" text="interleukin-2"/>
        <entity id="DDI-DrugBank.d114.s11.e2" charOffset="223-259"
            type="group" text="radiographic iodinated contrast media"/>
        <ddi id="DDI-DrugBank.d114.s11.d0" e1="DDI-DrugBank.d114.s11.e1"
            e2="DDI-DrugBank.d114.s11.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s12" text="The onset of symptoms usually occurred within hours (most commonly 1 to 4 hours) following the administration of contrast media."/>
    <sentence id="DDI-DrugBank.d114.s13" text="These reactions include fever, chills, nausea, vomiting, pruritus, rash, diarrhea, hypotension, edema, and oliguria."/>
    <sentence id="DDI-DrugBank.d114.s14" text="Some clinicians have noted that these reactions resemble the immediate side effects caused by interleukin-2 administration, however the cause of contrast reactions after interleukin-2 therapy is unknown.">
        <entity id="DDI-DrugBank.d114.s14.e0" charOffset="94-106"
            type="drug" text="interleukin-2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s15" text="Most events were reported to occur when contrast media was given within 4 weeks after the last dose of interleukin-2.">
        <entity id="DDI-DrugBank.d114.s15.e0" charOffset="103-115"
            type="drug" text="interleukin-2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d114.s16" text="These events were also reported to occur when contrast media was given several months after interleukin-2 treatment.">
        <entity id="DDI-DrugBank.d114.s16.e0" charOffset="92-104"
            type="drug" text="interleukin-2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s0" text="No formal interaction studies have been performed."/>
    <sentence id="DDI-DrugBank.d491.s1" text="The duration of the period following treatment with AMEVIVE  before one should consider starting other immunosuppressive therapy has not been evaluated.">
        <entity id="DDI-DrugBank.d491.s1.e0" charOffset="52-58"
            type="brand" text="AMEVIVE"/>
        <entity id="DDI-DrugBank.d491.s1.e1" charOffset="103-119"
            type="group" text="immunosuppressive"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s2" text="Carcinogenesis, Mutagenesis, and Fertility"/>
    <sentence id="DDI-DrugBank.d491.s3" text="In a chronic toxicity study, cynomolgus monkeys were dosed weekly for 52 weeks with intravenous alefacept at 1 mg/kg/dose or 20 mg/kg/dose.">
        <entity id="DDI-DrugBank.d491.s3.e0" charOffset="96-104"
            type="drug" text="alefacept"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s4" text="One animal in the high dose group developed a B-cell lymphoma that was detected after 28 weeks of dosing."/>
    <sentence id="DDI-DrugBank.d491.s5" text="Additional animals in both dose groups developed B-cell hyperplasia of the spleen and lymph nodes."/>
    <sentence id="DDI-DrugBank.d491.s6" text="All animals in the study were positive for an endemic primate gammaherpes virus also known as lymphocryptovirus (LCV)."/>
    <sentence id="DDI-DrugBank.d491.s7" text="Latent LCV infection is generally asymptomatic, but can lead to B-cell lymphomas when animals are immune suppressed."/>
    <sentence id="DDI-DrugBank.d491.s8" text="In a separate study, baboons given 3 doses of alefacept at 1 mg/kg every 8 weeks were found to have centroblast proliferation in B-cell dependent areas in the germinal centers of the spleen following a 116-day washout period.">
        <entity id="DDI-DrugBank.d491.s8.e0" charOffset="46-54"
            type="drug" text="alefacept"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s9" text="The role of AMEVIVE in the development of the lymphoid malignancy and the hyperplasia observed in non-human primates and the relevance to humans is unknown.">
        <entity id="DDI-DrugBank.d491.s9.e0" charOffset="12-18"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s10" text="Immunodeficiency-associated lymphocyte disorders (plasmacytic hyperplasia, polymorphic proliferation, and B-cell lymphomas) occur in patients who have congenital or acquired immunodeficiencies including those resulting from immunosuppressive therapy.">
        <entity id="DDI-DrugBank.d491.s10.e0" charOffset="224-240"
            type="group" text="immunosuppressive"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s11" text="No carcinogenicity or fertility studies were conducted."/>
    <sentence id="DDI-DrugBank.d491.s12" text="Mutagenicity studies were conducted in vitro and in vivo;"/>
    <sentence id="DDI-DrugBank.d491.s13" text="no evidence of mutagenicity was observed."/>
    <sentence id="DDI-DrugBank.d491.s14" text="Pregnancy (Category B)"/>
    <sentence id="DDI-DrugBank.d491.s15" text="Women of childbearing potential make up a considerable segment of the patient population affected by psoriasis."/>
    <sentence id="DDI-DrugBank.d491.s16" text="Since the effect of AMEVIVE on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking AMEVIVE who become pregnant into the Biogen Pregnancy Registry by calling 1-866-AMEVIVE (1-866-263-8483).">
        <entity id="DDI-DrugBank.d491.s16.e0" charOffset="20-26"
            type="brand" text="AMEVIVE"/>
        <entity id="DDI-DrugBank.d491.s16.e1" charOffset="188-194"
            type="brand" text="AMEVIVE"/>
        <entity id="DDI-DrugBank.d491.s16.e2" charOffset="268-274"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s17" text="Reproductive toxicology studies have been performed in cynomolgus monkeys at doses up to 5 mg/kg/week (about 62 times the human dose based on body weight) and have revealed no evidence of impaired fertility or harm to the fetus due to AMEVIVE.">
        <entity id="DDI-DrugBank.d491.s17.e0" charOffset="235-241"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s18" text="No abortifacient or teratogenic effects were observed in cynomolgus monkeys following intravenous bolus injections of AMEVIVE administered weekly during the period of organogenesis to gestation.">
        <entity id="DDI-DrugBank.d491.s18.e0" charOffset="118-124"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s19" text="AMEVIVE underwent trans-placental passage and produced in utero exposure in the developing monkeys.">
        <entity id="DDI-DrugBank.d491.s19.e0" charOffset="0-6"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s20" text="In utero, serum levels of exposure in these monkeys were 23% of maternal serum levels."/>
    <sentence id="DDI-DrugBank.d491.s21" text="No evidence of fetal toxicity including adverse effects on immune system development was observed in any of these animals."/>
    <sentence id="DDI-DrugBank.d491.s22" text="Animal reproduction studies, however, are not always predictive of human response and there are no adequate and well-controlled studies in pregnant women."/>
    <sentence id="DDI-DrugBank.d491.s23" text="Because the risk to the development of the fetal immune system and postnatal immune function in humans is unknown, AMEVIVE  should be used during pregnancy only if clearly needed.">
        <entity id="DDI-DrugBank.d491.s23.e0" charOffset="115-121"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s24" text="If pregnancy occurs while taking AMEVIVE, continued use of the drug should be assessed.">
        <entity id="DDI-DrugBank.d491.s24.e0" charOffset="33-39"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s25" text="Nursing Mothers"/>
    <sentence id="DDI-DrugBank.d491.s26" text="It is not known whether AMEVIVE is excreted in human milk.">
        <entity id="DDI-DrugBank.d491.s26.e0" charOffset="24-30"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s27" text="Because many drugs are excreted in human milk, and because there exists the potential for serious adverse reactions in nursing infants from AMEVIVE, a decision should be made whether to discontinue nursing while taking the drug or to discontinue the use of the drug, taking into account the importance of the drug to the mother.">
        <entity id="DDI-DrugBank.d491.s27.e0" charOffset="140-146"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s28" text="Geriatric Use"/>
    <sentence id="DDI-DrugBank.d491.s29" text="Of the 1357 patients who received AMEVIVE in clinical trials, a total of 100 patients were">
        <entity id="DDI-DrugBank.d491.s29.e0" charOffset="34-40"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s30" text="65 years of age and 13 patients were"/>
    <sentence id="DDI-DrugBank.d491.s31" text="75 years of age."/>
    <sentence id="DDI-DrugBank.d491.s32" text="No differences in safety or efficacy were observed between older and younger patients, but there were not sufficient data to exclude important differences."/>
    <sentence id="DDI-DrugBank.d491.s33" text="Because the incidence of infections and certain malignancies is higher in the elderly population, in general, caution should be used in treating the elderly."/>
    <sentence id="DDI-DrugBank.d491.s34" text="Pediatric Use"/>
    <sentence id="DDI-DrugBank.d491.s35" text="The safety and efficacy of AMEVIVE in pediatric patients have not been studied.">
        <entity id="DDI-DrugBank.d491.s35.e0" charOffset="27-33"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d491.s36" text="AMEVIVE is not indicated for pediatric patients.">
        <entity id="DDI-DrugBank.d491.s36.e0" charOffset="0-6"
            type="brand" text="AMEVIVE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d407.s0" text="Drug/Laboratory Interactions No formal drug interaction studies have been performed with Campath.">
        <entity id="DDI-DrugBank.d407.s0.e0" charOffset="89-95"
            type="brand" text="Campath"/>
    </sentence>
    <sentence id="DDI-DrugBank.d407.s1" text="An immune response to Campath may interfere with subsequent diagnostic serum tests that utilize antibodies">
        <entity id="DDI-DrugBank.d407.s1.e0" charOffset="22-28"
            type="brand" text="Campath"/>
        <entity id="DDI-DrugBank.d407.s1.e1" charOffset="96-105"
            type="group" text="antibodies"/>
    </sentence>
    <sentence id="DDI-DrugBank.d407.s2" text="."/>
    <sentence id="DDI-DrugBank.d407.s3" text=""/>
    <sentence id="DDI-DrugBank.d430.s0" text="Intravenous ranitidine was shown to double the bioavailability of oral alendronate.">
        <entity id="DDI-DrugBank.d430.s0.e0" charOffset="12-21"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d430.s0.e1" charOffset="71-81"
            type="drug" text="alendronate"/>
        <ddi id="DDI-DrugBank.d430.s0.d0" e1="DDI-DrugBank.d430.s0.e0"
            e2="DDI-DrugBank.d430.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d430.s1" text="The clinical significance of this increased bioavailability and whether similar increases will occur in patients given oral H2-antagonists is unknown;">
        <entity id="DDI-DrugBank.d430.s1.e0" charOffset="124-137"
            type="group" text="H2-antagonists"/>
    </sentence>
    <sentence id="DDI-DrugBank.d430.s2" text="no other specific drug interaction studies were performed."/>
    <sentence id="DDI-DrugBank.d430.s3" text="Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.">
        <entity id="DDI-DrugBank.d430.s3.e0" charOffset="20-26"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d430.s3.e1" charOffset="38-56"
            type="drug" text="multivalent cations"/>
        <entity id="DDI-DrugBank.d430.s3.e2" charOffset="99-109"
            type="drug" text="alendronate"/>
        <ddi id="DDI-DrugBank.d430.s3.d0" e1="DDI-DrugBank.d430.s3.e0"
            e2="DDI-DrugBank.d430.s3.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d430.s3.d1" e1="DDI-DrugBank.d430.s3.e1"
            e2="DDI-DrugBank.d430.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d8.s0" text="Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.">
        <entity id="DDI-DrugBank.d8.s0.e0" charOffset="106-112"
            type="brand" text="ALFENTA"/>
        <entity id="DDI-DrugBank.d8.s0.e1" charOffset="156-170"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d8.s0.e2" charOffset="180-191"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d8.s0.e3" charOffset="194-206"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d8.s0.e4" charOffset="209-215"
            type="group" text="opioids"/>
        <entity id="DDI-DrugBank.d8.s0.e5" charOffset="240-250"
            type="group" text="anesthetics"/>
        <ddi id="DDI-DrugBank.d8.s0.d0" e1="DDI-DrugBank.d8.s0.e0"
            e2="DDI-DrugBank.d8.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d8.s0.d1" e1="DDI-DrugBank.d8.s0.e0"
            e2="DDI-DrugBank.d8.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d8.s0.d2" e1="DDI-DrugBank.d8.s0.e0"
            e2="DDI-DrugBank.d8.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d8.s0.d3" e1="DDI-DrugBank.d8.s0.e0"
            e2="DDI-DrugBank.d8.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d8.s0.d4" e1="DDI-DrugBank.d8.s0.e0"
            e2="DDI-DrugBank.d8.s0.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d8.s1" text="Postoperative respiratory depression may be enhanced or prolonged by these agents."/>
    <sentence id="DDI-DrugBank.d8.s2" text="In such cases of combined treatment, the dose of one or both agents should be reduced."/>
    <sentence id="DDI-DrugBank.d8.s3" text="Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.">
        <entity id="DDI-DrugBank.d8.s3.e0" charOffset="60-90"
            type="group" text="volatile inhalation anesthetics"/>
        <entity id="DDI-DrugBank.d8.s3.e1" charOffset="160-166"
            type="brand" text="ALFENTA"/>
        <entity id="DDI-DrugBank.d8.s3.e2" charOffset="201-212"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d8.s3.e3" charOffset="219-225"
            type="brand" text="ALFENTA"/>
        <entity id="DDI-DrugBank.d8.s3.e4" charOffset="253-259"
            type="brand" text="ALFENTA"/>
        <ddi id="DDI-DrugBank.d8.s3.d0" e1="DDI-DrugBank.d8.s3.e0"
            e2="DDI-DrugBank.d8.s3.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d8.s3.d1" e1="DDI-DrugBank.d8.s3.e2"
            e2="DDI-DrugBank.d8.s3.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d8.s4" text="Cimetidine reduces the clearance of ALFENTA.">
        <entity id="DDI-DrugBank.d8.s4.e0" charOffset="0-9" type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d8.s4.e1" charOffset="36-42"
            type="brand" text="ALFENTA"/>
        <ddi id="DDI-DrugBank.d8.s4.d0" e1="DDI-DrugBank.d8.s4.e0"
            e2="DDI-DrugBank.d8.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d8.s5" text="Therefore smaller ALFENTA doses will be required with prolonged administration and the duration of action of ALFENTA my be extended.">
        <entity id="DDI-DrugBank.d8.s5.e0" charOffset="18-24"
            type="brand" text="ALFENTA"/>
        <entity id="DDI-DrugBank.d8.s5.e1" charOffset="109-115"
            type="brand" text="ALFENTA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d8.s6" text="Perioperative administration of drugs affecting hepatic blood flow or enzyme function may reduce plasma clearance and prolong recovery."/>
    <sentence id="DDI-DrugBank.d273.s0" text="Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between UROXATRAL and other alpha-blockers have not been determined.">
        <entity id="DDI-DrugBank.d273.s0.e0" charOffset="85-93"
            type="brand" text="UROXATRAL"/>
        <entity id="DDI-DrugBank.d273.s0.e1" charOffset="105-118"
            type="group" text="alpha-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d273.s1" text="However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.">
        <entity id="DDI-DrugBank.d273.s1.e0" charOffset="43-51"
            type="brand" text="UROXATRAL"/>
        <entity id="DDI-DrugBank.d273.s1.e1" charOffset="98-111"
            type="group" text="alpha-blockers"/>
        <ddi id="DDI-DrugBank.d273.s1.d0" e1="DDI-DrugBank.d273.s1.e0"
            e2="DDI-DrugBank.d273.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d90.s0" text="No drug interaction studies have been performed."/>
    <sentence id="DDI-DrugBank.d533.s0" text="Effects of Other Drugs on Aliskiren Based on in-vitro studies, aliskiren is metabolized by CYP 3A4.">
        <entity id="DDI-DrugBank.d533.s0.e0" charOffset="26-34"
            type="drug" text="Aliskiren"/>
        <entity id="DDI-DrugBank.d533.s0.e1" charOffset="63-71"
            type="drug" text="aliskiren"/>
    </sentence>
    <sentence id="DDI-DrugBank.d533.s1" text="Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.">
        <entity id="DDI-DrugBank.d533.s1.e0" charOffset="21-30"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d533.s1.e1" charOffset="33-40"
            type="drug" text="atenolol"/>
        <entity id="DDI-DrugBank.d533.s1.e2" charOffset="43-50"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d533.s1.e3" charOffset="53-62"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d533.s1.e4" charOffset="65-71"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d533.s1.e5" charOffset="74-82"
            type="drug" text="celecoxib"/>
        <entity id="DDI-DrugBank.d533.s1.e6" charOffset="85-103"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d533.s1.e7" charOffset="106-113"
            type="drug" text="ramipril"/>
        <entity id="DDI-DrugBank.d533.s1.e8" charOffset="116-124"
            type="drug" text="valsartan"/>
        <entity id="DDI-DrugBank.d533.s1.e9" charOffset="127-135"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d533.s1.e10" charOffset="141-150"
            type="drug" text="amlodipine"/>
        <entity id="DDI-DrugBank.d533.s1.e11" charOffset="206-214"
            type="drug" text="aliskiren"/>
    </sentence>
    <sentence id="DDI-DrugBank.d533.s2" text="Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.">
        <entity id="DDI-DrugBank.d533.s2.e0" charOffset="21-30"
            type="drug" text="irbesartan"/>
        <entity id="DDI-DrugBank.d533.s2.e1" charOffset="40-48"
            type="drug" text="aliskiren"/>
        <ddi id="DDI-DrugBank.d533.s2.d0" e1="DDI-DrugBank.d533.s2.e0"
            e2="DDI-DrugBank.d533.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d533.s3" text="Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.">
        <entity id="DDI-DrugBank.d533.s3.e0" charOffset="21-32"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d533.s3.e1" charOffset="70-78"
            type="drug" text="aliskiren"/>
        <ddi id="DDI-DrugBank.d533.s3.d0" e1="DDI-DrugBank.d533.s3.e0"
            e2="DDI-DrugBank.d533.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d533.s4" text="Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.">
        <entity id="DDI-DrugBank.d533.s4.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d533.s4.e1" charOffset="54-65"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d533.s4.e2" charOffset="72-80"
            type="drug" text="aliskiren"/>
        <entity id="DDI-DrugBank.d533.s4.e3" charOffset="142-150"
            type="drug" text="aliskiren"/>
        <ddi id="DDI-DrugBank.d533.s4.d0" e1="DDI-DrugBank.d533.s4.e1"
            e2="DDI-DrugBank.d533.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d533.s5" text="A 400 mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.">
        <entity id="DDI-DrugBank.d533.s5.e0" charOffset="75-83"
            type="drug" text="aliskiren"/>
    </sentence>
    <sentence id="DDI-DrugBank.d533.s6" text="Effects of Aliskiren on Other Drugs Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4.">
        <entity id="DDI-DrugBank.d533.s6.e0" charOffset="11-19"
            type="drug" text="Aliskiren"/>
        <entity id="DDI-DrugBank.d533.s6.e1" charOffset="36-44"
            type="drug" text="Aliskiren"/>
    </sentence>
    <sentence id="DDI-DrugBank.d533.s7" text="Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.">
        <entity id="DDI-DrugBank.d533.s7.e0" charOffset="21-29"
            type="drug" text="aliskiren"/>
        <entity id="DDI-DrugBank.d533.s7.e1" charOffset="84-93"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d533.s7.e2" charOffset="96-102"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d533.s7.e3" charOffset="105-113"
            type="drug" text="valsartan"/>
        <entity id="DDI-DrugBank.d533.s7.e4" charOffset="116-125"
            type="drug" text="amlodipine"/>
        <entity id="DDI-DrugBank.d533.s7.e5" charOffset="128-136"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d533.s7.e6" charOffset="139-147"
            type="drug" text="celecoxib"/>
        <entity id="DDI-DrugBank.d533.s7.e7" charOffset="150-157"
            type="drug" text="atenolol"/>
        <entity id="DDI-DrugBank.d533.s7.e8" charOffset="160-171"
            type="drug" text="atorvastatin"/>
        <entity id="DDI-DrugBank.d533.s7.e9" charOffset="174-181"
            type="drug" text="ramipril"/>
        <entity id="DDI-DrugBank.d533.s7.e10" charOffset="186-204"
            type="drug" text="hydrochlorothiazide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d533.s8" text="Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated in a well-controlled clinical trial.">
        <entity id="DDI-DrugBank.d533.s8.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d533.s8.e1" charOffset="25-33"
            type="drug" text="aliskiren"/>
        <entity id="DDI-DrugBank.d533.s8.e2" charOffset="38-45"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d533.s9" text="Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.">
        <entity id="DDI-DrugBank.d533.s9.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d533.s9.e1" charOffset="17-25"
            type="drug" text="aliskiren"/>
        <entity id="DDI-DrugBank.d533.s9.e2" charOffset="52-61"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d533.s9.e3" charOffset="84-93"
            type="drug" text="furosemide"/>
        <ddi id="DDI-DrugBank.d533.s9.d0" e1="DDI-DrugBank.d533.s9.e1"
            e2="DDI-DrugBank.d533.s9.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d392.s0" text="Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.">
        <entity id="DDI-DrugBank.d392.s0.e0" charOffset="26-33"
            type="brand" text="Panretin"/>
        <entity id="DDI-DrugBank.d392.s0.e1" charOffset="89-92"
            type="drug" text="DEET"/>
        <entity id="DDI-DrugBank.d392.s0.e2" charOffset="98-118"
            type="drug" text="N-diethyl-m-toluamide"/>
        <ddi id="DDI-DrugBank.d392.s0.d0" e1="DDI-DrugBank.d392.s0.e0"
            e2="DDI-DrugBank.d392.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d392.s0.d1" e1="DDI-DrugBank.d392.s0.e0"
            e2="DDI-DrugBank.d392.s0.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d392.s1" text="Animal toxicology studies showed increased DEET toxicity when DEET was included as proof of the formulation.">
        <entity id="DDI-DrugBank.d392.s1.e0" charOffset="43-46"
            type="drug" text="DEET"/>
        <entity id="DDI-DrugBank.d392.s1.e1" charOffset="62-65"
            type="drug" text="DEET"/>
    </sentence>
    <sentence id="DDI-DrugBank.d392.s2" text="Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors, macrolide antibiotics, and azole antifungals, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.">
        <entity id="DDI-DrugBank.d392.s2.e0" charOffset="109-129"
            type="group" text="antiretroviral agents"/>
        <entity id="DDI-DrugBank.d392.s2.e1" charOffset="142-160"
            type="group" text="protease inhibitors"/>
        <entity id="DDI-DrugBank.d392.s2.e2" charOffset="163-183"
            type="group" text="macrolide antibiotics"/>
        <entity id="DDI-DrugBank.d392.s2.e3" charOffset="190-206"
            type="group" text="azole antifungals"/>
        <entity id="DDI-DrugBank.d392.s2.e4" charOffset="223-230"
            type="brand" text="Panretin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d392.s3" text="No drug interaction data are available on concomitant administration of Panretin gel and systemic anti-KS agents.">
        <entity id="DDI-DrugBank.d392.s3.e0" charOffset="72-79"
            type="brand" text="Panretin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s0" text="The following drug interactions were observed in some patients undergoing treatment with oral allopurinol.">
        <entity id="DDI-DrugBank.d413.s0.e0" charOffset="94-104"
            type="drug" text="allopurinol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s1" text="Although the pattern of use for oral allopurinol includes longer term therapy, particularly for gout and renal calculi, the experience gained may be relevant.">
        <entity id="DDI-DrugBank.d413.s1.e0" charOffset="37-47"
            type="drug" text="allopurinol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s2" text="Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.">
        <entity id="DDI-DrugBank.d413.s2.e0" charOffset="0-13"
            type="drug" text="Mercaptopurine"/>
        <entity id="DDI-DrugBank.d413.s2.e1" charOffset="15-26"
            type="drug" text="Azathioprine"/>
        <entity id="DDI-DrugBank.d413.s2.e2" charOffset="29-39"
            type="drug" text="Allopurinol"/>
        <entity id="DDI-DrugBank.d413.s2.e3" charOffset="77-90"
            type="drug" text="mercaptopurine"/>
        <entity id="DDI-DrugBank.d413.s2.e4" charOffset="96-107"
            type="drug" text="azathioprine"/>
        <entity id="DDI-DrugBank.d413.s2.e5" charOffset="112-126"
            type="drug" text="6-thiouric acid"/>
        <ddi id="DDI-DrugBank.d413.s2.d0" e1="DDI-DrugBank.d413.s2.e2"
            e2="DDI-DrugBank.d413.s2.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d413.s2.d1" e1="DDI-DrugBank.d413.s2.e2"
            e2="DDI-DrugBank.d413.s2.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s3" text="This oxidation, which is catalyzed by xanthine oxidase, inactivates mercaptopurine.">
        <entity id="DDI-DrugBank.d413.s3.e0" charOffset="68-81"
            type="drug" text="mercaptopurine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s4" text="In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.">
        <entity id="DDI-DrugBank.d413.s4.e0" charOffset="22-35"
            type="drug" text="mercaptopurine"/>
        <entity id="DDI-DrugBank.d413.s4.e1" charOffset="38-47"
            type="brand" text="Purinethol"/>
        <entity id="DDI-DrugBank.d413.s4.e2" charOffset="53-64"
            type="drug" text="azathioprine"/>
        <entity id="DDI-DrugBank.d413.s4.e3" charOffset="67-72"
            type="brand" text="Imuran"/>
        <entity id="DDI-DrugBank.d413.s4.e4" charOffset="124-134"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d413.s4.e5" charOffset="239-252"
            type="drug" text="mercaptopurine"/>
        <entity id="DDI-DrugBank.d413.s4.e6" charOffset="257-268"
            type="drug" text="azathioprine"/>
        <ddi id="DDI-DrugBank.d413.s4.d0" e1="DDI-DrugBank.d413.s4.e4"
            e2="DDI-DrugBank.d413.s4.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d413.s4.d1" e1="DDI-DrugBank.d413.s4.e4"
            e2="DDI-DrugBank.d413.s4.e6" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s5" text="Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects.">
        <entity id="DDI-DrugBank.d413.s5.e0" charOffset="34-47"
            type="drug" text="mercaptopurine"/>
        <entity id="DDI-DrugBank.d413.s5.e1" charOffset="52-63"
            type="drug" text="azathioprine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s6" text="Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.">
        <entity id="DDI-DrugBank.d413.s6.e0" charOffset="0-8"
            type="drug" text="Dicumarol"/>
        <entity id="DDI-DrugBank.d413.s6.e1" charOffset="37-47"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d413.s6.e2" charOffset="79-91"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d413.s6.e3" charOffset="94-102"
            type="drug" text="dicumarol"/>
        <ddi id="DDI-DrugBank.d413.s6.d0" e1="DDI-DrugBank.d413.s6.e1"
            e2="DDI-DrugBank.d413.s6.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s7" text="The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.">
        <entity id="DDI-DrugBank.d413.s7.e0" charOffset="94-104"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d413.s7.e1" charOffset="138-146"
            type="drug" text="dicumarol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s8" text="Consequently, prothrombin time should be reassessed periodically in patients receiving both drugs."/>
    <sentence id="DDI-DrugBank.d413.s9" text="Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.">
        <entity id="DDI-DrugBank.d413.s9.e0" charOffset="0-16"
            type="group" text="Uricosuric Agents"/>
        <entity id="DDI-DrugBank.d413.s9.e1" charOffset="42-51"
            type="drug" text="oxipurinol"/>
        <entity id="DDI-DrugBank.d413.s9.e2" charOffset="82-98"
            type="group" text="uricosuric agents"/>
        <entity id="DDI-DrugBank.d413.s9.e3" charOffset="185-194"
            type="drug" text="oxipurinol"/>
        <ddi id="DDI-DrugBank.d413.s9.d0" e1="DDI-DrugBank.d413.s9.e2"
            e2="DDI-DrugBank.d413.s9.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s10" text="The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.">
        <entity id="DDI-DrugBank.d413.s10.e0" charOffset="34-50"
            type="group" text="uricosuric agents"/>
        <entity id="DDI-DrugBank.d413.s10.e1" charOffset="56-66"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d413.s10.e2" charOffset="243-253"
            type="drug" text="allopurinol"/>
        <ddi id="DDI-DrugBank.d413.s10.d0" e1="DDI-DrugBank.d413.s10.e0"
            e2="DDI-DrugBank.d413.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s11" text="Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on allopurinol alone or in combination with uricosuric agents, the possibility should be kept in mind.">
        <entity id="DDI-DrugBank.d413.s11.e0" charOffset="112-122"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d413.s11.e1" charOffset="153-169"
            type="group" text="uricosuric agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s12" text="Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.">
        <entity id="DDI-DrugBank.d413.s12.e0" charOffset="0-17"
            type="group" text="Thiazide Diuretics"/>
        <entity id="DDI-DrugBank.d413.s12.e1" charOffset="60-70"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d413.s12.e2" charOffset="76-93"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d413.s12.e3" charOffset="132-142"
            type="drug" text="allopurinol"/>
        <ddi id="DDI-DrugBank.d413.s12.d0" e1="DDI-DrugBank.d413.s12.e1"
            e2="DDI-DrugBank.d413.s12.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s13" text="Review of these case reports indicates that the patients were mainly receiving thiazide diuretics for hypertension and that tests to rule out decreased renal function secondary to hypertensive nephropathy were not often performed.">
        <entity id="DDI-DrugBank.d413.s13.e0" charOffset="79-96"
            type="group" text="thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s14" text="In those patients in whom renal insufficiency was documented, however, the recommendation to lower the dose of allopurinol was not followed.">
        <entity id="DDI-DrugBank.d413.s14.e0" charOffset="111-121"
            type="drug" text="allopurinol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s15" text="Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..">
        <entity id="DDI-DrugBank.d413.s15.e0" charOffset="172-189"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d413.s15.e1" charOffset="195-205"
            type="drug" text="allopurinol"/>
        <ddi id="DDI-DrugBank.d413.s15.d0" e1="DDI-DrugBank.d413.s15.e0"
            e2="DDI-DrugBank.d413.s15.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s16" text="Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.">
        <entity id="DDI-DrugBank.d413.s16.e0" charOffset="0-9"
            type="drug" text="Ampicillin"/>
        <entity id="DDI-DrugBank.d413.s16.e1" charOffset="11-21"
            type="drug" text="Amoxicillin"/>
        <entity id="DDI-DrugBank.d413.s16.e2" charOffset="109-118"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d413.s16.e3" charOffset="123-133"
            type="drug" text="amoxicillin"/>
        <entity id="DDI-DrugBank.d413.s16.e4" charOffset="153-163"
            type="drug" text="allopurinol"/>
        <ddi id="DDI-DrugBank.d413.s16.d0" e1="DDI-DrugBank.d413.s16.e2"
            e2="DDI-DrugBank.d413.s16.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d413.s16.d1" e1="DDI-DrugBank.d413.s16.e3"
            e2="DDI-DrugBank.d413.s16.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s17" text="The cause of the reported association has not been established."/>
    <sentence id="DDI-DrugBank.d413.s18" text="Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.">
        <entity id="DDI-DrugBank.d413.s18.e0" charOffset="0-15"
            type="group" text="Cytotoxic Agents"/>
        <entity id="DDI-DrugBank.d413.s18.e1" charOffset="54-69"
            type="drug" text="cyclophosphamide"/>
        <entity id="DDI-DrugBank.d413.s18.e2" charOffset="81-96"
            type="group" text="cytotoxic agents"/>
        <entity id="DDI-DrugBank.d413.s18.e3" charOffset="192-202"
            type="drug" text="allopurinol"/>
        <ddi id="DDI-DrugBank.d413.s18.d0" e1="DDI-DrugBank.d413.s18.e1"
            e2="DDI-DrugBank.d413.s18.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d413.s18.d1" e1="DDI-DrugBank.d413.s18.e2"
            e2="DDI-DrugBank.d413.s18.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s19" text="However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechlorethamine.">
        <entity id="DDI-DrugBank.d413.s19.e0" charOffset="86-96"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d413.s19.e1" charOffset="160-175"
            type="drug" text="cyclophosphamide"/>
        <entity id="DDI-DrugBank.d413.s19.e2" charOffset="178-188"
            type="drug" text="doxorubicin"/>
        <entity id="DDI-DrugBank.d413.s19.e3" charOffset="191-199"
            type="drug" text="bleomycin"/>
        <entity id="DDI-DrugBank.d413.s19.e4" charOffset="202-213"
            type="drug" text="procarbazine"/>
        <entity id="DDI-DrugBank.d413.s19.e5" charOffset="222-236"
            type="drug" text="mechlorethamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s20" text="Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.">
        <entity id="DDI-DrugBank.d413.s20.e0" charOffset="0-13"
            type="drug" text="Chlorpropamide"/>
        <entity id="DDI-DrugBank.d413.s20.e1" charOffset="16-29"
            type="drug" text="Chlorpropamide"/>
        <entity id="DDI-DrugBank.d413.s20.e2" charOffset="69-79"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d413.s20.e3" charOffset="88-98"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d413.s20.e4" charOffset="104-117"
            type="drug" text="chlorpropamide"/>
        <ddi id="DDI-DrugBank.d413.s20.d0" e1="DDI-DrugBank.d413.s20.e1"
            e2="DDI-DrugBank.d413.s20.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d413.s20.d1" e1="DDI-DrugBank.d413.s20.e3"
            e2="DDI-DrugBank.d413.s20.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s21" text="The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.">
        <entity id="DDI-DrugBank.d413.s21.e0" charOffset="73-83"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d413.s21.e1" charOffset="89-102"
            type="drug" text="chlorpropamide"/>
        <ddi id="DDI-DrugBank.d413.s21.d0" e1="DDI-DrugBank.d413.s21.e0"
            e2="DDI-DrugBank.d413.s21.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s22" text="Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.">
        <entity id="DDI-DrugBank.d413.s22.e0" charOffset="0-10"
            type="drug" text="Cyclosporin"/>
        <entity id="DDI-DrugBank.d413.s22.e1" charOffset="35-46"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d413.s22.e2" charOffset="106-123"
            type="drug" text="allopurinol sodium"/>
        <ddi id="DDI-DrugBank.d413.s22.d0" e1="DDI-DrugBank.d413.s22.e1"
            e2="DDI-DrugBank.d413.s22.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s23" text="Monitoring of cyclosporine levels and possible adjustment of cyclosporine dosage should be considered when these drugs are co-administered.">
        <entity id="DDI-DrugBank.d413.s23.e0" charOffset="14-25"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d413.s23.e1" charOffset="61-72"
            type="drug" text="cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s24" text="Tolbutamides conversion to inactive metabolites has been shown to be catalyzed by xanthine oxidase from rat liver.">
        <entity id="DDI-DrugBank.d413.s24.e0" charOffset="0-10"
            type="drug" text="Tolbutamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d413.s25" text="The clinical significance, if any, of these observations is unknown."/>
    <sentence id="DDI-DrugBank.d299.s0" text="Ergot-Containing Drugs: These drugs have been reported to cause prolonged vasospastic reactions.">
        <entity id="DDI-DrugBank.d299.s0.e0" charOffset="0-21"
            type="group" text="Ergot-Containing Drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d299.s1" text="Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.">
        <entity id="DDI-DrugBank.d299.s1.e0" charOffset="80-89"
            type="drug" text="ergotamine"/>
        <entity id="DDI-DrugBank.d299.s1.e1" charOffset="105-126"
            type="group" text="ergot-type medications"/>
        <entity id="DDI-DrugBank.d299.s1.e2" charOffset="134-150"
            type="drug" text="dihydroergotamine"/>
        <entity id="DDI-DrugBank.d299.s1.e3" charOffset="155-166"
            type="drug" text="methysergide"/>
        <entity id="DDI-DrugBank.d299.s1.e4" charOffset="173-177"
            type="brand" text="AXERT"/>
        <ddi id="DDI-DrugBank.d299.s1.d0" e1="DDI-DrugBank.d299.s1.e0"
            e2="DDI-DrugBank.d299.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d299.s1.d1" e1="DDI-DrugBank.d299.s1.e1"
            e2="DDI-DrugBank.d299.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d299.s1.d2" e1="DDI-DrugBank.d299.s1.e2"
            e2="DDI-DrugBank.d299.s1.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d299.s1.d3" e1="DDI-DrugBank.d299.s1.e3"
            e2="DDI-DrugBank.d299.s1.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d299.s2" text="Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.">
        <entity id="DDI-DrugBank.d299.s2.e0" charOffset="0-27"
            type="group" text="Monoamine Oxidase Inhibitors"/>
        <entity id="DDI-DrugBank.d299.s2.e1" charOffset="50-60"
            type="drug" text="moclobemide"/>
        <entity id="DDI-DrugBank.d299.s2.e2" charOffset="92-102"
            type="drug" text="almotriptan"/>
        <ddi id="DDI-DrugBank.d299.s2.d0" e1="DDI-DrugBank.d299.s2.e1"
            e2="DDI-DrugBank.d299.s2.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d299.s3" text="No dose adjustment is necessary."/>
    <sentence id="DDI-DrugBank.d299.s4" text="Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.">
        <entity id="DDI-DrugBank.d299.s4.e0" charOffset="6-23"
            type="group" text="5-HT1B/1D Agonists"/>
        <entity id="DDI-DrugBank.d299.s4.e1" charOffset="50-67"
            type="group" text="5-HT1B/1D agonists"/>
        <entity id="DDI-DrugBank.d299.s4.e2" charOffset="103-107"
            type="brand" text="AXERT"/>
        <ddi id="DDI-DrugBank.d299.s4.d0" e1="DDI-DrugBank.d299.s4.e1"
            e2="DDI-DrugBank.d299.s4.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d299.s5" text="Propanolol: The pharmacokinetics of almotriptan were not affected by coadministration of propranolol.">
        <entity id="DDI-DrugBank.d299.s5.e0" charOffset="0-9"
            type="drug" text="Propanolol"/>
        <entity id="DDI-DrugBank.d299.s5.e1" charOffset="36-46"
            type="drug" text="almotriptan"/>
        <entity id="DDI-DrugBank.d299.s5.e2" charOffset="89-99"
            type="drug" text="propranolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d299.s6" text="Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.">
        <entity id="DDI-DrugBank.d299.s6.e0" charOffset="0-38"
            type="group" text="Selective Serotonin Reuptake Inhibitors"/>
        <entity id="DDI-DrugBank.d299.s6.e1" charOffset="41-45"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d299.s6.e2" charOffset="49-53"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d299.s6.e3" charOffset="62-71"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d299.s6.e4" charOffset="74-84"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d299.s6.e5" charOffset="87-96"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d299.s6.e6" charOffset="99-108"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d299.s6.e7" charOffset="215-228"
            type="group" text="5-HT1 agonists"/>
        <ddi id="DDI-DrugBank.d299.s6.d0" e1="DDI-DrugBank.d299.s6.e2"
            e2="DDI-DrugBank.d299.s6.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d299.s6.d1" e1="DDI-DrugBank.d299.s6.e3"
            e2="DDI-DrugBank.d299.s6.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d299.s6.d2" e1="DDI-DrugBank.d299.s6.e4"
            e2="DDI-DrugBank.d299.s6.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d299.s6.d3" e1="DDI-DrugBank.d299.s6.e5"
            e2="DDI-DrugBank.d299.s6.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d299.s6.d4" e1="DDI-DrugBank.d299.s6.e6"
            e2="DDI-DrugBank.d299.s6.e7" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d299.s7" text="If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.">
        <entity id="DDI-DrugBank.d299.s7.e0" charOffset="30-34"
            type="brand" text="AXERT"/>
        <entity id="DDI-DrugBank.d299.s7.e1" charOffset="43-46"
            type="group" text="SSRI"/>
        <ddi id="DDI-DrugBank.d299.s7.d0" e1="DDI-DrugBank.d299.s7.e0"
            e2="DDI-DrugBank.d299.s7.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d299.s8" text="Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.">
        <entity id="DDI-DrugBank.d299.s8.e0" charOffset="0-8"
            type="drug" text="Verapamil"/>
        <entity id="DDI-DrugBank.d299.s8.e1" charOffset="31-41"
            type="drug" text="almotriptan"/>
        <entity id="DDI-DrugBank.d299.s8.e2" charOffset="47-55"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d299.s8.e3" charOffset="112-122"
            type="drug" text="almotriptan"/>
        <ddi id="DDI-DrugBank.d299.s8.d0" e1="DDI-DrugBank.d299.s8.e1"
            e2="DDI-DrugBank.d299.s8.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d299.s9" text="No dose adjustment is necessary."/>
    <sentence id="DDI-DrugBank.d299.s10" text="Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.">
        <entity id="DDI-DrugBank.d299.s10.e0" charOffset="20-30"
            type="drug" text="almotriptan"/>
        <entity id="DDI-DrugBank.d299.s10.e1" charOffset="64-75"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d299.s10.e2" charOffset="235-245"
            type="drug" text="almotriptan"/>
        <ddi id="DDI-DrugBank.d299.s10.d0" e1="DDI-DrugBank.d299.s10.e0"
            e2="DDI-DrugBank.d299.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d299.s11" text="Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.">
        <entity id="DDI-DrugBank.d299.s11.e0" charOffset="33-43"
            type="drug" text="almotriptan"/>
        <entity id="DDI-DrugBank.d299.s11.e1" charOffset="87-98"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d299.s11.e2" charOffset="101-109"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d299.s11.e3" charOffset="116-127"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d299.s11.e4" charOffset="175-185"
            type="drug" text="almotriptan"/>
        <entity id="DDI-DrugBank.d299.s11.e5" charOffset="208-218"
            type="drug" text="almotriptan"/>
        <ddi id="DDI-DrugBank.d299.s11.d0" e1="DDI-DrugBank.d299.s11.e1"
            e2="DDI-DrugBank.d299.s11.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d299.s11.d1" e1="DDI-DrugBank.d299.s11.e2"
            e2="DDI-DrugBank.d299.s11.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d299.s11.d2" e1="DDI-DrugBank.d299.s11.e3"
            e2="DDI-DrugBank.d299.s11.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d299.s12" text="AXERT is not known to interfere with commonly employed clinical laboratory tests.">
        <entity id="DDI-DrugBank.d299.s12.e0" charOffset="0-4"
            type="brand" text="AXERT"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s0" text="Because alosetron is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of alosetron.">
        <entity id="DDI-DrugBank.d364.s0.e0" charOffset="8-16"
            type="drug" text="alosetron"/>
        <entity id="DDI-DrugBank.d364.s0.e1" charOffset="156-164"
            type="drug" text="alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s1" text="Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9, and CYP2C19.">
        <entity id="DDI-DrugBank.d364.s1.e0" charOffset="0-10"
            type="drug" text="Fluvoxamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s2" text="In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of alosetron 1 mg on the last day.">
        <entity id="DDI-DrugBank.d364.s2.e0" charOffset="64-74"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d364.s2.e1" charOffset="160-168"
            type="drug" text="alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s3" text="Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.">
        <entity id="DDI-DrugBank.d364.s3.e0" charOffset="0-10"
            type="drug" text="Fluvoxamine"/>
        <entity id="DDI-DrugBank.d364.s3.e1" charOffset="27-35"
            type="drug" text="alosetron"/>
        <ddi id="DDI-DrugBank.d364.s3.d0" e1="DDI-DrugBank.d364.s3.e0"
            e2="DDI-DrugBank.d364.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s4" text="Concomitant administration of alosetron and fluvoxamine is contraindicated.">
        <entity id="DDI-DrugBank.d364.s4.e0" charOffset="30-38"
            type="drug" text="alosetron"/>
        <entity id="DDI-DrugBank.d364.s4.e1" charOffset="44-54"
            type="drug" text="fluvoxamine"/>
        <ddi id="DDI-DrugBank.d364.s4.d0" e1="DDI-DrugBank.d364.s4.e0"
            e2="DDI-DrugBank.d364.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s5" text="Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.">
        <entity id="DDI-DrugBank.d364.s5.e0" charOffset="30-38"
            type="drug" text="alosetron"/>
        <entity id="DDI-DrugBank.d364.s5.e1" charOffset="82-102"
            type="group" text="quinolone antibiotics"/>
        <entity id="DDI-DrugBank.d364.s5.e2" charOffset="108-117"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d364.s5.d0" e1="DDI-DrugBank.d364.s5.e0"
            e2="DDI-DrugBank.d364.s5.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d364.s5.d1" e1="DDI-DrugBank.d364.s5.e0"
            e2="DDI-DrugBank.d364.s5.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s6" text="Ketoconazole is a known strong inhibitor of CYP3A4.">
        <entity id="DDI-DrugBank.d364.s6.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s7" text="In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day.">
        <entity id="DDI-DrugBank.d364.s7.e0" charOffset="64-75"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d364.s7.e1" charOffset="133-141"
            type="drug" text="alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s8" text="Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.">
        <entity id="DDI-DrugBank.d364.s8.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d364.s8.e1" charOffset="28-36"
            type="drug" text="alosetron"/>
        <ddi id="DDI-DrugBank.d364.s8.d0" e1="DDI-DrugBank.d364.s8.e0"
            e2="DDI-DrugBank.d364.s8.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s9" text="Caution should be used when alosetron and ketoconazole are administered concomitantly.">
        <entity id="DDI-DrugBank.d364.s9.e0" charOffset="28-36"
            type="drug" text="alosetron"/>
        <entity id="DDI-DrugBank.d364.s9.e1" charOffset="42-53"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d364.s9.d0" e1="DDI-DrugBank.d364.s9.e0"
            e2="DDI-DrugBank.d364.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s10" text="Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.">
        <entity id="DDI-DrugBank.d364.s10.e0" charOffset="20-28"
            type="drug" text="alosetron"/>
        <entity id="DDI-DrugBank.d364.s10.e1" charOffset="68-81"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d364.s10.e2" charOffset="84-96"
            type="drug" text="telithromycin"/>
        <entity id="DDI-DrugBank.d364.s10.e3" charOffset="99-117"
            type="group" text="protease inhibitors"/>
        <entity id="DDI-DrugBank.d364.s10.e4" charOffset="120-131"
            type="drug" text="voriconazole"/>
        <entity id="DDI-DrugBank.d364.s10.e5" charOffset="138-149"
            type="drug" text="itraconazole"/>
        <ddi id="DDI-DrugBank.d364.s10.d0" e1="DDI-DrugBank.d364.s10.e0"
            e2="DDI-DrugBank.d364.s10.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d364.s10.d1" e1="DDI-DrugBank.d364.s10.e0"
            e2="DDI-DrugBank.d364.s10.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d364.s10.d2" e1="DDI-DrugBank.d364.s10.e0"
            e2="DDI-DrugBank.d364.s10.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d364.s10.d3" e1="DDI-DrugBank.d364.s10.e0"
            e2="DDI-DrugBank.d364.s10.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d364.s10.d4" e1="DDI-DrugBank.d364.s10.e0"
            e2="DDI-DrugBank.d364.s10.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s11" text="The effect of induction or inhibition of other pathways on exposure to alosetron and its metabolites is not known.">
        <entity id="DDI-DrugBank.d364.s11.e0" charOffset="71-79"
            type="drug" text="alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s12" text="In vitro human liver microsome studies and an in vivo metabolic probe study demonstrated that alosetron did not inhibit CYP enzymes 2D6, 3A4, 2C9, or 2C19.">
        <entity id="DDI-DrugBank.d364.s12.e0" charOffset="94-102"
            type="drug" text="alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s13" text="In vitro, at total drug concentrations 27-fold higher than peak plasma concentrations observed with the 1-mg dosage, alosetron inhibited CYP enzymes 1A2 (60%) and 2E1 (50%).">
        <entity id="DDI-DrugBank.d364.s13.e0" charOffset="117-125"
            type="drug" text="alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s14" text="In an in vivo metabolic probe study, alosetron did not inhibit CYP2E1 but did produce 30% inhibition of both CYP1A2 and N-acetyltransferase.">
        <entity id="DDI-DrugBank.d364.s14.e0" charOffset="37-45"
            type="drug" text="alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s15" text="Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.">
        <entity id="DDI-DrugBank.d364.s15.e0" charOffset="26-34"
            type="drug" text="alosetron"/>
        <entity id="DDI-DrugBank.d364.s15.e1" charOffset="131-139"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d364.s15.e2" charOffset="142-153"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d364.s15.e3" charOffset="160-170"
            type="drug" text="hydralazine"/>
        <ddi id="DDI-DrugBank.d364.s15.d0" e1="DDI-DrugBank.d364.s15.e0"
            e2="DDI-DrugBank.d364.s15.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d364.s15.d1" e1="DDI-DrugBank.d364.s15.e0"
            e2="DDI-DrugBank.d364.s15.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d364.s15.d2" e1="DDI-DrugBank.d364.s15.e0"
            e2="DDI-DrugBank.d364.s15.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s16" text="The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed.">
        <entity id="DDI-DrugBank.d364.s16.e0" charOffset="79-90"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s17" text="Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates).">
        <entity id="DDI-DrugBank.d364.s17.e0" charOffset="26-34"
            type="drug" text="alosetron"/>
        <entity id="DDI-DrugBank.d364.s17.e1" charOffset="110-129"
            type="group" text="contraceptive agents"/>
        <entity id="DDI-DrugBank.d364.s17.e2" charOffset="131-147"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d364.s17.e3" charOffset="153-166"
            type="drug" text="levonorgestrel"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s18" text="A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride.">
        <entity id="DDI-DrugBank.d364.s18.e0" charOffset="53-61"
            type="drug" text="alosetron"/>
        <entity id="DDI-DrugBank.d364.s18.e1" charOffset="88-96"
            type="drug" text="cisapride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s19" text="No significant effects on cisapride metabolism or QT interval were noted.">
        <entity id="DDI-DrugBank.d364.s19.e0" charOffset="26-34"
            type="drug" text="cisapride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s20" text="The effect of alosetron on monoamine oxidases and on intestinal first pass secondary to high intraluminal concentrations have not been examined.">
        <entity id="DDI-DrugBank.d364.s20.e0" charOffset="14-22"
            type="drug" text="alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s21" text="Based on the above data from in vitro and in vivo studies, it is unlikely that alosetron will inhibit the hepatic metabolic clearance of drugs metabolized by the major CYP enzyme 3A4, as well as the CYP enzymes 2D6, 2C9, 2C19, 2E1, or 1A2.">
        <entity id="DDI-DrugBank.d364.s21.e0" charOffset="79-87"
            type="drug" text="alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s22" text="Alosetron does not appear to induce the major cytochrome P450 (CYP) drug metabolizing enzyme 3A.">
        <entity id="DDI-DrugBank.d364.s22.e0" charOffset="0-8"
            type="drug" text="Alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s23" text="Alosetron also does not appear to induce CYP enzymes 2E1 or 2C19.">
        <entity id="DDI-DrugBank.d364.s23.e0" charOffset="0-8"
            type="drug" text="Alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d364.s24" text="It is not known whether alosetron might induce other enzymes.">
        <entity id="DDI-DrugBank.d364.s24.e0" charOffset="24-32"
            type="drug" text="alosetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d131.s0" text="The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.">
        <entity id="DDI-DrugBank.d131.s0.e0" charOffset="4-18"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d131.s0.e1" charOffset="31-40"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d131.s0.e2" charOffset="115-138"
            type="group" text="psychotropic medications"/>
        <entity id="DDI-DrugBank.d131.s0.e3" charOffset="141-155"
            type="group" text="anticonvulsants"/>
        <entity id="DDI-DrugBank.d131.s0.e4" charOffset="158-172"
            type="group" text="antihistaminics"/>
        <entity id="DDI-DrugBank.d131.s0.e5" charOffset="175-181"
            type="drug" text="ethanol"/>
        <ddi id="DDI-DrugBank.d131.s0.d0" e1="DDI-DrugBank.d131.s0.e0"
            e2="DDI-DrugBank.d131.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d131.s0.d1" e1="DDI-DrugBank.d131.s0.e0"
            e2="DDI-DrugBank.d131.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d131.s0.d2" e1="DDI-DrugBank.d131.s0.e0"
            e2="DDI-DrugBank.d131.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d131.s0.d3" e1="DDI-DrugBank.d131.s0.e0"
            e2="DDI-DrugBank.d131.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d131.s0.d4" e1="DDI-DrugBank.d131.s0.e1"
            e2="DDI-DrugBank.d131.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d131.s0.d5" e1="DDI-DrugBank.d131.s0.e1"
            e2="DDI-DrugBank.d131.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d131.s0.d6" e1="DDI-DrugBank.d131.s0.e1"
            e2="DDI-DrugBank.d131.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d131.s0.d7" e1="DDI-DrugBank.d131.s0.e1"
            e2="DDI-DrugBank.d131.s0.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d131.s1" text="The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.">
        <entity id="DDI-DrugBank.d131.s1.e0" charOffset="42-51"
            type="drug" text="imipramine"/>
        <entity id="DDI-DrugBank.d131.s1.e1" charOffset="57-67"
            type="drug" text="desipramine"/>
        <entity id="DDI-DrugBank.d131.s1.e2" charOffset="182-191"
            type="drug" text="alprazolam"/>
        <ddi id="DDI-DrugBank.d131.s1.d0" e1="DDI-DrugBank.d131.s1.e0"
            e2="DDI-DrugBank.d131.s1.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d131.s1.d1" e1="DDI-DrugBank.d131.s1.e1"
            e2="DDI-DrugBank.d131.s1.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d131.s2" text="The clinical significance of these changes is unknown."/>
    <sentence id="DDI-DrugBank.d131.s3" text="Drugs That Inhibit Alprazolam Metabolism Via Cytochrome P450 3A: The initial step in alprazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).">
        <entity id="DDI-DrugBank.d131.s3.e0" charOffset="19-28"
            type="drug" text="Alprazolam"/>
        <entity id="DDI-DrugBank.d131.s3.e1" charOffset="85-94"
            type="drug" text="alprazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d131.s4" text="Drugs which inhibit this metabolic pathway may have a profound effect on the clearance of alprazolam .">
        <entity id="DDI-DrugBank.d131.s4.e0" charOffset="90-99"
            type="drug" text="alprazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d131.s5" text="Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.">
        <entity id="DDI-DrugBank.d131.s5.e0" charOffset="120-129"
            type="drug" text="Alprazolam"/>
        <entity id="DDI-DrugBank.d131.s5.e1" charOffset="184-193"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d131.s5.e2" charOffset="217-226"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d131.s5.e3" charOffset="233-242"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d131.s5.e4" charOffset="290-299"
            type="drug" text="alprazolam"/>
        <ddi id="DDI-DrugBank.d131.s5.d0" e1="DDI-DrugBank.d131.s5.e2"
            e2="DDI-DrugBank.d131.s5.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d131.s6" text="Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.">
        <entity id="DDI-DrugBank.d131.s6.e0" charOffset="20-31"
            type="drug" text="propoxyphene"/>
        <entity id="DDI-DrugBank.d131.s6.e1" charOffset="79-88"
            type="drug" text="alprazolam"/>
        <ddi id="DDI-DrugBank.d131.s6.d0" e1="DDI-DrugBank.d131.s6.e0"
            e2="DDI-DrugBank.d131.s6.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d131.s7" text="Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.">
        <entity id="DDI-DrugBank.d131.s7.e0" charOffset="25-38"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d131.s7.e1" charOffset="86-95"
            type="drug" text="alprazolam"/>
        <ddi id="DDI-DrugBank.d131.s7.d0" e1="DDI-DrugBank.d131.s7.e0"
            e2="DDI-DrugBank.d131.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d131.s8" text="Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.">
        <entity id="DDI-DrugBank.d131.s8.e0" charOffset="107-121"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d131.s8.e1" charOffset="148-157"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d131.s8.e2" charOffset="200-209"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d131.s8.e3" charOffset="220-234"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d131.s8.e4" charOffset="289-298"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d131.s8.e5" charOffset="342-356"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d131.s8.e6" charOffset="369-378"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d131.s8.e7" charOffset="421-430"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d131.s8.e8" charOffset="451-459"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d131.s8.e9" charOffset="462-470"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d131.s8.e10" charOffset="473-493"
            type="group" text="macrolide antibiotics"/>
        <entity id="DDI-DrugBank.d131.s8.e11" charOffset="503-514"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d131.s8.e12" charOffset="520-533"
            type="drug" text="clarithromycin"/>
        <ddi id="DDI-DrugBank.d131.s8.d0" e1="DDI-DrugBank.d131.s8.e7"
            e2="DDI-DrugBank.d131.s8.e8" type="int"/>
        <ddi id="DDI-DrugBank.d131.s8.d1" e1="DDI-DrugBank.d131.s8.e7"
            e2="DDI-DrugBank.d131.s8.e9" type="int"/>
        <ddi id="DDI-DrugBank.d131.s8.d2" e1="DDI-DrugBank.d131.s8.e7"
            e2="DDI-DrugBank.d131.s8.e10" type="int"/>
        <ddi id="DDI-DrugBank.d131.s8.d3" e1="DDI-DrugBank.d131.s8.e7"
            e2="DDI-DrugBank.d131.s8.e11" type="int"/>
        <ddi id="DDI-DrugBank.d131.s8.d4" e1="DDI-DrugBank.d131.s8.e7"
            e2="DDI-DrugBank.d131.s8.e12" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d131.s9" text="Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.">
        <entity id="DDI-DrugBank.d131.s9.e0" charOffset="30-39"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d131.s9.e1" charOffset="82-91"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d131.s9.e2" charOffset="112-121"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d131.s9.e3" charOffset="127-136"
            type="drug" text="paroxetine"/>
        <ddi id="DDI-DrugBank.d131.s9.d0" e1="DDI-DrugBank.d131.s9.e1"
            e2="DDI-DrugBank.d131.s9.e2" type="int"/>
        <ddi id="DDI-DrugBank.d131.s9.d1" e1="DDI-DrugBank.d131.s9.e1"
            e2="DDI-DrugBank.d131.s9.e3" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d131.s10" text="Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.">
        <entity id="DDI-DrugBank.d131.s10.e0" charOffset="30-44"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d131.s10.e1" charOffset="57-66"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d131.s10.e2" charOffset="123-132"
            type="drug" text="ergotamine"/>
        <entity id="DDI-DrugBank.d131.s10.e3" charOffset="135-146"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d131.s10.e4" charOffset="149-158"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d131.s10.e5" charOffset="161-171"
            type="drug" text="nicardipine"/>
        <entity id="DDI-DrugBank.d131.s10.e6" charOffset="178-187"
            type="drug" text="nifedipine"/>
        <ddi id="DDI-DrugBank.d131.s10.d0" e1="DDI-DrugBank.d131.s10.e0"
            e2="DDI-DrugBank.d131.s10.e2" type="int"/>
        <ddi id="DDI-DrugBank.d131.s10.d1" e1="DDI-DrugBank.d131.s10.e0"
            e2="DDI-DrugBank.d131.s10.e3" type="int"/>
        <ddi id="DDI-DrugBank.d131.s10.d2" e1="DDI-DrugBank.d131.s10.e0"
            e2="DDI-DrugBank.d131.s10.e4" type="int"/>
        <ddi id="DDI-DrugBank.d131.s10.d3" e1="DDI-DrugBank.d131.s10.e0"
            e2="DDI-DrugBank.d131.s10.e5" type="int"/>
        <ddi id="DDI-DrugBank.d131.s10.d4" e1="DDI-DrugBank.d131.s10.e0"
            e2="DDI-DrugBank.d131.s10.e6" type="int"/>
        <ddi id="DDI-DrugBank.d131.s10.d5" e1="DDI-DrugBank.d131.s10.e1"
            e2="DDI-DrugBank.d131.s10.e2" type="int"/>
        <ddi id="DDI-DrugBank.d131.s10.d6" e1="DDI-DrugBank.d131.s10.e1"
            e2="DDI-DrugBank.d131.s10.e3" type="int"/>
        <ddi id="DDI-DrugBank.d131.s10.d7" e1="DDI-DrugBank.d131.s10.e1"
            e2="DDI-DrugBank.d131.s10.e4" type="int"/>
        <ddi id="DDI-DrugBank.d131.s10.d8" e1="DDI-DrugBank.d131.s10.e1"
            e2="DDI-DrugBank.d131.s10.e5" type="int"/>
        <ddi id="DDI-DrugBank.d131.s10.d9" e1="DDI-DrugBank.d131.s10.e1"
            e2="DDI-DrugBank.d131.s10.e6" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d131.s11" text="Caution is recommended during the coadministration of any of these with alprazolam.">
        <entity id="DDI-DrugBank.d131.s11.e0" charOffset="72-81"
            type="drug" text="alprazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d290.s0" text="No drug interactions have been reported between Prostin VR Pediatric and the therapy standard in neonates with restricted pulmonary or systemic blood flow.">
        <entity id="DDI-DrugBank.d290.s0.e0" charOffset="48-67"
            type="brand" text="Prostin VR Pediatric"/>
    </sentence>
    <sentence id="DDI-DrugBank.d290.s1" text="Standard therapy includes antibiotics, such as penicillin and gentamicin;">
        <entity id="DDI-DrugBank.d290.s1.e0" charOffset="26-36"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d290.s1.e1" charOffset="47-56"
            type="drug" text="penicillin"/>
        <entity id="DDI-DrugBank.d290.s1.e2" charOffset="62-71"
            type="drug" text="gentamicin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d290.s2" text="vasopressors, such as dopamine and isoproterenol;">
        <entity id="DDI-DrugBank.d290.s2.e0" charOffset="0-11"
            type="group" text="vasopressors"/>
        <entity id="DDI-DrugBank.d290.s2.e1" charOffset="22-29"
            type="drug" text="dopamine"/>
        <entity id="DDI-DrugBank.d290.s2.e2" charOffset="35-47"
            type="drug" text="isoproterenol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d290.s3" text="cardiac glycosides;">
        <entity id="DDI-DrugBank.d290.s3.e0" charOffset="0-17"
            type="group" text="cardiac glycosides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d290.s4" text="and diuretics, such as furosemide.">
        <entity id="DDI-DrugBank.d290.s4.e0" charOffset="4-12"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d290.s4.e1" charOffset="23-32"
            type="drug" text="furosemide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d290.s5" text="Caverject: The potential for pharmacokinetic drug-drug interactions between alprostadil and other agents has not been formally studied.">
        <entity id="DDI-DrugBank.d290.s5.e0" charOffset="0-8"
            type="brand" text="Caverject"/>
        <entity id="DDI-DrugBank.d290.s5.e1" charOffset="76-86"
            type="drug" text="alprostadil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d508.s0" text="The interaction of Activase with other cardioactive or cerebroactive drugs has not been studied.">
        <entity id="DDI-DrugBank.d508.s0.e0" charOffset="19-26"
            type="brand" text="Activase"/>
    </sentence>
    <sentence id="DDI-DrugBank.d508.s1" text="In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.">
        <entity id="DDI-DrugBank.d508.s1.e0" charOffset="40-46"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d508.s1.e1" charOffset="52-72"
            type="group" text="vitamin K antagonists"/>
        <entity id="DDI-DrugBank.d508.s1.e2" charOffset="119-138"
            type="drug" text="acetylsalicylic acid"/>
        <entity id="DDI-DrugBank.d508.s1.e3" charOffset="141-152"
            type="drug" text="dipyridamole"/>
        <entity id="DDI-DrugBank.d508.s1.e4" charOffset="158-166"
            type="drug" text="Abciximab"/>
        <entity id="DDI-DrugBank.d508.s1.e5" charOffset="246-253"
            type="brand" text="Activase"/>
        <ddi id="DDI-DrugBank.d508.s1.d0" e1="DDI-DrugBank.d508.s1.e0"
            e2="DDI-DrugBank.d508.s1.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d508.s1.d1" e1="DDI-DrugBank.d508.s1.e1"
            e2="DDI-DrugBank.d508.s1.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d508.s1.d2" e1="DDI-DrugBank.d508.s1.e2"
            e2="DDI-DrugBank.d508.s1.e5" type="int"/>
        <ddi id="DDI-DrugBank.d508.s1.d3" e1="DDI-DrugBank.d508.s1.e3"
            e2="DDI-DrugBank.d508.s1.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d508.s1.d4" e1="DDI-DrugBank.d508.s1.e4"
            e2="DDI-DrugBank.d508.s1.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d508.s2" text="Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.">
        <entity id="DDI-DrugBank.d508.s2.e0" charOffset="7-21"
            type="group" text="Antithrombotics"/>
        <entity id="DDI-DrugBank.d508.s2.e1" charOffset="23-29"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d508.s2.e2" charOffset="35-41"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d508.s2.e3" charOffset="112-119"
            type="brand" text="Activase"/>
    </sentence>
    <sentence id="DDI-DrugBank.d508.s3" text="Because heparin, aspirin, or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.">
        <entity id="DDI-DrugBank.d508.s3.e0" charOffset="8-14"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d508.s3.e1" charOffset="17-23"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d508.s3.e2" charOffset="29-36"
            type="brand" text="Activase"/>
    </sentence>
    <sentence id="DDI-DrugBank.d508.s4" text="The concomitant use of heparin or aspirin during the first 24 hours following symptom onset were prohibited in The NINDS t-PA Stroke Trial.">
        <entity id="DDI-DrugBank.d508.s4.e0" charOffset="23-29"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d508.s4.e1" charOffset="34-40"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d508.s5" text="The safety of such concomitant use with Activase for the management of acute ischemic stroke is unknown.">
        <entity id="DDI-DrugBank.d508.s5.e0" charOffset="40-47"
            type="brand" text="Activase"/>
    </sentence>
    <sentence id="DDI-DrugBank.d188.s0" text="Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.">
        <entity id="DDI-DrugBank.d188.s0.e0" charOffset="29-35"
            type="brand" text="HEXALEN"/>
        <entity id="DDI-DrugBank.d188.s0.e1" charOffset="41-82"
            type="group" text="antidepressants of the MAO inhibitor class"/>
        <entity id="DDI-DrugBank.d188.s0.e2" charOffset="125-134"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d188.s0.e3" charOffset="191-201"
            type="drug" text="altretamine"/>
        <ddi id="DDI-DrugBank.d188.s0.d0" e1="DDI-DrugBank.d188.s0.e0"
            e2="DDI-DrugBank.d188.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d188.s0.d1" e1="DDI-DrugBank.d188.s0.e2"
            e2="DDI-DrugBank.d188.s0.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d188.s1" text="Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;">
        <entity id="DDI-DrugBank.d188.s1.e0" charOffset="32-38"
            type="brand" text="HEXALEN"/>
        <entity id="DDI-DrugBank.d188.s1.e1" charOffset="44-52"
            type="drug" text="cisplatin"/>
        <entity id="DDI-DrugBank.d188.s1.e2" charOffset="68-77"
            type="drug" text="pyridoxine"/>
        <entity id="DDI-DrugBank.d188.s1.e3" charOffset="112-121"
            type="drug" text="pyridoxine"/>
        <ddi id="DDI-DrugBank.d188.s1.d0" e1="DDI-DrugBank.d188.s1.e0"
            e2="DDI-DrugBank.d188.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d188.s2" text="however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1">
        <entity id="DDI-DrugBank.d188.s2.e0" charOffset="65-74"
            type="drug" text="pyridoxine"/>
        <entity id="DDI-DrugBank.d188.s2.e1" charOffset="108-114"
            type="brand" text="HEXALEN"/>
        <entity id="DDI-DrugBank.d188.s2.e2" charOffset="123-131"
            type="drug" text="cisplatin"/>
        <ddi id="DDI-DrugBank.d188.s2.d0" e1="DDI-DrugBank.d188.s2.e0"
            e2="DDI-DrugBank.d188.s2.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d188.s2.d1" e1="DDI-DrugBank.d188.s2.e0"
            e2="DDI-DrugBank.d188.s2.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d188.s2.d2" e1="DDI-DrugBank.d188.s2.e0"
            e2="DDI-DrugBank.d188.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d116.s0" text="Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.">
        <entity id="DDI-DrugBank.d116.s0.e0" charOffset="37-46"
            type="drug" text="amantadine"/>
        <entity id="DDI-DrugBank.d116.s0.e1" charOffset="82-114"
            type="group" text="central nervous system stimulants"/>
        <ddi id="DDI-DrugBank.d116.s0.d0" e1="DDI-DrugBank.d116.s0.e0"
            e2="DDI-DrugBank.d116.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d116.s1" text="Coadministration of thioridazine has been reported to worsen the tremor in elderly patients with Parkinsons disease;">
        <entity id="DDI-DrugBank.d116.s1.e0" charOffset="20-31"
            type="drug" text="thioridazine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d116.s2" text="however, it is not known if other phenothiazines produce a similar response.">
        <entity id="DDI-DrugBank.d116.s2.e0" charOffset="34-47"
            type="group" text="phenothiazines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d563.s0" text="Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.">
        <entity id="DDI-DrugBank.d563.s0.e0" charOffset="63-68"
            type="brand" text="ETHYOL"/>
        <entity id="DDI-DrugBank.d563.s0.e1" charOffset="92-119"
            type="group" text="antihypertensive medications"/>
        <ddi id="DDI-DrugBank.d563.s0.d0" e1="DDI-DrugBank.d563.s0.e0"
            e2="DDI-DrugBank.d563.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d356.s0" text="When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.">
        <entity id="DDI-DrugBank.d356.s0.e0" charOffset="5-13"
            type="drug" text="amiloride"/>
        <entity id="DDI-DrugBank.d356.s0.e1" charOffset="57-95"
            type="group" text="angiotensin-converting enzyme inhibitor"/>
        <ddi id="DDI-DrugBank.d356.s0.d0" e1="DDI-DrugBank.d356.s0.e0"
            e2="DDI-DrugBank.d356.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d356.s1" text="Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium."/>
    <sentence id="DDI-DrugBank.d356.s2" text="Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.">
        <entity id="DDI-DrugBank.d356.s2.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d356.s2.e1" charOffset="43-51"
            type="group" text="diuretics"/>
        <ddi id="DDI-DrugBank.d356.s2.d0" e1="DDI-DrugBank.d356.s2.e0"
            e2="DDI-DrugBank.d356.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d356.s3" text="Read circulars for lithium preparations before use of such concomitant therapy.">
        <entity id="DDI-DrugBank.d356.s3.e0" charOffset="19-25"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d356.s4" text="In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.">
        <entity id="DDI-DrugBank.d356.s4.e0" charOffset="42-78"
            type="group" text="non-steroidal anti-inflammatory agent"/>
        <entity id="DDI-DrugBank.d356.s4.e1"
            charOffset="150-153;187-195" type="group" text="loop diuretics"/>
        <entity id="DDI-DrugBank.d356.s4.e2"
            charOffset="156-172;187-195" type="group" text="potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d356.s4.e3" charOffset="178-195"
            type="group" text="thiazide diuretics"/>
        <ddi id="DDI-DrugBank.d356.s4.d0" e1="DDI-DrugBank.d356.s4.e0"
            e2="DDI-DrugBank.d356.s4.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d356.s4.d1" e1="DDI-DrugBank.d356.s4.e0"
            e2="DDI-DrugBank.d356.s4.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d356.s4.d2" e1="DDI-DrugBank.d356.s4.e0"
            e2="DDI-DrugBank.d356.s4.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d356.s5" text="Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.">
        <entity id="DDI-DrugBank.d356.s5.e0" charOffset="16-22"
            type="brand" text="MIDAMOR"/>
        <entity id="DDI-DrugBank.d356.s5.e1" charOffset="28-65"
            type="group" text="non-steroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d356.s5.e2" charOffset="172-179"
            type="group" text="diuretic"/>
        <ddi id="DDI-DrugBank.d356.s5.d0" e1="DDI-DrugBank.d356.s5.e0"
            e2="DDI-DrugBank.d356.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d356.s6" text="Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.">
        <entity id="DDI-DrugBank.d356.s6.e0" charOffset="6-17"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d356.s6.e1" charOffset="23-49"
            type="group" text="potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d356.s6.e2" charOffset="62-68"
            type="brand" text="MIDAMOR"/>
        <ddi id="DDI-DrugBank.d356.s6.d0" e1="DDI-DrugBank.d356.s6.e0"
            e2="DDI-DrugBank.d356.s6.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d356.s6.d1" e1="DDI-DrugBank.d356.s6.e0"
            e2="DDI-DrugBank.d356.s6.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d553.s0" text="Drug Laboratory Test Interactions: Prolongation of the template bleeding time has been reported during continuous intravenous infusion of AMICAR at dosages exceeding 24 g/day.">
        <entity id="DDI-DrugBank.d553.s0.e0" charOffset="138-143"
            type="brand" text="AMICAR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d553.s1" text="Platelet function studies in these patients have not demonstrated any significant platelet dysfunction."/>
    <sentence id="DDI-DrugBank.d553.s2" text="However, in vitro studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) EACA inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner.">
        <entity id="DDI-DrugBank.d553.s2.e0" charOffset="104-107"
            type="drug" text="EACA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d553.s3" text="Following a 10 g bolus of AMICAR, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained.">
        <entity id="DDI-DrugBank.d553.s3.e0" charOffset="26-31"
            type="brand" text="AMICAR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d553.s4" text="The concentration of AMICAR necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL.">
        <entity id="DDI-DrugBank.d553.s4.e0" charOffset="21-26"
            type="brand" text="AMICAR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d553.s5" text="Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL."/>
    <sentence id="DDI-DrugBank.d553.s6" text="Thus, concentrations which have been obtained in vivo clinically in patients with normal renal function are considerably lower than the in vitro concentrations found to induce abnormalities in platelet function tests."/>
    <sentence id="DDI-DrugBank.d553.s7" text="However, higher plasma concentrations of AMICAR may occur in patients with severe renal failure.">
        <entity id="DDI-DrugBank.d553.s7.e0" charOffset="41-46"
            type="brand" text="AMICAR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d372.s0" text="Cytadren accelerates the metabolism of dexamethasone;">
        <entity id="DDI-DrugBank.d372.s0.e0" charOffset="0-7"
            type="brand" text="Cytadren"/>
        <entity id="DDI-DrugBank.d372.s0.e1" charOffset="39-51"
            type="drug" text="dexamethasone"/>
        <ddi id="DDI-DrugBank.d372.s0.d0" e1="DDI-DrugBank.d372.s0.e0"
            e2="DDI-DrugBank.d372.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d372.s1" text="therefore, if glucocorticoid replacement is needed, hydrocortisone should be prescribed.">
        <entity id="DDI-DrugBank.d372.s1.e0" charOffset="14-27"
            type="group" text="glucocorticoid"/>
        <entity id="DDI-DrugBank.d372.s1.e1" charOffset="52-65"
            type="drug" text="hydrocortisone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d372.s2" text="Aminoglutethimide diminishes the effect of coumarin and warfarin.">
        <entity id="DDI-DrugBank.d372.s2.e0" charOffset="0-16"
            type="drug" text="Aminoglutethimide"/>
        <entity id="DDI-DrugBank.d372.s2.e1" charOffset="43-50"
            type="group" text="coumarin"/>
        <entity id="DDI-DrugBank.d372.s2.e2" charOffset="56-63"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d372.s2.d0" e1="DDI-DrugBank.d372.s2.e0"
            e2="DDI-DrugBank.d372.s2.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d372.s2.d1" e1="DDI-DrugBank.d372.s2.e0"
            e2="DDI-DrugBank.d372.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d416.s0" text="Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.">
        <entity id="DDI-DrugBank.d416.s0.e0" charOffset="32-34"
            type="drug" text="PAH"/>
        <entity id="DDI-DrugBank.d416.s0.e1" charOffset="103-114"
            type="group" text="sulfonamides"/>
        <entity id="DDI-DrugBank.d416.s0.e2" charOffset="117-124"
            type="drug" text="procaine"/>
        <entity id="DDI-DrugBank.d416.s0.e3" charOffset="130-144"
            type="drug" text="thiazolesulfone"/>
        <ddi id="DDI-DrugBank.d416.s0.d0" e1="DDI-DrugBank.d416.s0.e0"
            e2="DDI-DrugBank.d416.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d416.s0.d1" e1="DDI-DrugBank.d416.s0.e0"
            e2="DDI-DrugBank.d416.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d416.s0.d2" e1="DDI-DrugBank.d416.s0.e0"
            e2="DDI-DrugBank.d416.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d416.s1" text="These compounds interfere with chemical color development essential to the analytical procedures."/>
    <sentence id="DDI-DrugBank.d416.s2" text="Probenecid depresses tubular secretion of certain weak acids such as PAH.">
        <entity id="DDI-DrugBank.d416.s2.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d416.s2.e1" charOffset="69-71"
            type="drug" text="PAH"/>
        <ddi id="DDI-DrugBank.d416.s2.d0" e1="DDI-DrugBank.d416.s2.e0"
            e2="DDI-DrugBank.d416.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d416.s3" text="Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.">
        <entity id="DDI-DrugBank.d416.s3.e0" charOffset="30-39"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d416.s3.e1" charOffset="79-81"
            type="drug" text="PAH"/>
        <ddi id="DDI-DrugBank.d416.s3.d0" e1="DDI-DrugBank.d416.s3.e0"
            e2="DDI-DrugBank.d416.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d379.s0" text="There have been no formal studies of the interaction of LEVULAN KERASTICK for Topical Solution with any other drugs, and no drug-specific interactions were noted during any of the controlled clinical trials.">
        <entity id="DDI-DrugBank.d379.s0.e0" charOffset="56-72"
            type="brand" text="LEVULAN KERASTICK"/>
    </sentence>
    <sentence id="DDI-DrugBank.d379.s1" text="It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.">
        <entity id="DDI-DrugBank.d379.s1.e0" charOffset="61-83"
            type="group" text="photosensitizing agents"/>
        <entity id="DDI-DrugBank.d379.s1.e1" charOffset="93-104"
            type="drug" text="griseofulvin"/>
        <entity id="DDI-DrugBank.d379.s1.e2" charOffset="107-124"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d379.s1.e3" charOffset="127-139"
            type="group" text="sulfonylureas"/>
        <entity id="DDI-DrugBank.d379.s1.e4" charOffset="142-155"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d379.s1.e5" charOffset="158-169"
            type="group" text="sulfonamides"/>
        <entity id="DDI-DrugBank.d379.s1.e6" charOffset="175-187"
            type="group" text="tetracyclines"/>
        <entity id="DDI-DrugBank.d379.s1.e7" charOffset="272-288"
            type="brand" text="LEVULAN KERASTICK"/>
        <ddi id="DDI-DrugBank.d379.s1.d0" e1="DDI-DrugBank.d379.s1.e0"
            e2="DDI-DrugBank.d379.s1.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d379.s1.d1" e1="DDI-DrugBank.d379.s1.e1"
            e2="DDI-DrugBank.d379.s1.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d379.s1.d2" e1="DDI-DrugBank.d379.s1.e2"
            e2="DDI-DrugBank.d379.s1.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d379.s1.d3" e1="DDI-DrugBank.d379.s1.e3"
            e2="DDI-DrugBank.d379.s1.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d379.s1.d4" e1="DDI-DrugBank.d379.s1.e4"
            e2="DDI-DrugBank.d379.s1.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d379.s1.d5" e1="DDI-DrugBank.d379.s1.e5"
            e2="DDI-DrugBank.d379.s1.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d379.s1.d6" e1="DDI-DrugBank.d379.s1.e6"
            e2="DDI-DrugBank.d379.s1.e7" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d22.s0" text="Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.">
        <entity id="DDI-DrugBank.d22.s0.e0" charOffset="0-18"
            type="drug" text="Aminosalicylic acid"/>
        <entity id="DDI-DrugBank.d22.s0.e1" charOffset="47-53"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d22.s0.e2" charOffset="56-62"
            type="brand" text="Lanoxin"/>
        <entity id="DDI-DrugBank.d22.s0.e3" charOffset="65-74"
            type="drug" text="Lanoxicaps"/>
        <ddi id="DDI-DrugBank.d22.s0.d0" e1="DDI-DrugBank.d22.s0.e0"
            e2="DDI-DrugBank.d22.s0.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d22.s0.d1" e1="DDI-DrugBank.d22.s0.e0"
            e2="DDI-DrugBank.d22.s0.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d22.s0.d2" e1="DDI-DrugBank.d22.s0.e0"
            e2="DDI-DrugBank.d22.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d22.s1" text="In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.">
        <entity id="DDI-DrugBank.d22.s1.e0" charOffset="32-38"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d22.s1.e1" charOffset="53-71"
            type="drug" text="aminosalicylic acid"/>
        <entity id="DDI-DrugBank.d22.s1.e2" charOffset="90-96"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d22.s1.d0" e1="DDI-DrugBank.d22.s1.e0"
            e2="DDI-DrugBank.d22.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d22.s2" text="Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.">
        <entity id="DDI-DrugBank.d22.s2.e0" charOffset="0-18"
            type="drug" text="Aminosalicylic acid"/>
        <entity id="DDI-DrugBank.d22.s2.e1" charOffset="56-66"
            type="drug" text="vitamin B12"/>
        <ddi id="DDI-DrugBank.d22.s2.d0" e1="DDI-DrugBank.d22.s2.e0"
            e2="DDI-DrugBank.d22.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d22.s3" text="Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.">
        <entity id="DDI-DrugBank.d22.s3.e0" charOffset="33-43"
            type="drug" text="vitamin B12"/>
        <entity id="DDI-DrugBank.d22.s3.e1" charOffset="69-87"
            type="drug" text="aminosalicylic acid"/>
        <ddi id="DDI-DrugBank.d22.s3.d0" e1="DDI-DrugBank.d22.s3.e0"
            e2="DDI-DrugBank.d22.s3.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s0" text="Amiodarone is metabolized to desethylamiodarone by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.">
        <entity id="DDI-DrugBank.d143.s0.e0" charOffset="0-9"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d143.s0.e1" charOffset="29-46"
            type="drug" text="desethylamiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s1" text="The CYP3A4 isoenzyme is present in both the liver and intestines."/>
    <sentence id="DDI-DrugBank.d143.s2" text="Amiodarone is also known to be an inhibitor of CYP3A4.">
        <entity id="DDI-DrugBank.d143.s2.e0" charOffset="0-9"
            type="drug" text="Amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s3" text="Therefore, amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP3A4.">
        <entity id="DDI-DrugBank.d143.s3.e0" charOffset="11-20"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s4" text="While only a limited number of in vivo drug-drug interactions with amiodarone have been reported, chiefly with the oral formulation, the potential for other interactions should be anticipated.">
        <entity id="DDI-DrugBank.d143.s4.e0" charOffset="67-76"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s5" text="This is especially important for drugs associated with serious toxicity, such as other antiarrhythmics.">
        <entity id="DDI-DrugBank.d143.s5.e0" charOffset="87-101"
            type="group" text="antiarrhythmics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s6" text="If such drugs are needed, their dose should be reassessed and, where appropriate, plasma concentration measured."/>
    <sentence id="DDI-DrugBank.d143.s7" text="In view of the long and variable half-life of amiodarone, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of amiodarone.">
        <entity id="DDI-DrugBank.d143.s7.e0" charOffset="46-55"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s7.e1" charOffset="192-201"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s8" text="Since amiodarone is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone.">
        <entity id="DDI-DrugBank.d143.s8.e0" charOffset="6-15"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s8.e1" charOffset="166-175"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s9" text="Reported examples include the following: Protease Inhibitors: Protease inhibitors are known to inhibit CYP3A4 to varying degrees.">
        <entity id="DDI-DrugBank.d143.s9.e0" charOffset="41-59"
            type="group" text="Protease Inhibitors"/>
        <entity id="DDI-DrugBank.d143.s9.e1" charOffset="62-80"
            type="group" text="Protease inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s10" text="A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.">
        <entity id="DDI-DrugBank.d143.s10.e0" charOffset="36-45"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s10.e1" charOffset="58-66"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d143.s10.e2" charOffset="118-127"
            type="drug" text="amiodarone"/>
        <ddi id="DDI-DrugBank.d143.s10.d0" e1="DDI-DrugBank.d143.s10.e0"
            e2="DDI-DrugBank.d143.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s11" text="DEA concentrations were not affected."/>
    <sentence id="DDI-DrugBank.d143.s12" text="There was no evidence of toxicity."/>
    <sentence id="DDI-DrugBank.d143.s13" text="Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.">
        <entity id="DDI-DrugBank.d143.s13.e0" charOffset="15-24"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s13.e1" charOffset="61-70"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s13.e2" charOffset="111-128"
            type="group" text="protease inhibitor"/>
        <ddi id="DDI-DrugBank.d143.s13.d0" e1="DDI-DrugBank.d143.s13.e1"
            e2="DDI-DrugBank.d143.s13.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s14" text="Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.">
        <entity id="DDI-DrugBank.d143.s14.e0" charOffset="0-23"
            type="group" text="Histamine H2 antagonists"/>
        <entity id="DDI-DrugBank.d143.s14.e1" charOffset="26-35"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d143.s14.e2" charOffset="76-85"
            type="drug" text="amiodarone"/>
        <ddi id="DDI-DrugBank.d143.s14.d0" e1="DDI-DrugBank.d143.s14.e0"
            e2="DDI-DrugBank.d143.s14.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s15" text="Other substances: Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone.">
        <entity id="DDI-DrugBank.d143.s15.e0" charOffset="73-82"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s15.e1" charOffset="152-161"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s16" text="Grapefruit juice should not be taken during treatment with oral amiodarone."/>
    <sentence id="DDI-DrugBank.d143.s17" text="This information should be considered when changing from intravenous amiodarone to oral amiodarone .">
        <entity id="DDI-DrugBank.d143.s17.e0" charOffset="69-78"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s17.e1" charOffset="88-97"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s18" text="Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4.">
        <entity id="DDI-DrugBank.d143.s18.e0" charOffset="0-9"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d143.s18.e1" charOffset="58-63"
            type="drug" text="CYP1A2"/>
        <entity id="DDI-DrugBank.d143.s18.e2" charOffset="66-71"
            type="drug" text="CYP2C9"/>
        <entity id="DDI-DrugBank.d143.s18.e3" charOffset="74-79"
            type="drug" text="CYP2D6"/>
        <entity id="DDI-DrugBank.d143.s18.e4" charOffset="86-91"
            type="drug" text="CYP3A4"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s19" text="This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes.">
        <entity id="DDI-DrugBank.d143.s19.e0" charOffset="71-75"
            type="drug" text="drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s20" text="Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.">
        <entity id="DDI-DrugBank.d143.s20.e0" charOffset="61-77"
            type="drug" text="Immunosuppressive"/>
        <entity id="DDI-DrugBank.d143.s20.e1" charOffset="81-92"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d143.s20.e2" charOffset="95-100"
            type="drug" text="CYP3A4"/>
        <entity id="DDI-DrugBank.d143.s20.e3" charOffset="151-160"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s20.e4" charOffset="238-249"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d143.s20.e5" charOffset="314-325"
            type="drug" text="cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s21" text="HMG-CoA Reductase Inhibitors: Simvastatin (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.">
        <entity id="DDI-DrugBank.d143.s21.e0" charOffset="0-27"
            type="drug" text="HMG-CoA Reductase Inhibitors"/>
        <entity id="DDI-DrugBank.d143.s21.e1" charOffset="30-40"
            type="drug" text="Simvastatin"/>
        <entity id="DDI-DrugBank.d143.s21.e2" charOffset="43-48"
            type="drug" text="CYP3A4"/>
        <entity id="DDI-DrugBank.d143.s21.e3" charOffset="81-90"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s22" text="Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.">
        <entity id="DDI-DrugBank.d143.s22.e0" charOffset="17-34"
            type="drug" text="Cardiac glycosides"/>
        <entity id="DDI-DrugBank.d143.s22.e1" charOffset="59-65"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d143.s22.e2" charOffset="99-108"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s22.e3" charOffset="152-158"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s23" text="Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day.">
        <entity id="DDI-DrugBank.d143.s23.e0" charOffset="0-9"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d143.s23.e1" charOffset="36-42"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d143.s23.e2" charOffset="64-70"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s24" text="On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.">
        <entity id="DDI-DrugBank.d143.s24.e0" charOffset="26-35"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s24.e1" charOffset="51-59"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d143.s24.d0" e1="DDI-DrugBank.d143.s24.e0"
            e2="DDI-DrugBank.d143.s24.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s25" text="If digitalis treatment is continued, serum levels should be closely monitored and patients observed for clinical evidence of toxicity.">
        <entity id="DDI-DrugBank.d143.s25.e0" charOffset="3-11"
            type="drug" text="digitalis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s26" text="These precautions probably should apply to digitoxin administration as well.">
        <entity id="DDI-DrugBank.d143.s26.e0" charOffset="43-51"
            type="drug" text="digitoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s27" text="Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.">
        <entity id="DDI-DrugBank.d143.s27.e0" charOffset="0-14"
            type="drug" text="Antiarrhythmics"/>
        <entity id="DDI-DrugBank.d143.s27.e1" charOffset="23-36"
            type="drug" text="antiarrhythmic"/>
        <entity id="DDI-DrugBank.d143.s27.e2" charOffset="53-61"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d143.s27.e3" charOffset="64-75"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d143.s27.e4" charOffset="78-89"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d143.s27.e5" charOffset="96-104"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d143.s27.e6" charOffset="140-149"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s28" text="There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone.">
        <entity id="DDI-DrugBank.d143.s28.e0" charOffset="65-73"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d143.s28.e1" charOffset="76-87"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d143.s28.e2" charOffset="94-102"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d143.s28.e3" charOffset="136-145"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s29" text="Phenytoin decreases serum amiodarone levels.">
        <entity id="DDI-DrugBank.d143.s29.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s30" text="Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days.">
        <entity id="DDI-DrugBank.d143.s30.e0" charOffset="0-9"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d143.s30.e1" charOffset="36-44"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d143.s30.e2" charOffset="56-64"
            type="drug" text="quinidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s31" text="Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.">
        <entity id="DDI-DrugBank.d143.s31.e0" charOffset="0-9"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d143.s31.e1" charOffset="36-47"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d143.s31.e2" charOffset="109-120"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d143.s31.e3" charOffset="135-146"
            type="drug" text="procainamide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s32" text="Quinidine and procainamide doses should be reduced by one-third when either is administered with amiodarone.">
        <entity id="DDI-DrugBank.d143.s32.e0" charOffset="0-8"
            type="drug" text="Quinidine"/>
        <entity id="DDI-DrugBank.d143.s32.e1" charOffset="97-106"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s33" text="Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone;">
        <entity id="DDI-DrugBank.d143.s33.e0" charOffset="17-26"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d143.s33.e1" charOffset="83-92"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s34" text="because of this, the dosage of flecainide should be adjusted when these drugs are administered concomitantly.">
        <entity id="DDI-DrugBank.d143.s34.e0" charOffset="31-40"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d143.s34.e1" charOffset="72-76"
            type="drug" text="drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s35" text="In general, any added antiarrhythmic drug should be initiated at a lower than usual dose with careful monitoring.">
        <entity id="DDI-DrugBank.d143.s35.e0" charOffset="22-40"
            type="drug" text="antiarrhythmic drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s36" text="Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.">
        <entity id="DDI-DrugBank.d143.s36.e0" charOffset="15-24"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s36.e1" charOffset="37-50"
            type="drug" text="antiarrhythmic"/>
        <entity id="DDI-DrugBank.d143.s36.e2" charOffset="218-227"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s37" text="During transfer to oral amiodarone, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral amiodarone.">
        <entity id="DDI-DrugBank.d143.s37.e0" charOffset="24-33"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s37.e1" charOffset="157-166"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s38" text="The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted.">
        <entity id="DDI-DrugBank.d143.s38.e0" charOffset="33-46"
            type="drug" text="antiarrhythmic"/>
        <entity id="DDI-DrugBank.d143.s38.e1" charOffset="94-103"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s39" text="If the treatment is continued, these patients should be particularly carefully monitored for adverse effects, especially conduction disturbances and exacerbation of tachyarrhythmias, as amiodarone is continued.">
        <entity id="DDI-DrugBank.d143.s39.e0" charOffset="186-195"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s40" text="In amiodarone-treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.">
        <entity id="DDI-DrugBank.d143.s40.e0" charOffset="3-12"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s40.e1" charOffset="54-67"
            type="drug" text="antiarrhythmic"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s41" text="Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;">
        <entity id="DDI-DrugBank.d143.s41.e0" charOffset="0-16"
            type="drug" text="Antihypertensives"/>
        <entity id="DDI-DrugBank.d143.s41.e1" charOffset="19-28"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d143.s41.e2" charOffset="82-89"
            type="drug" text="receptor"/>
        <entity id="DDI-DrugBank.d143.s41.e3" charOffset="114-124"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d143.s41.e4" charOffset="129-134"
            type="drug" text="CYP3A4"/>
        <entity id="DDI-DrugBank.d143.s41.e5" charOffset="150-164"
            type="drug" text="calcium channel"/>
        <entity id="DDI-DrugBank.d143.s41.e6" charOffset="185-193"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d143.s41.e7" charOffset="198-203"
            type="drug" text="CYP3A4"/>
        <entity id="DDI-DrugBank.d143.s41.e8" charOffset="220-228"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d143.s41.e9" charOffset="233-238"
            type="drug" text="CYP3A4"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s42" text="if necessary, amiodarone can continue to be used after insertion of a pacemaker in patients with severe bradycardia or sinus arrest.">
        <entity id="DDI-DrugBank.d143.s42.e0" charOffset="14-23"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s43" text="Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.">
        <entity id="DDI-DrugBank.d143.s43.e0" charOffset="0-13"
            type="drug" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d143.s43.e1" charOffset="32-39"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d143.s43.e2" charOffset="47-52"
            type="drug" text="CYP2C9"/>
        <entity id="DDI-DrugBank.d143.s43.e3" charOffset="58-63"
            type="drug" text="CYP3A4"/>
        <entity id="DDI-DrugBank.d143.s43.e4" charOffset="76-88"
            type="drug" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d143.s43.e5" charOffset="143-152"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s44" text="Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.">
        <entity id="DDI-DrugBank.d143.s44.e0" charOffset="40-47"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d143.s44.e1" charOffset="54-63"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s44.e2" charOffset="139-151"
            type="drug" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s45" text="Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).">
        <entity id="DDI-DrugBank.d143.s45.e0" charOffset="5-9"
            type="drug" text="drugs"/>
        <entity id="DDI-DrugBank.d143.s45.e1" charOffset="64-73"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s45.e2" charOffset="107-112"
            type="drug" text="CYP3A4"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s46" text="This may lead to low amiodarone serum levels and potential decrease in efficacy.">
        <entity id="DDI-DrugBank.d143.s46.e0" charOffset="21-30"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s47" text="Reported examples of this interaction include the following: Antibiotics: Rifampin is a potent inducer of CYP3A4.">
        <entity id="DDI-DrugBank.d143.s47.e0" charOffset="61-71"
            type="drug" text="Antibiotics"/>
        <entity id="DDI-DrugBank.d143.s47.e1" charOffset="74-81"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d143.s47.e2" charOffset="106-111"
            type="drug" text="CYP3A4"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s48" text="Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.">
        <entity id="DDI-DrugBank.d143.s48.e0" charOffset="18-25"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d143.s48.e1" charOffset="51-60"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s48.e2" charOffset="127-136"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s48.e3" charOffset="142-159"
            type="drug" text="desethylamiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s49" text="Other substances, including herbal preparations: St. John s Wort (Hypericum perforatum) induces CYP3A4."/>
    <sentence id="DDI-DrugBank.d143.s50" text="Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.">
        <entity id="DDI-DrugBank.d143.s50.e0" charOffset="6-15"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s50.e1" charOffset="36-41"
            type="drug" text="CYP3A4"/>
        <entity id="DDI-DrugBank.d143.s50.e2" charOffset="121-130"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s50.e3" charOffset="156-165"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s51" text="Other reported interactions with amiodarone: Fentanyl (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.">
        <entity id="DDI-DrugBank.d143.s51.e0" charOffset="33-42"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s51.e1" charOffset="45-52"
            type="drug" text="Fentanyl"/>
        <entity id="DDI-DrugBank.d143.s51.e2" charOffset="55-60"
            type="drug" text="CYP3A4"/>
        <entity id="DDI-DrugBank.d143.s51.e3" charOffset="93-102"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s52" text="Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (CYP3A4 substrate) given for local anesthesia.">
        <entity id="DDI-DrugBank.d143.s52.e0" charOffset="46-55"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s52.e1" charOffset="77-85"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d143.s52.e2" charOffset="88-93"
            type="drug" text="CYP3A4"/>
        <entity id="DDI-DrugBank.d143.s52.e3" charOffset="122-131"
            type="drug" text="anesthesia"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s53" text="Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone.">
        <entity id="DDI-DrugBank.d143.s53.e0" charOffset="35-43"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d143.s53.e1" charOffset="126-135"
            type="drug" text="amiodarone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s54" text="Dextromethorphan is a substrate for both CYP2D6 and CYP3A4.">
        <entity id="DDI-DrugBank.d143.s54.e0" charOffset="0-15"
            type="drug" text="Dextromethorphan"/>
        <entity id="DDI-DrugBank.d143.s54.e1" charOffset="41-46"
            type="drug" text="CYP2D6"/>
        <entity id="DDI-DrugBank.d143.s54.e2" charOffset="52-57"
            type="drug" text="CYP3A4"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s55" text="Amiodarone inhibits CYP2D6.">
        <entity id="DDI-DrugBank.d143.s55.e0" charOffset="0-9"
            type="drug" text="Amiodarone"/>
        <entity id="DDI-DrugBank.d143.s55.e1" charOffset="20-25"
            type="drug" text="CYP2D6"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s56" text="Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1/2.">
        <entity id="DDI-DrugBank.d143.s56.e0" charOffset="0-13"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d143.s56.e1" charOffset="54-63"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s56.e2" charOffset="101-102"
            type="drug" text="t1"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s57" text="Disopyramide increases QT prolongation which could cause arrhythmia.">
        <entity id="DDI-DrugBank.d143.s57.e0" charOffset="0-11"
            type="drug" text="Disopyramide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s58" text="Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation.">
        <entity id="DDI-DrugBank.d143.s58.e0" charOffset="0-15"
            type="drug" text="Fluoroquinolones"/>
        <entity id="DDI-DrugBank.d143.s58.e1" charOffset="18-38"
            type="drug" text="macrolide antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s59" text="There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly.">
        <entity id="DDI-DrugBank.d143.s59.e0" charOffset="85-94"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d143.s59.e1" charOffset="101-116"
            type="drug" text="fluoroquinolones"/>
        <entity id="DDI-DrugBank.d143.s59.e2" charOffset="119-139"
            type="drug" text="macrolide antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s60" text="Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, diltiazem, and verapamil.">
        <entity id="DDI-DrugBank.d143.s60.e0" charOffset="110-120"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d143.s60.e1" charOffset="123-131"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d143.s60.e2" charOffset="138-146"
            type="drug" text="verapamil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s61" text="Volatile Anesthetic Agents:.">
        <entity id="DDI-DrugBank.d143.s61.e0" charOffset="9-18"
            type="drug" text="Anesthetic"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s62" text="In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, dextromethorphan, and methotrexate.">
        <entity id="DDI-DrugBank.d143.s62.e0" charOffset="70-78"
            type="drug" text="Cordarone"/>
        <entity id="DDI-DrugBank.d143.s62.e1" charOffset="117-125"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d143.s62.e2" charOffset="128-143"
            type="drug" text="dextromethorphan"/>
        <entity id="DDI-DrugBank.d143.s62.e3" charOffset="150-161"
            type="drug" text="methotrexate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s63" text="Electrolyte Disturbances Patients with hypokalemia or hypomagnesemia should have the condition corrected whenever possible before being treated with Cordarone I.V., as these disorders can exaggerate the degree of QTc prolongation and increase the potential for TdP.">
        <entity id="DDI-DrugBank.d143.s63.e0" charOffset="149-162"
            type="drug" text="Cordarone I.V."/>
    </sentence>
    <sentence id="DDI-DrugBank.d143.s64" text="Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics.">
        <entity id="DDI-DrugBank.d143.s64.e0" charOffset="162-170"
            type="drug" text="diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s0" text="Drugs Metabolized by P450 2D6 - The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called poor metabolizers);"/>
    <sentence id="DDI-DrugBank.d99.s1" text="reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available."/>
    <sentence id="DDI-DrugBank.d99.s2" text="Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.">
        <entity id="DDI-DrugBank.d99.s2.e0" charOffset="69-93"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d99.s2.e1" charOffset="96-99"
            type="group" text="TCAs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s3" text="Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).">
        <entity id="DDI-DrugBank.d99.s3.e0" charOffset="163-165"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s4" text="In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers."/>
    <sentence id="DDI-DrugBank.d99.s5" text="An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.">
        <entity id="DDI-DrugBank.d99.s5.e0" charOffset="47-49"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s6" text="The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;">
        <entity id="DDI-DrugBank.d99.s6.e0" charOffset="96-104"
            type="drug" text="quinidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s7" text="cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).">
        <entity id="DDI-DrugBank.d99.s7.e0" charOffset="0-9" type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d99.s7.e1" charOffset="66-80"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d99.s7.e2" charOffset="83-96"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d99.s7.e3" charOffset="107-129"
            type="group" text="Type 1C antiarrhythmics"/>
        <entity id="DDI-DrugBank.d99.s7.e4" charOffset="131-141"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d99.s7.e5" charOffset="147-156"
            type="drug" text="flecainide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s8" text="While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.">
        <entity id="DDI-DrugBank.d99.s8.e0" charOffset="24-52"
            type="group" text="serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d99.s8.e1" charOffset="55-59"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d99.s8.e2" charOffset="69-78"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d99.s8.e3" charOffset="81-90"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d99.s8.e4" charOffset="97-106"
            type="drug" text="paroxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s9" text="The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.">
        <entity id="DDI-DrugBank.d99.s9.e0" charOffset="20-23"
            type="group" text="SSRI"/>
        <entity id="DDI-DrugBank.d99.s9.e1" charOffset="25-27"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d99.s9.e2" charOffset="141-144"
            type="group" text="SSRI"/>
        <ddi id="DDI-DrugBank.d99.s9.d0" e1="DDI-DrugBank.d99.s9.e0"
            e2="DDI-DrugBank.d99.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s10" text="Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.">
        <entity id="DDI-DrugBank.d99.s10.e0" charOffset="62-65"
            type="group" text="TCAs"/>
        <entity id="DDI-DrugBank.d99.s10.e1" charOffset="83-87"
            type="group" text="SSRIs"/>
        <ddi id="DDI-DrugBank.d99.s10.d0" e1="DDI-DrugBank.d99.s10.e0"
            e2="DDI-DrugBank.d99.s10.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s11" text="Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).">
        <entity id="DDI-DrugBank.d99.s11.e0" charOffset="120-129"
            type="drug" text="fluoxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s12" text="Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.">
        <entity id="DDI-DrugBank.d99.s12.e0" charOffset="19-43"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d99.s12.e1" charOffset="156-179"
            type="group" text="tricyclic antidepressant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s13" text="Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.">
        <entity id="DDI-DrugBank.d99.s13.e0" charOffset="98-121"
            type="drug" text="tricyclic antidepressant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s14" text="It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.">
        <entity id="DDI-DrugBank.d99.s14.e0" charOffset="27-29"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d99.s14.e1" charOffset="56-58"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s15" text="Monoamine Oxidase Inhibitors: Guanethidine or similarly acting compounds;">
        <entity id="DDI-DrugBank.d99.s15.e0" charOffset="0-27"
            type="drug" text="Monoamine Oxidase Inhibitors"/>
        <entity id="DDI-DrugBank.d99.s15.e1" charOffset="30-41"
            type="drug" text="Guanethidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s16" text="thyroid medication;">
        <entity id="DDI-DrugBank.d99.s16.e0" charOffset="0-6"
            type="drug" text="thyroid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s17" text="alcohol, barbiturates and other CNS depressants;">
        <entity id="DDI-DrugBank.d99.s17.e0" charOffset="0-6"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d99.s17.e1" charOffset="9-20"
            type="drug" text="barbiturates"/>
        <entity id="DDI-DrugBank.d99.s17.e2" charOffset="32-46"
            type="drug" text="CNS depressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s18" text="and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.">
        <entity id="DDI-DrugBank.d99.s18.e0" charOffset="4-13"
            type="drug" text="disulfiram"/>
        <entity id="DDI-DrugBank.d99.s18.e1" charOffset="20-36"
            type="drug" text="amitriptyline HCl"/>
        <entity id="DDI-DrugBank.d99.s18.e2" charOffset="52-66"
            type="drug" text="anticholinergic"/>
        <entity id="DDI-DrugBank.d99.s18.e3" charOffset="78-92"
            type="drug" text="sympathomimetic"/>
        <entity id="DDI-DrugBank.d99.s18.e4" charOffset="111-121"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d99.s18.e5" charOffset="143-153"
            type="drug" text="anesthetics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s19" text="Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.">
        <entity id="DDI-DrugBank.d99.s19.e0" charOffset="36-52"
            type="drug" text="amitriptyline HCl"/>
        <entity id="DDI-DrugBank.d99.s19.e1" charOffset="75-89"
            type="drug" text="anticholinergic"/>
        <entity id="DDI-DrugBank.d99.s19.e2" charOffset="106-116"
            type="drug" text="neuroleptic"/>
        <ddi id="DDI-DrugBank.d99.s19.d0" e1="DDI-DrugBank.d99.s19.e0"
            e2="DDI-DrugBank.d99.s19.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s20" text="Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.">
        <entity id="DDI-DrugBank.d99.s20.e0" charOffset="45-69"
            type="drug" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d99.s20.e1" charOffset="91-105"
            type="drug" text="anticholinergic"/>
        <ddi id="DDI-DrugBank.d99.s20.d0" e1="DDI-DrugBank.d99.s20.e0"
            e2="DDI-DrugBank.d99.s20.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s21" text="Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.">
        <entity id="DDI-DrugBank.d99.s21.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d99.s21.e1" charOffset="63-87"
            type="drug" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d99.s21.e2" charOffset="171-175"
            type="drug" text="drugs"/>
        <ddi id="DDI-DrugBank.d99.s21.d0" e1="DDI-DrugBank.d99.s21.e0"
            e2="DDI-DrugBank.d99.s21.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s22" text="Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.">
        <entity id="DDI-DrugBank.d99.s22.e0" charOffset="59-83"
            type="drug" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d99.s22.e1" charOffset="114-123"
            type="drug" text="cimetidine"/>
        <ddi id="DDI-DrugBank.d99.s22.d0" e1="DDI-DrugBank.d99.s22.e0"
            e2="DDI-DrugBank.d99.s22.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s23" text="Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.">
        <entity id="DDI-DrugBank.d99.s23.e0" charOffset="30-54"
            type="drug" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d99.s23.e1" charOffset="121-135"
            type="drug" text="anticholinergic"/>
        <entity id="DDI-DrugBank.d99.s23.e2" charOffset="162-171"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d99.s23.e3" charOffset="190-193"
            type="drug" text="drug"/>
        <ddi id="DDI-DrugBank.d99.s23.d0" e1="DDI-DrugBank.d99.s23.e0"
            e2="DDI-DrugBank.d99.s23.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s24" text="Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.">
        <entity id="DDI-DrugBank.d99.s24.e0" charOffset="19-28"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d99.s24.e1" charOffset="68-92"
            type="drug" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d99.s24.e2" charOffset="98-107"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d99.s24.e3" charOffset="160-174"
            type="drug" text="antidepressants"/>
        <ddi id="DDI-DrugBank.d99.s24.d0" e1="DDI-DrugBank.d99.s24.e1"
            e2="DDI-DrugBank.d99.s24.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s25" text="Caution is advised if patients receive large doses of ethchlorvynol concurrently.">
        <entity id="DDI-DrugBank.d99.s25.e0" charOffset="54-66"
            type="drug" text="ethchlorvynol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d99.s26" text="Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.">
        <entity id="DDI-DrugBank.d99.s26.e0" charOffset="83-95"
            type="drug" text="ethchlorvynol"/>
        <entity id="DDI-DrugBank.d99.s26.e1" charOffset="116-132"
            type="drug" text="amitriptyline HCl"/>
        <ddi id="DDI-DrugBank.d99.s26.d0" e1="DDI-DrugBank.d99.s26.e0"
            e2="DDI-DrugBank.d99.s26.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d318.s0" text="When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.">
        <entity id="DDI-DrugBank.d318.s0.e0" charOffset="70-83"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d318.s0.e1" charOffset="86-106"
            type="group" text="Antineoplastic agents"/>
        <ddi id="DDI-DrugBank.d318.s0.d0" e1="DDI-DrugBank.d318.s0.e0"
            e2="DDI-DrugBank.d318.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d318.s1" text="Antineoplastic agents (e. g., nitrogen mustard, etc.) should be given concomitantly only with great caution.">
        <entity id="DDI-DrugBank.d318.s1.e0" charOffset="0-20"
            type="group" text="Antineoplastic agents"/>
        <entity id="DDI-DrugBank.d318.s1.e1" charOffset="30-45"
            type="drug" text="nitrogen mustard"/>
    </sentence>
    <sentence id="DDI-DrugBank.d318.s2" text="Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.">
        <entity id="DDI-DrugBank.d318.s2.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d318.s2.e1" charOffset="20-32"
            type="drug" text="Corticotropin"/>
        <entity id="DDI-DrugBank.d318.s2.e2" charOffset="35-38"
            type="group" text="ACTH"/>
        <entity id="DDI-DrugBank.d318.s2.e3" charOffset="57-70"
            type="drug" text="amphotericin B"/>
        <ddi id="DDI-DrugBank.d318.s2.d0" e1="DDI-DrugBank.d318.s2.e0"
            e2="DDI-DrugBank.d318.s2.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d318.s2.d1" e1="DDI-DrugBank.d318.s2.e1"
            e2="DDI-DrugBank.d318.s2.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d318.s2.d2" e1="DDI-DrugBank.d318.s2.e2"
            e2="DDI-DrugBank.d318.s2.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d318.s3" text="Avoid concomitant use unless necessary to control side effects of amphotericin B.">
        <entity id="DDI-DrugBank.d318.s3.e0" charOffset="66-79"
            type="drug" text="amphotericin B"/>
    </sentence>
    <sentence id="DDI-DrugBank.d318.s4" text="If used concomitantly, closely monitor serum electrolytes and cardiac function."/>
    <sentence id="DDI-DrugBank.d318.s5" text="Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.">
        <entity id="DDI-DrugBank.d318.s5.e0" charOffset="0-19"
            type="group" text="Digitalis glycosides"/>
        <entity id="DDI-DrugBank.d318.s5.e1" charOffset="22-35"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d318.s5.e2" charOffset="72-80"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d318.s5.d0" e1="DDI-DrugBank.d318.s5.e1"
            e2="DDI-DrugBank.d318.s5.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d318.s6" text="Serum potassium levels and cardiac function should be closely monitored and any deficit promptly corrected."/>
    <sentence id="DDI-DrugBank.d318.s7" text="Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.">
        <entity id="DDI-DrugBank.d318.s7.e0" charOffset="0-10"
            type="drug" text="Flucytosine"/>
        <entity id="DDI-DrugBank.d318.s7.e1" charOffset="51-64"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d318.s7.e2" charOffset="130-140"
            type="drug" text="flucytosine"/>
        <ddi id="DDI-DrugBank.d318.s7.d0" e1="DDI-DrugBank.d318.s7.e1"
            e2="DDI-DrugBank.d318.s7.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d318.s8" text="Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.">
        <entity id="DDI-DrugBank.d318.s8.e0" charOffset="0-9"
            type="group" text="Imidazoles"/>
        <entity id="DDI-DrugBank.d318.s8.e1" charOffset="19-30"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d318.s8.e2" charOffset="33-42"
            type="drug" text="miconazole"/>
        <entity id="DDI-DrugBank.d318.s8.e3" charOffset="45-56"
            type="drug" text="clotrimazole"/>
        <entity id="DDI-DrugBank.d318.s8.e4" charOffset="59-69"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d318.s8.e5" charOffset="131-144"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d318.s8.e6" charOffset="150-159"
            type="group" text="imidazoles"/>
        <entity id="DDI-DrugBank.d318.s8.e7" charOffset="174-183"
            type="group" text="imidazoles"/>
        <entity id="DDI-DrugBank.d318.s8.e8" charOffset="217-230"
            type="drug" text="amphotericin B"/>
        <ddi id="DDI-DrugBank.d318.s8.d0" e1="DDI-DrugBank.d318.s8.e7"
            e2="DDI-DrugBank.d318.s8.e8" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d318.s9" text="Combination therapy should be administered with caution, especially in immunocompromised patients."/>
    <sentence id="DDI-DrugBank.d318.s10" text="Other nephrotoxic medications: agents such as aminoglycosides, cyclosporine, and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.">
        <entity id="DDI-DrugBank.d318.s10.e0" charOffset="46-60"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d318.s10.e1" charOffset="63-74"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d318.s10.e2" charOffset="81-91"
            type="drug" text="pentamidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d318.s11" text="Intensive monitoring of renal function is recommended in patients requiring any combination of nephrotoxic medications ."/>
    <sentence id="DDI-DrugBank.d318.s12" text="Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).">
        <entity id="DDI-DrugBank.d318.s12.e0" charOffset="0-24"
            type="group" text="Skeletal muscle relaxants"/>
        <entity id="DDI-DrugBank.d318.s12.e1" charOffset="27-40"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d318.s12.e2" charOffset="99-123"
            type="group" text="skeletal muscle relaxants"/>
        <entity id="DDI-DrugBank.d318.s12.e3" charOffset="132-143"
            type="drug" text="tubocurarine"/>
        <ddi id="DDI-DrugBank.d318.s12.d0" e1="DDI-DrugBank.d318.s12.e1"
            e2="DDI-DrugBank.d318.s12.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d318.s12.d1" e1="DDI-DrugBank.d318.s12.e1"
            e2="DDI-DrugBank.d318.s12.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d318.s13" text="Serum potassium levels should be monitored and deficiencies corrected."/>
    <sentence id="DDI-DrugBank.d318.s14" text="Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.">
        <entity id="DDI-DrugBank.d318.s14.e0" charOffset="0-21"
            type="drug_n" text="Leukocyte transfusions"/>
        <entity id="DDI-DrugBank.d318.s14.e1" charOffset="101-114"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d318.s14.e2" charOffset="120-141"
            type="drug_n" text="leukocyte transfusions"/>
        <ddi id="DDI-DrugBank.d318.s14.d0" e1="DDI-DrugBank.d318.s14.e1"
            e2="DDI-DrugBank.d318.s14.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d211.s0" text="When administered concurrently, the following drugs may interact with ampicillin.">
        <entity id="DDI-DrugBank.d211.s0.e0" charOffset="70-79"
            type="drug" text="ampicillin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d211.s1" text="Allopurinol: Increased possibility of skin rash, particularly in hyperuricemic patients may occur.">
        <entity id="DDI-DrugBank.d211.s1.e0" charOffset="0-10"
            type="drug" text="Allopurinol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d211.s2" text="Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.">
        <entity id="DDI-DrugBank.d211.s2.e0" charOffset="0-25"
            type="group" text="Bacteriostatic Antibiotics"/>
        <entity id="DDI-DrugBank.d211.s2.e1" charOffset="28-42"
            type="drug" text="Chloramphenicol"/>
        <entity id="DDI-DrugBank.d211.s2.e2" charOffset="45-57"
            type="drug" text="erythromycins"/>
        <entity id="DDI-DrugBank.d211.s2.e3" charOffset="60-71"
            type="group" text="sulfonamides"/>
        <entity id="DDI-DrugBank.d211.s2.e4" charOffset="77-89"
            type="group" text="tetracyclines"/>
        <entity id="DDI-DrugBank.d211.s2.e5" charOffset="137-147"
            type="group" text="penicillins"/>
        <ddi id="DDI-DrugBank.d211.s2.d0" e1="DDI-DrugBank.d211.s2.e1"
            e2="DDI-DrugBank.d211.s2.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d211.s2.d1" e1="DDI-DrugBank.d211.s2.e2"
            e2="DDI-DrugBank.d211.s2.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d211.s2.d2" e1="DDI-DrugBank.d211.s2.e3"
            e2="DDI-DrugBank.d211.s2.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d211.s2.d3" e1="DDI-DrugBank.d211.s2.e4"
            e2="DDI-DrugBank.d211.s2.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d211.s3" text="This has been demonstrated in view, however, the clinical significance of this interaction is not well documented."/>
    <sentence id="DDI-DrugBank.d211.s4" text="Oral Contraceptives: May be less effective and increased breakthrough bleeding may occur.">
        <entity id="DDI-DrugBank.d211.s4.e0" charOffset="5-18"
            type="group" text="Contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d211.s5" text="Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.">
        <entity id="DDI-DrugBank.d211.s5.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d211.s5.e1" charOffset="52-61"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d211.s5.e2" charOffset="106-115"
            type="drug" text="ampicillin"/>
        <ddi id="DDI-DrugBank.d211.s5.d0" e1="DDI-DrugBank.d211.s5.e0"
            e2="DDI-DrugBank.d211.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d211.s6" text="Drug/Laboratory Test Interaction After treatment with ampicillin, a false-positive reaction for glucose in the urine may occur with copper sulfate tests (Benedicts solution, Fehlings solution, or Clinitest tablets) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP.">
        <entity id="DDI-DrugBank.d211.s6.e0" charOffset="54-63"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d211.s6.e1" charOffset="132-145"
            type="drug_n" text="copper sulfate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s0" text="Amprenavir is metabolized in the liver by the cytochrome P450 enzyme system.">
        <entity id="DDI-DrugBank.d437.s0.e0" charOffset="0-9"
            type="drug" text="Amprenavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s1" text="Amprenavir inhibits CYP3A4.">
        <entity id="DDI-DrugBank.d437.s1.e0" charOffset="0-9"
            type="drug" text="Amprenavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s2" text="Caution should be used when coadministering medications that are substrates, inhibitors, or inducers of CYP3A4, or potentially toxic medications that are metabolized by CYP3A4."/>
    <sentence id="DDI-DrugBank.d437.s3" text="Amprenavir does not inhibit CYP2D6, CYP1A2, CYP2C9, CYP2C19, CYP2E1, or uridine glucuronosyltransferase (UDPGT).">
        <entity id="DDI-DrugBank.d437.s3.e0" charOffset="0-9"
            type="drug" text="Amprenavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s4" text="HIV Protease Inhibitors: The effect of amprenavir on total drug concentrations of other HIV protease inhibitors in subjects receiving both agents was evaluated using comparisons to historical data.">
        <entity id="DDI-DrugBank.d437.s4.e0" charOffset="0-22"
            type="group" text="HIV Protease Inhibitors"/>
        <entity id="DDI-DrugBank.d437.s4.e1" charOffset="39-48"
            type="drug" text="amprenavir"/>
        <entity id="DDI-DrugBank.d437.s4.e2" charOffset="88-110"
            type="group" text="HIV protease inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s5" text="Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.">
        <entity id="DDI-DrugBank.d437.s5.e0" charOffset="0-8"
            type="drug" text="Indinavir"/>
        <entity id="DDI-DrugBank.d437.s5.e1" charOffset="109-118"
            type="drug" text="amprenavir"/>
        <ddi id="DDI-DrugBank.d437.s5.d0" e1="DDI-DrugBank.d437.s5.e0"
            e2="DDI-DrugBank.d437.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s6" text="Similar decreases in Cmax and AUC were seen after the first dose."/>
    <sentence id="DDI-DrugBank.d437.s7" text="Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.">
        <entity id="DDI-DrugBank.d437.s7.e0" charOffset="0-9"
            type="drug" text="Saquinavir"/>
        <entity id="DDI-DrugBank.d437.s7.e1" charOffset="127-136"
            type="drug" text="amprenavir"/>
        <ddi id="DDI-DrugBank.d437.s7.d0" e1="DDI-DrugBank.d437.s7.e0"
            e2="DDI-DrugBank.d437.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s8" text="Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.">
        <entity id="DDI-DrugBank.d437.s8.e0" charOffset="0-9"
            type="drug" text="Nelfinavir"/>
        <entity id="DDI-DrugBank.d437.s8.e1" charOffset="110-119"
            type="drug" text="amprenavir"/>
        <ddi id="DDI-DrugBank.d437.s8.d0" e1="DDI-DrugBank.d437.s8.e0"
            e2="DDI-DrugBank.d437.s8.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s9" text="Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.">
        <entity id="DDI-DrugBank.d437.s9.e0" charOffset="0-8"
            type="drug" text="Methadone"/>
        <entity id="DDI-DrugBank.d437.s9.e1" charOffset="31-40"
            type="drug" text="amprenavir"/>
        <entity id="DDI-DrugBank.d437.s9.e2" charOffset="46-54"
            type="drug" text="methadone"/>
        <entity id="DDI-DrugBank.d437.s9.e3" charOffset="86-94"
            type="drug" text="methadone"/>
        <ddi id="DDI-DrugBank.d437.s9.d0" e1="DDI-DrugBank.d437.s9.e1"
            e2="DDI-DrugBank.d437.s9.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s10" text="Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.">
        <entity id="DDI-DrugBank.d437.s10.e0" charOffset="20-29"
            type="drug" text="amprenavir"/>
        <entity id="DDI-DrugBank.d437.s10.e1" charOffset="35-43"
            type="drug" text="methadone"/>
        <entity id="DDI-DrugBank.d437.s10.e2" charOffset="148-157"
            type="drug" text="amprenavir"/>
        <ddi id="DDI-DrugBank.d437.s10.d0" e1="DDI-DrugBank.d437.s10.e0"
            e2="DDI-DrugBank.d437.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s11" text="Amprenavir is an inhibitor of cytochrome P450 C.P.A. metabolism and therefore should not be administered concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4.">
        <entity id="DDI-DrugBank.d437.s11.e0" charOffset="0-9"
            type="drug" text="Amprenavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s12" text="There are other agents that may result in serious and/or life-threatening drug interactions."/>
    <sentence id="DDI-DrugBank.d437.s13" text="Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.">
        <entity id="DDI-DrugBank.d437.s13.e0" charOffset="37-46"
            type="drug" text="Amprenavir"/>
        <entity id="DDI-DrugBank.d437.s13.e1" charOffset="61-69"
            type="drug" text="ritonavir"/>
        <ddi id="DDI-DrugBank.d437.s13.d0" e1="DDI-DrugBank.d437.s13.e0"
            e2="DDI-DrugBank.d437.s13.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s14" text="Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.">
        <entity id="DDI-DrugBank.d437.s14.e0" charOffset="97-106"
            type="drug" text="Amprenavir"/>
        <entity id="DDI-DrugBank.d437.s14.e1" charOffset="112-120"
            type="drug" text="ritonavir"/>
        <ddi id="DDI-DrugBank.d437.s14.d0" e1="DDI-DrugBank.d437.s14.e0"
            e2="DDI-DrugBank.d437.s14.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d437.s15" text="For comprehensive information concerning laboratory test alterations associated with ritonavir, physicians should refer to the complete prescribing information for NORVIR (ritonavir).">
        <entity id="DDI-DrugBank.d437.s15.e0" charOffset="85-93"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d437.s15.e1" charOffset="164-169"
            type="brand" text="NORVIR"/>
        <entity id="DDI-DrugBank.d437.s15.e2" charOffset="172-180"
            type="drug" text="ritonavir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d56.s0" text="Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.">
        <entity id="DDI-DrugBank.d56.s0.e0" charOffset="7-18"
            type="drug" text="amyl nitrite"/>
        <entity id="DDI-DrugBank.d56.s0.e1" charOffset="35-41"
            type="drug" text="alcohol"/>
        <ddi id="DDI-DrugBank.d56.s0.d0" e1="DDI-DrugBank.d56.s0.e0"
            e2="DDI-DrugBank.d56.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s0" text="Limited PK and/or PD studies investigating possible interactions between anagrelide and other medicinal products have been conducted.">
        <entity id="DDI-DrugBank.d75.s0.e0" charOffset="73-82"
            type="drug" text="anagrelide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s1" text="In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin.">
        <entity id="DDI-DrugBank.d75.s1.e0" charOffset="61-67"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d75.s1.e1" charOffset="73-80"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d75.s1.e2" charOffset="117-126"
            type="drug" text="anagrelide"/>
        <entity id="DDI-DrugBank.d75.s1.e3" charOffset="138-147"
            type="drug" text="anagrelide"/>
        <entity id="DDI-DrugBank.d75.s1.e4" charOffset="177-183"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d75.s1.e5" charOffset="188-195"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s2" text="Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.">
        <entity id="DDI-DrugBank.d75.s2.e0" charOffset="122-131"
            type="drug" text="anagrelide"/>
        <entity id="DDI-DrugBank.d75.s2.e1" charOffset="157-163"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d75.s2.e2" charOffset="166-178"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d75.s2.e3" charOffset="181-190"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d75.s2.e4" charOffset="193-196"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d75.s2.e5" charOffset="199-208"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d75.s2.e6" charOffset="211-221"
            type="drug" text="hydroxyurea"/>
        <entity id="DDI-DrugBank.d75.s2.e7" charOffset="228-238"
            type="drug" text="allopurinol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s3" text="There is no clinical evidence to suggest that anagrelide interacts with any of these compounds.">
        <entity id="DDI-DrugBank.d75.s3.e0" charOffset="46-55"
            type="drug" text="anagrelide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s4" text="An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated.">
        <entity id="DDI-DrugBank.d75.s4.e0" charOffset="78-87"
            type="drug" text="anagrelide"/>
        <entity id="DDI-DrugBank.d75.s4.e1" charOffset="145-151"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s5" text="There was no effect on bleeding time, PT or aPTT."/>
    <sentence id="DDI-DrugBank.d75.s6" text="No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed.">
        <entity id="DDI-DrugBank.d75.s6.e0" charOffset="60-69"
            type="drug" text="anagrelide"/>
        <entity id="DDI-DrugBank.d75.s6.e1" charOffset="75-94"
            type="drug" text="acetylsalicylic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s7" text="In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo.">
        <entity id="DDI-DrugBank.d75.s7.e0" charOffset="20-26"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s8" text="Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.">
        <entity id="DDI-DrugBank.d75.s8.e0" charOffset="0-9" type="drug" text="Anagrelide"/>
        <entity id="DDI-DrugBank.d75.s8.e1" charOffset="123-129"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d75.s8.d0" e1="DDI-DrugBank.d75.s8.e0"
            e2="DDI-DrugBank.d75.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s9" text="Anagrelide is metabolized at least in part by CYP1A2.">
        <entity id="DDI-DrugBank.d75.s9.e0" charOffset="0-9" type="drug" text="Anagrelide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s10" text="It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.">
        <entity id="DDI-DrugBank.d75.s10.e0" charOffset="78-88"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d75.s10.e1" charOffset="176-185"
            type="drug" text="anagrelide"/>
        <ddi id="DDI-DrugBank.d75.s10.d0" e1="DDI-DrugBank.d75.s10.e0"
            e2="DDI-DrugBank.d75.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s11" text="Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g.">
        <entity id="DDI-DrugBank.d75.s11.e0" charOffset="0-9"
            type="drug" text="Anagrelide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s12" text="Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.">
        <entity id="DDI-DrugBank.d75.s12.e0" charOffset="0-9"
            type="drug" text="Anagrelide"/>
        <entity id="DDI-DrugBank.d75.s12.e1" charOffset="213-224"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d75.s12.d0" e1="DDI-DrugBank.d75.s12.e0"
            e2="DDI-DrugBank.d75.s12.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s13" text="Anagrelide is an inhibitor of cyclic AMP PDE III.">
        <entity id="DDI-DrugBank.d75.s13.e0" charOffset="0-9"
            type="drug" text="Anagrelide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s14" text="The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.">
        <entity id="DDI-DrugBank.d75.s14.e0" charOffset="76-84"
            type="drug" text="milrinone"/>
        <entity id="DDI-DrugBank.d75.s14.e1" charOffset="87-95"
            type="drug" text="enoximone"/>
        <entity id="DDI-DrugBank.d75.s14.e2" charOffset="98-105"
            type="drug" text="amrinone"/>
        <entity id="DDI-DrugBank.d75.s14.e3" charOffset="108-116"
            type="drug_n" text="olprinone"/>
        <entity id="DDI-DrugBank.d75.s14.e4" charOffset="122-131"
            type="drug" text="cilostazol"/>
        <entity id="DDI-DrugBank.d75.s14.e5" charOffset="155-164"
            type="drug" text="anagrelide"/>
        <ddi id="DDI-DrugBank.d75.s14.d0" e1="DDI-DrugBank.d75.s14.e0"
            e2="DDI-DrugBank.d75.s14.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d75.s14.d1" e1="DDI-DrugBank.d75.s14.e1"
            e2="DDI-DrugBank.d75.s14.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d75.s14.d2" e1="DDI-DrugBank.d75.s14.e2"
            e2="DDI-DrugBank.d75.s14.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d75.s14.d3" e1="DDI-DrugBank.d75.s14.e3"
            e2="DDI-DrugBank.d75.s14.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d75.s14.d4" e1="DDI-DrugBank.d75.s14.e4"
            e2="DDI-DrugBank.d75.s14.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s15" text="There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.">
        <entity id="DDI-DrugBank.d75.s15.e0" charOffset="51-60"
            type="drug" text="sucralfate"/>
        <entity id="DDI-DrugBank.d75.s15.e1" charOffset="81-90"
            type="drug" text="anagrelide"/>
        <ddi id="DDI-DrugBank.d75.s15.d0" e1="DDI-DrugBank.d75.s15.e0"
            e2="DDI-DrugBank.d75.s15.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d75.s16" text="Food has no clinically significant effect on the bioavailability of anagrelide.">
        <entity id="DDI-DrugBank.d75.s16.e0" charOffset="68-77"
            type="drug" text="anagrelide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d275.s0" text="No drug-drug interaction studies in human subjects have been conducted."/>
    <sentence id="DDI-DrugBank.d275.s1" text="Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret when the two agents were administered together.">
        <entity id="DDI-DrugBank.d275.s1.e0" charOffset="132-143"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d275.s1.e1" charOffset="148-154"
            type="brand" text="Kineret"/>
    </sentence>
    <sentence id="DDI-DrugBank.d275.s2" text="In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).">
        <entity id="DDI-DrugBank.d275.s2.e0" charOffset="92-98"
            type="brand" text="Kineret"/>
        <entity id="DDI-DrugBank.d275.s2.e1" charOffset="104-113"
            type="drug" text="etanercept"/>
        <entity id="DDI-DrugBank.d275.s2.e2" charOffset="211-220"
            type="drug" text="etanercept"/>
        <ddi id="DDI-DrugBank.d275.s2.d0" e1="DDI-DrugBank.d275.s2.e0"
            e2="DDI-DrugBank.d275.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d275.s3" text="Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).">
        <entity id="DDI-DrugBank.d275.s3.e0" charOffset="50-56"
            type="brand" text="Kineret"/>
        <entity id="DDI-DrugBank.d275.s3.e1" charOffset="62-71"
            type="drug" text="etanercept"/>
        <ddi id="DDI-DrugBank.d275.s3.d0" e1="DDI-DrugBank.d275.s3.e0"
            e2="DDI-DrugBank.d275.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d195.s0" text="Anastrozole inhibited in vitro metabolic reactions catalyzed by cytochromes P450 1A2, 2C8/9, and 3A4 but only at relatively high concentrations.">
        <entity id="DDI-DrugBank.d195.s0.e0" charOffset="0-10"
            type="drug" text="Anastrozole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d195.s1" text="Anastrozole did not inhibit P450 2A6 or the polymorphic P450 2D6 in human liver microsomes.">
        <entity id="DDI-DrugBank.d195.s1.e0" charOffset="0-10"
            type="drug" text="Anastrozole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d195.s2" text="Anastrozole did not alter the pharmacokinetics of antipyrine.">
        <entity id="DDI-DrugBank.d195.s2.e0" charOffset="0-10"
            type="drug" text="Anastrozole"/>
        <entity id="DDI-DrugBank.d195.s2.e1" charOffset="50-59"
            type="drug" text="antipyrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d195.s3" text="Although there have been no formal interaction studies other than with antipyrine, based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of ARIMIDEX with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs.">
        <entity id="DDI-DrugBank.d195.s3.e0" charOffset="71-80"
            type="drug" text="antipyrine"/>
        <entity id="DDI-DrugBank.d195.s3.e1" charOffset="184-191"
            type="brand" text="ARIMIDEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d195.s4" text="An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.">
        <entity id="DDI-DrugBank.d195.s4.e0" charOffset="26-33"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d195.s4.e1" charOffset="78-88"
            type="drug" text="anastrozole"/>
        <entity id="DDI-DrugBank.d195.s4.e2" charOffset="93-100"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d195.s5" text="At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.">
        <entity id="DDI-DrugBank.d195.s5.e0" charOffset="55-62"
            type="brand" text="ARIMIDEX"/>
        <entity id="DDI-DrugBank.d195.s5.e1" charOffset="68-76"
            type="drug" text="tamoxifen"/>
        <entity id="DDI-DrugBank.d195.s5.e2" charOffset="138-146"
            type="drug" text="tamoxifen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d195.s6" text="This treatment arm was discontinued from the trial."/>
    <sentence id="DDI-DrugBank.d195.s7" text="Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).">
        <entity id="DDI-DrugBank.d195.s7.e0" charOffset="67-75"
            type="drug" text="tamoxifen"/>
        <entity id="DDI-DrugBank.d195.s7.e1" charOffset="109-119"
            type="drug" text="anastrozole"/>
        <ddi id="DDI-DrugBank.d195.s7.d0" e1="DDI-DrugBank.d195.s7.e0"
            e2="DDI-DrugBank.d195.s7.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d195.s8" text="Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.">
        <entity id="DDI-DrugBank.d195.s8.e0" charOffset="21-31"
            type="drug" text="anastrozole"/>
        <entity id="DDI-DrugBank.d195.s8.e1" charOffset="37-45"
            type="drug" text="tamoxifen"/>
        <entity id="DDI-DrugBank.d195.s8.e2" charOffset="74-84"
            type="drug" text="anastrozole"/>
        <entity id="DDI-DrugBank.d195.s8.e3" charOffset="141-151"
            type="drug" text="anastrozole"/>
        <ddi id="DDI-DrugBank.d195.s8.d0" e1="DDI-DrugBank.d195.s8.e0"
            e2="DDI-DrugBank.d195.s8.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d195.s9" text="Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.">
        <entity id="DDI-DrugBank.d195.s9.e0" charOffset="0-7"
            type="group" text="Estrogen"/>
        <entity id="DDI-DrugBank.d195.s9.e1" charOffset="54-61"
            type="brand" text="ARIMIDEX"/>
        <ddi id="DDI-DrugBank.d195.s9.d0" e1="DDI-DrugBank.d195.s9.e0"
            e2="DDI-DrugBank.d195.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d195.s10" text="Drug/Laboratory Test Interactions No clinically significant changes in the results of clinical laboratory tests have been observed"/>
    <sentence id="DDI-DrugBank.d195.s11" text="."/>
    <sentence id="DDI-DrugBank.d195.s12" text=""/>
    <sentence id="DDI-DrugBank.d445.s0" text="No clinically relevant drug-drug interactions have been observed with drugs likely to be co-administered with anidulafungin.">
        <entity id="DDI-DrugBank.d445.s0.e0" charOffset="110-122"
            type="drug" text="anidulafungin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d215.s0" text="Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.">
        <entity id="DDI-DrugBank.d215.s0.e0" charOffset="32-42"
            type="drug" text="anileridine"/>
        <entity id="DDI-DrugBank.d215.s0.e1" charOffset="73-79"
            type="group" text="opioids"/>
        <entity id="DDI-DrugBank.d215.s0.e2" charOffset="82-90"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d215.s0.e3" charOffset="93-106"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d215.s0.e4" charOffset="112-122"
            type="group" text="anesthetics"/>
        <ddi id="DDI-DrugBank.d215.s0.d0" e1="DDI-DrugBank.d215.s0.e0"
            e2="DDI-DrugBank.d215.s0.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d215.s0.d1" e1="DDI-DrugBank.d215.s0.e0"
            e2="DDI-DrugBank.d215.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d215.s0.d2" e1="DDI-DrugBank.d215.s0.e0"
            e2="DDI-DrugBank.d215.s0.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d215.s0.d3" e1="DDI-DrugBank.d215.s0.e0"
            e2="DDI-DrugBank.d215.s0.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s0" text="Addition or deletion of any drug from the therapeutic regimen of patients receiving oral anticoagulants may affect patient response to the anticoagulant.">
        <entity id="DDI-DrugBank.d64.s0.e0" charOffset="89-102"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d64.s0.e1" charOffset="139-151"
            type="group" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s1" text="Frequent determination of prothrombin time and close monitoring of the patient is essential to ascertain when adjustment of dosage of anticoagulant may be needed.">
        <entity id="DDI-DrugBank.d64.s1.e0" charOffset="134-146"
            type="group" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s2" text="Because of the variability of individual patient response, multiple interacting mechanisms with some drugs, the dependency of the extent of the interaction on the dosage and duration of therapy, and the possible administration of several interacting drugs simultaneously, it is difficult to predict the direction and degree of the ultimate effect of concomitant medications on anticoagulant response.">
        <entity id="DDI-DrugBank.d64.s2.e0" charOffset="377-389"
            type="group" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d64.s3" text="For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.">
        <entity id="DDI-DrugBank.d64.s3.e0" charOffset="19-32"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d64.s3.e1" charOffset="94-107"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d64.s3.e2" charOffset="113-121"
            type="group" text="vitamin K"/>
        <ddi id="DDI-DrugBank.d64.s3.d0" e1="DDI-DrugBank.d64.s3.e0"
            e2="DDI-DrugBank.d64.s3.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d64.s3.d1" e1="DDI-DrugBank.d64.s3.e0"
            e2="DDI-DrugBank.d64.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s10" text="Therefore, the potential exists for interaction between carbamazepine and any agent metabolized by one (or more) of these enzymes.">
        <entity id="DDI-DrugBank.d94.s10.e0" charOffset="56-68"
            type="drug" text="carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s11" text="Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.">
        <entity id="DDI-DrugBank.d94.s11.e0" charOffset="96-104"
            type="brand" text="EQUETROTM"/>
        <entity id="DDI-DrugBank.d94.s11.e1" charOffset="157-169"
            type="drug" text="Acetaminophen"/>
        <entity id="DDI-DrugBank.d94.s11.e2" charOffset="172-181"
            type="drug" text="alprazolam"/>
        <entity id="DDI-DrugBank.d94.s11.e3" charOffset="184-196"
            type="drug" text="amitriptyline"/>
        <entity id="DDI-DrugBank.d94.s11.e4" charOffset="199-207"
            type="drug" text="bupropion"/>
        <entity id="DDI-DrugBank.d94.s11.e5" charOffset="210-218"
            type="drug" text="buspirone"/>
        <entity id="DDI-DrugBank.d94.s11.e6" charOffset="221-230"
            type="drug" text="citalopram"/>
        <entity id="DDI-DrugBank.d94.s11.e7" charOffset="233-240"
            type="drug" text="clobazam"/>
        <entity id="DDI-DrugBank.d94.s11.e8" charOffset="243-252"
            type="drug" text="clonazepam"/>
        <entity id="DDI-DrugBank.d94.s11.e9" charOffset="255-263"
            type="drug" text="clozapine"/>
        <entity id="DDI-DrugBank.d94.s11.e10" charOffset="266-276"
            type="drug" text="cyclosporin"/>
        <entity id="DDI-DrugBank.d94.s11.e11" charOffset="279-289"
            type="drug" text="delavirdine"/>
        <entity id="DDI-DrugBank.d94.s11.e12" charOffset="292-302"
            type="drug" text="desipramine"/>
        <entity id="DDI-DrugBank.d94.s11.e13" charOffset="305-312"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d94.s11.e14" charOffset="315-323"
            type="drug" text="dicumarol"/>
        <entity id="DDI-DrugBank.d94.s11.e15" charOffset="326-336"
            type="drug" text="doxycycline"/>
        <entity id="DDI-DrugBank.d94.s11.e16" charOffset="339-350"
            type="drug" text="ethosuximide"/>
        <entity id="DDI-DrugBank.d94.s11.e17" charOffset="353-361"
            type="drug" text="felbamate"/>
        <entity id="DDI-DrugBank.d94.s11.e18" charOffset="364-373"
            type="drug" text="felodipine"/>
        <entity id="DDI-DrugBank.d94.s11.e19" charOffset="376-390"
            type="group" text="glucocorticoids"/>
        <entity id="DDI-DrugBank.d94.s11.e20" charOffset="393-403"
            type="drug" text="haloperidol"/>
        <entity id="DDI-DrugBank.d94.s11.e21" charOffset="406-417"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d94.s11.e22" charOffset="420-430"
            type="drug" text="lamotrigine"/>
        <entity id="DDI-DrugBank.d94.s11.e23" charOffset="433-445"
            type="drug" text="levothyroxine"/>
        <entity id="DDI-DrugBank.d94.s11.e24" charOffset="448-456"
            type="drug" text="lorazepam"/>
        <entity id="DDI-DrugBank.d94.s11.e25" charOffset="459-467"
            type="drug" text="methadone"/>
        <entity id="DDI-DrugBank.d94.s11.e26" charOffset="470-478"
            type="drug" text="midazolam"/>
        <entity id="DDI-DrugBank.d94.s11.e27" charOffset="481-491"
            type="drug" text="mirtazapine"/>
        <entity id="DDI-DrugBank.d94.s11.e28" charOffset="494-506"
            type="drug" text="nortriptyline"/>
        <entity id="DDI-DrugBank.d94.s11.e29" charOffset="509-518"
            type="drug" text="olanzapine"/>
        <entity id="DDI-DrugBank.d94.s11.e30" charOffset="526-539"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d94.s11.e31" charOffset="545-557"
            type="drug" text="oxcarbazepine"/>
        <entity id="DDI-DrugBank.d94.s11.e32" charOffset="560-568"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d94.s11.e33" charOffset="574-585"
            type="drug" text="praziquantel"/>
        <entity id="DDI-DrugBank.d94.s11.e34" charOffset="588-606"
            type="group" text="protease inhibitors"/>
        <entity id="DDI-DrugBank.d94.s11.e35" charOffset="609-618"
            type="drug" text="quetiapine"/>
        <entity id="DDI-DrugBank.d94.s11.e36" charOffset="621-631"
            type="drug" text="risperidone"/>
        <entity id="DDI-DrugBank.d94.s11.e37" charOffset="634-645"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d94.s11.e38" charOffset="648-657"
            type="drug" text="topiramate"/>
        <entity id="DDI-DrugBank.d94.s11.e39" charOffset="660-668"
            type="drug" text="tiagabine"/>
        <entity id="DDI-DrugBank.d94.s11.e40" charOffset="671-678"
            type="drug" text="tramadol"/>
        <entity id="DDI-DrugBank.d94.s11.e41" charOffset="681-689"
            type="drug" text="triazolam"/>
        <entity id="DDI-DrugBank.d94.s11.e42" charOffset="692-700"
            type="drug" text="valproate"/>
        <entity id="DDI-DrugBank.d94.s11.e43" charOffset="703-710"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d94.s11.e44" charOffset="717-727"
            type="drug" text="ziprasidone"/>
        <entity id="DDI-DrugBank.d94.s11.e45" charOffset="734-743"
            type="drug" text="zonisamide"/>
        <ddi id="DDI-DrugBank.d94.s11.d0" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d1" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d2" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d3" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d4" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d5" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d6" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d7" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d8" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d9" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e10" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d10" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e11" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d11" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e12" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d12" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e13" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d13" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e14" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d14" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e15" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d15" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e16" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d16" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e17" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d17" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e18" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d18" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e19" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d19" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e20" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d20" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e21" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d21" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e22" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d22" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e23" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d23" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e24" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d24" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e25" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d25" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e26" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d26" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e27" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d27" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e28" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d28" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e29" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d29" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e30" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d30" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e31" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d31" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e32" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d32" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e33" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d33" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e34" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d34" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e35" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d35" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e36" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d36" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e37" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d37" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e38" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d38" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e39" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d39" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e40" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d40" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e41" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d41" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e42" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d42" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e43" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d43" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e44" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s11.d44" e1="DDI-DrugBank.d94.s11.e0"
            e2="DDI-DrugBank.d94.s11.e45" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s12" text="Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with EQUETROTM, it is reasonable to expect that a dose increase for the concomitant agent may be necessary.">
        <entity id="DDI-DrugBank.d94.s12.e0" charOffset="138-146"
            type="brand" text="EQUETROTM"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s13" text="Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.">
        <entity id="DDI-DrugBank.d94.s13.e0" charOffset="48-60"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d94.s13.e1" charOffset="63-71"
            type="brand" text="EQUETROTM"/>
        <entity id="DDI-DrugBank.d94.s13.e2" charOffset="126-141"
            type="drug" text="Clomipramine HCl"/>
        <entity id="DDI-DrugBank.d94.s13.e3" charOffset="144-152"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d94.s13.e4" charOffset="162-170"
            type="drug" text="primidone"/>
        <entity id="DDI-DrugBank.d94.s13.e5" charOffset="314-322"
            type="brand" text="EQUETROTM"/>
        <ddi id="DDI-DrugBank.d94.s13.d0" e1="DDI-DrugBank.d94.s13.e1"
            e2="DDI-DrugBank.d94.s13.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s13.d1" e1="DDI-DrugBank.d94.s13.e1"
            e2="DDI-DrugBank.d94.s13.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d94.s13.d2" e1="DDI-DrugBank.d94.s13.e1"
            e2="DDI-DrugBank.d94.s13.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s14" text="Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.">
        <entity id="DDI-DrugBank.d94.s14.e0" charOffset="50-62"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d94.s14.e1" charOffset="94-106"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d94.s14.e2" charOffset="112-118"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d94.s14.d0" e1="DDI-DrugBank.d94.s14.e1"
            e2="DDI-DrugBank.d94.s14.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s15" text="Given the anticonvulsant properties of carbamazepine, EQUETROTM may reduce the thyroid function as has been reported with other anticonvulsants.">
        <entity id="DDI-DrugBank.d94.s15.e0" charOffset="39-51"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d94.s15.e1" charOffset="54-62"
            type="brand" text="EQUETROTM"/>
        <entity id="DDI-DrugBank.d94.s15.e2" charOffset="128-142"
            type="group" text="anticonvulsants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s16" text="Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.">
        <entity id="DDI-DrugBank.d94.s16.e0" charOffset="14-32"
            type="group" text="anti-malarial drugs"/>
        <entity id="DDI-DrugBank.d94.s16.e1" charOffset="43-53"
            type="drug" text="chloroquine"/>
        <entity id="DDI-DrugBank.d94.s16.e2" charOffset="59-68"
            type="drug" text="mefloquine"/>
        <entity id="DDI-DrugBank.d94.s16.e3" charOffset="102-114"
            type="drug" text="carbamazepine"/>
        <ddi id="DDI-DrugBank.d94.s16.d0" e1="DDI-DrugBank.d94.s16.e0"
            e2="DDI-DrugBank.d94.s16.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d94.s16.d1" e1="DDI-DrugBank.d94.s16.e1"
            e2="DDI-DrugBank.d94.s16.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d94.s16.d2" e1="DDI-DrugBank.d94.s16.e2"
            e2="DDI-DrugBank.d94.s16.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s17" text="Thus if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with EQUETROTM, it is reasonable to expect that a dose adjustment may be necessary.">
        <entity id="DDI-DrugBank.d94.s17.e0" charOffset="137-145"
            type="brand" text="EQUETROTM"/>
    </sentence>
    <sentence id="DDI-DrugBank.d94.s18" text="Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.">
        <entity id="DDI-DrugBank.d94.s18.e0" charOffset="63-71"
            type="brand" text="EQUETROTM"/>
        <entity id="DDI-DrugBank.d94.s18.e1" charOffset="93-114"
            type="group" text="centrally acting drugs"/>
        <entity id="DDI-DrugBank.d94.s18.e2" charOffset="120-126"
            type="drug" text="alcohol"/>
        <ddi id="DDI-DrugBank.d94.s18.d0" e1="DDI-DrugBank.d94.s18.e0"
            e2="DDI-DrugBank.d94.s18.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d94.s18.d1" e1="DDI-DrugBank.d94.s18.e0"
            e2="DDI-DrugBank.d94.s18.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d545.s0" text="Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.">
        <entity id="DDI-DrugBank.d545.s0.e0" charOffset="0-8"
            type="brand" text="Geocillin"/>
        <entity id="DDI-DrugBank.d545.s0.e1" charOffset="11-38"
            type="drug" text="carbenicillin indanyl sodium"/>
        <entity id="DDI-DrugBank.d545.s0.e2" charOffset="117-126"
            type="drug" text="probenecid"/>
        <ddi id="DDI-DrugBank.d545.s0.d0" e1="DDI-DrugBank.d545.s0.e0"
            e2="DDI-DrugBank.d545.s0.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d545.s0.d1" e1="DDI-DrugBank.d545.s0.e1"
            e2="DDI-DrugBank.d545.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d47.s0" text="Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.">
        <entity id="DDI-DrugBank.d47.s0.e0" charOffset="89-95"
            type="brand" text="LODOSYN"/>
        <entity id="DDI-DrugBank.d47.s0.e1" charOffset="98-106"
            type="drug" text="Carbidopa"/>
        <entity id="DDI-DrugBank.d47.s0.e2" charOffset="120-127"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d47.s0.e3" charOffset="132-140"
            type="drug" text="carbidopa"/>
        <entity id="DDI-DrugBank.d47.s0.e4" charOffset="142-149"
            type="drug" text="levodopa"/>
    </sentence>
    <sentence id="DDI-DrugBank.d47.s1" text="For patients receiving monoamine oxidase inhibitors, see CONTRAINDICATIONS.">
        <entity id="DDI-DrugBank.d47.s1.e0" charOffset="23-50"
            type="group" text="monoamine oxidase inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d47.s2" text="Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.">
        <entity id="DDI-DrugBank.d47.s2.e0" charOffset="0-31"
            type="group" text="Dopamine D2 receptor antagonists"/>
        <entity id="DDI-DrugBank.d47.s2.e1" charOffset="40-53"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d47.s2.e2" charOffset="56-69"
            type="group" text="butyrophenones"/>
        <entity id="DDI-DrugBank.d47.s2.e3" charOffset="72-82"
            type="drug" text="risperidone"/>
        <entity id="DDI-DrugBank.d47.s2.e4" charOffset="89-97"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d47.s2.e5" charOffset="137-144"
            type="drug" text="levodopa"/>
        <ddi id="DDI-DrugBank.d47.s2.d0" e1="DDI-DrugBank.d47.s2.e0"
            e2="DDI-DrugBank.d47.s2.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d47.s2.d1" e1="DDI-DrugBank.d47.s2.e1"
            e2="DDI-DrugBank.d47.s2.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d47.s2.d2" e1="DDI-DrugBank.d47.s2.e2"
            e2="DDI-DrugBank.d47.s2.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d47.s2.d3" e1="DDI-DrugBank.d47.s2.e3"
            e2="DDI-DrugBank.d47.s2.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d47.s2.d4" e1="DDI-DrugBank.d47.s2.e4"
            e2="DDI-DrugBank.d47.s2.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d47.s3" text="In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.">
        <entity id="DDI-DrugBank.d47.s3.e0" charOffset="39-46"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d47.s3.e1" charOffset="107-115"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d47.s3.e2" charOffset="121-130"
            type="drug" text="papaverine"/>
        <ddi id="DDI-DrugBank.d47.s3.d0" e1="DDI-DrugBank.d47.s3.e0"
            e2="DDI-DrugBank.d47.s3.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d47.s3.d1" e1="DDI-DrugBank.d47.s3.e0"
            e2="DDI-DrugBank.d47.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d47.s4" text="Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.">
        <entity id="DDI-DrugBank.d47.s4.e0" charOffset="33-39"
            type="brand" text="LODOSYN"/>
        <entity id="DDI-DrugBank.d47.s4.e1" charOffset="45-52"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d47.s4.e2" charOffset="57-65"
            type="drug" text="carbidopa"/>
        <entity id="DDI-DrugBank.d47.s4.e3" charOffset="67-74"
            type="drug" text="levodopa"/>
    </sentence>
    <sentence id="DDI-DrugBank.d47.s5" text="Iron salts may reduce the bioavailability of carbidopa and levodopa.">
        <entity id="DDI-DrugBank.d47.s5.e0" charOffset="0-3" type="drug" text="Iron"/>
        <entity id="DDI-DrugBank.d47.s5.e1" charOffset="45-53"
            type="drug" text="carbidopa"/>
        <entity id="DDI-DrugBank.d47.s5.e2" charOffset="59-66"
            type="drug" text="levodopa"/>
        <ddi id="DDI-DrugBank.d47.s5.d0" e1="DDI-DrugBank.d47.s5.e0"
            e2="DDI-DrugBank.d47.s5.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d47.s5.d1" e1="DDI-DrugBank.d47.s5.e0"
            e2="DDI-DrugBank.d47.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d47.s6" text="The clinical relevance is unclear."/>
    <sentence id="DDI-DrugBank.d47.s7" text="Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.">
        <entity id="DDI-DrugBank.d47.s7.e0" charOffset="9-22"
            type="drug" text="metoclopramide"/>
        <entity id="DDI-DrugBank.d47.s7.e1" charOffset="60-67"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d47.s7.e2" charOffset="101-114"
            type="drug" text="metoclopramide"/>
        <ddi id="DDI-DrugBank.d47.s7.d0" e1="DDI-DrugBank.d47.s7.e0"
            e2="DDI-DrugBank.d47.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d213.s0" text="Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.">
        <entity id="DDI-DrugBank.d213.s0.e0" charOffset="0-5"
            type="drug" text="Iodine"/>
        <entity id="DDI-DrugBank.d213.s0.e1" charOffset="10-15"
            type="drug" text="iodine"/>
        <entity id="DDI-DrugBank.d213.s0.e2" charOffset="51-61"
            type="drug" text="Carbimazole"/>
        <entity id="DDI-DrugBank.d213.s0.e3" charOffset="71-76"
            type="drug" text="iodine"/>
        <entity id="DDI-DrugBank.d213.s0.e4" charOffset="116-126"
            type="drug" text="Carbimazole"/>
        <ddi id="DDI-DrugBank.d213.s0.d0" e1="DDI-DrugBank.d213.s0.e0"
            e2="DDI-DrugBank.d213.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d213.s0.d1" e1="DDI-DrugBank.d213.s0.e3"
            e2="DDI-DrugBank.d213.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d213.s1" text="Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.">
        <entity id="DDI-DrugBank.d213.s1.e0" charOffset="23-29"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d213.s1.e1" charOffset="35-43"
            type="drug" text="digitoxin"/>
        <entity id="DDI-DrugBank.d213.s1.e2" charOffset="77-94"
            type="group" text="antithyroid agents"/>
        <ddi id="DDI-DrugBank.d213.s1.d0" e1="DDI-DrugBank.d213.s1.e0"
            e2="DDI-DrugBank.d213.s1.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d213.s1.d1" e1="DDI-DrugBank.d213.s1.e1"
            e2="DDI-DrugBank.d213.s1.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d213.s2" text="A decrease of the dosage may be necessary when patient becomes euthyroid."/>
    <sentence id="DDI-DrugBank.d213.s3" text="Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.">
        <entity id="DDI-DrugBank.d213.s3.e0" charOffset="0-17"
            type="group" text="Antithyroid agents"/>
        <entity id="DDI-DrugBank.d213.s3.e1" charOffset="52-69"
            type="drug" text="sodium iodide I131"/>
        <entity id="DDI-DrugBank.d213.s3.e2" charOffset="142-152"
            type="drug" text="Carbimazole"/>
        <ddi id="DDI-DrugBank.d213.s3.d0" e1="DDI-DrugBank.d213.s3.e0"
            e2="DDI-DrugBank.d213.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d213.s4" text="Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status.">
        <entity id="DDI-DrugBank.d213.s4.e0" charOffset="26-39"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d213.s5" text="An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended">
        <entity id="DDI-DrugBank.d213.s5.e0" charOffset="55-67"
            type="group" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d389.s0" text="Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.">
        <entity id="DDI-DrugBank.d389.s0.e0" charOffset="0-13"
            type="group" text="Antihistamines"/>
        <entity id="DDI-DrugBank.d389.s0.e1" charOffset="42-66"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d389.s0.e2" charOffset="69-80"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d389.s0.e3" charOffset="83-89"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d389.s0.e4" charOffset="102-116"
            type="group" text="CNS depressants"/>
        <ddi id="DDI-DrugBank.d389.s0.d0" e1="DDI-DrugBank.d389.s0.e0"
            e2="DDI-DrugBank.d389.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d389.s0.d1" e1="DDI-DrugBank.d389.s0.e0"
            e2="DDI-DrugBank.d389.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d389.s0.d2" e1="DDI-DrugBank.d389.s0.e0"
            e2="DDI-DrugBank.d389.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d389.s0.d3" e1="DDI-DrugBank.d389.s0.e0"
            e2="DDI-DrugBank.d389.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d389.s1" text="MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.">
        <entity id="DDI-DrugBank.d389.s1.e0" charOffset="0-13"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d389.s1.e1" charOffset="68-81"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d389.s1.d0" e1="DDI-DrugBank.d389.s1.e0"
            e2="DDI-DrugBank.d389.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d389.s2" text="Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.">
        <entity id="DDI-DrugBank.d389.s2.e0" charOffset="0-21"
            type="group" text="Sympathomimetic amines"/>
        <entity id="DDI-DrugBank.d389.s2.e1" charOffset="66-74"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d389.s2.e2" charOffset="77-94"
            type="group" text="veratrum alkaloids"/>
        <entity id="DDI-DrugBank.d389.s2.e3" charOffset="97-106"
            type="drug" text="methyldopa"/>
        <entity id="DDI-DrugBank.d389.s2.e4" charOffset="112-123"
            type="drug" text="mecamylamine"/>
        <ddi id="DDI-DrugBank.d389.s2.d0" e1="DDI-DrugBank.d389.s2.e0"
            e2="DDI-DrugBank.d389.s2.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d389.s2.d1" e1="DDI-DrugBank.d389.s2.e0"
            e2="DDI-DrugBank.d389.s2.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d389.s2.d2" e1="DDI-DrugBank.d389.s2.e0"
            e2="DDI-DrugBank.d389.s2.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d389.s2.d3" e1="DDI-DrugBank.d389.s2.e0"
            e2="DDI-DrugBank.d389.s2.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d389.s3" text="Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.">
        <entity id="DDI-DrugBank.d389.s3.e0" charOffset="11-26"
            type="group" text="sympathomimetics"/>
        <entity id="DDI-DrugBank.d389.s3.e1" charOffset="47-60"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d389.s3.e2" charOffset="66-89"
            type="group" text="beta adrenergic blockers"/>
        <ddi id="DDI-DrugBank.d389.s3.d0" e1="DDI-DrugBank.d389.s3.e0"
            e2="DDI-DrugBank.d389.s3.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d389.s3.d1" e1="DDI-DrugBank.d389.s3.e0"
            e2="DDI-DrugBank.d389.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d520.s0" text="The renal effects of nephrotoxic compounds may be potentiated by Carboplatin.">
        <entity id="DDI-DrugBank.d520.s0.e0" charOffset="65-75"
            type="drug" text="Carboplatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d23.s0" text="HEMABATE may augment the activity of other oxytocic agents.">
        <entity id="DDI-DrugBank.d23.s0.e0" charOffset="0-7"
            type="brand" text="HEMABATE"/>
        <entity id="DDI-DrugBank.d23.s0.e1" charOffset="43-57"
            type="group" text="oxytocic agents"/>
        <ddi id="DDI-DrugBank.d23.s0.d0" e1="DDI-DrugBank.d23.s0.e0"
            e2="DDI-DrugBank.d23.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d23.s1" text="Concomitant use with other oxytocic agents is not recommended">
        <entity id="DDI-DrugBank.d23.s1.e0" charOffset="27-41"
            type="group" text="oxytocic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d23.s2" text="."/>
    <sentence id="DDI-DrugBank.d23.s3" text=""/>
    <sentence id="DDI-DrugBank.d502.s0" text="Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.">
        <entity id="DDI-DrugBank.d502.s0.e0" charOffset="0-7"
            type="brand" text="Ocupress"/>
        <entity id="DDI-DrugBank.d502.s0.e1" charOffset="69-98"
            type="group" text="beta-adrenergic blocking agent"/>
        <ddi id="DDI-DrugBank.d502.s0.d0" e1="DDI-DrugBank.d502.s0.e0"
            e2="DDI-DrugBank.d502.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d502.s1" text="Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.">
        <entity id="DDI-DrugBank.d502.s1.e0" charOffset="55-66"
            type="group" text="beta-blocker"/>
        <entity id="DDI-DrugBank.d502.s1.e1" charOffset="144-152"
            type="drug" text="reserpine"/>
        <ddi id="DDI-DrugBank.d502.s1.d0" e1="DDI-DrugBank.d502.s1.e0"
            e2="DDI-DrugBank.d502.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s0" text="Inhibitors of CYP2D6;"/>
    <sentence id="DDI-DrugBank.d269.s1" text="poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .">
        <entity id="DDI-DrugBank.d269.s1.e0" charOffset="21-31"
            type="drug" text="debrisoquin"/>
        <entity id="DDI-DrugBank.d269.s1.e1" charOffset="50-59"
            type="drug" text="carvedilol"/>
        <entity id="DDI-DrugBank.d269.s1.e2" charOffset="103-111"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d269.s1.e3" charOffset="114-123"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d269.s1.e4" charOffset="126-135"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d269.s1.e5" charOffset="142-152"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d269.s1.e6" charOffset="263-272"
            type="drug" text="carvedilol"/>
        <ddi id="DDI-DrugBank.d269.s1.d0" e1="DDI-DrugBank.d269.s1.e2"
            e2="DDI-DrugBank.d269.s1.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d269.s1.d1" e1="DDI-DrugBank.d269.s1.e3"
            e2="DDI-DrugBank.d269.s1.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d269.s1.d2" e1="DDI-DrugBank.d269.s1.e4"
            e2="DDI-DrugBank.d269.s1.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d269.s1.d3" e1="DDI-DrugBank.d269.s1.e5"
            e2="DDI-DrugBank.d269.s1.e6" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s2" text="Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the a-blocking R(+) enantiomer."/>
    <sentence id="DDI-DrugBank.d269.s3" text="Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.">
        <entity id="DDI-DrugBank.d269.s3.e0" charOffset="53-85"
            type="group" text="agents with b-blocking properties"/>
        <entity id="DDI-DrugBank.d269.s3.e1" charOffset="137-145"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d269.s3.e2" charOffset="151-178"
            type="group" text="monoamine oxidase inhibitors"/>
        <ddi id="DDI-DrugBank.d269.s3.d0" e1="DDI-DrugBank.d269.s3.e0"
            e2="DDI-DrugBank.d269.s3.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d269.s3.d1" e1="DDI-DrugBank.d269.s3.e0"
            e2="DDI-DrugBank.d269.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s4" text="Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.">
        <entity id="DDI-DrugBank.d269.s4.e0" charOffset="0-8"
            type="drug" text="Clonidine"/>
        <entity id="DDI-DrugBank.d269.s4.e1" charOffset="41-49"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d269.s4.e2" charOffset="56-88"
            type="group" text="agents with b-blocking properties"/>
        <ddi id="DDI-DrugBank.d269.s4.d0" e1="DDI-DrugBank.d269.s4.e1"
            e2="DDI-DrugBank.d269.s4.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s5" text="When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.">
        <entity id="DDI-DrugBank.d269.s5.e0" charOffset="32-64"
            type="group" text="agents with b-blocking properties"/>
        <entity id="DDI-DrugBank.d269.s5.e1" charOffset="70-78"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d269.s5.e2" charOffset="105-120"
            type="group" text="b-blocking agent"/>
        <ddi id="DDI-DrugBank.d269.s5.d0" e1="DDI-DrugBank.d269.s5.e0"
            e2="DDI-DrugBank.d269.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s6" text="Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage.">
        <entity id="DDI-DrugBank.d269.s6.e0" charOffset="0-8"
            type="drug" text="Clonidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s7" text="Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.">
        <entity id="DDI-DrugBank.d269.s7.e0" charOffset="0-11"
            type="drug" text="Cyclosporine"/>
        <entity id="DDI-DrugBank.d269.s7.e1" charOffset="46-57"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d269.s7.e2" charOffset="112-121"
            type="drug" text="carvedilol"/>
        <ddi id="DDI-DrugBank.d269.s7.d0" e1="DDI-DrugBank.d269.s7.e1"
            e2="DDI-DrugBank.d269.s7.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s8" text="In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed.">
        <entity id="DDI-DrugBank.d269.s8.e0" charOffset="38-49"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d269.s8.e1" charOffset="90-101"
            type="drug" text="cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s9" text="On the average for the group, the dose of cyclosporine was reduced about 20% in these patients.">
        <entity id="DDI-DrugBank.d269.s9.e0" charOffset="42-53"
            type="drug" text="cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s10" text="Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.">
        <entity id="DDI-DrugBank.d269.s10.e0" charOffset="96-107"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d269.s10.e1" charOffset="165-174"
            type="drug" text="carvedilol"/>
        <entity id="DDI-DrugBank.d269.s10.e2" charOffset="205-216"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d269.s10.d0" e1="DDI-DrugBank.d269.s10.e0"
            e2="DDI-DrugBank.d269.s10.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d269.s10.d1" e1="DDI-DrugBank.d269.s10.e1"
            e2="DDI-DrugBank.d269.s10.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s11" text="Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.">
        <entity id="DDI-DrugBank.d269.s11.e0" charOffset="0-6"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d269.s11.e1" charOffset="9-15"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d269.s11.e2" charOffset="64-70"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d269.s11.e3" charOffset="76-85"
            type="drug" text="carvedilol"/>
        <ddi id="DDI-DrugBank.d269.s11.d0" e1="DDI-DrugBank.d269.s11.e2"
            e2="DDI-DrugBank.d269.s11.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s12" text="Both digoxin and COREG slow AV conduction.">
        <entity id="DDI-DrugBank.d269.s12.e0" charOffset="5-11"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d269.s12.e1" charOffset="17-21"
            type="brand" text="COREG"/>
        <ddi id="DDI-DrugBank.d269.s12.d0" e1="DDI-DrugBank.d269.s12.e0"
            e2="DDI-DrugBank.d269.s12.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s13" text="Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.">
        <entity id="DDI-DrugBank.d269.s13.e0" charOffset="35-41"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d269.s13.e1" charOffset="103-107"
            type="brand" text="COREG"/>
        <ddi id="DDI-DrugBank.d269.s13.d0" e1="DDI-DrugBank.d269.s13.e0"
            e2="DDI-DrugBank.d269.s13.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s14" text="Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.">
        <entity id="DDI-DrugBank.d269.s14.e0" charOffset="47-54"
            type="drug" text="Rifampin"/>
        <entity id="DDI-DrugBank.d269.s14.e1" charOffset="89-98"
            type="drug" text="carvedilol"/>
        <ddi id="DDI-DrugBank.d269.s14.d0" e1="DDI-DrugBank.d269.s14.e0"
            e2="DDI-DrugBank.d269.s14.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s15" text="Cimetidine increased AUC by about 30% but caused no change in Cmax.">
        <entity id="DDI-DrugBank.d269.s15.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s16" text="Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.">
        <entity id="DDI-DrugBank.d269.s16.e0" charOffset="0-23"
            type="group" text="Calcium Channel Blockers"/>
        <entity id="DDI-DrugBank.d269.s16.e1" charOffset="128-132"
            type="brand" text="COREG"/>
        <entity id="DDI-DrugBank.d269.s16.e2" charOffset="158-166"
            type="drug" text="diltiazem"/>
        <ddi id="DDI-DrugBank.d269.s16.d0" e1="DDI-DrugBank.d269.s16.e1"
            e2="DDI-DrugBank.d269.s16.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s17" text="As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.">
        <entity id="DDI-DrugBank.d269.s17.e0" charOffset="14-46"
            type="group" text="agents with b-blocking properties"/>
        <entity id="DDI-DrugBank.d269.s17.e1" charOffset="52-56"
            type="brand" text="COREG"/>
        <entity id="DDI-DrugBank.d269.s17.e2" charOffset="92-115"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d269.s17.e3" charOffset="124-132"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d269.s17.e4" charOffset="137-145"
            type="drug" text="diltiazem"/>
        <ddi id="DDI-DrugBank.d269.s17.d0" e1="DDI-DrugBank.d269.s17.e1"
            e2="DDI-DrugBank.d269.s17.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d269.s17.d1" e1="DDI-DrugBank.d269.s17.e1"
            e2="DDI-DrugBank.d269.s17.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s18" text="Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.">
        <entity id="DDI-DrugBank.d269.s18.e0" charOffset="0-6"
            type="drug" text="Insulin"/>
        <entity id="DDI-DrugBank.d269.s18.e1" charOffset="16-28"
            type="group" text="Hypoglycemics"/>
        <entity id="DDI-DrugBank.d269.s18.e2" charOffset="31-63"
            type="group" text="Agents with b-blocking properties"/>
        <entity id="DDI-DrugBank.d269.s18.e3" charOffset="112-118"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d269.s18.e4" charOffset="129-141"
            type="group" text="hypoglycemics"/>
        <ddi id="DDI-DrugBank.d269.s18.d0" e1="DDI-DrugBank.d269.s18.e2"
            e2="DDI-DrugBank.d269.s18.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d269.s18.d1" e1="DDI-DrugBank.d269.s18.e2"
            e2="DDI-DrugBank.d269.s18.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s19" text="Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended.">
        <entity id="DDI-DrugBank.d269.s19.e0" charOffset="30-36"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d269.s19.e1" charOffset="46-58"
            type="group" text="hypoglycemics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s0" text="Studies in vitro show that caspofungin acetate is not an inhibitor of any enzyme in the cytochrome P450 (CYP) system.">
        <entity id="DDI-DrugBank.d350.s0.e0" charOffset="27-45"
            type="drug" text="caspofungin acetate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s1" text="In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other drugs.">
        <entity id="DDI-DrugBank.d350.s1.e0" charOffset="21-31"
            type="drug" text="caspofungin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s2" text="Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes.">
        <entity id="DDI-DrugBank.d350.s2.e0" charOffset="0-10"
            type="drug" text="Caspofungin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s3" text="Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.">
        <entity id="DDI-DrugBank.d350.s3.e0" charOffset="73-80"
            type="brand" text="CANCIDAS"/>
        <entity id="DDI-DrugBank.d350.s3.e1" charOffset="101-112"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d350.s3.e2" charOffset="115-128"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d350.s3.e3" charOffset="131-143"
            type="drug" text="mycophenolate"/>
        <entity id="DDI-DrugBank.d350.s3.e4" charOffset="146-155"
            type="drug" text="nelfinavir"/>
        <entity id="DDI-DrugBank.d350.s3.e5" charOffset="161-170"
            type="drug" text="tacrolimus"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s4" text="CANCIDAS has no effect on the pharmacokinetics of itraconazole, amphotericin B, or the active metabolite of mycophenolate.">
        <entity id="DDI-DrugBank.d350.s4.e0" charOffset="0-7"
            type="brand" text="CANCIDAS"/>
        <entity id="DDI-DrugBank.d350.s4.e1" charOffset="50-61"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d350.s4.e2" charOffset="64-77"
            type="drug" text="amphotericin B"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s5" text="CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.">
        <entity id="DDI-DrugBank.d350.s5.e0" charOffset="0-7"
            type="brand" text="CANCIDAS"/>
        <entity id="DDI-DrugBank.d350.s5.e1" charOffset="38-47"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d350.s5.e2" charOffset="183-192"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d350.s5.e3" charOffset="268-275"
            type="brand" text="CANCIDAS"/>
        <entity id="DDI-DrugBank.d350.s5.e4" charOffset="344-353"
            type="drug" text="tacrolimus"/>
        <ddi id="DDI-DrugBank.d350.s5.d0" e1="DDI-DrugBank.d350.s5.e0"
            e2="DDI-DrugBank.d350.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s6" text="For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.">
        <entity id="DDI-DrugBank.d350.s6.e0" charOffset="62-71"
            type="drug" text="tacrolimus"/>
        <entity id="DDI-DrugBank.d350.s6.e1" charOffset="110-119"
            type="drug" text="tacrolimus"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s7" text="In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.">
        <entity id="DDI-DrugBank.d350.s7.e0" charOffset="25-36"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d350.s7.e1" charOffset="99-109"
            type="drug" text="caspofungin"/>
        <ddi id="DDI-DrugBank.d350.s7.d0" e1="DDI-DrugBank.d350.s7.e0"
            e2="DDI-DrugBank.d350.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s8" text="CANCIDAS did not increase the plasma levels of cyclosporine.">
        <entity id="DDI-DrugBank.d350.s8.e0" charOffset="0-7"
            type="brand" text="CANCIDAS"/>
        <entity id="DDI-DrugBank.d350.s8.e1" charOffset="47-58"
            type="drug" text="cyclosporine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s9" text="There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.">
        <entity id="DDI-DrugBank.d350.s9.e0" charOffset="57-64"
            type="brand" text="CANCIDAS"/>
        <entity id="DDI-DrugBank.d350.s9.e1" charOffset="70-81"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d350.s9.d0" e1="DDI-DrugBank.d350.s9.e0"
            e2="DDI-DrugBank.d350.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s10" text="A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.">
        <entity id="DDI-DrugBank.d350.s10.e0" charOffset="35-42"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d350.s10.e1" charOffset="94-104"
            type="drug" text="caspofungin"/>
        <ddi id="DDI-DrugBank.d350.s10.d0" e1="DDI-DrugBank.d350.s10.e0"
            e2="DDI-DrugBank.d350.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s11" text="Patients on rifampin should receive 70 mg of CANCIDAS daily.">
        <entity id="DDI-DrugBank.d350.s11.e0" charOffset="12-19"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d350.s11.e1" charOffset="45-52"
            type="brand" text="CANCIDAS"/>
        <ddi id="DDI-DrugBank.d350.s11.d0" e1="DDI-DrugBank.d350.s11.e0"
            e2="DDI-DrugBank.d350.s11.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s12" text="In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.">
        <entity id="DDI-DrugBank.d350.s12.e0" charOffset="146-154"
            type="drug" text="efavirenz"/>
        <entity id="DDI-DrugBank.d350.s12.e1" charOffset="157-166"
            type="drug" text="nevirapine"/>
        <entity id="DDI-DrugBank.d350.s12.e2" charOffset="169-177"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d350.s12.e3" charOffset="180-192"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d350.s12.e4" charOffset="198-210"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d350.s12.e5" charOffset="218-225"
            type="brand" text="CANCIDAS"/>
        <entity id="DDI-DrugBank.d350.s12.e6" charOffset="277-287"
            type="drug" text="caspofungin"/>
        <ddi id="DDI-DrugBank.d350.s12.d0" e1="DDI-DrugBank.d350.s12.e0"
            e2="DDI-DrugBank.d350.s12.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d350.s12.d1" e1="DDI-DrugBank.d350.s12.e1"
            e2="DDI-DrugBank.d350.s12.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d350.s12.d2" e1="DDI-DrugBank.d350.s12.e2"
            e2="DDI-DrugBank.d350.s12.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d350.s12.d3" e1="DDI-DrugBank.d350.s12.e3"
            e2="DDI-DrugBank.d350.s12.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d350.s12.d4" e1="DDI-DrugBank.d350.s12.e4"
            e2="DDI-DrugBank.d350.s12.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s13" text="It is not known which drug clearance mechanism involved in caspofungin disposition may be inducible.">
        <entity id="DDI-DrugBank.d350.s13.e0" charOffset="59-69"
            type="drug" text="caspofungin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s14" text="When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered">
        <entity id="DDI-DrugBank.d350.s14.e0" charOffset="5-12"
            type="brand" text="CANCIDAS"/>
        <entity id="DDI-DrugBank.d350.s14.e1" charOffset="74-82"
            type="drug" text="efavirenz"/>
        <entity id="DDI-DrugBank.d350.s14.e2" charOffset="85-94"
            type="drug" text="nevirapine"/>
        <entity id="DDI-DrugBank.d350.s14.e3" charOffset="97-105"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d350.s14.e4" charOffset="108-120"
            type="drug" text="dexamethasone"/>
        <entity id="DDI-DrugBank.d350.s14.e5" charOffset="126-138"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d350.s14.e6" charOffset="173-180"
            type="brand" text="CANCIDAS"/>
        <ddi id="DDI-DrugBank.d350.s14.d0" e1="DDI-DrugBank.d350.s14.e0"
            e2="DDI-DrugBank.d350.s14.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d350.s14.d1" e1="DDI-DrugBank.d350.s14.e0"
            e2="DDI-DrugBank.d350.s14.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d350.s14.d2" e1="DDI-DrugBank.d350.s14.e0"
            e2="DDI-DrugBank.d350.s14.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d350.s14.d3" e1="DDI-DrugBank.d350.s14.e0"
            e2="DDI-DrugBank.d350.s14.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d350.s14.d4" e1="DDI-DrugBank.d350.s14.e0"
            e2="DDI-DrugBank.d350.s14.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d350.s15" text="."/>
    <sentence id="DDI-DrugBank.d350.s16" text=""/>
    <sentence id="DDI-DrugBank.d557.s0" text="Drug/Laboratory Test Interactions Positive direct Coombs  tests have been reported during treatment with the cephalosporin antibiotics.">
        <entity id="DDI-DrugBank.d557.s0.e0" charOffset="109-133"
            type="group" text="cephalosporin antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d557.s1" text="In hematologic studies or in transfusion cross-matching procedures when anti-globulin tests are performed on the minor side or in Coombs  testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs  test may be due to the drug.">
        <entity id="DDI-DrugBank.d557.s1.e0" charOffset="186-210"
            type="group" text="cephalosporin antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d281.s0" text="Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.">
        <entity id="DDI-DrugBank.d281.s0.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d281.s0.e1" charOffset="51-64"
            type="group" text="cephalosporins"/>
        <entity id="DDI-DrugBank.d281.s0.e2" charOffset="132-144"
            type="group" text="cephalosporin"/>
        <ddi id="DDI-DrugBank.d281.s0.d0" e1="DDI-DrugBank.d281.s0.e0"
            e2="DDI-DrugBank.d281.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d281.s1" text="Drug/Laboratory Test Interactions A false positive reaction for glucose in the urine may occur with Benedicts solution, Fehlings solution or with CLINITEST  tablets, but not with enzyme-based tests such as CLINISTIX ."/>
    <sentence id="DDI-DrugBank.d281.s2" text="Positive direct and indirect antiglobulin (Coombs) tests have occurred;"/>
    <sentence id="DDI-DrugBank.d281.s3" text="these may also occur in neonates whose mothers received cephalosporins before delivery.">
        <entity id="DDI-DrugBank.d281.s3.e0" charOffset="56-69"
            type="group" text="cephalosporins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s0" text="Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.">
        <entity id="DDI-DrugBank.d420.s0.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d420.s0.e1" charOffset="10-17"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d420.s0.e2" charOffset="23-31"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d420.s0.e3" charOffset="83-90"
            type="drug" text="cefdinir"/>
        <entity id="DDI-DrugBank.d420.s0.e4" charOffset="112-120"
            type="brand" text="Maalox TC"/>
        <ddi id="DDI-DrugBank.d420.s0.d0" e1="DDI-DrugBank.d420.s0.e3"
            e2="DDI-DrugBank.d420.s0.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s1" text="Time to reach Cmax is also prolonged by 1 hour."/>
    <sentence id="DDI-DrugBank.d420.s2" text="There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.">
        <entity id="DDI-DrugBank.d420.s2.e0" charOffset="36-43"
            type="drug" text="cefdinir"/>
        <entity id="DDI-DrugBank.d420.s2.e1" charOffset="69-75"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d420.s2.e2" charOffset="125-132"
            type="drug" text="cefdinir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s3" text="If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.">
        <entity id="DDI-DrugBank.d420.s3.e0" charOffset="3-10"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d420.s3.e1" charOffset="32-38"
            type="brand" text="OMNICEF"/>
        <entity id="DDI-DrugBank.d420.s3.e2" charOffset="49-55"
            type="brand" text="OMNICEF"/>
        <entity id="DDI-DrugBank.d420.s3.e3" charOffset="110-116"
            type="group" text="antacid"/>
        <ddi id="DDI-DrugBank.d420.s3.d0" e1="DDI-DrugBank.d420.s3.e2"
            e2="DDI-DrugBank.d420.s3.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s4" text="Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.">
        <entity id="DDI-DrugBank.d420.s4.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d420.s4.e1" charOffset="26-45"
            type="group" text="b-lactam antibiotics"/>
        <entity id="DDI-DrugBank.d420.s4.e2" charOffset="48-57"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d420.s4.e3" charOffset="91-98"
            type="drug" text="cefdinir"/>
        <entity id="DDI-DrugBank.d420.s4.e4" charOffset="169-176"
            type="drug" text="cefdinir"/>
        <ddi id="DDI-DrugBank.d420.s4.d0" e1="DDI-DrugBank.d420.s4.e1"
            e2="DDI-DrugBank.d420.s4.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d420.s4.d1" e1="DDI-DrugBank.d420.s4.e2"
            e2="DDI-DrugBank.d420.s4.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s5" text="Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.">
        <entity id="DDI-DrugBank.d420.s5.e0" charOffset="0-15"
            type="group" text="Iron Supplements"/>
        <entity id="DDI-DrugBank.d420.s5.e1" charOffset="42-45"
            type="drug" text="Iron"/>
        <entity id="DDI-DrugBank.d420.s5.e2" charOffset="77-84"
            type="drug" text="cefdinir"/>
        <entity id="DDI-DrugBank.d420.s5.e3" charOffset="105-119"
            type="group" text="iron supplement"/>
        <entity id="DDI-DrugBank.d420.s5.e4" charOffset="151-154"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d420.s5.e5" charOffset="170-177"
            type="group" text="vitamins"/>
        <entity id="DDI-DrugBank.d420.s5.e6" charOffset="216-219"
            type="drug" text="iron"/>
        <ddi id="DDI-DrugBank.d420.s5.d0" e1="DDI-DrugBank.d420.s5.e2"
            e2="DDI-DrugBank.d420.s5.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d420.s5.d1" e1="DDI-DrugBank.d420.s5.e2"
            e2="DDI-DrugBank.d420.s5.e6" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s6" text="If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.">
        <entity id="DDI-DrugBank.d420.s6.e0" charOffset="3-18"
            type="group" text="iron supplements"/>
        <entity id="DDI-DrugBank.d420.s6.e1" charOffset="40-46"
            type="brand" text="OMNICEF"/>
        <entity id="DDI-DrugBank.d420.s6.e2" charOffset="57-63"
            type="brand" text="OMNICEF"/>
        <ddi id="DDI-DrugBank.d420.s6.d0" e1="DDI-DrugBank.d420.s6.e0"
            e2="DDI-DrugBank.d420.s6.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s7" text="The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.">
        <entity id="DDI-DrugBank.d420.s7.e0" charOffset="52-55"
            type="drug_n" text="iron"/>
        <entity id="DDI-DrugBank.d420.s7.e1" charOffset="68-71"
            type="drug_n" text="iron"/>
        <entity id="DDI-DrugBank.d420.s7.e2" charOffset="105-112"
            type="drug" text="cefdinir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s8" text="Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.">
        <entity id="DDI-DrugBank.d420.s8.e0" charOffset="27-30"
            type="drug_n" text="iron"/>
        <entity id="DDI-DrugBank.d420.s8.e1" charOffset="75-78"
            type="drug_n" text="iron"/>
        <entity id="DDI-DrugBank.d420.s8.e2" charOffset="115-122"
            type="drug" text="cefdinir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s9" text="Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula.">
        <entity id="DDI-DrugBank.d420.s9.e0" charOffset="11-17"
            type="brand" text="OMNICEF"/>
        <entity id="DDI-DrugBank.d420.s9.e1" charOffset="64-67"
            type="drug_n" text="iron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s10" text="There have been rare reports of reddish stools in patients who have received cefdinir in Japan.">
        <entity id="DDI-DrugBank.d420.s10.e0" charOffset="77-84"
            type="drug" text="cefdinir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s11" text="The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.">
        <entity id="DDI-DrugBank.d420.s11.e0" charOffset="77-84"
            type="drug" text="cefdinir"/>
        <entity id="DDI-DrugBank.d420.s11.e1" charOffset="116-119"
            type="drug" text="iron"/>
        <ddi id="DDI-DrugBank.d420.s11.d0" e1="DDI-DrugBank.d420.s11.e0"
            e2="DDI-DrugBank.d420.s11.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s12" text="Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide.">
        <entity id="DDI-DrugBank.d420.s12.e0" charOffset="112-124"
            type="drug" text="nitroprusside"/>
        <entity id="DDI-DrugBank.d420.s12.e1" charOffset="152-168"
            type="drug" text="nitroferricyanide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s13" text="The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest , Benedict s solution, or Fehlings solution.">
        <entity id="DDI-DrugBank.d420.s13.e0" charOffset="22-29"
            type="drug" text="cefdinir"/>
    </sentence>
    <sentence id="DDI-DrugBank.d420.s14" text="It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix  or Tes-Tape ) be used."/>
    <sentence id="DDI-DrugBank.d420.s15" text="Cephalosporins are known to occasionally induce a positive direct Coombs  test.">
        <entity id="DDI-DrugBank.d420.s15.e0" charOffset="0-13"
            type="group" text="Cephalosporins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d550.s0" text="Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.">
        <entity id="DDI-DrugBank.d550.s0.e0" charOffset="5-18"
            type="group" text="Contraceptives"/>
        <entity id="DDI-DrugBank.d550.s0.e1" charOffset="38-55"
            type="drug" text="cefditoren pivoxil"/>
        <entity id="DDI-DrugBank.d550.s0.e2" charOffset="98-114"
            type="drug" text="ethinyl estradiol"/>
        <entity id="DDI-DrugBank.d550.s0.e3" charOffset="155-168"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d550.s1" text="Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.">
        <entity id="DDI-DrugBank.d550.s1.e0" charOffset="76-93"
            type="drug" text="cefditoren pivoxil"/>
        <entity id="DDI-DrugBank.d550.s1.e1" charOffset="123-130"
            type="group" text="antacids"/>
        <ddi id="DDI-DrugBank.d550.s1.d0" e1="DDI-DrugBank.d550.s1.e0"
            e2="DDI-DrugBank.d550.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d550.s2" text="H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.">
        <entity id="DDI-DrugBank.d550.s2.e0" charOffset="0-22"
            type="group" text="H2-Receptor Antagonists"/>
        <entity id="DDI-DrugBank.d550.s2.e1" charOffset="90-99"
            type="drug" text="famotidine"/>
        <entity id="DDI-DrugBank.d550.s2.e2" charOffset="164-181"
            type="drug" text="cefditoren pivoxil"/>
        <ddi id="DDI-DrugBank.d550.s2.d0" e1="DDI-DrugBank.d550.s2.e1"
            e2="DDI-DrugBank.d550.s2.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d550.s3" text="Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with H2 receptor antagonists.">
        <entity id="DDI-DrugBank.d550.s3.e0" charOffset="76-93"
            type="drug" text="cefditoren pivoxil"/>
        <entity id="DDI-DrugBank.d550.s3.e1" charOffset="123-145"
            type="group" text="H2 receptor antagonists"/>
    </sentence>
    <sentence id="DDI-DrugBank.d550.s4" text="Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.">
        <entity id="DDI-DrugBank.d550.s4.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d550.s4.e1" charOffset="26-45"
            type="group" text="b-lactam antibiotics"/>
        <entity id="DDI-DrugBank.d550.s4.e2" charOffset="69-78"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d550.s4.e3" charOffset="85-102"
            type="drug" text="cefditoren pivoxil"/>
        <entity id="DDI-DrugBank.d550.s4.e4" charOffset="154-163"
            type="drug" text="cefditoren"/>
        <ddi id="DDI-DrugBank.d550.s4.d0" e1="DDI-DrugBank.d550.s4.e1"
            e2="DDI-DrugBank.d550.s4.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d550.s4.d1" e1="DDI-DrugBank.d550.s4.e2"
            e2="DDI-DrugBank.d550.s4.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d550.s5" text="Drug/Laboratory Test Interactions Cephalosporins are known to occasionally induce a positive direct Coombs test.">
        <entity id="DDI-DrugBank.d550.s5.e0" charOffset="34-47"
            type="group" text="Cephalosporins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d550.s6" text="A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedicts or Fehlings solution or with CLINITEST tablets), but not with enzyme-based tests for glycosuria (e.g., CLINISTIX, TES-TAPE)."/>
    <sentence id="DDI-DrugBank.d550.s7" text="As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood/plasma glucose levels in patients receiving cefditoren pivoxil.">
        <entity id="DDI-DrugBank.d550.s7.e0" charOffset="205-222"
            type="drug" text="cefditoren pivoxil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d378.s0" text="Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.">
        <entity id="DDI-DrugBank.d378.s0.e0" charOffset="62-76"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d378.s0.e1" charOffset="106-113"
            type="brand" text="MAXIPIME"/>
        <entity id="DDI-DrugBank.d378.s0.e2" charOffset="187-212"
            type="group" text="aminoglycoside antibiotics"/>
        <ddi id="DDI-DrugBank.d378.s0.d0" e1="DDI-DrugBank.d378.s0.e0"
            e2="DDI-DrugBank.d378.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d378.s1" text="Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.">
        <entity id="DDI-DrugBank.d378.s1.e0" charOffset="79-92"
            type="group" text="cephalosporins"/>
        <entity id="DDI-DrugBank.d378.s1.e1" charOffset="106-114"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d378.s1.e2" charOffset="124-133"
            type="drug" text="furosemide"/>
        <ddi id="DDI-DrugBank.d378.s1.d0" e1="DDI-DrugBank.d378.s1.e0"
            e2="DDI-DrugBank.d378.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d378.s1.d1" e1="DDI-DrugBank.d378.s1.e0"
            e2="DDI-DrugBank.d378.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d378.s2" text="Drug/Laboratory Test Interactions The administration of cefepime may result in a false-positive reaction for glucose in the urine when using Clinitest  tablets.">
        <entity id="DDI-DrugBank.d378.s2.e0" charOffset="56-63"
            type="drug" text="cefepime"/>
    </sentence>
    <sentence id="DDI-DrugBank.d378.s3" text="It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix  or Tes-Tape  ) be used."/>
    <sentence id="DDI-DrugBank.d339.s0" text="Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.">
        <entity id="DDI-DrugBank.d339.s0.e0" charOffset="0-12"
            type="drug" text="Carbamazepine"/>
        <entity id="DDI-DrugBank.d339.s0.e1" charOffset="24-36"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d339.s0.e2" charOffset="97-102"
            type="brand" text="SUPRAX"/>
        <ddi id="DDI-DrugBank.d339.s0.d0" e1="DDI-DrugBank.d339.s0.e1"
            e2="DDI-DrugBank.d339.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d339.s1" text="Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations.">
        <entity id="DDI-DrugBank.d339.s1.e0" charOffset="65-77"
            type="drug" text="carbamazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d339.s2" text="Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.">
        <entity id="DDI-DrugBank.d339.s2.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d339.s2.e1" charOffset="13-26"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d339.s2.e2" charOffset="115-122"
            type="drug" text="cefixime"/>
        <ddi id="DDI-DrugBank.d339.s2.d0" e1="DDI-DrugBank.d339.s2.e0"
            e2="DDI-DrugBank.d339.s2.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d339.s2.d1" e1="DDI-DrugBank.d339.s2.e1"
            e2="DDI-DrugBank.d339.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d339.s3" text="Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide.">
        <entity id="DDI-DrugBank.d339.s3.e0" charOffset="112-124"
            type="drug" text="nitroprusside"/>
        <entity id="DDI-DrugBank.d339.s3.e1" charOffset="151-167"
            type="drug" text="nitroferricyanide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d339.s4" text="The administration of SUPRAX may result in a false-positive reaction for glucose in the urine using Clinitest **, Benedict s solution, or Fehling s solution.">
        <entity id="DDI-DrugBank.d339.s4.e0" charOffset="22-27"
            type="brand" text="SUPRAX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d339.s5" text="It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix ** or Tes-Tape **) be used."/>
    <sentence id="DDI-DrugBank.d339.s6" text="A false-positive direct Coombs test has been reported during treatment with other cephalosporin antibiotics;">
        <entity id="DDI-DrugBank.d339.s6.e0" charOffset="82-106"
            type="group" text="cephalosporin antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d339.s7" text="therefore, it should be recognized that a positive Coombs test may be due to the drug."/>
    <sentence id="DDI-DrugBank.d100.s0" text="Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.">
        <entity id="DDI-DrugBank.d100.s0.e0" charOffset="83-96"
            type="group" text="cephalosporins"/>
        <entity id="DDI-DrugBank.d100.s0.e1" charOffset="102-127"
            type="group" text="aminoglycoside antibiotics"/>
        <ddi id="DDI-DrugBank.d100.s0.d0" e1="DDI-DrugBank.d100.s0.e0"
            e2="DDI-DrugBank.d100.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d100.s1" text="Drug/Laboratory Test Interactions Cephalosporins, including cefotaxime sodium, are known to occasionally induce a positive direct Coombs test.">
        <entity id="DDI-DrugBank.d100.s1.e0" charOffset="34-47"
            type="group" text="Cephalosporins"/>
        <entity id="DDI-DrugBank.d100.s1.e1" charOffset="60-76"
            type="drug" text="cefotaxime sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d483.s0" text="Increases in serum creatinine have occurred when CEFOTAN was given alone.">
        <entity id="DDI-DrugBank.d483.s0.e0" charOffset="49-55"
            type="brand" text="CEFOTAN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d483.s1" text="If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.">
        <entity id="DDI-DrugBank.d483.s1.e0" charOffset="3-9"
            type="brand" text="CEFOTAN"/>
        <entity id="DDI-DrugBank.d483.s1.e1" charOffset="18-31"
            type="group" text="aminoglycoside"/>
        <ddi id="DDI-DrugBank.d483.s1.d0" e1="DDI-DrugBank.d483.s1.e0"
            e2="DDI-DrugBank.d483.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d483.s2" text="Drug/Laboratory Test Interactions: The administration of CEFOTAN may result in a false positive reaction for glucose in the urine using Clinitest  , Benedicts solution, or Fehlings solution.">
        <entity id="DDI-DrugBank.d483.s2.e0" charOffset="57-63"
            type="brand" text="CEFOTAN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d483.s3" text="It is recommended that glucose tests based on enzymatic glucose oxidase be used."/>
    <sentence id="DDI-DrugBank.d483.s4" text="As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by Jaffe  reaction and produce false increases in the levels of creatinine reported.">
        <entity id="DDI-DrugBank.d483.s4.e0" charOffset="14-27"
            type="group" text="cephalosporins"/>
        <entity id="DDI-DrugBank.d483.s4.e1" charOffset="53-61"
            type="drug" text="cefotetan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d556.s0" text="Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.">
        <entity id="DDI-DrugBank.d556.s0.e0" charOffset="83-96"
            type="group" text="cephalosporins"/>
        <entity id="DDI-DrugBank.d556.s0.e1" charOffset="102-127"
            type="group" text="aminoglycoside antibiotics"/>
        <ddi id="DDI-DrugBank.d556.s0.d0" e1="DDI-DrugBank.d556.s0.e0"
            e2="DDI-DrugBank.d556.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d556.s1" text="Drug/Laboratory Test Interactions As with cephalothin, high concentrations of cefoxitin ( 100 micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the Jaff  reaction, and produce false increases of modest degree in the levels of creatinine reported.">
        <entity id="DDI-DrugBank.d556.s1.e0" charOffset="42-52"
            type="drug" text="cephalothin"/>
        <entity id="DDI-DrugBank.d556.s1.e1" charOffset="78-86"
            type="drug" text="cefoxitin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d556.s2" text="Serum samples from patients treated with cefoxitin should not be analyzed for creatinine if withdrawn within 2 hours of drug administration.">
        <entity id="DDI-DrugBank.d556.s2.e0" charOffset="41-49"
            type="drug" text="cefoxitin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d556.s3" text="High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported.">
        <entity id="DDI-DrugBank.d556.s3.e0" charOffset="23-31"
            type="drug" text="cefoxitin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d556.s4" text="A false-positive reaction for glucose in the urine may occur."/>
    <sentence id="DDI-DrugBank.d556.s5" text="This has been observed with CLINITEST  reagent tablets"/>
    <sentence id="DDI-DrugBank.d556.s6" text="."/>
    <sentence id="DDI-DrugBank.d556.s7" text="Registered trademark of Ames Company, Division of Miles Laboratories, Inc."/>
    <sentence id="DDI-DrugBank.d121.s0" text="Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.">
        <entity id="DDI-DrugBank.d121.s0.e0" charOffset="73-98"
            type="group" text="aminoglycoside antibiotics"/>
        <entity id="DDI-DrugBank.d121.s0.e1" charOffset="104-128"
            type="group" text="cephalosporin antibiotics"/>
        <ddi id="DDI-DrugBank.d121.s0.d0" e1="DDI-DrugBank.d121.s0.e0"
            e2="DDI-DrugBank.d121.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d121.s1" text="Concomitant administration of probenecid doubled the AUC for cefprozil.">
        <entity id="DDI-DrugBank.d121.s1.e0" charOffset="30-39"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d121.s1.e1" charOffset="61-69"
            type="drug" text="cefprozil"/>
        <ddi id="DDI-DrugBank.d121.s1.d0" e1="DDI-DrugBank.d121.s1.e0"
            e2="DDI-DrugBank.d121.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d121.s2" text="The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.">
        <entity id="DDI-DrugBank.d121.s2.e0" charOffset="50-58"
            type="drug" text="cefprozil"/>
        <entity id="DDI-DrugBank.d121.s2.e1" charOffset="118-124"
            type="group" text="antacid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d122.s0" text="Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.">
        <entity id="DDI-DrugBank.d122.s0.e0" charOffset="73-86"
            type="group" text="cephalosporins"/>
        <entity id="DDI-DrugBank.d122.s0.e1" charOffset="93-118"
            type="group" text="aminoglycoside antibiotics"/>
        <entity id="DDI-DrugBank.d122.s0.e2" charOffset="130-138"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d122.s0.e3" charOffset="148-157"
            type="drug" text="furosemide"/>
        <ddi id="DDI-DrugBank.d122.s0.d0" e1="DDI-DrugBank.d122.s0.e0"
            e2="DDI-DrugBank.d122.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d122.s0.d1" e1="DDI-DrugBank.d122.s0.e0"
            e2="DDI-DrugBank.d122.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d122.s0.d2" e1="DDI-DrugBank.d122.s0.e0"
            e2="DDI-DrugBank.d122.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d122.s1" text="Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics.">
        <entity id="DDI-DrugBank.d122.s1.e0" charOffset="82-96"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d122.s1.e1" charOffset="208-234"
            type="group" text="aminoglycosidic antibiotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d122.s2" text="Nephrotoxicity and ototoxicity were not noted when ceftazidime was given alone in clinical trials.">
        <entity id="DDI-DrugBank.d122.s2.e0" charOffset="51-61"
            type="drug" text="ceftazidime"/>
    </sentence>
    <sentence id="DDI-DrugBank.d122.s3" text="Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.">
        <entity id="DDI-DrugBank.d122.s3.e0" charOffset="0-14"
            type="drug" text="Chloramphenicol"/>
        <entity id="DDI-DrugBank.d122.s3.e1" charOffset="53-75"
            type="group" text="beta-lactam antibiotics"/>
        <entity id="DDI-DrugBank.d122.s3.e2" charOffset="88-98"
            type="drug" text="ceftazidime"/>
        <ddi id="DDI-DrugBank.d122.s3.d0" e1="DDI-DrugBank.d122.s3.e0"
            e2="DDI-DrugBank.d122.s3.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d122.s3.d1" e1="DDI-DrugBank.d122.s3.e0"
            e2="DDI-DrugBank.d122.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d122.s4" text="Due to the possibility of antagonism in vivo, particularly when bactericidal activity is desired, this drug combination should be avoided."/>
    <sentence id="DDI-DrugBank.d122.s5" text="Drug/Laboratory Test Interactions The administration of ceftazidime may result in a false-positive reaction for glucose in the urine when using CLINITEST  tablets, Benedicts solution, or Fehlings solution.">
        <entity id="DDI-DrugBank.d122.s5.e0" charOffset="56-66"
            type="drug" text="ceftazidime"/>
    </sentence>
    <sentence id="DDI-DrugBank.d122.s6" text="It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX  or TES-TAPE ) be used."/>
    <sentence id="DDI-DrugBank.d32.s0" text="Theophylline: Twelve healthy male volunteers were administered one 200-mg ceftibuten capsule twice daily for 6 days.">
        <entity id="DDI-DrugBank.d32.s0.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d32.s0.e1" charOffset="74-83"
            type="drug" text="ceftibuten"/>
    </sentence>
    <sentence id="DDI-DrugBank.d32.s1" text="With the morning dose of ceftibuten on day 6, each volunteer received a single intravenous infusion of theophylline (4 mg/kg).">
        <entity id="DDI-DrugBank.d32.s1.e0" charOffset="25-34"
            type="drug" text="ceftibuten"/>
        <entity id="DDI-DrugBank.d32.s1.e1" charOffset="103-114"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d32.s2" text="The pharmacokinetics of theophylline were not altered.">
        <entity id="DDI-DrugBank.d32.s2.e0" charOffset="24-35"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d32.s3" text="The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated.">
        <entity id="DDI-DrugBank.d32.s3.e0" charOffset="14-23"
            type="drug" text="ceftibuten"/>
        <entity id="DDI-DrugBank.d32.s3.e1" charOffset="52-63"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d32.s4" text="Antacids or H 2 -receptor antagonists: The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers.">
        <entity id="DDI-DrugBank.d32.s4.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d32.s4.e1" charOffset="12-36"
            type="group" text="H 2 -receptor antagonists"/>
        <entity id="DDI-DrugBank.d32.s4.e2" charOffset="100-109"
            type="drug" text="ceftibuten"/>
    </sentence>
    <sentence id="DDI-DrugBank.d32.s5" text="Each volunteer was administered one 400-mg ceftibuten capsule.">
        <entity id="DDI-DrugBank.d32.s5.e0" charOffset="43-52"
            type="drug" text="ceftibuten"/>
    </sentence>
    <sentence id="DDI-DrugBank.d32.s6" text="A single dose of liquid antacid did not affect the C max or AUC of ceftibuten;">
        <entity id="DDI-DrugBank.d32.s6.e0" charOffset="24-30"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d32.s6.e1" charOffset="67-76"
            type="drug" text="ceftibuten"/>
    </sentence>
    <sentence id="DDI-DrugBank.d32.s7" text="however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.">
        <entity id="DDI-DrugBank.d32.s7.e0" charOffset="19-28"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d32.s7.e1" charOffset="60-69"
            type="drug" text="ceftibuten"/>
        <entity id="DDI-DrugBank.d32.s7.e2" charOffset="88-97"
            type="drug" text="ceftibuten"/>
        <ddi id="DDI-DrugBank.d32.s7.d0" e1="DDI-DrugBank.d32.s7.e0"
            e2="DDI-DrugBank.d32.s7.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d32.s7.d1" e1="DDI-DrugBank.d32.s7.e0"
            e2="DDI-DrugBank.d32.s7.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d32.s8" text="The clinical relevance of these increases is not known."/>
    <sentence id="DDI-DrugBank.d32.s9" text="Drug/Laboratory Test Interactions: There have been no chemical or laboratory test interactions with ceftibuten noted to date.">
        <entity id="DDI-DrugBank.d32.s9.e0" charOffset="100-109"
            type="drug" text="ceftibuten"/>
    </sentence>
    <sentence id="DDI-DrugBank.d32.s10" text="False-positive direct Coombs tests have been reported during treatment with other cephalosporins.">
        <entity id="DDI-DrugBank.d32.s10.e0" charOffset="82-95"
            type="group" text="cephalosporins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d32.s11" text="Therefore, it should be recognized that a positive Coombs test could be due to the drug."/>
    <sentence id="DDI-DrugBank.d32.s12" text="The results of assays using red cells from healthy subjects to determine whether ceftibuten would cause direct Coombs reactions in vitro showed no positive reaction at ceftibuten concentrations as high as 40  g/mL.">
        <entity id="DDI-DrugBank.d32.s12.e0" charOffset="81-90"
            type="drug" text="ceftibuten"/>
        <entity id="DDI-DrugBank.d32.s12.e1" charOffset="168-177"
            type="drug" text="ceftibuten"/>
    </sentence>
    <sentence id="DDI-DrugBank.d33.s0" text="Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.">
        <entity id="DDI-DrugBank.d33.s0.e0" charOffset="51-57"
            type="brand" text="Cefizox"/>
        <entity id="DDI-DrugBank.d33.s0.e1" charOffset="139-152"
            type="group" text="cephalosporins"/>
        <entity id="DDI-DrugBank.d33.s0.e2" charOffset="158-172"
            type="group" text="aminoglycosides"/>
        <ddi id="DDI-DrugBank.d33.s0.d0" e1="DDI-DrugBank.d33.s0.e1"
            e2="DDI-DrugBank.d33.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d447.s0" text="Drug/Laboratory Test Interactions: A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict s or Fehling s solution or with Clinitest  tablets) but not with enzyme-based tests for glycosuria."/>
    <sentence id="DDI-DrugBank.d447.s1" text="As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving cefuroxime.">
        <entity id="DDI-DrugBank.d447.s1.e0" charOffset="205-214"
            type="drug" text="cefuroxime"/>
    </sentence>
    <sentence id="DDI-DrugBank.d447.s2" text="Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.">
        <entity id="DDI-DrugBank.d447.s2.e0" charOffset="0-9"
            type="drug" text="Cefuroxime"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s0" text="General: Significant interactions may occur when celecoxib is administered together with drugs that inhibit P450 2C9.">
        <entity id="DDI-DrugBank.d172.s0.e0" charOffset="49-57"
            type="drug" text="celecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s1" text="Celecoxib metabolism is predominantly mediated via cytochrome P450 2C9 in the liver.">
        <entity id="DDI-DrugBank.d172.s1.e0" charOffset="0-8"
            type="drug" text="Celecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s2" text="Co-administration of celecoxib with drugs that are known to inhibit 2C9 should be done with caution.">
        <entity id="DDI-DrugBank.d172.s2.e0" charOffset="21-29"
            type="drug" text="celecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s3" text="In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4.">
        <entity id="DDI-DrugBank.d172.s3.e0" charOffset="31-39"
            type="drug" text="celecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s4" text="In vitro studies also indicate that celecoxib, although not a substrate, is an inhibitor of cytochrome P450 2D6.">
        <entity id="DDI-DrugBank.d172.s4.e0" charOffset="36-44"
            type="drug" text="celecoxib"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s5" text="Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by P450 2D6."/>
    <sentence id="DDI-DrugBank.d172.s6" text="Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.">
        <entity id="DDI-DrugBank.d172.s6.e0" charOffset="22-30"
            type="drug" text="celecoxib"/>
        <entity id="DDI-DrugBank.d172.s6.e1" charOffset="90-100"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d172.s6.e2" charOffset="106-112"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d172.s6.d0" e1="DDI-DrugBank.d172.s6.e0"
            e2="DDI-DrugBank.d172.s6.e1" type="int"/>
        <ddi id="DDI-DrugBank.d172.s6.d1" e1="DDI-DrugBank.d172.s6.e0"
            e2="DDI-DrugBank.d172.s6.e2" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s7" text="Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.">
        <entity id="DDI-DrugBank.d172.s7.e0" charOffset="16-51"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d172.s7.e1" charOffset="54-59"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d172.s7.e2" charOffset="107-116"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d172.s7.e3" charOffset="122-135"
            type="group" text="ACE inhibitors"/>
        <ddi id="DDI-DrugBank.d172.s7.d0" e1="DDI-DrugBank.d172.s7.e0"
            e2="DDI-DrugBank.d172.s7.e2" type="int"/>
        <ddi id="DDI-DrugBank.d172.s7.d1" e1="DDI-DrugBank.d172.s7.e0"
            e2="DDI-DrugBank.d172.s7.e3" type="int"/>
        <ddi id="DDI-DrugBank.d172.s7.d2" e1="DDI-DrugBank.d172.s7.e1"
            e2="DDI-DrugBank.d172.s7.e2" type="int"/>
        <ddi id="DDI-DrugBank.d172.s7.d3" e1="DDI-DrugBank.d172.s7.e1"
            e2="DDI-DrugBank.d172.s7.e3" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s8" text="The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.">
        <entity id="DDI-DrugBank.d172.s8.e0" charOffset="12-20"
            type="drug" text="celecoxib"/>
        <entity id="DDI-DrugBank.d172.s8.e1" charOffset="73-81"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d172.s8.e2" charOffset="84-95"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d172.s8.e3" charOffset="98-109"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d172.s8.e4" charOffset="112-120"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d172.s8.e5" charOffset="123-133"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d172.s8.e6" charOffset="140-147"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s9" text="ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.">
        <entity id="DDI-DrugBank.d172.s9.e0" charOffset="0-13"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d172.s9.e1" charOffset="37-42"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d172.s9.e2" charOffset="88-133"
            type="group" text="Angiotensin Converting Enzyme (ACE) inhibitors"/>
        <ddi id="DDI-DrugBank.d172.s9.d0" e1="DDI-DrugBank.d172.s9.e1"
            e2="DDI-DrugBank.d172.s9.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s10" text="This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.">
        <entity id="DDI-DrugBank.d172.s10.e0" charOffset="66-73"
            type="brand" text="CELEBREX"/>
        <entity id="DDI-DrugBank.d172.s10.e1" charOffset="94-107"
            type="group" text="ACE-inhibitors"/>
        <ddi id="DDI-DrugBank.d172.s10.d0" e1="DDI-DrugBank.d172.s10.e0"
            e2="DDI-DrugBank.d172.s10.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s11" text="Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.">
        <entity id="DDI-DrugBank.d172.s11.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d172.s11.e1" charOffset="86-91"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d172.s11.e2" charOffset="130-139"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d172.s11.e3" charOffset="145-153"
            type="group" text="thiazides"/>
        <ddi id="DDI-DrugBank.d172.s11.d0" e1="DDI-DrugBank.d172.s11.e1"
            e2="DDI-DrugBank.d172.s11.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d172.s11.d1" e1="DDI-DrugBank.d172.s11.e1"
            e2="DDI-DrugBank.d172.s11.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s12" text="This response has been attributed to inhibition of renal prostaglandin synthesis."/>
    <sentence id="DDI-DrugBank.d172.s13" text="Aspirin: CELEBREX can be used with low dose aspirin.">
        <entity id="DDI-DrugBank.d172.s13.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d172.s13.e1" charOffset="9-16"
            type="brand" text="CELEBREX"/>
        <entity id="DDI-DrugBank.d172.s13.e2" charOffset="44-50"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d172.s13.d0" e1="DDI-DrugBank.d172.s13.e1"
            e2="DDI-DrugBank.d172.s13.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s14" text="However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.">
        <entity id="DDI-DrugBank.d172.s14.e0" charOffset="39-45"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d172.s14.e1" charOffset="52-59"
            type="brand" text="CELEBREX"/>
        <entity id="DDI-DrugBank.d172.s14.e2" charOffset="153-160"
            type="brand" text="CELEBREX"/>
        <ddi id="DDI-DrugBank.d172.s14.d0" e1="DDI-DrugBank.d172.s14.e0"
            e2="DDI-DrugBank.d172.s14.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s15" text="Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis.">
        <entity id="DDI-DrugBank.d172.s15.e0" charOffset="41-48"
            type="brand" text="CELEBREX"/>
        <entity id="DDI-DrugBank.d172.s15.e1" charOffset="74-80"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s16" text="Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.">
        <entity id="DDI-DrugBank.d172.s16.e0" charOffset="0-10"
            type="drug" text="Fluconazole"/>
        <entity id="DDI-DrugBank.d172.s16.e1" charOffset="43-53"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d172.s16.e2" charOffset="103-111"
            type="drug" text="celecoxib"/>
        <ddi id="DDI-DrugBank.d172.s16.d0" e1="DDI-DrugBank.d172.s16.e1"
            e2="DDI-DrugBank.d172.s16.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s17" text="This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).">
        <entity id="DDI-DrugBank.d172.s17.e0" charOffset="42-50"
            type="drug" text="celecoxib"/>
        <entity id="DDI-DrugBank.d172.s17.e1" charOffset="79-89"
            type="drug" text="fluconazole"/>
        <ddi id="DDI-DrugBank.d172.s17.d0" e1="DDI-DrugBank.d172.s17.e0"
            e2="DDI-DrugBank.d172.s17.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s18" text="CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.">
        <entity id="DDI-DrugBank.d172.s18.e0" charOffset="0-7"
            type="brand" text="CELEBREX"/>
        <entity id="DDI-DrugBank.d172.s18.e1" charOffset="83-93"
            type="drug" text="fluconazole"/>
        <ddi id="DDI-DrugBank.d172.s18.d0" e1="DDI-DrugBank.d172.s18.e0"
            e2="DDI-DrugBank.d172.s18.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s19" text="Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.">
        <entity id="DDI-DrugBank.d172.s19.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d172.s19.e1" charOffset="69-75"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d172.s19.e2" charOffset="141-147"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d172.s19.e3" charOffset="165-172"
            type="brand" text="CELEBREX"/>
        <entity id="DDI-DrugBank.d172.s19.e4" charOffset="219-225"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d172.s19.d0" e1="DDI-DrugBank.d172.s19.e2"
            e2="DDI-DrugBank.d172.s19.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s20" text="Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.">
        <entity id="DDI-DrugBank.d172.s20.e0" charOffset="12-18"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d172.s20.e1" charOffset="63-70"
            type="brand" text="CELEBREX"/>
        <ddi id="DDI-DrugBank.d172.s20.d0" e1="DDI-DrugBank.d172.s20.e0"
            e2="DDI-DrugBank.d172.s20.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s21" text="Methotrexate: In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate.">
        <entity id="DDI-DrugBank.d172.s21.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d172.s21.e1" charOffset="78-89"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d172.s21.e2" charOffset="92-99"
            type="brand" text="CELEBREX"/>
        <entity id="DDI-DrugBank.d172.s21.e3" charOffset="162-173"
            type="drug" text="methotrexate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s22" text="Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.">
        <entity id="DDI-DrugBank.d172.s22.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d172.s22.e1" charOffset="24-32"
            type="drug" text="celecoxib"/>
        <entity id="DDI-DrugBank.d172.s22.e2" charOffset="66-73"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d172.s22.e3" charOffset="153-160"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s23" text="In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time.">
        <entity id="DDI-DrugBank.d172.s23.e0" charOffset="19-27"
            type="drug" text="celecoxib"/>
        <entity id="DDI-DrugBank.d172.s23.e1" charOffset="71-78"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d172.s24" text="However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.">
        <entity id="DDI-DrugBank.d172.s24.e0" charOffset="51-58"
            type="brand" text="CELEBREX"/>
        <entity id="DDI-DrugBank.d172.s24.e1" charOffset="65-72"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d172.s24.d0" e1="DDI-DrugBank.d172.s24.e0"
            e2="DDI-DrugBank.d172.s24.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d303.s0" text="Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.">
        <entity id="DDI-DrugBank.d303.s0.e0" charOffset="0-8"
            type="drug" text="Metformin"/>
        <entity id="DDI-DrugBank.d303.s0.e1" charOffset="60-69"
            type="drug" text="cephalexin"/>
        <entity id="DDI-DrugBank.d303.s0.e2" charOffset="75-83"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d303.s0.e3" charOffset="93-101"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d303.s0.e4" charOffset="179-187"
            type="drug" text="metformin"/>
        <ddi id="DDI-DrugBank.d303.s0.d0" e1="DDI-DrugBank.d303.s0.e1"
            e2="DDI-DrugBank.d303.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d303.s1" text="No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.">
        <entity id="DDI-DrugBank.d303.s1.e0" charOffset="53-62"
            type="drug" text="cephalexin"/>
        <entity id="DDI-DrugBank.d303.s1.e1" charOffset="68-76"
            type="drug" text="metformin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d303.s2" text="Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.">
        <entity id="DDI-DrugBank.d303.s2.e0" charOffset="103-112"
            type="drug" text="cephalexin"/>
        <entity id="DDI-DrugBank.d303.s2.e1" charOffset="118-126"
            type="drug" text="metformin"/>
        <ddi id="DDI-DrugBank.d303.s2.d0" e1="DDI-DrugBank.d303.s2.e0"
            e2="DDI-DrugBank.d303.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d303.s3" text="Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.">
        <entity id="DDI-DrugBank.d303.s3.e0" charOffset="63-71"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d303.s3.e1" charOffset="121-130"
            type="drug" text="cephalexin"/>
        <entity id="DDI-DrugBank.d303.s3.e2" charOffset="136-144"
            type="drug" text="metformin"/>
        <ddi id="DDI-DrugBank.d303.s3.d0" e1="DDI-DrugBank.d303.s3.e1"
            e2="DDI-DrugBank.d303.s3.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d303.s4" text="Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.">
        <entity id="DDI-DrugBank.d303.s4.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d303.s4.e1" charOffset="26-34"
            type="group" text="b-lactams"/>
        <entity id="DDI-DrugBank.d303.s4.e2" charOffset="60-69"
            type="drug" text="cephalexin"/>
        <entity id="DDI-DrugBank.d303.s4.e3" charOffset="87-96"
            type="drug" text="probenecid"/>
        <ddi id="DDI-DrugBank.d303.s4.d0" e1="DDI-DrugBank.d303.s4.e2"
            e2="DDI-DrugBank.d303.s4.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d303.s5" text="Drug / Laboratory Test Interactions As a result of administration of Keflex, a false-positive reaction for glucose in the urine may occur.">
        <entity id="DDI-DrugBank.d303.s5.e0" charOffset="69-74"
            type="brand" text="Keflex"/>
    </sentence>
    <sentence id="DDI-DrugBank.d303.s6" text="This has been observed with Benedict s and Fehling s solutions and also with Clinitest  tablets."/>
    <sentence id="DDI-DrugBank.d141.s0" text="Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.">
        <entity id="DDI-DrugBank.d141.s0.e0" charOffset="0-22"
            type="group" text="Immunosuppressive Drugs"/>
        <entity id="DDI-DrugBank.d141.s0.e1" charOffset="25-47"
            type="group" text="Fibric Acid Derivatives"/>
        <entity id="DDI-DrugBank.d141.s0.e2" charOffset="50-55"
            type="drug" text="Niacin"/>
        <entity id="DDI-DrugBank.d141.s0.e3" charOffset="58-71"
            type="drug" text="Nicotinic Acid"/>
        <entity id="DDI-DrugBank.d141.s0.e4" charOffset="74-85"
            type="drug" text="Erythromycin"/>
        <entity id="DDI-DrugBank.d141.s0.e5" charOffset="88-104"
            type="group" text="Azole Antifungals"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s1" text="ANTACID (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of antacid.">
        <entity id="DDI-DrugBank.d141.s1.e0" charOffset="0-6"
            type="group" text="ANTACID"/>
        <entity id="DDI-DrugBank.d141.s1.e1" charOffset="9-36"
            type="drug" text="Magnesium-Aluminum Hydroxide"/>
        <entity id="DDI-DrugBank.d141.s1.e2" charOffset="40-51"
            type="drug" text="Cerivastatin"/>
        <entity id="DDI-DrugBank.d141.s1.e3" charOffset="117-123"
            type="group" text="antacid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s2" text="CIMETlDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine.">
        <entity id="DDI-DrugBank.d141.s2.e0" charOffset="0-9"
            type="drug" text="CIMETlDINE"/>
        <entity id="DDI-DrugBank.d141.s2.e1" charOffset="12-23"
            type="drug" text="Cerivastatin"/>
        <entity id="DDI-DrugBank.d141.s2.e2" charOffset="89-98"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s3" text="CHOLESTYRAMINE: The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.">
        <entity id="DDI-DrugBank.d141.s3.e0" charOffset="0-13"
            type="drug" text="CHOLESTYRAMINE"/>
        <entity id="DDI-DrugBank.d141.s3.e1" charOffset="65-78"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d141.s3.e2" charOffset="107-125"
            type="drug" text="cerivastatin sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s4" text="In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.">
        <entity id="DDI-DrugBank.d141.s4.e0" charOffset="57-75"
            type="drug" text="cerivastatin sodium"/>
        <entity id="DDI-DrugBank.d141.s4.e1" charOffset="86-99"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d141.s4.e2" charOffset="189-207"
            type="drug" text="cerivastatin sodium"/>
        <ddi id="DDI-DrugBank.d141.s4.d0" e1="DDI-DrugBank.d141.s4.e0"
            e2="DDI-DrugBank.d141.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s5" text="However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.">
        <entity id="DDI-DrugBank.d141.s5.e0" charOffset="53-66"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d141.s5.e1" charOffset="110-128"
            type="drug" text="cerivastatin sodium"/>
        <entity id="DDI-DrugBank.d141.s5.e2" charOffset="210-221"
            type="drug" text="cerivastatin"/>
        <entity id="DDI-DrugBank.d141.s5.e3" charOffset="304-322"
            type="drug" text="cerivastatin sodium"/>
        <ddi id="DDI-DrugBank.d141.s5.d0" e1="DDI-DrugBank.d141.s5.e0"
            e2="DDI-DrugBank.d141.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s6" text="Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.">
        <entity id="DDI-DrugBank.d141.s6.e0" charOffset="58-76"
            type="drug" text="cerivastatin sodium"/>
        <entity id="DDI-DrugBank.d141.s6.e1" charOffset="99-112"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d141.s6.e2" charOffset="213-231"
            type="drug" text="cerivastatin sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s7" text="DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.">
        <entity id="DDI-DrugBank.d141.s7.e0" charOffset="0-6"
            type="drug" text="DIGOXIN"/>
        <entity id="DDI-DrugBank.d141.s7.e1" charOffset="16-22"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d141.s7.e2" charOffset="35-41"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d141.s7.e3" charOffset="118-136"
            type="drug" text="cerivastatin sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s8" text="Cerivastatin plasma concentrations were also not affected by co-administration of digoxin.">
        <entity id="DDI-DrugBank.d141.s8.e0" charOffset="0-11"
            type="drug" text="Cerivastatin"/>
        <entity id="DDI-DrugBank.d141.s8.e1" charOffset="82-88"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s9" text="WARFARIN: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.">
        <entity id="DDI-DrugBank.d141.s9.e0" charOffset="0-7"
            type="drug" text="WARFARIN"/>
        <entity id="DDI-DrugBank.d141.s9.e1" charOffset="32-39"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d141.s9.e2" charOffset="45-56"
            type="drug" text="cerivastatin"/>
        <entity id="DDI-DrugBank.d141.s9.e3" charOffset="191-198"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s10" text="The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium.">
        <entity id="DDI-DrugBank.d141.s10.e0" charOffset="52-59"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d141.s10.e1" charOffset="108-126"
            type="drug" text="cerivastatin sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s11" text="Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium.">
        <entity id="DDI-DrugBank.d141.s11.e0" charOffset="21-28"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d141.s11.e1" charOffset="34-45"
            type="drug" text="cerivastatin"/>
        <entity id="DDI-DrugBank.d141.s11.e2" charOffset="85-103"
            type="drug" text="cerivastatin sodium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s12" text="ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.">
        <entity id="DDI-DrugBank.d141.s12.e0" charOffset="0-11"
            type="drug" text="ERYTHROMYCIN"/>
        <entity id="DDI-DrugBank.d141.s12.e1" charOffset="61-72"
            type="drug" text="cerivastatin"/>
        <entity id="DDI-DrugBank.d141.s12.e2" charOffset="176-187"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d141.s12.d0" e1="DDI-DrugBank.d141.s12.e1"
            e2="DDI-DrugBank.d141.s12.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d141.s13" text="OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.">
        <entity id="DDI-DrugBank.d141.s13.e0" charOffset="106-124"
            type="drug" text="cerivastatin sodium"/>
        <entity id="DDI-DrugBank.d141.s13.e1" charOffset="154-200"
            type="group" text="angiotensin- converting enzyme (ACE) inhibitors"/>
        <entity id="DDI-DrugBank.d141.s13.e2" charOffset="203-214"
            type="group" text="betablockers"/>
        <entity id="DDI-DrugBank.d141.s13.e3" charOffset="217-240"
            type="group" text="calcium-channel blockers"/>
        <entity id="DDI-DrugBank.d141.s13.e4" charOffset="243-251"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d141.s13.e5" charOffset="258-293"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d141.s13.e6" charOffset="296-301"
            type="group" text="NSAIDs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d393.s0" text="Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin.">
        <entity id="DDI-DrugBank.d393.s0.e0" charOffset="41-50"
            type="drug" text="cetirizine"/>
        <entity id="DDI-DrugBank.d393.s0.e1" charOffset="82-96"
            type="drug" text="pseudoephedrine"/>
        <entity id="DDI-DrugBank.d393.s0.e2" charOffset="99-108"
            type="drug" text="antipyrine"/>
        <entity id="DDI-DrugBank.d393.s0.e3" charOffset="111-122"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d393.s0.e4" charOffset="125-136"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d393.s0.e5" charOffset="142-153"
            type="drug" text="azithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d393.s1" text="No interactions were observed."/>
    <sentence id="DDI-DrugBank.d393.s2" text="In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.">
        <entity id="DDI-DrugBank.d393.s2.e0" charOffset="28-39"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d393.s2.e1" charOffset="76-85"
            type="drug" text="cetirizine"/>
        <entity id="DDI-DrugBank.d393.s2.e2" charOffset="153-162"
            type="drug" text="cetirizine"/>
        <ddi id="DDI-DrugBank.d393.s2.d0" e1="DDI-DrugBank.d393.s2.e0"
            e2="DDI-DrugBank.d393.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d393.s3" text="The disposition of theophylline was not altered by concomitant cetirizine administration.">
        <entity id="DDI-DrugBank.d393.s3.e0" charOffset="19-30"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d393.s3.e1" charOffset="63-72"
            type="drug" text="cetirizine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d393.s4" text="Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.">
        <entity id="DDI-DrugBank.d393.s4.e0" charOffset="89-100"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d393.s4.e1" charOffset="117-128"
            type="drug" text="azithromycin"/>
        <entity id="DDI-DrugBank.d393.s4.e2" charOffset="131-145"
            type="drug" text="pseudoephedrine"/>
        <entity id="DDI-DrugBank.d393.s4.e3" charOffset="148-159"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d393.s4.e4" charOffset="165-176"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d393.s5" text="There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;">
        <entity id="DDI-DrugBank.d393.s5.e0" charOffset="47-56"
            type="drug" text="cetirizine"/>
        <entity id="DDI-DrugBank.d393.s5.e1" charOffset="85-96"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d393.s5.d0" e1="DDI-DrugBank.d393.s5.e0"
            e2="DDI-DrugBank.d393.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d393.s6" text="it is possible that larger theophylline doses could have a greater effect.">
        <entity id="DDI-DrugBank.d393.s6.e0" charOffset="27-38"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d540.s0" text="No formal drug interaction studies have been performed with Cetrotide .">
        <entity id="DDI-DrugBank.d540.s0.e0" charOffset="60-68"
            type="brand" text="Cetrotide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d193.s0" text="A drug interaction study was performed in which ERBITUX was administered in combination with irinotecan.">
        <entity id="DDI-DrugBank.d193.s0.e0" charOffset="48-54"
            type="brand" text="ERBITUX"/>
        <entity id="DDI-DrugBank.d193.s0.e1" charOffset="93-102"
            type="drug" text="irinotecan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d193.s1" text="There was no evidence of any pharmacokinetic interactions between ERBITUX and irinotecan.">
        <entity id="DDI-DrugBank.d193.s1.e0" charOffset="66-72"
            type="brand" text="ERBITUX"/>
        <entity id="DDI-DrugBank.d193.s1.e1" charOffset="78-87"
            type="drug" text="irinotecan"/>
    </sentence>
    <sentence id="DDI-DrugBank.d287.s0" text="Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.">
        <entity id="DDI-DrugBank.d287.s0.e0" charOffset="0-9"
            type="drug" text="Cevimeline"/>
        <entity id="DDI-DrugBank.d287.s0.e1" charOffset="66-92"
            type="group" text="beta adrenergic antagonists"/>
        <ddi id="DDI-DrugBank.d287.s0.d0" e1="DDI-DrugBank.d287.s0.e0"
            e2="DDI-DrugBank.d287.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d287.s1" text="Drugs with parasympathomimetic effects administered concurrently with cevimeline can be expected to have additive effects.">
        <entity id="DDI-DrugBank.d287.s1.e0" charOffset="70-79"
            type="drug" text="cevimeline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d287.s2" text="Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly.">
        <entity id="DDI-DrugBank.d287.s2.e0" charOffset="0-9"
            type="drug" text="Cevimeline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d287.s3" text="Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline.">
        <entity id="DDI-DrugBank.d287.s3.e0" charOffset="71-80"
            type="drug" text="cevimeline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d287.s4" text="Cevimeline should be used with caution in individuals known or suspected to be deficient in CYP2D6 activity, based on previous experience, as they may be at a higher risk of adverse events.">
        <entity id="DDI-DrugBank.d287.s4.e0" charOffset="0-9"
            type="drug" text="Cevimeline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d287.s5" text="In an in vitro study, cytochrome P450 isozymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 were not inhibited by exposure to cevimeline.">
        <entity id="DDI-DrugBank.d287.s5.e0" charOffset="120-129"
            type="drug" text="cevimeline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d255.s0" text="There are no known drug/drug interactions with chlorambucil.">
        <entity id="DDI-DrugBank.d255.s0.e0" charOffset="47-58"
            type="drug" text="chlorambucil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d336.s0" text="Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.">
        <entity id="DDI-DrugBank.d336.s0.e0" charOffset="208-221"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d336.s0.e1" charOffset="227-242"
            type="drug" text="chlordiazepoxide"/>
        <ddi id="DDI-DrugBank.d336.s0.d0" e1="DDI-DrugBank.d336.s0.e0"
            e2="DDI-DrugBank.d336.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d336.s1" text="The concomitant use of alcohol or other central nervous system depressants may have an additive effect.">
        <entity id="DDI-DrugBank.d336.s1.e0" charOffset="23-29"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d336.s1.e1" charOffset="40-73"
            type="group" text="central nervous system depressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d110.s0" text="The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.">
        <entity id="DDI-DrugBank.d110.s0.e0" charOffset="28-47"
            type="group" text="anesthetic solutions"/>
        <entity id="DDI-DrugBank.d110.s0.e1" charOffset="60-70"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d110.s0.e2" charOffset="75-88"
            type="drug" text="norepinephrine"/>
        <entity id="DDI-DrugBank.d110.s0.e3" charOffset="112-139"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d110.s0.e4" charOffset="142-166"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d110.s0.e5" charOffset="171-184"
            type="group" text="phenothiazines"/>
        <ddi id="DDI-DrugBank.d110.s0.d0" e1="DDI-DrugBank.d110.s0.e0"
            e2="DDI-DrugBank.d110.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d110.s0.d1" e1="DDI-DrugBank.d110.s0.e0"
            e2="DDI-DrugBank.d110.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d110.s0.d2" e1="DDI-DrugBank.d110.s0.e1"
            e2="DDI-DrugBank.d110.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d110.s0.d3" e1="DDI-DrugBank.d110.s0.e1"
            e2="DDI-DrugBank.d110.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d110.s0.d4" e1="DDI-DrugBank.d110.s0.e1"
            e2="DDI-DrugBank.d110.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d110.s0.d5" e1="DDI-DrugBank.d110.s0.e2"
            e2="DDI-DrugBank.d110.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d110.s0.d6" e1="DDI-DrugBank.d110.s0.e2"
            e2="DDI-DrugBank.d110.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d110.s0.d7" e1="DDI-DrugBank.d110.s0.e2"
            e2="DDI-DrugBank.d110.s0.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d110.s1" text="Concurrent use of these agents should generally be avoided."/>
    <sentence id="DDI-DrugBank.d110.s2" text="In situations when concurrent therapy is necessary, careful patient monitoring is essential."/>
    <sentence id="DDI-DrugBank.d110.s3" text="Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.">
        <entity id="DDI-DrugBank.d110.s3.e0" charOffset="29-45"
            type="group" text="vasopressor drugs"/>
        <entity id="DDI-DrugBank.d110.s3.e1" charOffset="114-138"
            type="group" text="ergot-type oxytocic drugs"/>
        <ddi id="DDI-DrugBank.d110.s3.d0" e1="DDI-DrugBank.d110.s3.e0"
            e2="DDI-DrugBank.d110.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d110.s4" text="The para-aminobenzoic acid metabolite of chloroprocaine inhibits the action of sulfonamides.">
        <entity id="DDI-DrugBank.d110.s4.e0" charOffset="79-90"
            type="group" text="sulfonamides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d110.s5" text="Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.">
        <entity id="DDI-DrugBank.d110.s5.e0" charOffset="11-24"
            type="drug" text="chloroprocaine"/>
        <entity id="DDI-DrugBank.d110.s5.e1" charOffset="73-88"
            type="group" text="sulfonamide drug"/>
        <ddi id="DDI-DrugBank.d110.s5.d0" e1="DDI-DrugBank.d110.s5.e0"
            e2="DDI-DrugBank.d110.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d429.s0" text="Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;">
        <entity id="DDI-DrugBank.d429.s0.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d429.s0.e1" charOffset="13-18"
            type="drug" text="kaolin"/>
        <entity id="DDI-DrugBank.d429.s0.e2" charOffset="21-28"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d429.s0.e3" charOffset="34-39"
            type="drug" text="kaolin"/>
        <entity id="DDI-DrugBank.d429.s0.e4" charOffset="66-76"
            type="drug" text="chloroquine"/>
        <ddi id="DDI-DrugBank.d429.s0.d0" e1="DDI-DrugBank.d429.s0.e2"
            e2="DDI-DrugBank.d429.s0.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d429.s0.d1" e1="DDI-DrugBank.d429.s0.e3"
            e2="DDI-DrugBank.d429.s0.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d429.s1" text="an interval of at least 4 hours between intake of these agents and chloroquine should be observed.">
        <entity id="DDI-DrugBank.d429.s1.e0" charOffset="67-77"
            type="drug" text="chloroquine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d429.s2" text="Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.">
        <entity id="DDI-DrugBank.d429.s2.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d429.s2.e1" charOffset="12-21"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d429.s2.e2" charOffset="53-63"
            type="drug" text="chloroquine"/>
        <ddi id="DDI-DrugBank.d429.s2.d0" e1="DDI-DrugBank.d429.s2.e1"
            e2="DDI-DrugBank.d429.s2.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d429.s3" text="Concomitant use of cimetidine should be avoided.">
        <entity id="DDI-DrugBank.d429.s3.e0" charOffset="19-28"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d429.s4" text="Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.">
        <entity id="DDI-DrugBank.d429.s4.e0" charOffset="0-9"
            type="drug" text="Ampicillin"/>
        <entity id="DDI-DrugBank.d429.s4.e1" charOffset="46-56"
            type="drug" text="chloroquine"/>
        <entity id="DDI-DrugBank.d429.s4.e2" charOffset="103-112"
            type="drug" text="ampicillin"/>
        <ddi id="DDI-DrugBank.d429.s4.d0" e1="DDI-DrugBank.d429.s4.e1"
            e2="DDI-DrugBank.d429.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d429.s5" text="An interval of at least two hours between intake of this agent and chloroquine should be observed.">
        <entity id="DDI-DrugBank.d429.s5.e0" charOffset="67-77"
            type="drug" text="chloroquine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d429.s6" text="Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.">
        <entity id="DDI-DrugBank.d429.s6.e0" charOffset="0-10"
            type="drug" text="Cyclosporin"/>
        <entity id="DDI-DrugBank.d429.s6.e1" charOffset="35-45"
            type="drug" text="chloroquine"/>
        <entity id="DDI-DrugBank.d429.s6.e2" charOffset="87-97"
            type="drug" text="cyclosporin"/>
        <ddi id="DDI-DrugBank.d429.s6.d0" e1="DDI-DrugBank.d429.s6.e1"
            e2="DDI-DrugBank.d429.s6.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d429.s7" text="Therefore, close monitoring of serum cyclosporin level is recommended and, if necessary, chloroquine should be discontinued.">
        <entity id="DDI-DrugBank.d429.s7.e0" charOffset="37-47"
            type="drug" text="cyclosporin"/>
        <entity id="DDI-DrugBank.d429.s7.e1" charOffset="89-99"
            type="drug" text="chloroquine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s0" text="When given concurrently the following drugs may interact with thiazide diuretics.">
        <entity id="DDI-DrugBank.d46.s0.e0" charOffset="62-79"
            type="group" text="thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s1" text="- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur">
        <entity id="DDI-DrugBank.d46.s1.e0" charOffset="2-8" type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d46.s1.e1" charOffset="11-22"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d46.s1.e2" charOffset="28-36"
            type="group" text="narcotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s2" text="."/>
    <sentence id="DDI-DrugBank.d46.s3" text="- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required">
        <entity id="DDI-DrugBank.d46.s3.e0" charOffset="2-19"
            type="group" text="Antidiabetic drugs"/>
        <entity id="DDI-DrugBank.d46.s3.e1" charOffset="39-45"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d46.s3.e2" charOffset="73-89"
            type="group" text="antidiabetic drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s4" text="."/>
    <sentence id="DDI-DrugBank.d46.s5" text="- Other antihypertensive drugs: Additive effect or potentiation">
        <entity id="DDI-DrugBank.d46.s5.e0" charOffset="8-29"
            type="group" text="antihypertensive drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s6" text="."/>
    <sentence id="DDI-DrugBank.d46.s7" text="- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract">
        <entity id="DDI-DrugBank.d46.s7.e0" charOffset="2-15"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d46.s7.e1" charOffset="21-30"
            type="drug" text="colestipol"/>
        <entity id="DDI-DrugBank.d46.s7.e2" charOffset="32-37"
            type="group" text="resins"/>
        <entity id="DDI-DrugBank.d46.s7.e3" charOffset="40-53"
            type="drug" text="Cholestytamine"/>
        <entity id="DDI-DrugBank.d46.s7.e4" charOffset="59-68"
            type="drug" text="colestipol"/>
        <entity id="DDI-DrugBank.d46.s7.e5" charOffset="70-75"
            type="group" text="resins"/>
        <entity id="DDI-DrugBank.d46.s7.e6" charOffset="107-124"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d46.s7.e7" charOffset="139-146"
            type="group" text="diuretic"/>
        <ddi id="DDI-DrugBank.d46.s7.d0" e1="DDI-DrugBank.d46.s7.e3"
            e2="DDI-DrugBank.d46.s7.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d46.s7.d1" e1="DDI-DrugBank.d46.s7.e4"
            e2="DDI-DrugBank.d46.s7.e6" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s8" text="."/>
    <sentence id="DDI-DrugBank.d46.s9" text="- Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia">
        <entity id="DDI-DrugBank.d46.s9.e0" charOffset="2-16"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d46.s9.e1" charOffset="19-22"
            type="drug" text="ACTH"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s10" text="."/>
    <sentence id="DDI-DrugBank.d46.s11" text="- Pressor amines (e.g., norepinephrine): Possible decreased response to pressor amines but not sufficient to preclude their use">
        <entity id="DDI-DrugBank.d46.s11.e0" charOffset="24-37"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s12" text="."/>
    <sentence id="DDI-DrugBank.d46.s13" text="- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant">
        <entity id="DDI-DrugBank.d46.s13.e0" charOffset="2-26"
            type="group" text="Skeletal muscle relaxants"/>
        <entity id="DDI-DrugBank.d46.s13.e1" charOffset="52-63"
            type="drug" text="tubocurarine"/>
        <entity id="DDI-DrugBank.d46.s13.e2" charOffset="108-122"
            type="group" text="muscle relaxant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s14" text="."/>
    <sentence id="DDI-DrugBank.d46.s15" text="- Lithium: Generally should not be given with diuretics.">
        <entity id="DDI-DrugBank.d46.s15.e0" charOffset="2-8"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d46.s15.e1" charOffset="46-54"
            type="group" text="diuretics"/>
        <ddi id="DDI-DrugBank.d46.s15.d0" e1="DDI-DrugBank.d46.s15.e0"
            e2="DDI-DrugBank.d46.s15.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s16" text="Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.">
        <entity id="DDI-DrugBank.d46.s16.e0" charOffset="0-14"
            type="group" text="Diuretic agents"/>
        <entity id="DDI-DrugBank.d46.s16.e1" charOffset="46-52"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d46.s16.e2" charOffset="77-83"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d46.s16.d0" e1="DDI-DrugBank.d46.s16.e0"
            e2="DDI-DrugBank.d46.s16.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d46.s16.d1" e1="DDI-DrugBank.d46.s16.e0"
            e2="DDI-DrugBank.d46.s16.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s17" text="Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide">
        <entity id="DDI-DrugBank.d46.s17.e0" charOffset="32-38"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d46.s17.e1" charOffset="90-103"
            type="drug" text="chlorothiazide"/>
        <ddi id="DDI-DrugBank.d46.s17.d0" e1="DDI-DrugBank.d46.s17.e0"
            e2="DDI-DrugBank.d46.s17.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s18" text="."/>
    <sentence id="DDI-DrugBank.d46.s19" text="- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.">
        <entity id="DDI-DrugBank.d46.s19.e0" charOffset="2-38"
            type="group" text="Non-steroidal Anti-inflammatory Drugs"/>
        <entity id="DDI-DrugBank.d46.s19.e1" charOffset="83-119"
            type="group" text="non-steroidal anti-inflammatory agent"/>
        <entity id="DDI-DrugBank.d46.s19.e2"
            charOffset="191-194;228-236" type="group" text="loop diuretics"/>
        <entity id="DDI-DrugBank.d46.s19.e3"
            charOffset="197-213;228-236" type="group" text="potassium-sparing diuretics"/>
        <entity id="DDI-DrugBank.d46.s19.e4" charOffset="219-236"
            type="drug" text="thiazide diuretics"/>
        <ddi id="DDI-DrugBank.d46.s19.d0" e1="DDI-DrugBank.d46.s19.e1"
            e2="DDI-DrugBank.d46.s19.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d46.s19.d1" e1="DDI-DrugBank.d46.s19.e1"
            e2="DDI-DrugBank.d46.s19.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d46.s19.d2" e1="DDI-DrugBank.d46.s19.e1"
            e2="DDI-DrugBank.d46.s19.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s20" text="Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained">
        <entity id="DDI-DrugBank.d46.s20.e0" charOffset="16-29"
            type="drug" text="chlorothiazide"/>
        <entity id="DDI-DrugBank.d46.s20.e1" charOffset="35-72"
            type="group" text="non-steroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d46.s20.e2" charOffset="179-186"
            type="group" text="diuretic"/>
        <ddi id="DDI-DrugBank.d46.s20.d0" e1="DDI-DrugBank.d46.s20.e0"
            e2="DDI-DrugBank.d46.s20.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d46.s21" text="."/>
    <sentence id="DDI-DrugBank.d46.s22" text="- Drug/Laboratory Test Interactions: Thiazides should be discontinued before carrying out tests for parathyroid function.">
        <entity id="DDI-DrugBank.d46.s22.e0" charOffset="37-45"
            type="group" text="Thiazides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d446.s0" text="Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.">
        <entity id="DDI-DrugBank.d446.s0.e0" charOffset="0-15"
            type="drug" text="Chlorotrianisene"/>
        <entity id="DDI-DrugBank.d446.s0.e1" charOffset="35-49"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d446.s0.e2" charOffset="52-58"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d446.s0.e3" charOffset="61-72"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d446.s0.e4" charOffset="75-87"
            type="drug" text="bromocriptine"/>
        <entity id="DDI-DrugBank.d446.s0.e5" charOffset="90-96"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d446.s0.e6" charOffset="111-125"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d446.s0.e7" charOffset="128-140"
            type="drug" text="corticotropin"/>
        <entity id="DDI-DrugBank.d446.s0.e8" charOffset="143-154"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d446.s0.e9" charOffset="157-166"
            type="drug" text="dantrolene"/>
        <entity id="DDI-DrugBank.d446.s0.e10" charOffset="169-176"
            type="drug" text="nicotine"/>
        <entity id="DDI-DrugBank.d446.s0.e11" charOffset="179-188"
            type="drug" text="somatropin"/>
        <entity id="DDI-DrugBank.d446.s0.e12" charOffset="191-199"
            type="drug" text="tamoxifen"/>
        <entity id="DDI-DrugBank.d446.s0.e13" charOffset="206-213"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d446.s0.d0" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e1" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d1" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e2" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d2" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e3" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d3" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e4" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d4" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e5" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d5" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e6" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d6" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e7" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d7" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e8" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d8" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e9" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d9" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e10" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d10" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e11" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d11" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e12" type="int"/>
        <ddi id="DDI-DrugBank.d446.s0.d12" e1="DDI-DrugBank.d446.s0.e0"
            e2="DDI-DrugBank.d446.s0.e13" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d366.s0" text="May interact with skin products or shampoos for dandruff or psoriasis."/>
    <sentence id="DDI-DrugBank.d235.s0" text="Substrate of CYP2D6 (minor), 3A4 (major);"/>
    <sentence id="DDI-DrugBank.d235.s1" text="Inhibits CYP2D6 (weak)."/>
    <sentence id="DDI-DrugBank.d235.s2" text="Increased toxicity (CNS depression): CNS depressants, MAO inhibitors, tricyclic antidepressants, phenothiazines.">
        <entity id="DDI-DrugBank.d235.s2.e0" charOffset="37-51"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d235.s2.e1" charOffset="54-67"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d235.s2.e2" charOffset="70-94"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d235.s2.e3" charOffset="97-110"
            type="group" text="phenothiazines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d235.s3" text="CYP3A4 inhibitors: May increase the levels/effects of chlorpheniramine.">
        <entity id="DDI-DrugBank.d235.s3.e0" charOffset="54-69"
            type="drug" text="chlorpheniramine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d235.s4" text="Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.">
        <entity id="DDI-DrugBank.d235.s4.e0" charOffset="27-43"
            type="group" text="azole antifungals"/>
        <entity id="DDI-DrugBank.d235.s4.e1" charOffset="46-58"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d235.s4.e2" charOffset="61-74"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d235.s4.e3" charOffset="77-86"
            type="drug" text="diclofenac"/>
        <entity id="DDI-DrugBank.d235.s4.e4" charOffset="89-99"
            type="drug" text="doxycycline"/>
        <entity id="DDI-DrugBank.d235.s4.e5" charOffset="102-113"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d235.s4.e6" charOffset="116-123"
            type="drug" text="imatinib"/>
        <entity id="DDI-DrugBank.d235.s4.e7" charOffset="126-134"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d235.s4.e8" charOffset="137-146"
            type="drug" text="nefazodone"/>
        <entity id="DDI-DrugBank.d235.s4.e9" charOffset="149-159"
            type="drug" text="nicardipine"/>
        <entity id="DDI-DrugBank.d235.s4.e10" charOffset="162-169"
            type="drug" text="propofol"/>
        <entity id="DDI-DrugBank.d235.s4.e11" charOffset="172-190"
            type="group" text="protease inhibitors"/>
        <entity id="DDI-DrugBank.d235.s4.e12" charOffset="193-201"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d235.s4.e13" charOffset="208-216"
            type="drug" text="verapamil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d86.s0" text="The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.">
        <entity id="DDI-DrugBank.d86.s0.e0" charOffset="82-99"
            type="group" text="antipsychotic drug"/>
        <entity id="DDI-DrugBank.d86.s0.e1" charOffset="106-119"
            type="drug" text="chlorpromazine"/>
        <entity id="DDI-DrugBank.d86.s0.e2" charOffset="126-146"
            type="group" text="antiparkinsonian drug"/>
        <entity id="DDI-DrugBank.d86.s0.e3" charOffset="153-167"
            type="drug" text="trihexyphenidyl"/>
        <entity id="DDI-DrugBank.d86.s0.e4" charOffset="180-203"
            type="group" text="tricyclic antidepressant"/>
        <entity id="DDI-DrugBank.d86.s0.e5" charOffset="210-222"
            type="drug" text="amitriptyline"/>
        <ddi id="DDI-DrugBank.d86.s0.d0" e1="DDI-DrugBank.d86.s0.e0"
            e2="DDI-DrugBank.d86.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d1" e1="DDI-DrugBank.d86.s0.e0"
            e2="DDI-DrugBank.d86.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d2" e1="DDI-DrugBank.d86.s0.e0"
            e2="DDI-DrugBank.d86.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d3" e1="DDI-DrugBank.d86.s0.e0"
            e2="DDI-DrugBank.d86.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d4" e1="DDI-DrugBank.d86.s0.e1"
            e2="DDI-DrugBank.d86.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d5" e1="DDI-DrugBank.d86.s0.e1"
            e2="DDI-DrugBank.d86.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d6" e1="DDI-DrugBank.d86.s0.e1"
            e2="DDI-DrugBank.d86.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d7" e1="DDI-DrugBank.d86.s0.e1"
            e2="DDI-DrugBank.d86.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d8" e1="DDI-DrugBank.d86.s0.e2"
            e2="DDI-DrugBank.d86.s0.e0" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d9" e1="DDI-DrugBank.d86.s0.e2"
            e2="DDI-DrugBank.d86.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d10" e1="DDI-DrugBank.d86.s0.e2"
            e2="DDI-DrugBank.d86.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d11" e1="DDI-DrugBank.d86.s0.e2"
            e2="DDI-DrugBank.d86.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d12" e1="DDI-DrugBank.d86.s0.e3"
            e2="DDI-DrugBank.d86.s0.e0" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d13" e1="DDI-DrugBank.d86.s0.e3"
            e2="DDI-DrugBank.d86.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d14" e1="DDI-DrugBank.d86.s0.e3"
            e2="DDI-DrugBank.d86.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d15" e1="DDI-DrugBank.d86.s0.e3"
            e2="DDI-DrugBank.d86.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d16" e1="DDI-DrugBank.d86.s0.e4"
            e2="DDI-DrugBank.d86.s0.e0" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d17" e1="DDI-DrugBank.d86.s0.e4"
            e2="DDI-DrugBank.d86.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d18" e1="DDI-DrugBank.d86.s0.e4"
            e2="DDI-DrugBank.d86.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d19" e1="DDI-DrugBank.d86.s0.e4"
            e2="DDI-DrugBank.d86.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d20" e1="DDI-DrugBank.d86.s0.e5"
            e2="DDI-DrugBank.d86.s0.e0" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d21" e1="DDI-DrugBank.d86.s0.e5"
            e2="DDI-DrugBank.d86.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d22" e1="DDI-DrugBank.d86.s0.e5"
            e2="DDI-DrugBank.d86.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d86.s0.d23" e1="DDI-DrugBank.d86.s0.e5"
            e2="DDI-DrugBank.d86.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d86.s1" text="Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.">
        <entity id="DDI-DrugBank.d86.s1.e0" charOffset="48-63"
            type="group" text="anti-depressants"/>
        <entity id="DDI-DrugBank.d86.s1.e1" charOffset="65-82"
            type="group" text="anti-anxiety drugs"/>
        <entity id="DDI-DrugBank.d86.s1.e2" charOffset="128-140"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d86.s1.e3" charOffset="149-159"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d86.s1.e4" charOffset="163-174"
            type="drug" text="sparfloxacin"/>
        <entity id="DDI-DrugBank.d86.s1.e5" charOffset="177-189"
            type="drug" text="grepafloxacin"/>
        <entity id="DDI-DrugBank.d86.s1.e6" charOffset="192-203"
            type="drug" text="guanethidine"/>
        <entity id="DDI-DrugBank.d86.s1.e7" charOffset="206-214"
            type="drug" text="guanadrel"/>
        <entity id="DDI-DrugBank.d86.s1.e8" charOffset="217-227"
            type="drug" text="metrizamide"/>
        <entity id="DDI-DrugBank.d86.s1.e9" charOffset="230-240"
            type="drug" text="cabergoline"/>
        <entity id="DDI-DrugBank.d86.s1.e10" charOffset="243-249"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d86.s1.e11" charOffset="252-259"
            type="group" text="narcotic"/>
        <entity id="DDI-DrugBank.d86.s1.e12" charOffset="284-290"
            type="drug" text="codeine"/>
        <entity id="DDI-DrugBank.d86.s1.e13" charOffset="338-351"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d86.s1.e14" charOffset="360-374"
            type="drug" text="diphenhydramine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d245.s0" text="The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.">
        <entity id="DDI-DrugBank.d245.s0.e0" charOffset="27-38"
            type="group" text="sulfonylurea"/>
        <entity id="DDI-DrugBank.d245.s0.e1" charOffset="86-122"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d245.s0.e2" charOffset="171-181"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d245.s0.e3" charOffset="184-195"
            type="group" text="sulfonamides"/>
        <entity id="DDI-DrugBank.d245.s0.e4" charOffset="198-212"
            type="drug" text="chloramphenicol"/>
        <entity id="DDI-DrugBank.d245.s0.e5" charOffset="215-224"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d245.s0.e6" charOffset="227-235"
            type="group" text="coumarins"/>
        <entity id="DDI-DrugBank.d245.s0.e7" charOffset="238-265"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d245.s0.e8" charOffset="272-302"
            type="group" text="beta adrenergic blocking agents"/>
        <ddi id="DDI-DrugBank.d245.s0.d0" e1="DDI-DrugBank.d245.s0.e0"
            e2="DDI-DrugBank.d245.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d245.s0.d1" e1="DDI-DrugBank.d245.s0.e0"
            e2="DDI-DrugBank.d245.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d245.s0.d2" e1="DDI-DrugBank.d245.s0.e0"
            e2="DDI-DrugBank.d245.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d245.s0.d3" e1="DDI-DrugBank.d245.s0.e0"
            e2="DDI-DrugBank.d245.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d245.s0.d4" e1="DDI-DrugBank.d245.s0.e0"
            e2="DDI-DrugBank.d245.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d245.s0.d5" e1="DDI-DrugBank.d245.s0.e0"
            e2="DDI-DrugBank.d245.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d245.s0.d6" e1="DDI-DrugBank.d245.s0.e0"
            e2="DDI-DrugBank.d245.s0.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d245.s0.d7" e1="DDI-DrugBank.d245.s0.e0"
            e2="DDI-DrugBank.d245.s0.e8" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d245.s1" text="When such drugs are administered to a patient receiving DIABINESE, the patient should be observed closely for hypoglycemia.">
        <entity id="DDI-DrugBank.d245.s1.e0" charOffset="56-64"
            type="brand" text="DIABINESE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d245.s2" text="When such drugs are withdrawn from a patient receiving DIABINESE, the patient should be observed closely for loss of control.">
        <entity id="DDI-DrugBank.d245.s2.e0" charOffset="55-63"
            type="brand" text="DIABINESE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d245.s3" text="Certain drugs tend to produce hyperglycemia and may lead to loss of control."/>
    <sentence id="DDI-DrugBank.d245.s4" text="These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.">
        <entity id="DDI-DrugBank.d245.s4.e0" charOffset="24-32"
            type="group" text="thiazides"/>
        <entity id="DDI-DrugBank.d245.s4.e1" charOffset="44-52"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d245.s4.e2" charOffset="55-69"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d245.s4.e3" charOffset="72-85"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d245.s4.e4" charOffset="106-114"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d245.s4.e5" charOffset="122-135"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d245.s4.e6" charOffset="138-146"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d245.s4.e7" charOffset="149-162"
            type="drug" text="nicotinic acid"/>
        <entity id="DDI-DrugBank.d245.s4.e8" charOffset="165-180"
            type="group" text="sympathomimetics"/>
        <entity id="DDI-DrugBank.d245.s4.e9" charOffset="183-212"
            type="group" text="calcium channel blocking drugs"/>
        <entity id="DDI-DrugBank.d245.s4.e10" charOffset="219-227"
            type="drug" text="isoniazid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d245.s5" text="When such drugs are administered to a patient receiving DIABINESE, the patient should be closely observed for loss of control.">
        <entity id="DDI-DrugBank.d245.s5.e0" charOffset="56-64"
            type="brand" text="DIABINESE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d245.s6" text="When such drugs are withdrawn from a patient receiving DIABINESE, the patient should be observed closely for hypoglycemia.">
        <entity id="DDI-DrugBank.d245.s6.e0" charOffset="55-63"
            type="brand" text="DIABINESE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d245.s7" text="Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.">
        <entity id="DDI-DrugBank.d245.s7.e0" charOffset="48-59"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d245.s7.e1" charOffset="94-107"
            type="drug" text="chlorpropamide"/>
        <entity id="DDI-DrugBank.d245.s7.e2" charOffset="110-121"
            type="group" text="barbiturates"/>
        <ddi id="DDI-DrugBank.d245.s7.d0" e1="DDI-DrugBank.d245.s7.e0"
            e2="DDI-DrugBank.d245.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d245.s8" text="In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol.">
        <entity id="DDI-DrugBank.d245.s8.e0" charOffset="20-29"
            type="drug" text="disulfiram"/>
        <entity id="DDI-DrugBank.d245.s8.e1" charOffset="81-87"
            type="drug" text="alcohol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d245.s9" text="A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.">
        <entity id="DDI-DrugBank.d245.s9.e0" charOffset="37-46"
            type="drug" text="miconazole"/>
        <entity id="DDI-DrugBank.d245.s9.e1" charOffset="57-75"
            type="group" text="hypoglycemic agents"/>
        <ddi id="DDI-DrugBank.d245.s9.d0" e1="DDI-DrugBank.d245.s9.e0"
            e2="DDI-DrugBank.d245.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d245.s10" text="Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.">
        <entity id="DDI-DrugBank.d245.s10.e0" charOffset="95-104"
            type="drug" text="miconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d503.s0" text="Chlorprothixene may increase the plasma-level of concomitantly given lithium.">
        <entity id="DDI-DrugBank.d503.s0.e0" charOffset="0-14"
            type="drug" text="Chlorprothixene"/>
        <entity id="DDI-DrugBank.d503.s0.e1" charOffset="69-75"
            type="drug" text="lithium"/>
        <ddi id="DDI-DrugBank.d503.s0.d0" e1="DDI-DrugBank.d503.s0.e0"
            e2="DDI-DrugBank.d503.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d503.s1" text="In order to avoid lithium intoxication, lithium plasma levels should be monitored closely.">
        <entity id="DDI-DrugBank.d503.s1.e0" charOffset="18-24"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d503.s1.e1" charOffset="40-46"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d503.s2" text="If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.">
        <entity id="DDI-DrugBank.d503.s2.e0" charOffset="3-17"
            type="drug" text="chlorprothixene"/>
        <entity id="DDI-DrugBank.d503.s2.e1" charOffset="47-53"
            type="group" text="opioids"/>
        <entity id="DDI-DrugBank.d503.s2.e2" charOffset="60-65"
            type="group" text="opioid"/>
        <entity id="DDI-DrugBank.d503.s2.e3" charOffset="116-130"
            type="drug" text="chlorprothixene"/>
        <entity id="DDI-DrugBank.d503.s2.e4" charOffset="186-192"
            type="group" text="opioids"/>
        <ddi id="DDI-DrugBank.d503.s2.d0" e1="DDI-DrugBank.d503.s2.e0"
            e2="DDI-DrugBank.d503.s2.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d503.s2.d1" e1="DDI-DrugBank.d503.s2.e3"
            e2="DDI-DrugBank.d503.s2.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d503.s3" text="Avoid the concomitant use of chlorprothixene and tramadol (Ultram).">
        <entity id="DDI-DrugBank.d503.s3.e0" charOffset="29-43"
            type="drug" text="chlorprothixene"/>
        <entity id="DDI-DrugBank.d503.s3.e1" charOffset="49-56"
            type="drug" text="tramadol"/>
        <entity id="DDI-DrugBank.d503.s3.e2" charOffset="59-64"
            type="brand" text="Ultram"/>
        <ddi id="DDI-DrugBank.d503.s3.d0" e1="DDI-DrugBank.d503.s3.e0"
            e2="DDI-DrugBank.d503.s3.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d503.s3.d1" e1="DDI-DrugBank.d503.s3.e0"
            e2="DDI-DrugBank.d503.s3.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d503.s4" text="Massive seizures may be encountered with this combination."/>
    <sentence id="DDI-DrugBank.d503.s5" text="Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.">
        <entity id="DDI-DrugBank.d503.s5.e0" charOffset="72-86"
            type="drug" text="chlorprothixene"/>
        <entity id="DDI-DrugBank.d503.s5.e1" charOffset="102-116"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d503.s5.e2" charOffset="121-131"
            type="group" text="barbituates"/>
        <ddi id="DDI-DrugBank.d503.s5.d0" e1="DDI-DrugBank.d503.s5.e0"
            e2="DDI-DrugBank.d503.s5.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d503.s5.d1" e1="DDI-DrugBank.d503.s5.e0"
            e2="DDI-DrugBank.d503.s5.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d503.s6" text="Choose particular low doses of these drugs."/>
    <sentence id="DDI-DrugBank.d503.s7" text="Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.">
        <entity id="DDI-DrugBank.d503.s7.e0" charOffset="38-52"
            type="drug" text="chlorprothixene"/>
        <entity id="DDI-DrugBank.d503.s7.e1" charOffset="65-85"
            type="group" text="anticholinergic drugs"/>
        <entity id="DDI-DrugBank.d503.s7.e2" charOffset="88-112"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d503.s7.e3" charOffset="118-140"
            type="group" text="antiparkinsonian agents"/>
        <ddi id="DDI-DrugBank.d503.s7.d0" e1="DDI-DrugBank.d503.s7.e0"
            e2="DDI-DrugBank.d503.s7.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d503.s7.d1" e1="DDI-DrugBank.d503.s7.e0"
            e2="DDI-DrugBank.d503.s7.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d503.s7.d2" e1="DDI-DrugBank.d503.s7.e0"
            e2="DDI-DrugBank.d503.s7.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d265.s0" text="Chlorthalidone may add to or potentiate the action of other antihypertensive drugs.">
        <entity id="DDI-DrugBank.d265.s0.e0" charOffset="0-13"
            type="drug" text="Chlorthalidone"/>
        <entity id="DDI-DrugBank.d265.s0.e1" charOffset="60-81"
            type="group" text="antihypertensive drugs"/>
        <ddi id="DDI-DrugBank.d265.s0.d0" e1="DDI-DrugBank.d265.s0.e0"
            e2="DDI-DrugBank.d265.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d265.s1" text="Potentiation occurs with ganglionic peripheral adrenergic blocking drugs.">
        <entity id="DDI-DrugBank.d265.s1.e0" charOffset="25-71"
            type="group" text="ganglionic peripheral adrenergic blocking drugs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d265.s2" text="Medication such as digitalis may also influence serum electrolytes.">
        <entity id="DDI-DrugBank.d265.s2.e0" charOffset="19-27"
            type="group" text="digitalis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d265.s3" text="Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting."/>
    <sentence id="DDI-DrugBank.d265.s4" text="Insulin requirements in diabetic patients may be increased, decreased, or unchanged.">
        <entity id="DDI-DrugBank.d265.s4.e0" charOffset="0-6"
            type="drug" text="Insulin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d265.s5" text="Higher dosage of oral hypoglycemic agents may be required.">
        <entity id="DDI-DrugBank.d265.s5.e0" charOffset="22-40"
            type="group" text="hypoglycemic agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d265.s6" text="Latent diabetes mellitus may become manifest during chlorthalidone administration.">
        <entity id="DDI-DrugBank.d265.s6.e0" charOffset="52-65"
            type="drug" text="chlorthalidone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d265.s7" text="Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.">
        <entity id="DDI-DrugBank.d265.s7.e0" charOffset="0-13"
            type="drug" text="Chlorthalidone"/>
        <entity id="DDI-DrugBank.d265.s7.e1" charOffset="68-79"
            type="drug" text="tubocurarine"/>
        <ddi id="DDI-DrugBank.d265.s7.d0" e1="DDI-DrugBank.d265.s7.e0"
            e2="DDI-DrugBank.d265.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d265.s8" text="Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.">
        <entity id="DDI-DrugBank.d265.s8.e0" charOffset="0-13"
            type="drug" text="Chlorthalidone"/>
        <entity id="DDI-DrugBank.d265.s8.e1" charOffset="73-86"
            type="drug" text="norepinephrine"/>
        <ddi id="DDI-DrugBank.d265.s8.d0" e1="DDI-DrugBank.d265.s8.e0"
            e2="DDI-DrugBank.d265.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d265.s9" text="This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use."/>
    <sentence id="DDI-DrugBank.d262.s0" text="The concomitant use of alcohol or other central nervous system depressants may have an additive effect.">
        <entity id="DDI-DrugBank.d262.s0.e0" charOffset="23-29"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d262.s0.e1" charOffset="40-73"
            type="group" text="central nervous system depressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s0" text="Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;">
        <entity id="DDI-DrugBank.d404.s0.e0" charOffset="17-25"
            type="group" text="vitamin D"/>
        <entity id="DDI-DrugBank.d404.s0.e1" charOffset="38-47"
            type="drug" text="Vitamin D2"/>
        <entity id="DDI-DrugBank.d404.s0.e2" charOffset="50-59"
            type="drug" text="Vitamin D3"/>
        <entity id="DDI-DrugBank.d404.s0.e3" charOffset="62-71"
            type="drug" text="Calcitriol"/>
        <entity id="DDI-DrugBank.d404.s0.e4" charOffset="78-86"
            type="drug" text="Calcidiol"/>
        <entity id="DDI-DrugBank.d404.s0.e5" charOffset="90-103"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d404.s0.e6" charOffset="106-119"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d404.s0.e7" charOffset="174-193"
            type="group" text="fat soluble vitamins"/>
        <ddi id="DDI-DrugBank.d404.s0.d0" e1="DDI-DrugBank.d404.s0.e6"
            e2="DDI-DrugBank.d404.s0.e7" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s1" text="as such it may impair intestinal absorption of any of vitamin D.">
        <entity id="DDI-DrugBank.d404.s1.e0" charOffset="54-62"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s2" text="Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.">
        <entity id="DDI-DrugBank.d404.s2.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d404.s2.e1" charOffset="10-22"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d404.s2.e2" charOffset="49-57"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d404.s2.e3" charOffset="62-74"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d404.s2.e4" charOffset="117-125"
            type="group" text="vitamin D"/>
        <entity id="DDI-DrugBank.d404.s2.e5" charOffset="171-180"
            type="drug" text="calcitriol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s3" text="Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.">
        <entity id="DDI-DrugBank.d404.s3.e0" charOffset="21-30"
            type="drug" text="calcitriol"/>
        <entity id="DDI-DrugBank.d404.s3.e1" charOffset="80-88"
            type="brand" text="Rocaltrol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s4" text="Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.">
        <entity id="DDI-DrugBank.d404.s4.e0" charOffset="0-8"
            type="group" text="Thiazides"/>
        <entity id="DDI-DrugBank.d404.s4.e1" charOffset="11-19"
            type="group" text="Thiazides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s5" text="Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.">
        <entity id="DDI-DrugBank.d404.s5.e0" charOffset="63-71"
            type="group" text="thiazides"/>
        <entity id="DDI-DrugBank.d404.s5.e1" charOffset="78-86"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d404.s5.d0" e1="DDI-DrugBank.d404.s5.e0"
            e2="DDI-DrugBank.d404.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s6" text="Therefore, precaution should be taken when coadministration is necessary."/>
    <sentence id="DDI-DrugBank.d404.s7" text="Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.">
        <entity id="DDI-DrugBank.d404.s7.e0" charOffset="0-8"
            type="group" text="Digitalis"/>
        <entity id="DDI-DrugBank.d404.s7.e1" charOffset="11-19"
            type="group" text="Vitamin D"/>
        <entity id="DDI-DrugBank.d404.s7.e2" charOffset="95-103"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d404.s7.d0" e1="DDI-DrugBank.d404.s7.e1"
            e2="DDI-DrugBank.d404.s7.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s8" text="Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.">
        <entity id="DDI-DrugBank.d404.s8.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d404.s8.e1" charOffset="14-25"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d404.s8.e2" charOffset="79-87"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d404.s8.d0" e1="DDI-DrugBank.d404.s8.e1"
            e2="DDI-DrugBank.d404.s8.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s9" text="Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.">
        <entity id="DDI-DrugBank.d404.s9.e0" charOffset="133-144"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s10" text="However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.">
        <entity id="DDI-DrugBank.d404.s10.e0" charOffset="45-56"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d404.s10.e1" charOffset="63-71"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s11" text="Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.">
        <entity id="DDI-DrugBank.d404.s11.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d404.s11.e1" charOffset="72-80"
            type="group" text="vitamin D"/>
        <entity id="DDI-DrugBank.d404.s11.e2" charOffset="131-145"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d404.s11.d0" e1="DDI-DrugBank.d404.s11.e1"
            e2="DDI-DrugBank.d404.s11.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s12" text="Phosphate-Binding Agents: Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.">
        <entity id="DDI-DrugBank.d404.s12.e0" charOffset="32-40"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s13" text="Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.">
        <entity id="DDI-DrugBank.d404.s13.e0" charOffset="0-8"
            type="group" text="Vitamin D"/>
        <entity id="DDI-DrugBank.d404.s13.e1" charOffset="46-54"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s14" text="Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.">
        <entity id="DDI-DrugBank.d404.s14.e0" charOffset="0-6"
            type="drug" text="Calcium"/>
        <entity id="DDI-DrugBank.d404.s14.e1" charOffset="55-61"
            type="drug" text="calcium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d404.s15" text="Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.">
        <entity id="DDI-DrugBank.d404.s15.e0" charOffset="0-8"
            type="drug" text="Magnesium"/>
        <entity id="DDI-DrugBank.d404.s15.e1" charOffset="11-19"
            type="drug" text="Magnesium"/>
        <entity id="DDI-DrugBank.d404.s15.e2" charOffset="50-57"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d404.s15.e3" charOffset="140-148"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d404.s15.d0" e1="DDI-DrugBank.d404.s15.e1"
            e2="DDI-DrugBank.d404.s15.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d404.s15.d1" e1="DDI-DrugBank.d404.s15.e2"
            e2="DDI-DrugBank.d404.s15.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d566.s0" text="Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.">
        <entity id="DDI-DrugBank.d566.s0.e0" charOffset="0-13"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d566.s0.e1" charOffset="15-19"
            type="group" text="resin"/>
        <entity id="DDI-DrugBank.d566.s0.e2" charOffset="95-108"
            type="group" text="phenylbutazone"/>
        <entity id="DDI-DrugBank.d566.s0.e3" charOffset="111-118"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d566.s0.e4" charOffset="121-138"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d566.s0.e5" charOffset="152-162"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d566.s0.e6" charOffset="184-195"
            type="drug" text="tetracycline"/>
        <entity id="DDI-DrugBank.d566.s0.e7" charOffset="197-208"
            type="drug" text="penicillin G"/>
        <entity id="DDI-DrugBank.d566.s0.e8" charOffset="211-223"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d566.s0.e9" charOffset="238-246"
            type="drug" text="thyroxine"/>
        <entity id="DDI-DrugBank.d566.s0.e10" charOffset="262-270"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d566.s0.e11" charOffset="276-285"
            type="group" text="progestins"/>
        <entity id="DDI-DrugBank.d566.s0.e12" charOffset="292-300"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d566.s0.d0" e1="DDI-DrugBank.d566.s0.e0"
            e2="DDI-DrugBank.d566.s0.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d566.s0.d1" e1="DDI-DrugBank.d566.s0.e0"
            e2="DDI-DrugBank.d566.s0.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d566.s0.d2" e1="DDI-DrugBank.d566.s0.e0"
            e2="DDI-DrugBank.d566.s0.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d566.s0.d3" e1="DDI-DrugBank.d566.s0.e0"
            e2="DDI-DrugBank.d566.s0.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d566.s0.d4" e1="DDI-DrugBank.d566.s0.e0"
            e2="DDI-DrugBank.d566.s0.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d566.s0.d5" e1="DDI-DrugBank.d566.s0.e0"
            e2="DDI-DrugBank.d566.s0.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d566.s0.d6" e1="DDI-DrugBank.d566.s0.e0"
            e2="DDI-DrugBank.d566.s0.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d566.s0.d7" e1="DDI-DrugBank.d566.s0.e0"
            e2="DDI-DrugBank.d566.s0.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d566.s0.d8" e1="DDI-DrugBank.d566.s0.e0"
            e2="DDI-DrugBank.d566.s0.e10" type="mechanism"/>
        <ddi id="DDI-DrugBank.d566.s0.d9" e1="DDI-DrugBank.d566.s0.e0"
            e2="DDI-DrugBank.d566.s0.e11" type="mechanism"/>
        <ddi id="DDI-DrugBank.d566.s0.d10" e1="DDI-DrugBank.d566.s0.e0"
            e2="DDI-DrugBank.d566.s0.e12" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d566.s1" text="Interference with the absorption of oral phosphate supplements has been observed with another positively-charged bile acid sequestrant.">
        <entity id="DDI-DrugBank.d566.s1.e0" charOffset="41-49"
            type="drug_n" text="phosphate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d566.s2" text="Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.">
        <entity id="DDI-DrugBank.d566.s2.e0" charOffset="0-13"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d566.s2.e1" charOffset="15-19"
            type="group" text="resin"/>
        <entity id="DDI-DrugBank.d566.s2.e2" charOffset="132-145"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d566.s2.e3" charOffset="147-151"
            type="group" text="resin"/>
        <entity id="DDI-DrugBank.d566.s2.e4" charOffset="219-227"
            type="group" text="digitalis"/>
        <entity id="DDI-DrugBank.d566.s2.e5" charOffset="300-313"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d566.s2.e6" charOffset="315-319"
            type="group" text="resin"/>
        <ddi id="DDI-DrugBank.d566.s2.d0" e1="DDI-DrugBank.d566.s2.e2"
            e2="DDI-DrugBank.d566.s2.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d566.s3" text="Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.">
        <entity id="DDI-DrugBank.d566.s3.e0" charOffset="8-21"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d566.s3.e1" charOffset="41-54"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d566.s3.e2" charOffset="56-60"
            type="group" text="resin"/>
        <entity id="DDI-DrugBank.d566.s3.e3" charOffset="152-171"
            type="group" text="fat soluble vitamins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d566.s4" text="When cholestyramine resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.">
        <entity id="DDI-DrugBank.d566.s4.e0" charOffset="5-18"
            type="drug" text="cholestyramine"/>
        <entity id="DDI-DrugBank.d566.s4.e1" charOffset="20-24"
            type="group" text="resin"/>
        <entity id="DDI-DrugBank.d566.s4.e2" charOffset="134-153"
            type="group" text="fat-soluble vitamins"/>
    </sentence>
    <sentence id="DDI-DrugBank.d566.s5" text="SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.">
        <entity id="DDI-DrugBank.d566.s5.e0" charOffset="6-19"
            type="drug" text="CHOLESTYRAMINE"/>
        <entity id="DDI-DrugBank.d566.s5.e1" charOffset="21-25"
            type="group" text="RESIN"/>
        <entity id="DDI-DrugBank.d566.s5.e2" charOffset="162-175"
            type="drug" text="CHOLESTYRAMINE"/>
        <entity id="DDI-DrugBank.d566.s5.e3" charOffset="177-181"
            type="group" text="RESIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d362.s0" text="Based on in vitro studies in human liver microsomes, des-ciclesonide appears to have no inhibitory or induction potential on the metabolism of other drugs metabolized by CYP 450 enzymes.">
        <entity id="DDI-DrugBank.d362.s0.e0" charOffset="53-67"
            type="drug" text="des-ciclesonide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d362.s1" text="The inhibitory potential of ciclesonide on CYP450 isoenzymes has not been studied.">
        <entity id="DDI-DrugBank.d362.s1.e0" charOffset="28-38"
            type="drug" text="ciclesonide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d362.s2" text="In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by warfarin or salicylic acid, indicating no potential for protein binding-based drug interactions.">
        <entity id="DDI-DrugBank.d362.s2.e0" charOffset="65-79"
            type="drug" text="des-ciclesonide"/>
        <entity id="DDI-DrugBank.d362.s2.e1" charOffset="101-108"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d362.s2.e2" charOffset="113-126"
            type="drug" text="salicylic acid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d362.s3" text="In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin.">
        <entity id="DDI-DrugBank.d362.s3.e0" charOffset="65-75"
            type="drug" text="ciclesonide"/>
        <entity id="DDI-DrugBank.d362.s3.e1" charOffset="86-97"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d362.s3.e2" charOffset="185-199"
            type="drug" text="des-ciclesonide"/>
        <entity id="DDI-DrugBank.d362.s3.e3" charOffset="204-215"
            type="drug" text="erythromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d362.s4" text="In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.">
        <entity id="DDI-DrugBank.d362.s4.e0" charOffset="71-81"
            type="drug" text="ciclesonide"/>
        <entity id="DDI-DrugBank.d362.s4.e1" charOffset="92-103"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d362.s4.e2" charOffset="181-195"
            type="drug" text="des-ciclesonide"/>
        <entity id="DDI-DrugBank.d362.s4.e3" charOffset="256-266"
            type="drug" text="ciclesonide"/>
        <ddi id="DDI-DrugBank.d362.s4.d0" e1="DDI-DrugBank.d362.s4.e0"
            e2="DDI-DrugBank.d362.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d362.s5" text="Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.">
        <entity id="DDI-DrugBank.d362.s5.e0" charOffset="11-22"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d362.s5.e1" charOffset="76-86"
            type="drug" text="ciclesonide"/>
        <ddi id="DDI-DrugBank.d362.s5.d0" e1="DDI-DrugBank.d362.s5.e0"
            e2="DDI-DrugBank.d362.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d260.s0" text="Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).">
        <entity id="DDI-DrugBank.d260.s0.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d260.s0.e1" charOffset="13-22"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d260.s0.e2" charOffset="113-125"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d260.s0.e3" charOffset="128-136"
            type="drug" text="acyclovir"/>
        <entity id="DDI-DrugBank.d260.s0.e4" charOffset="139-178"
            type="group" text="angiotensin-converting enzyme inhibitors"/>
        <entity id="DDI-DrugBank.d260.s0.e5" charOffset="181-199"
            type="drug" text="aminosalicylic acid"/>
        <entity id="DDI-DrugBank.d260.s0.e6" charOffset="202-213"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d260.s0.e7" charOffset="216-230"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d260.s0.e8" charOffset="233-242"
            type="drug" text="bumetanide"/>
        <entity id="DDI-DrugBank.d260.s0.e9" charOffset="245-254"
            type="drug" text="clofibrate"/>
        <entity id="DDI-DrugBank.d260.s0.e10" charOffset="257-268"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d260.s0.e11" charOffset="271-280"
            type="drug" text="famotidine"/>
        <entity id="DDI-DrugBank.d260.s0.e12" charOffset="283-292"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d260.s0.e13" charOffset="295-324"
            type="group" text="nonsteroidal anti-inflammatory"/>
        <entity id="DDI-DrugBank.d260.s0.e14" charOffset="334-345"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d260.s0.e15" charOffset="352-361"
            type="drug" text="zidovudine"/>
        <ddi id="DDI-DrugBank.d260.s0.d0" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d1" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d2" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d3" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d4" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d5" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d6" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d7" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d8" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e10" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d9" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e11" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d10" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e12" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d11" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e13" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d12" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e14" type="mechanism"/>
        <ddi id="DDI-DrugBank.d260.s0.d13" e1="DDI-DrugBank.d260.s0.e1"
            e2="DDI-DrugBank.d260.s0.e15" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d260.s1" text="Concomitant medications should be carefully assessed."/>
    <sentence id="DDI-DrugBank.d260.s2" text="Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.">
        <entity id="DDI-DrugBank.d260.s2.e0" charOffset="0-9"
            type="drug" text="Zidovudine"/>
        <entity id="DDI-DrugBank.d260.s2.e1" charOffset="98-107"
            type="drug" text="probenecid"/>
        <entity id="DDI-DrugBank.d260.s2.e2" charOffset="123-129"
            type="brand" text="VISTIDE"/>
        <ddi id="DDI-DrugBank.d260.s2.d0" e1="DDI-DrugBank.d260.s2.e0"
            e2="DDI-DrugBank.d260.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d260.s3" text="Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.">
        <entity id="DDI-DrugBank.d260.s3.e0" charOffset="51-57"
            type="brand" text="VISTIDE"/>
        <entity id="DDI-DrugBank.d260.s3.e1" charOffset="116-130"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d260.s3.e2" charOffset="139-148"
            type="drug" text="tobramycin"/>
        <entity id="DDI-DrugBank.d260.s3.e3" charOffset="151-160"
            type="drug" text="gentamicin"/>
        <entity id="DDI-DrugBank.d260.s3.e4" charOffset="167-174"
            type="drug" text="amikacin"/>
        <entity id="DDI-DrugBank.d260.s3.e5" charOffset="178-191"
            type="drug" text="amphotericin B"/>
        <entity id="DDI-DrugBank.d260.s3.e6" charOffset="194-202"
            type="drug" text="foscarnet"/>
        <entity id="DDI-DrugBank.d260.s3.e7" charOffset="217-227"
            type="drug" text="pentamidine"/>
        <entity id="DDI-DrugBank.d260.s3.e8" charOffset="230-239"
            type="drug" text="vancomycin"/>
        <entity id="DDI-DrugBank.d260.s3.e9" charOffset="246-283"
            type="group" text="non-steroidal anti-inflammatory agents"/>
        <ddi id="DDI-DrugBank.d260.s3.d0" e1="DDI-DrugBank.d260.s3.e0"
            e2="DDI-DrugBank.d260.s3.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d260.s3.d1" e1="DDI-DrugBank.d260.s3.e0"
            e2="DDI-DrugBank.d260.s3.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d260.s3.d2" e1="DDI-DrugBank.d260.s3.e0"
            e2="DDI-DrugBank.d260.s3.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d260.s3.d3" e1="DDI-DrugBank.d260.s3.e0"
            e2="DDI-DrugBank.d260.s3.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d260.s3.d4" e1="DDI-DrugBank.d260.s3.e0"
            e2="DDI-DrugBank.d260.s3.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d260.s3.d5" e1="DDI-DrugBank.d260.s3.e0"
            e2="DDI-DrugBank.d260.s3.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d260.s3.d6" e1="DDI-DrugBank.d260.s3.e0"
            e2="DDI-DrugBank.d260.s3.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d260.s3.d7" e1="DDI-DrugBank.d260.s3.e0"
            e2="DDI-DrugBank.d260.s3.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d260.s3.d8" e1="DDI-DrugBank.d260.s3.e0"
            e2="DDI-DrugBank.d260.s3.e9" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d260.s4" text="Such agents must be discontinued at least seven days prior to starting therapy with VISTIDE.">
        <entity id="DDI-DrugBank.d260.s4.e0" charOffset="84-90"
            type="brand" text="VISTIDE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d358.s0" text="Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.">
        <entity id="DDI-DrugBank.d358.s0.e0" charOffset="6-11"
            type="brand" text="PLETAL"/>
        <entity id="DDI-DrugBank.d358.s0.e1" charOffset="105-110"
            type="brand" text="PLETAL"/>
        <entity id="DDI-DrugBank.d358.s0.e2" charOffset="164-175"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d358.s0.e3" charOffset="181-192"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d358.s0.e4" charOffset="227-236"
            type="drug" text="omeprazole"/>
        <ddi id="DDI-DrugBank.d358.s0.d0" e1="DDI-DrugBank.d358.s0.e1"
            e2="DDI-DrugBank.d358.s0.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d358.s0.d1" e1="DDI-DrugBank.d358.s0.e1"
            e2="DDI-DrugBank.d358.s0.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d358.s0.d2" e1="DDI-DrugBank.d358.s0.e1"
            e2="DDI-DrugBank.d358.s0.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d358.s1" text="Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.">
        <entity id="DDI-DrugBank.d358.s1.e0" charOffset="47-56"
            type="drug" text="omeprazole"/>
        <entity id="DDI-DrugBank.d358.s1.e1" charOffset="62-73"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d358.s1.e2" charOffset="124-133"
            type="drug" text="cilostazol"/>
        <ddi id="DDI-DrugBank.d358.s1.d0" e1="DDI-DrugBank.d358.s1.e0"
            e2="DDI-DrugBank.d358.s1.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d358.s1.d1" e1="DDI-DrugBank.d358.s1.e1"
            e2="DDI-DrugBank.d358.s1.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d358.s2" text="Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..">
        <entity id="DDI-DrugBank.d358.s2.e0" charOffset="67-76"
            type="drug" text="cilostazol"/>
        <entity id="DDI-DrugBank.d358.s2.e1" charOffset="119-127"
            type="drug" text="diltiazem"/>
        <ddi id="DDI-DrugBank.d358.s2.d0" e1="DDI-DrugBank.d358.s2.e0"
            e2="DDI-DrugBank.d358.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d358.s3" text="Pletal does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to C.P.A. inhibition.">
        <entity id="DDI-DrugBank.d358.s3.e0" charOffset="0-5"
            type="brand" text="Pletal"/>
        <entity id="DDI-DrugBank.d358.s3.e1" charOffset="120-129"
            type="drug" text="lovastatin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s0" text="Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.">
        <entity id="DDI-DrugBank.d171.s0.e0" charOffset="0-6"
            type="brand" text="Tagamet"/>
        <entity id="DDI-DrugBank.d171.s0.e1" charOffset="130-157"
            type="group" text="warfarin-type anticoagulants"/>
        <entity id="DDI-DrugBank.d171.s0.e2" charOffset="160-168"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d171.s0.e3" charOffset="171-181"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d171.s0.e4" charOffset="184-193"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d171.s0.e5" charOffset="196-211"
            type="drug" text="chlordiazepoxide"/>
        <entity id="DDI-DrugBank.d171.s0.e6" charOffset="214-221"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d171.s0.e7" charOffset="232-256"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d171.s0.e8" charOffset="259-267"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d171.s0.e9" charOffset="270-281"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d171.s0.e10" charOffset="287-299"
            type="drug" text="metronidazole"/>
        <ddi id="DDI-DrugBank.d171.s0.d0" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d1" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d2" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d3" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d4" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d5" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d6" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d7" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d8" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d9" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e10" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s1" text="Clinically significant effects have been reported with the warfarin anticoagulants;">
        <entity id="DDI-DrugBank.d171.s1.e0" charOffset="59-81"
            type="group" text="warfarin anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s2" text="therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.">
        <entity id="DDI-DrugBank.d171.s2.e0" charOffset="86-98"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d171.s2.e1" charOffset="127-133"
            type="brand" text="Tagamet"/>
        <ddi id="DDI-DrugBank.d171.s2.d0" e1="DDI-DrugBank.d171.s2.e0"
            e2="DDI-DrugBank.d171.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s3" text="Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects.">
        <entity id="DDI-DrugBank.d171.s3.e0" charOffset="17-25"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d171.s3.e1" charOffset="28-36"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d171.s3.e2" charOffset="42-53"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s4" text="However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.">
        <entity id="DDI-DrugBank.d171.s4.e0" charOffset="64-70"
            type="brand" text="Tagamet"/>
        <entity id="DDI-DrugBank.d171.s4.e1" charOffset="146-157"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d171.s4.e2" charOffset="160-167"
            type="brand" text="Theo-Dur"/>
        <entity id="DDI-DrugBank.d171.s4.e3" charOffset="243-254"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d171.s4.d0" e1="DDI-DrugBank.d171.s4.e0"
            e2="DDI-DrugBank.d171.s4.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s4.d1" e1="DDI-DrugBank.d171.s4.e0"
            e2="DDI-DrugBank.d171.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s5" text="Data beyond 10 days are not available."/>
    <sentence id="DDI-DrugBank.d171.s6" text="(Note: All patients receiving theophylline should be monitored appropriately, regardless of concomitant drug therapy.)">
        <entity id="DDI-DrugBank.d171.s6.e0" charOffset="30-41"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s7" text="Dosage of the drugs mentioned above and other similarly metabolized drugs, particularly those of low therapeutic ratio or in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping concomitantly administered Tagamet to maintain optimum therapeutic blood levels.">
        <entity id="DDI-DrugBank.d171.s7.e0" charOffset="248-254"
            type="brand" text="Tagamet"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s8" text="Alteration of pH may affect absorption of certain drugs (e.g., ketoconazole).">
        <entity id="DDI-DrugBank.d171.s8.e0" charOffset="63-74"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s9" text="If these products are needed, they should be given at least 2 hours before cimetidine administration.">
        <entity id="DDI-DrugBank.d171.s9.e0" charOffset="75-84"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s10" text="Additional clinical experience may reveal other drugs affected by the concomitant administration of Tagamet.">
        <entity id="DDI-DrugBank.d171.s10.e0" charOffset="100-106"
            type="brand" text="Tagamet"/>
    </sentence>
    <sentence id="DDI-DrugBank.d512.s0" text="and/or Drug/Laboratory Test Interactions See CLINICAL PHARMACOLOGY, Pharmacokinetics and Drug Interactions."/>
    <sentence id="DDI-DrugBank.d512.s1" text="Effect of Sensipar on other drugs: Drugs metabolized by cytochrome P450 2D6 (CYP2D6): Sensipar  is a strong in vitro inhibitor of CYP2D6.">
        <entity id="DDI-DrugBank.d512.s1.e0" charOffset="10-17"
            type="brand" text="Sensipar"/>
        <entity id="DDI-DrugBank.d512.s1.e1" charOffset="86-93"
            type="brand" text="Sensipar"/>
    </sentence>
    <sentence id="DDI-DrugBank.d512.s2" text="Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide, vinblastine, thioridazine and most tricyclic antidepressants) may be required.">
        <entity id="DDI-DrugBank.d512.s2.e0" charOffset="143-152"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d512.s2.e1" charOffset="155-165"
            type="drug" text="vinblastine"/>
        <entity id="DDI-DrugBank.d512.s2.e2" charOffset="168-179"
            type="drug" text="thioridazine"/>
        <entity id="DDI-DrugBank.d512.s2.e3" charOffset="190-214"
            type="group" text="tricyclic antidepressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d512.s3" text="Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.">
        <entity id="DDI-DrugBank.d512.s3.e0" charOffset="0-12"
            type="drug" text="Amitriptyline"/>
        <entity id="DDI-DrugBank.d512.s3.e1" charOffset="60-69"
            type="drug" text="cinacalcet"/>
        <entity id="DDI-DrugBank.d512.s3.e2" charOffset="82-94"
            type="drug" text="amitriptyline"/>
        <entity id="DDI-DrugBank.d512.s3.e3" charOffset="106-118"
            type="drug" text="amitriptyline"/>
        <entity id="DDI-DrugBank.d512.s3.e4" charOffset="133-145"
            type="drug_n" text="nortriptyline"/>
        <ddi id="DDI-DrugBank.d512.s3.d0" e1="DDI-DrugBank.d512.s3.e1"
            e2="DDI-DrugBank.d512.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d512.s4" text="Effect of other drugs on Sensipar : Sensipar  is metabolized by multiple cytochrome P450 enzymes, primarily CYP3A4, CYP2D6, and CYP1A2.">
        <entity id="DDI-DrugBank.d512.s4.e0" charOffset="25-32"
            type="brand" text="Sensipar"/>
        <entity id="DDI-DrugBank.d512.s4.e1" charOffset="36-43"
            type="brand" text="Sensipar"/>
    </sentence>
    <sentence id="DDI-DrugBank.d512.s5" text="Ketoconazole: Sensipar is metabolized in part by CYP3A4.">
        <entity id="DDI-DrugBank.d512.s5.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d512.s5.e1" charOffset="14-21"
            type="brand" text="Sensipar"/>
    </sentence>
    <sentence id="DDI-DrugBank.d512.s6" text="Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.">
        <entity id="DDI-DrugBank.d512.s6.e0" charOffset="21-32"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d512.s6.e1" charOffset="75-84"
            type="drug" text="cinacalcet"/>
        <entity id="DDI-DrugBank.d512.s6.e2" charOffset="128-135"
            type="brand" text="Sensipar"/>
        <ddi id="DDI-DrugBank.d512.s6.d0" e1="DDI-DrugBank.d512.s6.e0"
            e2="DDI-DrugBank.d512.s6.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d512.s7" text="Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;">
        <entity id="DDI-DrugBank.d512.s7.e0" charOffset="19-26"
            type="brand" text="Sensipar"/>
        <entity id="DDI-DrugBank.d512.s7.e1" charOffset="198-209"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d512.s7.e2" charOffset="212-223"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d512.s7.e3" charOffset="226-237"
            type="drug" text="itraconazole"/>
        <ddi id="DDI-DrugBank.d512.s7.d0" e1="DDI-DrugBank.d512.s7.e0"
            e2="DDI-DrugBank.d512.s7.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d512.s7.d1" e1="DDI-DrugBank.d512.s7.e0"
            e2="DDI-DrugBank.d512.s7.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d512.s7.d2" e1="DDI-DrugBank.d512.s7.e0"
            e2="DDI-DrugBank.d512.s7.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d512.s8" text="see DOSAGE AND ADMINISTRATION)."/>
    <sentence id="DDI-DrugBank.d562.s0" text="Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.">
        <entity id="DDI-DrugBank.d562.s0.e0" charOffset="26-37"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d562.s0.e1" charOffset="87-96"
            type="group" text="quinolones"/>
        <ddi id="DDI-DrugBank.d562.s0.d0" e1="DDI-DrugBank.d562.s0.e0"
            e2="DDI-DrugBank.d562.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s1" text="There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.">
        <entity id="DDI-DrugBank.d562.s1.e0" charOffset="27-38"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d562.s1.e1" charOffset="88-99"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d562.s1.e2" charOffset="101-109"
            type="group" text="quinolone"/>
        <ddi id="DDI-DrugBank.d562.s1.d0" e1="DDI-DrugBank.d562.s1.e1"
            e2="DDI-DrugBank.d562.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s2" text="Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.">
        <entity id="DDI-DrugBank.d562.s2.e0" charOffset="25-36"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d562.s2.e1" charOffset="87-98"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s3" text="Quinolones have also been shown to interfere with the metabolism of caffeine.">
        <entity id="DDI-DrugBank.d562.s3.e0" charOffset="0-9"
            type="group" text="Quinolones"/>
        <entity id="DDI-DrugBank.d562.s3.e1" charOffset="68-75"
            type="drug" text="caffeine"/>
        <ddi id="DDI-DrugBank.d562.s3.d0" e1="DDI-DrugBank.d562.s3.e0"
            e2="DDI-DrugBank.d562.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s4" text="This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life.">
        <entity id="DDI-DrugBank.d562.s4.e0" charOffset="38-45"
            type="drug" text="caffeine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s5" text="Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.">
        <entity id="DDI-DrugBank.d562.s5.e0" charOffset="53-61"
            type="drug" text="cinoxacin"/>
        <entity id="DDI-DrugBank.d562.s5.e1" charOffset="97-105"
            type="drug" text="cinoxacin"/>
        <entity id="DDI-DrugBank.d562.s5.e2" charOffset="135-142"
            type="drug" text="caffeine"/>
        <ddi id="DDI-DrugBank.d562.s5.d0" e1="DDI-DrugBank.d562.s5.e1"
            e2="DDI-DrugBank.d562.s5.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s6" text="Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.">
        <entity id="DDI-DrugBank.d562.s6.e0" charOffset="0-7"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d562.s6.e1" charOffset="12-21"
            type="drug" text="sucralfate"/>
        <entity id="DDI-DrugBank.d562.s6.e2" charOffset="75-84"
            type="group" text="quinolones"/>
        <ddi id="DDI-DrugBank.d562.s6.d0" e1="DDI-DrugBank.d562.s6.e0"
            e2="DDI-DrugBank.d562.s6.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d562.s6.d1" e1="DDI-DrugBank.d562.s6.e1"
            e2="DDI-DrugBank.d562.s6.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s7" text="Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.">
        <entity id="DDI-DrugBank.d562.s7.e0" charOffset="36-45"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d562.s7.e1" charOffset="72-75"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d562.s7.e2" charOffset="78-90"
            type="group" text="multivitamins"/>
        <entity id="DDI-DrugBank.d562.s7.e3" charOffset="103-106"
            type="drug" text="zinc"/>
        <entity id="DDI-DrugBank.d562.s7.e4" charOffset="112-116"
            type="brand" text="Videx"/>
        <entity id="DDI-DrugBank.d562.s7.e5" charOffset="119-128"
            type="drug" text="didanosine"/>
        <ddi id="DDI-DrugBank.d562.s7.d0" e1="DDI-DrugBank.d562.s7.e0"
            e2="DDI-DrugBank.d562.s7.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d562.s7.d1" e1="DDI-DrugBank.d562.s7.e0"
            e2="DDI-DrugBank.d562.s7.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d562.s7.d2" e1="DDI-DrugBank.d562.s7.e0"
            e2="DDI-DrugBank.d562.s7.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d562.s7.d3" e1="DDI-DrugBank.d562.s7.e0"
            e2="DDI-DrugBank.d562.s7.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s8" text="Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.">
        <entity id="DDI-DrugBank.d562.s8.e0" charOffset="0-9"
            type="group" text="Quinolones"/>
        <entity id="DDI-DrugBank.d562.s8.e1" charOffset="22-30"
            type="drug" text="cinoxacin"/>
        <entity id="DDI-DrugBank.d562.s8.e2" charOffset="65-78"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d562.s8.e3" charOffset="89-96"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d562.s8.d0" e1="DDI-DrugBank.d562.s8.e0"
            e2="DDI-DrugBank.d562.s8.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d562.s8.d1" e1="DDI-DrugBank.d562.s8.e0"
            e2="DDI-DrugBank.d562.s8.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d562.s8.d2" e1="DDI-DrugBank.d562.s8.e1"
            e2="DDI-DrugBank.d562.s8.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d562.s8.d3" e1="DDI-DrugBank.d562.s8.e1"
            e2="DDI-DrugBank.d562.s8.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s9" text="When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored."/>
    <sentence id="DDI-DrugBank.d562.s10" text="Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.">
        <entity id="DDI-DrugBank.d562.s10.e0" charOffset="55-83"
            type="group" text="quinolone class antimicrobial"/>
        <entity id="DDI-DrugBank.d562.s10.e1" charOffset="93-127"
            type="group" text="nonsteroidal anti-inflammatory drug"/>
        <entity id="DDI-DrugBank.d562.s10.e2" charOffset="129-136"
            type="drug" text="fenbufen"/>
        <ddi id="DDI-DrugBank.d562.s10.d0" e1="DDI-DrugBank.d562.s10.e0"
            e2="DDI-DrugBank.d562.s10.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d562.s10.d1" e1="DDI-DrugBank.d562.s10.e0"
            e2="DDI-DrugBank.d562.s10.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s11" text="Animal studies also suggest an increased potential for seizures when these 2 drugs are given concomitantly."/>
    <sentence id="DDI-DrugBank.d562.s12" text="Fenbufen is not approved in the United States at this time.">
        <entity id="DDI-DrugBank.d562.s12.e0" charOffset="0-7"
            type="drug" text="Fenbufen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s13" text="Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.">
        <entity id="DDI-DrugBank.d562.s13.e0" charOffset="110-118"
            type="drug" text="cinoxacin"/>
        <entity id="DDI-DrugBank.d562.s13.e1" charOffset="132-168"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <ddi id="DDI-DrugBank.d562.s13.d0" e1="DDI-DrugBank.d562.s13.e0"
            e2="DDI-DrugBank.d562.s13.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d562.s14" text="Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.">
        <entity id="DDI-DrugBank.d562.s14.e0" charOffset="9-20"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d562.s14.e1" charOffset="82-91"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d562.s14.e2" charOffset="97-108"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d562.s14.d0" e1="DDI-DrugBank.d562.s14.e1"
            e2="DDI-DrugBank.d562.s14.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s0" text="Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.">
        <entity id="DDI-DrugBank.d123.s0.e0" charOffset="5-14"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d123.s0.e1" charOffset="27-39"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d123.s0.e2" charOffset="99-106"
            type="drug" text="caffeine"/>
        <ddi id="DDI-DrugBank.d123.s0.d0" e1="DDI-DrugBank.d123.s0.e0"
            e2="DDI-DrugBank.d123.s0.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s0.d1" e1="DDI-DrugBank.d123.s0.e1"
            e2="DDI-DrugBank.d123.s0.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s1" text="This may lead to reduced clearance of caffeine and a prolongation of its serum half-life.">
        <entity id="DDI-DrugBank.d123.s1.e0" charOffset="38-45"
            type="drug" text="caffeine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s2" text="Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.">
        <entity id="DDI-DrugBank.d123.s2.e0" charOffset="5-14"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d123.s2.e1" charOffset="27-39"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d123.s2.e2" charOffset="131-142"
            type="drug" text="cyclosporine"/>
        <ddi id="DDI-DrugBank.d123.s2.d0" e1="DDI-DrugBank.d123.s2.e0"
            e2="DDI-DrugBank.d123.s2.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d123.s2.d1" e1="DDI-DrugBank.d123.s2.e1"
            e2="DDI-DrugBank.d123.s2.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s3" text="Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.">
        <entity id="DDI-DrugBank.d123.s3.e0" charOffset="0-8"
            type="drug" text="Glyburide"/>
        <entity id="DDI-DrugBank.d123.s3.e1" charOffset="45-57"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d123.s3.e2" charOffset="68-79"
            type="group" text="sulfonylurea"/>
        <entity id="DDI-DrugBank.d123.s3.e3" charOffset="81-89"
            type="drug" text="glyburide"/>
        <ddi id="DDI-DrugBank.d123.s3.d0" e1="DDI-DrugBank.d123.s3.e1"
            e2="DDI-DrugBank.d123.s3.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d123.s3.d1" e1="DDI-DrugBank.d123.s3.e1"
            e2="DDI-DrugBank.d123.s3.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s4" text="Histamine H2-receptor antagonists: Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of ciprofloxacin.">
        <entity id="DDI-DrugBank.d123.s4.e0" charOffset="0-32"
            type="group" text="Histamine H2-receptor antagonists"/>
        <entity id="DDI-DrugBank.d123.s4.e1" charOffset="35-67"
            type="group" text="Histamine H2-receptor antagonists"/>
        <entity id="DDI-DrugBank.d123.s4.e2" charOffset="132-144"
            type="drug" text="ciprofloxacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s5" text="Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.">
        <entity id="DDI-DrugBank.d123.s5.e0" charOffset="0-11"
            type="drug" text="Methotrexate"/>
        <entity id="DDI-DrugBank.d123.s5.e1" charOffset="40-51"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d123.s5.e2" charOffset="103-115"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d123.s5.e3" charOffset="168-179"
            type="drug" text="methotrexate"/>
        <ddi id="DDI-DrugBank.d123.s5.d0" e1="DDI-DrugBank.d123.s5.e1"
            e2="DDI-DrugBank.d123.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s6" text="This might increase the risk of methotrexate toxic reactions.">
        <entity id="DDI-DrugBank.d123.s6.e0" charOffset="32-43"
            type="drug" text="methotrexate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s7" text="Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.">
        <entity id="DDI-DrugBank.d123.s7.e0" charOffset="26-37"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d123.s7.e1" charOffset="94-106"
            type="drug" text="ciprofloxacin"/>
        <ddi id="DDI-DrugBank.d123.s7.d0" e1="DDI-DrugBank.d123.s7.e0"
            e2="DDI-DrugBank.d123.s7.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s8" text="Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.">
        <entity id="DDI-DrugBank.d123.s8.e0" charOffset="71-79"
            type="group" text="quinolone"/>
        <entity id="DDI-DrugBank.d123.s8.e1" charOffset="92-104"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d123.s8.e2" charOffset="159-167"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d123.s8.e3" charOffset="172-179"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d123.s8.e4" charOffset="181-188"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d123.s8.e5" charOffset="191-200"
            type="drug" text="sucralfate"/>
        <entity id="DDI-DrugBank.d123.s8.e6" charOffset="203-207"
            type="brand" text="VIDEX"/>
        <entity id="DDI-DrugBank.d123.s8.e7" charOffset="279-285"
            type="drug" text="calcium"/>
        <entity id="DDI-DrugBank.d123.s8.e8" charOffset="288-291"
            type="drug" text="iron"/>
        <entity id="DDI-DrugBank.d123.s8.e9" charOffset="297-300"
            type="drug" text="zinc"/>
        <entity id="DDI-DrugBank.d123.s8.e10" charOffset="347-359"
            type="drug" text="ciprofloxacin"/>
        <ddi id="DDI-DrugBank.d123.s8.d0" e1="DDI-DrugBank.d123.s8.e0"
            e2="DDI-DrugBank.d123.s8.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d1" e1="DDI-DrugBank.d123.s8.e0"
            e2="DDI-DrugBank.d123.s8.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d2" e1="DDI-DrugBank.d123.s8.e0"
            e2="DDI-DrugBank.d123.s8.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d3" e1="DDI-DrugBank.d123.s8.e0"
            e2="DDI-DrugBank.d123.s8.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d4" e1="DDI-DrugBank.d123.s8.e0"
            e2="DDI-DrugBank.d123.s8.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d5" e1="DDI-DrugBank.d123.s8.e0"
            e2="DDI-DrugBank.d123.s8.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d6" e1="DDI-DrugBank.d123.s8.e0"
            e2="DDI-DrugBank.d123.s8.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d7" e1="DDI-DrugBank.d123.s8.e0"
            e2="DDI-DrugBank.d123.s8.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d8" e1="DDI-DrugBank.d123.s8.e1"
            e2="DDI-DrugBank.d123.s8.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d9" e1="DDI-DrugBank.d123.s8.e1"
            e2="DDI-DrugBank.d123.s8.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d10" e1="DDI-DrugBank.d123.s8.e1"
            e2="DDI-DrugBank.d123.s8.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d11" e1="DDI-DrugBank.d123.s8.e1"
            e2="DDI-DrugBank.d123.s8.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d12" e1="DDI-DrugBank.d123.s8.e1"
            e2="DDI-DrugBank.d123.s8.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d13" e1="DDI-DrugBank.d123.s8.e1"
            e2="DDI-DrugBank.d123.s8.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d14" e1="DDI-DrugBank.d123.s8.e1"
            e2="DDI-DrugBank.d123.s8.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d15" e1="DDI-DrugBank.d123.s8.e1"
            e2="DDI-DrugBank.d123.s8.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s8.d16" e1="DDI-DrugBank.d123.s8.e1"
            e2="DDI-DrugBank.d123.s8.e10" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s9" text="Proquin XR should be administered at least 4 hours before or 2 hours after these products.">
        <entity id="DDI-DrugBank.d123.s9.e0" charOffset="0-9"
            type="brand" text="Proquin XR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s10" text="This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.">
        <entity id="DDI-DrugBank.d123.s10.e0" charOffset="66-78"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d123.s10.e1" charOffset="144-151"
            type="group" text="antacids"/>
        <ddi id="DDI-DrugBank.d123.s10.d0" e1="DDI-DrugBank.d123.s10.e0"
            e2="DDI-DrugBank.d123.s10.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s11" text="Non-steroidal anti-inflammatory drugs (but not aspirin): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.">
        <entity id="DDI-DrugBank.d123.s11.e0" charOffset="0-36"
            type="group" text="Non-steroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d123.s11.e1" charOffset="47-53"
            type="brand" text="aspirin"/>
        <entity id="DDI-DrugBank.d123.s11.e2" charOffset="108-117"
            type="group" text="quinolones"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s12" text="Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.">
        <entity id="DDI-DrugBank.d123.s12.e0" charOffset="0-9"
            type="drug" text="Omeprazole"/>
        <entity id="DDI-DrugBank.d123.s12.e1" charOffset="49-61"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d123.s12.e2" charOffset="86-95"
            type="brand" text="Proquin XR"/>
        <entity id="DDI-DrugBank.d123.s12.e3" charOffset="121-130"
            type="brand" text="Proquin XR"/>
        <entity id="DDI-DrugBank.d123.s12.e4" charOffset="156-165"
            type="drug" text="omeprazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s13" text="Omeprazole should be taken as directed and Proquin XR should be taken with a main meal of the day, preferably the evening meal..">
        <entity id="DDI-DrugBank.d123.s13.e0" charOffset="0-9"
            type="drug" text="Omeprazole"/>
        <entity id="DDI-DrugBank.d123.s13.e1" charOffset="43-52"
            type="brand" text="Proquin XR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s14" text="Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.">
        <entity id="DDI-DrugBank.d123.s14.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d123.s14.e1" charOffset="35-43"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d123.s14.e2" charOffset="124-136"
            type="drug" text="ciprofloxacin"/>
        <ddi id="DDI-DrugBank.d123.s14.d0" e1="DDI-DrugBank.d123.s14.e1"
            e2="DDI-DrugBank.d123.s14.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s15" text="Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.">
        <entity id="DDI-DrugBank.d123.s15.e0" charOffset="0-9"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d123.s15.e1" charOffset="12-21"
            type="drug" text="Probenecid"/>
        <entity id="DDI-DrugBank.d123.s15.e2" charOffset="66-78"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d123.s15.e3" charOffset="121-133"
            type="drug" text="ciprofloxacin"/>
        <ddi id="DDI-DrugBank.d123.s15.d0" e1="DDI-DrugBank.d123.s15.e1"
            e2="DDI-DrugBank.d123.s15.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s15.d1" e1="DDI-DrugBank.d123.s15.e1"
            e2="DDI-DrugBank.d123.s15.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s16" text="Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.">
        <entity id="DDI-DrugBank.d123.s16.e0" charOffset="0-11"
            type="drug" text="Theophylline"/>
        <entity id="DDI-DrugBank.d123.s16.e1" charOffset="33-42"
            type="group" text="quinolones"/>
        <entity id="DDI-DrugBank.d123.s16.e2" charOffset="74-86"
            type="drug" text="ciprofloxacin"/>
        <entity id="DDI-DrugBank.d123.s16.e3" charOffset="93-104"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d123.s16.e4" charOffset="151-162"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d123.s16.d0" e1="DDI-DrugBank.d123.s16.e1"
            e2="DDI-DrugBank.d123.s16.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d123.s16.d1" e1="DDI-DrugBank.d123.s16.e2"
            e2="DDI-DrugBank.d123.s16.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s17" text="This may result in increased risk of theophylline-related adverse reactions.">
        <entity id="DDI-DrugBank.d123.s17.e0" charOffset="37-48"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s18" text="If concomitant use cannot be avoided, serum levels of theophylline should be monitored and dosage adjustments made as appropriate.">
        <entity id="DDI-DrugBank.d123.s18.e0" charOffset="54-65"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s19" text="Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.">
        <entity id="DDI-DrugBank.d123.s19.e0" charOffset="0-7"
            type="drug" text="Warfarin"/>
        <entity id="DDI-DrugBank.d123.s19.e1" charOffset="10-19"
            type="group" text="Quinolones"/>
        <entity id="DDI-DrugBank.d123.s19.e2" charOffset="75-87"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d123.s19.e3" charOffset="89-96"
            type="drug" text="warfarin"/>
        <ddi id="DDI-DrugBank.d123.s19.d0" e1="DDI-DrugBank.d123.s19.e1"
            e2="DDI-DrugBank.d123.s19.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d123.s20" text="When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be monitored."/>
    <sentence id="DDI-DrugBank.d237.s0" text="Cisapride is metabolized mainly via the cytochrome P450 3A4 enzyme.">
        <entity id="DDI-DrugBank.d237.s0.e0" charOffset="0-8"
            type="drug" text="Cisapride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s1" text="In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when cisapride was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood cisapride levels were noted at the time of the QT prolongation.">
        <entity id="DDI-DrugBank.d237.s1.e0" charOffset="113-121"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d237.s1.e1" charOffset="211-219"
            type="drug" text="cisapride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s2" text="Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.">
        <entity id="DDI-DrugBank.d237.s2.e0" charOffset="0-10"
            type="group" text="Antibiotics"/>
        <entity id="DDI-DrugBank.d237.s2.e1" charOffset="52-65"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d237.s2.e2" charOffset="68-79"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d237.s2.e3" charOffset="86-99"
            type="drug" text="troleandomycin"/>
        <entity id="DDI-DrugBank.d237.s2.e4" charOffset="136-144"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d237.s2.e5" charOffset="189-197"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d237.s2.d0" e1="DDI-DrugBank.d237.s2.e1"
            e2="DDI-DrugBank.d237.s2.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d237.s2.d1" e1="DDI-DrugBank.d237.s2.e2"
            e2="DDI-DrugBank.d237.s2.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d237.s2.d2" e1="DDI-DrugBank.d237.s2.e3"
            e2="DDI-DrugBank.d237.s2.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s3" text="Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.">
        <entity id="DDI-DrugBank.d237.s3.e0" charOffset="0-15"
            type="group" text="Anticholinergics"/>
        <entity id="DDI-DrugBank.d237.s3.e1" charOffset="55-79"
            type="group" text="anticholinergic compounds"/>
        <entity id="DDI-DrugBank.d237.s3.e2" charOffset="90-109"
            type="group" text="belladonna alkaloids"/>
        <entity id="DDI-DrugBank.d237.s3.e3" charOffset="115-125"
            type="drug" text="dicyclomine"/>
        <entity id="DDI-DrugBank.d237.s3.e4" charOffset="186-194"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d237.s3.d0" e1="DDI-DrugBank.d237.s3.e1"
            e2="DDI-DrugBank.d237.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d237.s3.d1" e1="DDI-DrugBank.d237.s3.e2"
            e2="DDI-DrugBank.d237.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d237.s3.d2" e1="DDI-DrugBank.d237.s3.e3"
            e2="DDI-DrugBank.d237.s3.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s4" text="Anticoagulants (Oral): In patients receiving oral anticoagulants, the coagulation times were increased in some cases.">
        <entity id="DDI-DrugBank.d237.s4.e0" charOffset="0-13"
            type="group" text="Anticoagulants"/>
        <entity id="DDI-DrugBank.d237.s4.e1" charOffset="50-63"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s5" text="It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.">
        <entity id="DDI-DrugBank.d237.s5.e0" charOffset="107-115"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d237.s5.e1" charOffset="164-176"
            type="group" text="anticoagulant"/>
        <ddi id="DDI-DrugBank.d237.s5.d0" e1="DDI-DrugBank.d237.s5.e0"
            e2="DDI-DrugBank.d237.s5.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s6" text="Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.">
        <entity id="DDI-DrugBank.d237.s6.e0" charOffset="0-14"
            type="group" text="Antidepressants"/>
        <entity id="DDI-DrugBank.d237.s6.e1" charOffset="45-54"
            type="drug" text="nefazodone"/>
        <entity id="DDI-DrugBank.d237.s6.e2" charOffset="83-91"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d237.s6.e3" charOffset="136-144"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d237.s6.d0" e1="DDI-DrugBank.d237.s6.e1"
            e2="DDI-DrugBank.d237.s6.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s7" text="Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.">
        <entity id="DDI-DrugBank.d237.s7.e0" charOffset="0-10"
            type="group" text="Antifungals"/>
        <entity id="DDI-DrugBank.d237.s7.e1" charOffset="56-66"
            type="drug" text="fluconazole"/>
        <entity id="DDI-DrugBank.d237.s7.e2" charOffset="69-80"
            type="drug" text="itraconazole"/>
        <entity id="DDI-DrugBank.d237.s7.e3" charOffset="92-103"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d237.s7.e4" charOffset="140-148"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d237.s7.e5" charOffset="193-201"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d237.s7.d0" e1="DDI-DrugBank.d237.s7.e1"
            e2="DDI-DrugBank.d237.s7.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d237.s7.d1" e1="DDI-DrugBank.d237.s7.e2"
            e2="DDI-DrugBank.d237.s7.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d237.s7.d2" e1="DDI-DrugBank.d237.s7.e3"
            e2="DDI-DrugBank.d237.s7.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s8" text="Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.">
        <entity id="DDI-DrugBank.d237.s8.e0" charOffset="46-57"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d237.s8.e1" charOffset="95-103"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d237.s8.e2" charOffset="156-164"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d237.s8.d0" e1="DDI-DrugBank.d237.s8.e0"
            e2="DDI-DrugBank.d237.s8.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s9" text="A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.">
        <entity id="DDI-DrugBank.d237.s9.e0" charOffset="82-90"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d237.s9.e1" charOffset="96-107"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d237.s9.d0" e1="DDI-DrugBank.d237.s9.e0"
            e2="DDI-DrugBank.d237.s9.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s10" text="H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.">
        <entity id="DDI-DrugBank.d237.s10.e0" charOffset="0-22"
            type="group" text="H2 Receptor Antagonists"/>
        <entity id="DDI-DrugBank.d237.s10.e1" charOffset="25-34"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d237.s10.e2" charOffset="112-120"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d237.s10.e3" charOffset="145-153"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d237.s10.e4" charOffset="197-206"
            type="drug" text="ranitidine"/>
        <ddi id="DDI-DrugBank.d237.s10.d0" e1="DDI-DrugBank.d237.s10.e1"
            e2="DDI-DrugBank.d237.s10.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s11" text="The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.">
        <entity id="DDI-DrugBank.d237.s11.e0" charOffset="35-44"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d237.s11.e1" charOffset="50-59"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d237.s11.e2" charOffset="110-118"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d237.s11.d0" e1="DDI-DrugBank.d237.s11.e0"
            e2="DDI-DrugBank.d237.s11.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d237.s11.d1" e1="DDI-DrugBank.d237.s11.e1"
            e2="DDI-DrugBank.d237.s11.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s12" text="Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.">
        <entity id="DDI-DrugBank.d237.s12.e0" charOffset="0-18"
            type="group" text="Protease Inhibitors"/>
        <entity id="DDI-DrugBank.d237.s12.e1" charOffset="49-57"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d237.s12.e2" charOffset="63-71"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d237.s12.e3" charOffset="108-116"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d237.s12.e4" charOffset="160-168"
            type="drug" text="cisapride"/>
        <ddi id="DDI-DrugBank.d237.s12.d0" e1="DDI-DrugBank.d237.s12.e1"
            e2="DDI-DrugBank.d237.s12.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d237.s12.d1" e1="DDI-DrugBank.d237.s12.e2"
            e2="DDI-DrugBank.d237.s12.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s13" text="Other: Coadministration of grapefruit juice with cisapride increases the bioavailability of cisapride and concomitant use should be avoided.">
        <entity id="DDI-DrugBank.d237.s13.e0" charOffset="49-57"
            type="drug" text="cisapride"/>
        <entity id="DDI-DrugBank.d237.s13.e1" charOffset="92-100"
            type="drug" text="cisapride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s14" text="Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);">
        <entity id="DDI-DrugBank.d237.s14.e0" charOffset="0-8"
            type="drug" text="Cisapride"/>
        <entity id="DDI-DrugBank.d237.s14.e1" charOffset="102-116"
            type="group" text="antiarrhythmics"/>
        <entity id="DDI-DrugBank.d237.s14.e2" charOffset="156-164"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d237.s14.e3" charOffset="170-181"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d237.s14.e4" charOffset="207-213"
            type="drug" text="sotalol"/>
        <ddi id="DDI-DrugBank.d237.s14.d0" e1="DDI-DrugBank.d237.s14.e0"
            e2="DDI-DrugBank.d237.s14.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d237.s14.d1" e1="DDI-DrugBank.d237.s14.e0"
            e2="DDI-DrugBank.d237.s14.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d237.s14.d2" e1="DDI-DrugBank.d237.s14.e0"
            e2="DDI-DrugBank.d237.s14.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d237.s14.d3" e1="DDI-DrugBank.d237.s14.e0"
            e2="DDI-DrugBank.d237.s14.e4" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s15" text="tricyclic antidepressants (such as amitriptyline);">
        <entity id="DDI-DrugBank.d237.s15.e0" charOffset="0-24"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d237.s15.e1" charOffset="35-47"
            type="drug" text="amitriptyline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s16" text="certain tetracyclic antidepressants (such as maprotiline);">
        <entity id="DDI-DrugBank.d237.s16.e0" charOffset="8-34"
            type="group" text="tetracyclic antidepressants"/>
        <entity id="DDI-DrugBank.d237.s16.e1" charOffset="45-55"
            type="drug" text="maprotiline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s17" text="certain antipsychotic medications (such as sertindole);">
        <entity id="DDI-DrugBank.d237.s17.e0" charOffset="8-32"
            type="group" text="antipsychotic medications"/>
        <entity id="DDI-DrugBank.d237.s17.e1" charOffset="43-52"
            type="drug" text="sertindole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s18" text="astemizole, bepridil, sparfloxacin, and terodiline.">
        <entity id="DDI-DrugBank.d237.s18.e0" charOffset="0-9"
            type="drug" text="astemizole"/>
        <entity id="DDI-DrugBank.d237.s18.e1" charOffset="12-19"
            type="drug" text="bepridil"/>
        <entity id="DDI-DrugBank.d237.s18.e2" charOffset="22-33"
            type="drug" text="sparfloxacin"/>
        <entity id="DDI-DrugBank.d237.s18.e3" charOffset="40-49"
            type="drug" text="terodiline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s19" text="The preceding lists of drugs are not comprehensive."/>
    <sentence id="DDI-DrugBank.d237.s20" text="The acceleration of gastric emptying by cisapride could affect the rate of absorption of other drugs.">
        <entity id="DDI-DrugBank.d237.s20.e0" charOffset="40-48"
            type="drug" text="cisapride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d237.s21" text="Patients receiving narrow therapeutic ratio drugs or other drugs that require careful titration should be followed closely;"/>
    <sentence id="DDI-DrugBank.d237.s22" text="if plasma levels are being monitored, they should be reassessed."/>
    <sentence id="DDI-DrugBank.d60.s0" text="Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.">
        <entity id="DDI-DrugBank.d60.s0.e0" charOffset="39-44"
            type="brand" text="NIMBEX"/>
        <entity id="DDI-DrugBank.d60.s0.e1" charOffset="101-115"
            type="drug" text="succinylcholine"/>
        <ddi id="DDI-DrugBank.d60.s0.d0" e1="DDI-DrugBank.d60.s0.e0"
            e2="DDI-DrugBank.d60.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s1" text="The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.">
        <entity id="DDI-DrugBank.d60.s1.e0" charOffset="45-50"
            type="brand" text="NIMBEX"/>
        <entity id="DDI-DrugBank.d60.s1.e1" charOffset="115-129"
            type="drug" text="succinylcholine"/>
        <ddi id="DDI-DrugBank.d60.s1.d0" e1="DDI-DrugBank.d60.s1.e0"
            e2="DDI-DrugBank.d60.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s2" text="Prior administration of succinylcholine had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of NIMBEX.">
        <entity id="DDI-DrugBank.d60.s2.e0" charOffset="24-38"
            type="drug" text="succinylcholine"/>
        <entity id="DDI-DrugBank.d60.s2.e1" charOffset="141-146"
            type="brand" text="NIMBEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s3" text="Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.">
        <entity id="DDI-DrugBank.d60.s3.e0" charOffset="25-30"
            type="brand" text="NIMBEX"/>
        <entity id="DDI-DrugBank.d60.s3.e1" charOffset="57-71"
            type="drug" text="succinylcholine"/>
        <entity id="DDI-DrugBank.d60.s3.e2" charOffset="95-100"
            type="brand" text="NIMBEX"/>
        <entity id="DDI-DrugBank.d60.s3.e3" charOffset="151-165"
            type="drug" text="succinylcholine"/>
        <ddi id="DDI-DrugBank.d60.s3.d0" e1="DDI-DrugBank.d60.s3.e1"
            e2="DDI-DrugBank.d60.s3.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s4" text="The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.">
        <entity id="DDI-DrugBank.d60.s4.e0" charOffset="11-16"
            type="brand" text="NIMBEX"/>
        <entity id="DDI-DrugBank.d60.s4.e1" charOffset="25-39"
            type="drug" text="succinylcholine"/>
        <entity id="DDI-DrugBank.d60.s4.e2" charOffset="82-96"
            type="drug" text="succinylcholine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s5" text="Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium, pancuronium, or atracurium were administered following varying degrees of recovery from single doses or infusions of NIMBEX.">
        <entity id="DDI-DrugBank.d60.s5.e0" charOffset="96-105"
            type="drug" text="vecuronium"/>
        <entity id="DDI-DrugBank.d60.s5.e1" charOffset="108-118"
            type="drug" text="pancuronium"/>
        <entity id="DDI-DrugBank.d60.s5.e2" charOffset="124-133"
            type="drug" text="atracurium"/>
        <entity id="DDI-DrugBank.d60.s5.e3" charOffset="225-230"
            type="brand" text="NIMBEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s6" text="Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.">
        <entity id="DDI-DrugBank.d60.s6.e0" charOffset="0-9" type="drug" text="Isoflurane"/>
        <entity id="DDI-DrugBank.d60.s6.e1" charOffset="14-22"
            type="drug" text="enflurane"/>
        <entity id="DDI-DrugBank.d60.s6.e2" charOffset="42-54"
            type="drug" text="nitrous oxide"/>
        <entity id="DDI-DrugBank.d60.s6.e3" charOffset="56-61"
            type="drug" text="oxygen"/>
        <entity id="DDI-DrugBank.d60.s6.e4" charOffset="208-213"
            type="brand" text="NIMBEX"/>
        <entity id="DDI-DrugBank.d60.s6.e5" charOffset="258-263"
            type="brand" text="NIMBEX"/>
        <ddi id="DDI-DrugBank.d60.s6.d0" e1="DDI-DrugBank.d60.s6.e0"
            e2="DDI-DrugBank.d60.s6.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s6.d1" e1="DDI-DrugBank.d60.s6.e1"
            e2="DDI-DrugBank.d60.s6.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s6.d2" e1="DDI-DrugBank.d60.s6.e2"
            e2="DDI-DrugBank.d60.s6.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s6.d3" e1="DDI-DrugBank.d60.s6.e0"
            e2="DDI-DrugBank.d60.s6.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s6.d4" e1="DDI-DrugBank.d60.s6.e1"
            e2="DDI-DrugBank.d60.s6.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s6.d5" e1="DDI-DrugBank.d60.s6.e2"
            e2="DDI-DrugBank.d60.s6.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s7" text="The magnitude of these effects may depend on the duration of administration of the volatile agents."/>
    <sentence id="DDI-DrugBank.d60.s8" text="Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.">
        <entity id="DDI-DrugBank.d60.s8.e0" charOffset="46-55"
            type="drug" text="isoflurane"/>
        <entity id="DDI-DrugBank.d60.s8.e1" charOffset="60-68"
            type="drug" text="enflurane"/>
        <entity id="DDI-DrugBank.d60.s8.e2" charOffset="136-141"
            type="brand" text="NIMBEX"/>
        <entity id="DDI-DrugBank.d60.s8.e3" charOffset="217-222"
            type="brand" text="NIMBEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s9" text="In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.">
        <entity id="DDI-DrugBank.d60.s9.e0" charOffset="35-43"
            type="drug" text="enflurane"/>
        <entity id="DDI-DrugBank.d60.s9.e1" charOffset="48-57"
            type="drug" text="isoflurane"/>
        <entity id="DDI-DrugBank.d60.s9.e2" charOffset="159-164"
            type="brand" text="NIMBEX"/>
        <ddi id="DDI-DrugBank.d60.s9.d0" e1="DDI-DrugBank.d60.s9.e0"
            e2="DDI-DrugBank.d60.s9.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d60.s9.d1" e1="DDI-DrugBank.d60.s9.e1"
            e2="DDI-DrugBank.d60.s9.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s10" text="The average infusion rate requirement may be decreased by as much as 30% to 40%."/>
    <sentence id="DDI-DrugBank.d60.s11" text="In clinical studies propofol had no effect on the duration of action or dosing requirements for NIMBEX.">
        <entity id="DDI-DrugBank.d60.s11.e0" charOffset="20-27"
            type="drug" text="propofol"/>
        <entity id="DDI-DrugBank.d60.s11.e1" charOffset="96-101"
            type="brand" text="NIMBEX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s12" text="Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.">
        <entity id="DDI-DrugBank.d60.s12.e0" charOffset="67-88"
            type="group" text="nondepolarizing agents"/>
        <entity id="DDI-DrugBank.d60.s12.e1" charOffset="98-103"
            type="brand" text="NIMBEX"/>
        <entity id="DDI-DrugBank.d60.s12.e2" charOffset="121-131"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d60.s12.e3" charOffset="141-155"
            type="group" text="aminoglycosides"/>
        <entity id="DDI-DrugBank.d60.s12.e4" charOffset="158-170"
            type="group" text="tetracyclines"/>
        <entity id="DDI-DrugBank.d60.s12.e5" charOffset="173-182"
            type="drug" text="bacitracin"/>
        <entity id="DDI-DrugBank.d60.s12.e6" charOffset="185-194"
            type="group" text="polymyxins"/>
        <entity id="DDI-DrugBank.d60.s12.e7" charOffset="197-206"
            type="drug" text="lincomycin"/>
        <entity id="DDI-DrugBank.d60.s12.e8" charOffset="209-219"
            type="drug" text="clindamycin"/>
        <entity id="DDI-DrugBank.d60.s12.e9" charOffset="222-229"
            type="drug" text="colistin"/>
        <entity id="DDI-DrugBank.d60.s12.e10" charOffset="236-256"
            type="drug" text="sodium colistemethate"/>
        <entity id="DDI-DrugBank.d60.s12.e11" charOffset="260-268"
            type="group" text="magnesium"/>
        <entity id="DDI-DrugBank.d60.s12.e12" charOffset="277-283"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d60.s12.e13" charOffset="292-302"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d60.s12.e14" charOffset="305-316"
            type="drug" text="procainamide"/>
        <entity id="DDI-DrugBank.d60.s12.e15" charOffset="323-331"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d60.s12.d0" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d1" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d2" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d3" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d4" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d5" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d6" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d7" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d8" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d9" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e10" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d10" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e11" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d11" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e12" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d12" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e13" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d13" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e14" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d14" e1="DDI-DrugBank.d60.s12.e0"
            e2="DDI-DrugBank.d60.s12.e15" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d15" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d16" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d17" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d18" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d19" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d20" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d21" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d22" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d23" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e10" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d24" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e11" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d25" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e12" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d26" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e13" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d27" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e14" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s12.d28" e1="DDI-DrugBank.d60.s12.e1"
            e2="DDI-DrugBank.d60.s12.e15" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s13" text="Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.">
        <entity id="DDI-DrugBank.d60.s13.e0" charOffset="51-95"
            type="group" text="nondepolarizing neuromuscular blocking agents"/>
        <entity id="DDI-DrugBank.d60.s13.e1" charOffset="156-164"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d60.s13.e2" charOffset="169-181"
            type="drug" text="carbamazepine"/>
        <ddi id="DDI-DrugBank.d60.s13.d0" e1="DDI-DrugBank.d60.s13.e0"
            e2="DDI-DrugBank.d60.s13.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s13.d1" e1="DDI-DrugBank.d60.s13.e0"
            e2="DDI-DrugBank.d60.s13.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s14" text="While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.">
        <entity id="DDI-DrugBank.d60.s14.e0" charOffset="29-37"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d60.s14.e1" charOffset="42-54"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d60.s14.e2" charOffset="81-86"
            type="brand" text="NIMBEX"/>
        <ddi id="DDI-DrugBank.d60.s14.d0" e1="DDI-DrugBank.d60.s14.e0"
            e2="DDI-DrugBank.d60.s14.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d60.s14.d1" e1="DDI-DrugBank.d60.s14.e1"
            e2="DDI-DrugBank.d60.s14.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d60.s15" text="Drug/Laboratory Test Interactions None known."/>
    <sentence id="DDI-DrugBank.d145.s0" text="Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.">
        <entity id="DDI-DrugBank.d145.s0.e0" charOffset="17-37"
            type="group" text="anticonvulsant agents"/>
        <entity id="DDI-DrugBank.d145.s0.e1" charOffset="72-80"
            type="drug" text="cisplatin"/>
        <ddi id="DDI-DrugBank.d145.s0.d0" e1="DDI-DrugBank.d145.s0.e0"
            e2="DDI-DrugBank.d145.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d472.s0" text="Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers">
        <entity id="DDI-DrugBank.d472.s0.e0" charOffset="0-32"
            type="group" text="Central nervous system depressant"/>
        <entity id="DDI-DrugBank.d472.s0.e1" charOffset="56-62"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d472.s0.e2" charOffset="65-79"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d472.s0.e3" charOffset="82-95"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d472.s0.e4" charOffset="98-111"
            type="group" text="antipsychotics"/>
        <entity id="DDI-DrugBank.d472.s0.e5" charOffset="142-150"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d472.s0.e6" charOffset="153-162"
            type="drug" text="methyldopa"/>
        <entity id="DDI-DrugBank.d472.s0.e7" charOffset="165-177"
            type="group" text="beta-blockers"/>
        <entity id="DDI-DrugBank.d472.s0.e8" charOffset="210-225"
            type="group" text="muscle relaxants"/>
        <entity id="DDI-DrugBank.d472.s0.e9" charOffset="228-236"
            type="group" text="narcotics"/>
        <entity id="DDI-DrugBank.d472.s0.e10" charOffset="239-247"
            type="group" text="sedatives"/>
        <entity id="DDI-DrugBank.d472.s0.e11" charOffset="269-281"
            type="group" text="tranquilizers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d134.s0" text="There are no known drug interactions with LEUSTATIN Injection.">
        <entity id="DDI-DrugBank.d134.s0.e0" charOffset="42-50"
            type="brand" text="LEUSTATIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d134.s1" text="Caution should be exercised if LEUSTATIN Injection is administered before, after, or in conjunction with other drugs known to cause immunosuppression or myelosuppression.">
        <entity id="DDI-DrugBank.d134.s1.e0" charOffset="31-39"
            type="brand" text="LEUSTATIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d419.s0" text="The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.">
        <entity id="DDI-DrugBank.d419.s0.e0" charOffset="33-43"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d419.s0.e1" charOffset="49-58"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d419.s0.e2" charOffset="175-184"
            type="drug" text="ampicillin"/>
        <ddi id="DDI-DrugBank.d419.s0.d0" e1="DDI-DrugBank.d419.s0.e0"
            e2="DDI-DrugBank.d419.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d419.s1" text="It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.">
        <entity id="DDI-DrugBank.d419.s1.e0" charOffset="45-54"
            type="drug" text="ampicillin"/>
        <entity id="DDI-DrugBank.d419.s1.e1" charOffset="73-83"
            type="drug" text="allopurinol"/>
        <ddi id="DDI-DrugBank.d419.s1.d0" e1="DDI-DrugBank.d419.s1.e0"
            e2="DDI-DrugBank.d419.s1.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d419.s2" text="In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.">
        <entity id="DDI-DrugBank.d419.s2.e0" charOffset="33-44"
            type="brand" text="AUGMENTIN XR"/>
        <entity id="DDI-DrugBank.d419.s2.e1" charOffset="80-90"
            type="drug" text="allopurinol"/>
        <entity id="DDI-DrugBank.d419.s2.e2" charOffset="96-107"
            type="brand" text="AUGMENTIN XR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d419.s3" text="No rashes were reported in these patients."/>
    <sentence id="DDI-DrugBank.d419.s4" text="However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use.">
        <entity id="DDI-DrugBank.d419.s4.e0" charOffset="126-137"
            type="brand" text="AUGMENTIN XR"/>
        <entity id="DDI-DrugBank.d419.s4.e1" charOffset="143-153"
            type="drug" text="allopurinol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d419.s5" text="In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives">
        <entity id="DDI-DrugBank.d419.s5.e0" charOffset="21-46"
            type="group" text="broad-spectrum antibiotics"/>
        <entity id="DDI-DrugBank.d419.s5.e1" charOffset="49-60"
            type="brand" text="AUGMENTIN XR"/>
        <entity id="DDI-DrugBank.d419.s5.e2" charOffset="94-107"
            type="group" text="contraceptives"/>
        <ddi id="DDI-DrugBank.d419.s5.d0" e1="DDI-DrugBank.d419.s5.e0"
            e2="DDI-DrugBank.d419.s5.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d419.s5.d1" e1="DDI-DrugBank.d419.s5.e1"
            e2="DDI-DrugBank.d419.s5.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d309.s0" text="Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.">
        <entity id="DDI-DrugBank.d309.s0.e0" charOffset="39-52"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d309.s0.e1" charOffset="96-110"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d309.s0.e2" charOffset="122-133"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d309.s0.e3" charOffset="136-148"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d309.s0.e4" charOffset="155-161"
            type="drug" text="alcohol"/>
        <ddi id="DDI-DrugBank.d309.s0.d0" e1="DDI-DrugBank.d309.s0.e0"
            e2="DDI-DrugBank.d309.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d309.s0.d1" e1="DDI-DrugBank.d309.s0.e0"
            e2="DDI-DrugBank.d309.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d309.s0.d2" e1="DDI-DrugBank.d309.s0.e0"
            e2="DDI-DrugBank.d309.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d309.s0.d3" e1="DDI-DrugBank.d309.s0.e0"
            e2="DDI-DrugBank.d309.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d309.s1" text="Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.">
        <entity id="DDI-DrugBank.d309.s1.e0" charOffset="19-32"
            type="group" text="antihistamines"/>
        <entity id="DDI-DrugBank.d309.s1.e1" charOffset="88-107"
            type="group" text="CNS depressant drugs"/>
        <ddi id="DDI-DrugBank.d309.s1.d0" e1="DDI-DrugBank.d309.s1.e0"
            e2="DDI-DrugBank.d309.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d309.s2" text="Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.">
        <entity id="DDI-DrugBank.d309.s2.e0" charOffset="0-33"
            type="group" text="Monoamine oxidase (MAO) inhibitors"/>
        <entity id="DDI-DrugBank.d309.s2.e1" charOffset="88-101"
            type="group" text="antihistamines"/>
        <ddi id="DDI-DrugBank.d309.s2.d0" e1="DDI-DrugBank.d309.s2.e0"
            e2="DDI-DrugBank.d309.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d322.s0" text="Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.">
        <entity id="DDI-DrugBank.d322.s0.e0" charOffset="0-9"
            type="drug" text="Amantadine"/>
        <entity id="DDI-DrugBank.d322.s0.e1" charOffset="12-36"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d322.s0.e2" charOffset="43-47"
            type="group" text="MAOIs"/>
        <entity id="DDI-DrugBank.d322.s0.e3" charOffset="88-96"
            type="drug" text="clidinium"/>
        <ddi id="DDI-DrugBank.d322.s0.d0" e1="DDI-DrugBank.d322.s0.e0"
            e2="DDI-DrugBank.d322.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d322.s0.d1" e1="DDI-DrugBank.d322.s0.e1"
            e2="DDI-DrugBank.d322.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d322.s0.d2" e1="DDI-DrugBank.d322.s0.e2"
            e2="DDI-DrugBank.d322.s0.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d322.s1" text="Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.">
        <entity id="DDI-DrugBank.d322.s1.e0" charOffset="0-8"
            type="drug" text="Clidinium"/>
        <entity id="DDI-DrugBank.d322.s1.e1" charOffset="37-50"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d322.s1.e2" charOffset="53-60"
            type="drug" text="levodopa"/>
        <entity id="DDI-DrugBank.d322.s1.e3" charOffset="67-78"
            type="drug" text="ketoconazole"/>
        <ddi id="DDI-DrugBank.d322.s1.d0" e1="DDI-DrugBank.d322.s1.e0"
            e2="DDI-DrugBank.d322.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d322.s1.d1" e1="DDI-DrugBank.d322.s1.e0"
            e2="DDI-DrugBank.d322.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d322.s1.d2" e1="DDI-DrugBank.d322.s1.e0"
            e2="DDI-DrugBank.d322.s1.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d256.s0" text="Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.">
        <entity id="DDI-DrugBank.d256.s0.e0" charOffset="0-10"
            type="drug" text="Clindamycin"/>
        <entity id="DDI-DrugBank.d256.s0.e1" charOffset="106-134"
            type="group" text="neuromuscular blocking agents"/>
        <ddi id="DDI-DrugBank.d256.s0.d0" e1="DDI-DrugBank.d256.s0.e0"
            e2="DDI-DrugBank.d256.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d256.s1" text="Therefore, it should be used with caution in patients receiving such agents."/>
    <sentence id="DDI-DrugBank.d256.s2" text="Antagonism has been demonstrated between clindamycin and erythromycin in vitro.">
        <entity id="DDI-DrugBank.d256.s2.e0" charOffset="41-51"
            type="drug" text="clindamycin"/>
        <entity id="DDI-DrugBank.d256.s2.e1" charOffset="57-68"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d256.s2.d0" e1="DDI-DrugBank.d256.s2.e0"
            e2="DDI-DrugBank.d256.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d256.s3" text="Because of possible clinical significance, these two drugs should not be administered concurrently."/>
    <sentence id="DDI-DrugBank.d136.s0" text="Alcohol (increases bioavailability by 50%), cimetidine, and valproates.">
        <entity id="DDI-DrugBank.d136.s0.e0" charOffset="0-6"
            type="drug" text="Alcohol"/>
        <entity id="DDI-DrugBank.d136.s0.e1" charOffset="44-53"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d391.s0" text="No separate information available"/>
    <sentence id="DDI-DrugBank.d473.s0" text="Although no clinical drug-drug interaction studies have been conducted to date, on the basis of the in vitro studies, cytochrome p450 inhibitors and inducers are unlikely to affect the metabolism of clofarabine.">
        <entity id="DDI-DrugBank.d473.s0.e0" charOffset="199-209"
            type="drug" text="clofarabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d473.s1" text="The effect of clofarabine on the metabolism of cytochrome p450 substrates has not been studied.">
        <entity id="DDI-DrugBank.d473.s1.e0" charOffset="14-24"
            type="drug" text="clofarabine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d473.s2" text="Drug/Laboratory Tests Interactions There are no known clinically significant interactions of CLOLAR  with other medications or laboratory tests.">
        <entity id="DDI-DrugBank.d473.s2.e0" charOffset="93-98"
            type="brand" text="CLOLAR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d473.s3" text="No formal drug/laboratory test interaction studies have been conducted with CLOLAR  .">
        <entity id="DDI-DrugBank.d473.s3.e0" charOffset="76-81"
            type="brand" text="CLOLAR"/>
    </sentence>
    <sentence id="DDI-DrugBank.d399.s0" text="Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.">
        <entity id="DDI-DrugBank.d399.s0.e0" charOffset="36-42"
            type="drug" text="dapsone"/>
        <entity id="DDI-DrugBank.d399.s0.e1" charOffset="90-97"
            type="brand" text="Lamprene"/>
        <ddi id="DDI-DrugBank.d399.s0.d0" e1="DDI-DrugBank.d399.s0.e0"
            e2="DDI-DrugBank.d399.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d399.s1" text="If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.">
        <entity id="DDI-DrugBank.d399.s1.e0" charOffset="84-90"
            type="drug" text="dapsone"/>
        <entity id="DDI-DrugBank.d399.s1.e1" charOffset="96-106"
            type="drug" text="clofazimine"/>
        <ddi id="DDI-DrugBank.d399.s1.d0" e1="DDI-DrugBank.d399.s1.e0"
            e2="DDI-DrugBank.d399.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d12.s0" text="Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.">
        <entity id="DDI-DrugBank.d12.s0.e0" charOffset="33-46"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d12.s0.e1" charOffset="78-86"
            type="brand" text="Atromid-S"/>
        <ddi id="DDI-DrugBank.d12.s0.d0" e1="DDI-DrugBank.d12.s0.e0"
            e2="DDI-DrugBank.d12.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d12.s1" text="Usually, the dosage of the anticoagulant should be reduced by one-half (depending on the individual case) to maintain the prothrombin time at the desired level to prevent bleeding complications.">
        <entity id="DDI-DrugBank.d12.s1.e0" charOffset="27-39"
            type="group" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d12.s2" text="Frequent prothrombin determinations are advisable until it has been determined definitely that the prothrombin level has been stabilized."/>
    <sentence id="DDI-DrugBank.d12.s3" text="Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.">
        <entity id="DDI-DrugBank.d12.s3.e0" charOffset="0-8"
            type="brand" text="Atromid-S"/>
        <entity id="DDI-DrugBank.d12.s3.e1" charOffset="44-52"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d12.s3.e2" charOffset="57-67"
            type="drug" text="tolbutamide"/>
        <ddi id="DDI-DrugBank.d12.s3.d0" e1="DDI-DrugBank.d12.s3.e0"
            e2="DDI-DrugBank.d12.s3.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d12.s3.d1" e1="DDI-DrugBank.d12.s3.e0"
            e2="DDI-DrugBank.d12.s3.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d12.s4" text="Caution should be exercised when treating patients with either of these drugs or other highly protein-bound drugs and Atromid-S.">
        <entity id="DDI-DrugBank.d12.s4.e0" charOffset="118-126"
            type="brand" text="Atromid-S"/>
    </sentence>
    <sentence id="DDI-DrugBank.d12.s5" text="The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.">
        <entity id="DDI-DrugBank.d12.s5.e0" charOffset="27-37"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d12.s5.e1" charOffset="74-82"
            type="brand" text="Atromid-S"/>
        <ddi id="DDI-DrugBank.d12.s5.d0" e1="DDI-DrugBank.d12.s5.e0"
            e2="DDI-DrugBank.d12.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d12.s6" text="Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.">
        <entity id="DDI-DrugBank.d12.s6.e0" charOffset="113-119"
            type="group" text="fibrate"/>
        <entity id="DDI-DrugBank.d12.s6.e1" charOffset="125-134"
            type="drug" text="lovastatin"/>
        <ddi id="DDI-DrugBank.d12.s6.d0" e1="DDI-DrugBank.d12.s6.e0"
            e2="DDI-DrugBank.d12.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d12.s7" text="For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.">
        <entity id="DDI-DrugBank.d12.s7.e0" charOffset="168-177"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d12.s7.e1" charOffset="185-191"
            type="group" text="fibrate"/>
        <ddi id="DDI-DrugBank.d12.s7.d0" e1="DDI-DrugBank.d12.s7.e0"
            e2="DDI-DrugBank.d12.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d12.s8" text="While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.">
        <entity id="DDI-DrugBank.d12.s8.e0" charOffset="59-66"
            type="group" text="fibrates"/>
        <entity id="DDI-DrugBank.d12.s8.e1" charOffset="79-89"
            type="drug" text="gemfibrozil"/>
        <entity id="DDI-DrugBank.d12.s8.e2" charOffset="170-177"
            type="group" text="fibrates"/>
        <entity id="DDI-DrugBank.d12.s8.e3" charOffset="196-205"
            type="drug" text="clofibrate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d12.s9" text="Therefore, the combined use of lovastatin with fibrates should generally be avoided.">
        <entity id="DDI-DrugBank.d12.s9.e0" charOffset="31-40"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d12.s9.e1" charOffset="47-54"
            type="group" text="fibrates"/>
        <ddi id="DDI-DrugBank.d12.s9.d0" e1="DDI-DrugBank.d12.s9.e0"
            e2="DDI-DrugBank.d12.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d451.s0" text="Drug interactions with clomiphene citrate tablets USP have not been documented.">
        <entity id="DDI-DrugBank.d451.s0.e0" charOffset="23-40"
            type="drug" text="clomiphene citrate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s0" text="The risks of using Anafranil in combination with other drugs have not been systematically evaluated.">
        <entity id="DDI-DrugBank.d238.s0.e0" charOffset="19-27"
            type="brand" text="Anafranil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s1" text="Given the primary CNS effects of Anafranil, caution is advised in using it concomitantly with other CNS-active drugs.">
        <entity id="DDI-DrugBank.d238.s1.e0" charOffset="33-41"
            type="brand" text="Anafranil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s2" text="Anafranil should not be used with MAO inhibitors.">
        <entity id="DDI-DrugBank.d238.s2.e0" charOffset="0-8"
            type="brand" text="Anafranil"/>
        <entity id="DDI-DrugBank.d238.s2.e1" charOffset="34-47"
            type="group" text="MAO inhibitors"/>
        <ddi id="DDI-DrugBank.d238.s2.d0" e1="DDI-DrugBank.d238.s2.e0"
            e2="DDI-DrugBank.d238.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s3" text="Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.">
        <entity id="DDI-DrugBank.d238.s3.e0" charOffset="69-77"
            type="brand" text="Anafranil"/>
        <entity id="DDI-DrugBank.d238.s3.e1" charOffset="100-114"
            type="group" text="anticholinergic"/>
        <entity id="DDI-DrugBank.d238.s3.e2" charOffset="119-139"
            type="group" text="sympathomimetic drugs"/>
        <ddi id="DDI-DrugBank.d238.s3.d0" e1="DDI-DrugBank.d238.s3.e0"
            e2="DDI-DrugBank.d238.s3.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d238.s3.d1" e1="DDI-DrugBank.d238.s3.e0"
            e2="DDI-DrugBank.d238.s3.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s4" text="Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.">
        <entity id="DDI-DrugBank.d238.s4.e0" charOffset="8-32"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d238.s4.e1" charOffset="91-102"
            type="drug" text="guanethidine"/>
        <entity id="DDI-DrugBank.d238.s4.e2" charOffset="105-113"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d238.s4.e3" charOffset="178-180"
            type="drug" text="CMI"/>
        <entity id="DDI-DrugBank.d238.s4.e4" charOffset="228-252"
            type="group" text="tricyclic antidepressants"/>
        <ddi id="DDI-DrugBank.d238.s4.d0" e1="DDI-DrugBank.d238.s4.e0"
            e2="DDI-DrugBank.d238.s4.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d238.s4.d1" e1="DDI-DrugBank.d238.s4.e0"
            e2="DDI-DrugBank.d238.s4.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d238.s4.d2" e1="DDI-DrugBank.d238.s4.e0"
            e2="DDI-DrugBank.d238.s4.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d238.s4.d3" e1="DDI-DrugBank.d238.s4.e0"
            e2="DDI-DrugBank.d238.s4.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s5" text="The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol;">
        <entity id="DDI-DrugBank.d238.s5.e0" charOffset="28-30"
            type="drug" text="CMI"/>
        <entity id="DDI-DrugBank.d238.s5.e1" charOffset="103-113"
            type="drug" text="haloperidol"/>
        <ddi id="DDI-DrugBank.d238.s5.d0" e1="DDI-DrugBank.d238.s5.e0"
            e2="DDI-DrugBank.d238.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s6" text="plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.">
        <entity id="DDI-DrugBank.d238.s6.e0" charOffset="41-65"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d238.s6.e1" charOffset="139-153"
            type="drug" text="methylphenidate"/>
        <entity id="DDI-DrugBank.d238.s6.e2" charOffset="191-200"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d238.s6.e3" charOffset="203-212"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d238.s6.e4" charOffset="297-308"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d238.s6.e5" charOffset="311-319"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d238.s6.e6" charOffset="366-368"
            type="drug" text="CMI"/>
        <ddi id="DDI-DrugBank.d238.s6.d0" e1="DDI-DrugBank.d238.s6.e0"
            e2="DDI-DrugBank.d238.s6.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d238.s6.d1" e1="DDI-DrugBank.d238.s6.e0"
            e2="DDI-DrugBank.d238.s6.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d238.s6.d2" e1="DDI-DrugBank.d238.s6.e0"
            e2="DDI-DrugBank.d238.s6.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d238.s6.d3" e1="DDI-DrugBank.d238.s6.e0"
            e2="DDI-DrugBank.d238.s6.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d238.s6.d4" e1="DDI-DrugBank.d238.s6.e0"
            e2="DDI-DrugBank.d238.s6.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d238.s6.d5" e1="DDI-DrugBank.d238.s6.e6"
            e2="DDI-DrugBank.d238.s6.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d238.s6.d6" e1="DDI-DrugBank.d238.s6.e6"
            e2="DDI-DrugBank.d238.s6.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d238.s6.d7" e1="DDI-DrugBank.d238.s6.e6"
            e2="DDI-DrugBank.d238.s6.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d238.s6.d8" e1="DDI-DrugBank.d238.s6.e6"
            e2="DDI-DrugBank.d238.s6.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d238.s6.d9" e1="DDI-DrugBank.d238.s6.e6"
            e2="DDI-DrugBank.d238.s6.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s7" text="Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly.">
        <entity id="DDI-DrugBank.d238.s7.e0" charOffset="18-20"
            type="drug" text="CMI"/>
        <entity id="DDI-DrugBank.d238.s7.e1" charOffset="73-85"
            type="drug" text="phenobarbital"/>
        <ddi id="DDI-DrugBank.d238.s7.d0" e1="DDI-DrugBank.d238.s7.e0"
            e2="DDI-DrugBank.d238.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s8" text="Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the aucasian population (about 7%-10% of Caucasians are so-called poor metabolizers);"/>
    <sentence id="DDI-DrugBank.d238.s9" text="reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available."/>
    <sentence id="DDI-DrugBank.d238.s10" text="Poor metabolizers have higher than expected lasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.">
        <entity id="DDI-DrugBank.d238.s10.e0" charOffset="68-92"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d238.s10.e1" charOffset="95-98"
            type="group" text="TCAs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s11" text="Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).">
        <entity id="DDI-DrugBank.d238.s11.e0" charOffset="163-165"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s12" text="In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers."/>
    <sentence id="DDI-DrugBank.d238.s13" text="An individual who is stable on a given dose of TCAmay become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.">
        <entity id="DDI-DrugBank.d238.s13.e0" charOffset="47-49"
            type="group" text="TCA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s14" text="The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;">
        <entity id="DDI-DrugBank.d238.s14.e0" charOffset="96-104"
            type="drug" text="quinidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s15" text="cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).">
        <entity id="DDI-DrugBank.d238.s15.e0" charOffset="0-9"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d238.s15.e1" charOffset="66-80"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d238.s15.e2" charOffset="83-96"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d238.s15.e3" charOffset="107-129"
            type="group" text="Type 1C antiarrhythmics"/>
        <entity id="DDI-DrugBank.d238.s15.e4" charOffset="131-141"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d238.s15.e5" charOffset="147-156"
            type="drug" text="flecainide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s16" text="While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.">
        <entity id="DDI-DrugBank.d238.s16.e0" charOffset="14-52"
            type="group" text="selective serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d238.s16.e1" charOffset="55-59"
            type="group" text="SSRIs"/>
        <entity id="DDI-DrugBank.d238.s16.e2" charOffset="69-78"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d238.s16.e3" charOffset="81-90"
            type="drug" text="sertraline"/>
        <entity id="DDI-DrugBank.d238.s16.e4" charOffset="93-102"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d238.s16.e5" charOffset="109-119"
            type="drug" text="fluvoxamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s17" text="Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCAmetabolism.">
        <entity id="DDI-DrugBank.d238.s17.e0" charOffset="0-10"
            type="drug" text="Fluvoxamine"/>
        <entity id="DDI-DrugBank.d238.s17.e1" charOffset="81-83"
            type="group" text="TCA"/>
        <ddi id="DDI-DrugBank.d238.s17.d0" e1="DDI-DrugBank.d238.s17.e0"
            e2="DDI-DrugBank.d238.s17.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s18" text="The extent to which SSRI-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.">
        <entity id="DDI-DrugBank.d238.s18.e0" charOffset="20-23"
            type="group" text="SSRI"/>
        <entity id="DDI-DrugBank.d238.s18.e1" charOffset="25-27"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d238.s18.e2" charOffset="140-143"
            type="group" text="SSRI"/>
        <ddi id="DDI-DrugBank.d238.s18.d0" e1="DDI-DrugBank.d238.s18.e0"
            e2="DDI-DrugBank.d238.s18.e1" type="int"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s19" text="Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.">
        <entity id="DDI-DrugBank.d238.s19.e0" charOffset="63-66"
            type="group" text="TCAs"/>
        <entity id="DDI-DrugBank.d238.s19.e1" charOffset="84-88"
            type="group" text="SSRIs"/>
        <ddi id="DDI-DrugBank.d238.s19.d0" e1="DDI-DrugBank.d238.s19.e0"
            e2="DDI-DrugBank.d238.s19.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s20" text="Of particular importance, sufficient time must elapse before initiating TCAtreatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).">
        <entity id="DDI-DrugBank.d238.s20.e0" charOffset="72-74"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d238.s20.e1" charOffset="119-128"
            type="drug" text="fluoxetine"/>
        <ddi id="DDI-DrugBank.d238.s20.d0" e1="DDI-DrugBank.d238.s20.e0"
            e2="DDI-DrugBank.d238.s20.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s21" text="Concomitant use of agents in the tricyclic antidepressant class (which includes Anafranil) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug.">
        <entity id="DDI-DrugBank.d238.s21.e0" charOffset="33-62"
            type="group" text="tricyclic antidepressant class"/>
        <entity id="DDI-DrugBank.d238.s21.e1" charOffset="80-88"
            type="brand" text="Anafranil"/>
        <entity id="DDI-DrugBank.d238.s21.e2" charOffset="202-231"
            type="group" text="tricyclic antidepressant agent"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s22" text="Furthermore, whenever one of these drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant agent may be required.">
        <entity id="DDI-DrugBank.d238.s22.e0" charOffset="92-121"
            type="group" text="tricyclic antidepressant agent"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s23" text="It is desirable to monitor TCAplasma levels whenever an agent of the tricyclic antidepressant class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).">
        <entity id="DDI-DrugBank.d238.s23.e0" charOffset="27-29"
            type="group" text="TCA"/>
        <entity id="DDI-DrugBank.d238.s23.e1" charOffset="69-98"
            type="group" text="tricyclic antidepressant class"/>
        <entity id="DDI-DrugBank.d238.s23.e2" charOffset="110-118"
            type="brand" text="Anafranil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s24" text="Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.">
        <entity id="DDI-DrugBank.d238.s24.e0" charOffset="8-16"
            type="brand" text="Anafranil"/>
        <entity id="DDI-DrugBank.d238.s24.e1" charOffset="74-82"
            type="brand" text="Anafranil"/>
        <entity id="DDI-DrugBank.d238.s24.e2" charOffset="155-162"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d238.s24.e3" charOffset="165-171"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d238.s24.d0" e1="DDI-DrugBank.d238.s24.e1"
            e2="DDI-DrugBank.d238.s24.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d238.s24.d1" e1="DDI-DrugBank.d238.s24.e1"
            e2="DDI-DrugBank.d238.s24.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d238.s25" text="Conversely, adverse effects may result from displacement of protein-bound Anafranil by other highly bound drugs.">
        <entity id="DDI-DrugBank.d238.s25.e0" charOffset="74-82"
            type="brand" text="Anafranil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d333.s0" text="Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital.">
        <entity id="DDI-DrugBank.d333.s0.e0" charOffset="10-19"
            type="drug" text="Clonazepam"/>
        <entity id="DDI-DrugBank.d333.s0.e1" charOffset="61-70"
            type="drug" text="Clonazepam"/>
        <entity id="DDI-DrugBank.d333.s0.e2" charOffset="121-129"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d333.s0.e3" charOffset="132-144"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d333.s0.e4" charOffset="150-162"
            type="drug" text="phenobarbital"/>
    </sentence>
    <sentence id="DDI-DrugBank.d333.s1" text="The effect of clonazepam on the metabolism of other drugs has not been investigated.">
        <entity id="DDI-DrugBank.d333.s1.e0" charOffset="14-23"
            type="drug" text="clonazepam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d333.s2" text="Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.">
        <entity id="DDI-DrugBank.d333.s2.e0" charOffset="49-58"
            type="drug" text="Clonazepam"/>
        <entity id="DDI-DrugBank.d333.s2.e1" charOffset="93-102"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d333.s2.e2" charOffset="169-178"
            type="drug" text="clonazepam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d333.s3" text="In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.">
        <entity id="DDI-DrugBank.d333.s3.e0" charOffset="29-38"
            type="drug" text="clonazepam"/>
        <entity id="DDI-DrugBank.d333.s3.e1" charOffset="103-115"
            type="drug" text="propantheline"/>
        <entity id="DDI-DrugBank.d333.s3.e2" charOffset="121-141"
            type="group" text="anticholinergic agent"/>
        <entity id="DDI-DrugBank.d333.s3.e3" charOffset="216-225"
            type="drug" text="clonazepam"/>
        <entity id="DDI-DrugBank.d333.s3.e4" charOffset="257-266"
            type="drug" text="clonazepam"/>
        <entity id="DDI-DrugBank.d333.s3.e5" charOffset="335-347"
            type="drug" text="propantheline"/>
        <ddi id="DDI-DrugBank.d333.s3.d0" e1="DDI-DrugBank.d333.s3.e0"
            e2="DDI-DrugBank.d333.s3.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d333.s3.d1" e1="DDI-DrugBank.d333.s3.e4"
            e2="DDI-DrugBank.d333.s3.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d333.s4" text="Fluoxetine does not affect the pharmacokinetics of clonazepam.">
        <entity id="DDI-DrugBank.d333.s4.e0" charOffset="0-9"
            type="drug" text="Fluoxetine"/>
        <entity id="DDI-DrugBank.d333.s4.e1" charOffset="51-60"
            type="drug" text="clonazepam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d333.s5" text="Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.">
        <entity id="DDI-DrugBank.d333.s5.e0" charOffset="35-43"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d333.s5.e1" charOffset="46-58"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d333.s5.e2" charOffset="64-76"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d333.s5.e3" charOffset="86-95"
            type="drug" text="clonazepam"/>
        <entity id="DDI-DrugBank.d333.s5.e4" charOffset="157-166"
            type="drug" text="clonazepam"/>
        <ddi id="DDI-DrugBank.d333.s5.d0" e1="DDI-DrugBank.d333.s5.e0"
            e2="DDI-DrugBank.d333.s5.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d333.s5.d1" e1="DDI-DrugBank.d333.s5.e1"
            e2="DDI-DrugBank.d333.s5.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d333.s5.d2" e1="DDI-DrugBank.d333.s5.e2"
            e2="DDI-DrugBank.d333.s5.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d333.s6" text="Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.">
        <entity id="DDI-DrugBank.d333.s6.e0" charOffset="113-122"
            type="drug" text="clonazepam"/>
        <entity id="DDI-DrugBank.d333.s6.e1" charOffset="183-199"
            type="group" text="antifungal agents"/>
        <entity id="DDI-DrugBank.d333.s6.e2" charOffset="250-259"
            type="drug" text="clonazepam"/>
        <ddi id="DDI-DrugBank.d333.s6.d0" e1="DDI-DrugBank.d333.s6.e1"
            e2="DDI-DrugBank.d333.s6.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d333.s7" text="Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.">
        <entity id="DDI-DrugBank.d333.s7.e0" charOffset="63-82"
            type="group" text="benzodiazepine class"/>
        <entity id="DDI-DrugBank.d333.s7.e1" charOffset="115-121"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d333.s7.e2" charOffset="124-132"
            type="group" text="narcotics"/>
        <entity id="DDI-DrugBank.d333.s7.e3" charOffset="135-146"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d333.s7.e4" charOffset="149-172"
            type="group" text="nonbarbiturate hypnotics"/>
        <entity id="DDI-DrugBank.d333.s7.e5" charOffset="175-192"
            type="group" text="antianxiety agents"/>
        <entity id="DDI-DrugBank.d333.s7.e6"
            charOffset="199-212;246-276" type="group" text="phenothiazines classes of antipsychotic agents"/>
        <entity id="DDI-DrugBank.d333.s7.e7"
            charOffset="215-226;246-276" type="group" text="thioxanthene classes of antipsychotic agents"/>
        <entity id="DDI-DrugBank.d333.s7.e8" charOffset="232-276"
            type="group" text="butyrophenone classes of antipsychotic agents"/>
        <entity id="DDI-DrugBank.d333.s7.e9" charOffset="279-306"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d333.s7.e10" charOffset="316-340"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d333.s7.e11" charOffset="356-375"
            type="group" text="anticonvulsant drugs"/>
        <ddi id="DDI-DrugBank.d333.s7.d0" e1="DDI-DrugBank.d333.s7.e0"
            e2="DDI-DrugBank.d333.s7.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d333.s7.d1" e1="DDI-DrugBank.d333.s7.e0"
            e2="DDI-DrugBank.d333.s7.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d333.s7.d2" e1="DDI-DrugBank.d333.s7.e0"
            e2="DDI-DrugBank.d333.s7.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d333.s7.d3" e1="DDI-DrugBank.d333.s7.e0"
            e2="DDI-DrugBank.d333.s7.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d333.s7.d4" e1="DDI-DrugBank.d333.s7.e0"
            e2="DDI-DrugBank.d333.s7.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d333.s7.d5" e1="DDI-DrugBank.d333.s7.e0"
            e2="DDI-DrugBank.d333.s7.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d333.s7.d6" e1="DDI-DrugBank.d333.s7.e0"
            e2="DDI-DrugBank.d333.s7.e7" type="effect"/>
        <ddi id="DDI-DrugBank.d333.s7.d7" e1="DDI-DrugBank.d333.s7.e0"
            e2="DDI-DrugBank.d333.s7.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d333.s7.d8" e1="DDI-DrugBank.d333.s7.e0"
            e2="DDI-DrugBank.d333.s7.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d333.s7.d9" e1="DDI-DrugBank.d333.s7.e0"
            e2="DDI-DrugBank.d333.s7.e10" type="effect"/>
        <ddi id="DDI-DrugBank.d333.s7.d10" e1="DDI-DrugBank.d333.s7.e0"
            e2="DDI-DrugBank.d333.s7.e11" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d495.s0" text="Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.">
        <entity id="DDI-DrugBank.d495.s0.e0" charOffset="30-52"
            type="drug" text="clonidine hydrochloride"/>
        <entity id="DDI-DrugBank.d495.s0.e1" charOffset="69-93"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d495.s0.e2" charOffset="110-118"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d495.s0.d0" e1="DDI-DrugBank.d495.s0.e0"
            e2="DDI-DrugBank.d495.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d495.s1" text="Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.">
        <entity id="DDI-DrugBank.d495.s1.e0" charOffset="0-22"
            type="drug" text="Clonidine hydrochloride"/>
        <entity id="DDI-DrugBank.d495.s1.e1" charOffset="66-72"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d495.s1.e2" charOffset="75-86"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d495.s1.e3" charOffset="97-105"
            type="group" text="sedatives"/>
        <ddi id="DDI-DrugBank.d495.s1.d0" e1="DDI-DrugBank.d495.s1.e0"
            e2="DDI-DrugBank.d495.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d495.s1.d1" e1="DDI-DrugBank.d495.s1.e0"
            e2="DDI-DrugBank.d495.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d495.s1.d2" e1="DDI-DrugBank.d495.s1.e0"
            e2="DDI-DrugBank.d495.s1.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d495.s2" text="Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.">
        <entity id="DDI-DrugBank.d495.s2.e0" charOffset="0-12"
            type="drug" text="Amitriptyline"/>
        <entity id="DDI-DrugBank.d495.s2.e1" charOffset="34-42"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d495.s2.e2" charOffset="117-125"
            type="drug" text="Clonidine"/>
        <entity id="DDI-DrugBank.d495.s2.e3" charOffset="171-177"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d495.s2.e4" charOffset="180-191"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d495.s2.e5" charOffset="202-215"
            type="group" text="sedating drugs"/>
        <ddi id="DDI-DrugBank.d495.s2.d0" e1="DDI-DrugBank.d495.s2.e0"
            e2="DDI-DrugBank.d495.s2.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d495.s2.d1" e1="DDI-DrugBank.d495.s2.e2"
            e2="DDI-DrugBank.d495.s2.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d495.s2.d2" e1="DDI-DrugBank.d495.s2.e2"
            e2="DDI-DrugBank.d495.s2.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d495.s2.d3" e1="DDI-DrugBank.d495.s2.e2"
            e2="DDI-DrugBank.d495.s2.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d495.s3" text="Narcotic analgesics may potentiate the hypotensive effects of clonidine.">
        <entity id="DDI-DrugBank.d495.s3.e0" charOffset="0-18"
            type="group" text="Narcotic analgesics"/>
        <entity id="DDI-DrugBank.d495.s3.e1" charOffset="62-70"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d495.s3.d0" e1="DDI-DrugBank.d495.s3.e0"
            e2="DDI-DrugBank.d495.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d495.s4" text="Tricyclic antidepressants may antagonize the hypotensive effects of clonidine.">
        <entity id="DDI-DrugBank.d495.s4.e0" charOffset="0-24"
            type="group" text="Tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d495.s4.e1" charOffset="68-76"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d495.s4.d0" e1="DDI-DrugBank.d495.s4.e0"
            e2="DDI-DrugBank.d495.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d495.s5" text="The effects of tricyclic antidepressants on clonidines analgesic actions are not known.">
        <entity id="DDI-DrugBank.d495.s5.e0" charOffset="15-39"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d495.s5.e1" charOffset="44-52"
            type="drug" text="clonidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d495.s6" text="Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.">
        <entity id="DDI-DrugBank.d495.s6.e0" charOffset="0-12"
            type="group" text="Beta blockers"/>
        <entity id="DDI-DrugBank.d495.s6.e1" charOffset="65-73"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d495.s6.d0" e1="DDI-DrugBank.d495.s6.e0"
            e2="DDI-DrugBank.d495.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d495.s7" text="Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)">
        <entity id="DDI-DrugBank.d495.s7.e0" charOffset="125-133"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d495.s7.e1" charOffset="213-221"
            type="group" text="digitalis"/>
        <entity id="DDI-DrugBank.d495.s7.e2" charOffset="224-247"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d495.s7.e3" charOffset="254-266"
            type="group" text="beta-blockers"/>
        <ddi id="DDI-DrugBank.d495.s7.d0" e1="DDI-DrugBank.d495.s7.e0"
            e2="DDI-DrugBank.d495.s7.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d495.s7.d1" e1="DDI-DrugBank.d495.s7.e0"
            e2="DDI-DrugBank.d495.s7.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d495.s7.d2" e1="DDI-DrugBank.d495.s7.e0"
            e2="DDI-DrugBank.d495.s7.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d495.s8" text="There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.">
        <entity id="DDI-DrugBank.d495.s8.e0" charOffset="100-111"
            type="drug" text="fluphenazine"/>
        <entity id="DDI-DrugBank.d495.s8.e1" charOffset="122-130"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d495.s8.d0" e1="DDI-DrugBank.d495.s8.e0"
            e2="DDI-DrugBank.d495.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d495.s9" text="Symptoms resolved when clonidine was withdrawn and recurred when the patient was rechallenged with clonidine.">
        <entity id="DDI-DrugBank.d495.s9.e0" charOffset="23-31"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d495.s9.e1" charOffset="99-107"
            type="drug" text="clonidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d495.s10" text="Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.">
        <entity id="DDI-DrugBank.d495.s10.e0" charOffset="9-17"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d495.s10.e1" charOffset="87-97"
            type="group" text="anesthetics"/>
        <ddi id="DDI-DrugBank.d495.s10.d0" e1="DDI-DrugBank.d495.s10.e0"
            e2="DDI-DrugBank.d495.s10.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d343.s0" text="Aspirin, warfarin, heparin, NSAIDs">
        <entity id="DDI-DrugBank.d343.s0.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
        <entity id="DDI-DrugBank.d343.s0.e1" charOffset="9-16"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d343.s0.e2" charOffset="19-25"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d343.s0.e3" charOffset="28-33"
            type="group" text="NSAIDs"/>
    </sentence>
    <sentence id="DDI-DrugBank.d335.s0" text="If TRANXENE is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed.">
        <entity id="DDI-DrugBank.d335.s0.e0" charOffset="3-10"
            type="brand" text="TRANXENE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d335.s1" text="Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.">
        <entity id="DDI-DrugBank.d335.s1.e0" charOffset="33-55"
            type="drug" text="clorazepate dipotassium"/>
        <entity id="DDI-DrugBank.d335.s1.e1" charOffset="90-101"
            type="drug" text="hexobarbital"/>
        <entity id="DDI-DrugBank.d335.s1.e2" charOffset="112-124"
            type="drug" text="ethyl alcohol"/>
        <entity id="DDI-DrugBank.d335.s1.e3" charOffset="163-176"
            type="drug" text="chlorpromazine"/>
        <ddi id="DDI-DrugBank.d335.s1.d0" e1="DDI-DrugBank.d335.s1.e0"
            e2="DDI-DrugBank.d335.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d335.s1.d1" e1="DDI-DrugBank.d335.s1.e0"
            e2="DDI-DrugBank.d335.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d335.s1.d2" e1="DDI-DrugBank.d335.s1.e0"
            e2="DDI-DrugBank.d335.s1.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d335.s2" text="Clinical studies have shown increased sedation with concurrent hypnotic medications.">
        <entity id="DDI-DrugBank.d335.s2.e0" charOffset="63-82"
            type="group" text="hypnotic medications"/>
    </sentence>
    <sentence id="DDI-DrugBank.d335.s3" text="The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.">
        <entity id="DDI-DrugBank.d335.s3.e0" charOffset="19-33"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d335.s3.e1" charOffset="57-68"
            type="group" text="barbiturates"/>
        <entity id="DDI-DrugBank.d335.s3.e2" charOffset="71-79"
            type="group" text="narcotics"/>
        <entity id="DDI-DrugBank.d335.s3.e3" charOffset="82-95"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d335.s3.e4" charOffset="98-125"
            type="group" text="monoamine oxidase inhibitors"/>
        <entity id="DDI-DrugBank.d335.s3.e5" charOffset="136-150"
            type="group" text="antidepressants"/>
        <ddi id="DDI-DrugBank.d335.s3.d0" e1="DDI-DrugBank.d335.s3.e0"
            e2="DDI-DrugBank.d335.s3.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d335.s3.d1" e1="DDI-DrugBank.d335.s3.e0"
            e2="DDI-DrugBank.d335.s3.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d335.s3.d2" e1="DDI-DrugBank.d335.s3.e0"
            e2="DDI-DrugBank.d335.s3.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d335.s3.d3" e1="DDI-DrugBank.d335.s3.e0"
            e2="DDI-DrugBank.d335.s3.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d335.s3.d4" e1="DDI-DrugBank.d335.s3.e0"
            e2="DDI-DrugBank.d335.s3.e5" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d335.s4" text="If TRANXENE tablets are used to treat anxiety associated with somatic disease states, careful attention must be paid to possible drug interaction with concomitant medication.">
        <entity id="DDI-DrugBank.d335.s4.e0" charOffset="3-10"
            type="brand" text="TRANXENE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d335.s5" text="In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of TRANXENE tablets.">
        <entity id="DDI-DrugBank.d335.s5.e0" charOffset="82-89"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d335.s5.e1" charOffset="168-175"
            type="brand" text="TRANXENE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s0" text="The risks of using Clozapine in combination with other drugs have not been systematically evaluated.">
        <entity id="DDI-DrugBank.d480.s0.e0" charOffset="19-27"
            type="drug" text="Clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s1" text="Pharmacodynamic-related Interactions: The mechanism of Clozapine induced agranulocytosis is unknown;">
        <entity id="DDI-DrugBank.d480.s1.e0" charOffset="55-63"
            type="drug" text="Clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s2" text="nonetheless, the possibility that causative factors may interact synergistically to increase the risk and/or severity of bone marrow suppression warrants consideration."/>
    <sentence id="DDI-DrugBank.d480.s3" text="Therefore, Clozapine should not be used with other agents having a well-known potential to suppress bone marrow function.">
        <entity id="DDI-DrugBank.d480.s3.e0" charOffset="11-19"
            type="drug" text="Clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s4" text="Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.">
        <entity id="DDI-DrugBank.d480.s4.e0" charOffset="33-41"
            type="drug" text="Clozapine"/>
        <entity id="DDI-DrugBank.d480.s4.e1" charOffset="120-126"
            type="drug" text="alcohol"/>
        <ddi id="DDI-DrugBank.d480.s4.d0" e1="DDI-DrugBank.d480.s4.e0"
            e2="DDI-DrugBank.d480.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s5" text="Orthostatic hypotension in patients taking clozapine can, in rare cases (approximately 1 case per 3,000 patients), be accompanied by profound collapse and respiratory and/or cardiac arrest.">
        <entity id="DDI-DrugBank.d480.s5.e0" charOffset="43-51"
            type="drug" text="clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s6" text="Some of the cases of collapse/respiratory arrest/cardiac arrest during initial treatment occurred in patients who were being administered benzodiazepines;">
        <entity id="DDI-DrugBank.d480.s6.e0" charOffset="138-152"
            type="group" text="benzodiazepines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s7" text="similar events have been reported in patients taking other psychotropic drugs or even Clozapine by itself.">
        <entity id="DDI-DrugBank.d480.s7.e0" charOffset="59-76"
            type="group" text="psychotropic drugs"/>
        <entity id="DDI-DrugBank.d480.s7.e1" charOffset="86-94"
            type="drug" text="Clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s8" text="Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.">
        <entity id="DDI-DrugBank.d480.s8.e0" charOffset="74-82"
            type="drug" text="Clozapine"/>
        <entity id="DDI-DrugBank.d480.s8.e1" charOffset="88-102"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d480.s8.e2" charOffset="113-125"
            type="group" text="psychotropics"/>
        <entity id="DDI-DrugBank.d480.s8.e3" charOffset="152-160"
            type="drug" text="clozapine"/>
        <entity id="DDI-DrugBank.d480.s8.e4" charOffset="196-209"
            type="group" text="benzodiazepine"/>
        <entity id="DDI-DrugBank.d480.s8.e5" charOffset="224-240"
            type="group" text="psychotropic drug"/>
        <ddi id="DDI-DrugBank.d480.s8.d0" e1="DDI-DrugBank.d480.s8.e3"
            e2="DDI-DrugBank.d480.s8.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d480.s8.d1" e1="DDI-DrugBank.d480.s8.e3"
            e2="DDI-DrugBank.d480.s8.e5" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s9" text="Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.">
        <entity id="DDI-DrugBank.d480.s9.e0" charOffset="0-8"
            type="drug" text="Clozapine"/>
        <entity id="DDI-DrugBank.d480.s9.e1" charOffset="52-73"
            type="group" text="antihypertensive drugs"/>
        <entity id="DDI-DrugBank.d480.s9.e2" charOffset="110-117"
            type="drug" text="atropine"/>
        <ddi id="DDI-DrugBank.d480.s9.d0" e1="DDI-DrugBank.d480.s9.e0"
            e2="DDI-DrugBank.d480.s9.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d480.s9.d1" e1="DDI-DrugBank.d480.s9.e0"
            e2="DDI-DrugBank.d480.s9.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s10" text="The administration of epinephrine should be avoided in the treatment of drug induced hypotension because of a possible reverse epinephrine effect.">
        <entity id="DDI-DrugBank.d480.s10.e0" charOffset="22-32"
            type="drug" text="epinephrine"/>
        <entity id="DDI-DrugBank.d480.s10.e1" charOffset="127-137"
            type="drug" text="epinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s11" text="Pharmacokinetic-related Interactions: Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4.">
        <entity id="DDI-DrugBank.d480.s11.e0" charOffset="38-46"
            type="drug" text="Clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s12" text="The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized."/>
    <sentence id="DDI-DrugBank.d480.s13" text="Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."/>
    <sentence id="DDI-DrugBank.d480.s14" text="Concomitant administration of drugs known to induce cytochrome P450 enzymes may decrease the plasma levels of clozapine.">
        <entity id="DDI-DrugBank.d480.s14.e0" charOffset="110-118"
            type="drug" text="clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s15" text="Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.">
        <entity id="DDI-DrugBank.d480.s15.e0" charOffset="0-8"
            type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d480.s15.e1" charOffset="11-18"
            type="drug" text="nicotine"/>
        <entity id="DDI-DrugBank.d480.s15.e2" charOffset="25-32"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d480.s15.e3" charOffset="47-55"
            type="drug" text="Clozapine"/>
        <entity id="DDI-DrugBank.d480.s15.e4" charOffset="139-147"
            type="drug" text="Clozapine"/>
        <ddi id="DDI-DrugBank.d480.s15.d0" e1="DDI-DrugBank.d480.s15.e0"
            e2="DDI-DrugBank.d480.s15.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d480.s15.d1" e1="DDI-DrugBank.d480.s15.e1"
            e2="DDI-DrugBank.d480.s15.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d480.s15.d2" e1="DDI-DrugBank.d480.s15.e2"
            e2="DDI-DrugBank.d480.s15.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s16" text="Concomitant administration of drugs known to inhibit the activity of cytochrome P450 isozymes may increase the plasma levels of clozapine.">
        <entity id="DDI-DrugBank.d480.s16.e0" charOffset="128-136"
            type="drug" text="clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s17" text="Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.">
        <entity id="DDI-DrugBank.d480.s17.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d480.s17.e1" charOffset="12-19"
            type="drug" text="caffeine"/>
        <entity id="DDI-DrugBank.d480.s17.e2" charOffset="26-37"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d480.s17.e3" charOffset="69-77"
            type="drug" text="Clozapine"/>
        <ddi id="DDI-DrugBank.d480.s17.d0" e1="DDI-DrugBank.d480.s17.e0"
            e2="DDI-DrugBank.d480.s17.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d480.s17.d1" e1="DDI-DrugBank.d480.s17.e1"
            e2="DDI-DrugBank.d480.s17.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d480.s17.d2" e1="DDI-DrugBank.d480.s17.e2"
            e2="DDI-DrugBank.d480.s17.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s18" text="Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.">
        <entity id="DDI-DrugBank.d480.s18.e0" charOffset="28-36"
            type="drug" text="Clozapine"/>
        <entity id="DDI-DrugBank.d480.s18.e1" charOffset="42-54"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d480.s18.e2" charOffset="131-143"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d480.s18.e3" charOffset="189-197"
            type="drug" text="Clozapine"/>
        <ddi id="DDI-DrugBank.d480.s18.d0" e1="DDI-DrugBank.d480.s18.e0"
            e2="DDI-DrugBank.d480.s18.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d480.s18.d1" e1="DDI-DrugBank.d480.s18.e2"
            e2="DDI-DrugBank.d480.s18.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s19" text="In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.">
        <entity id="DDI-DrugBank.d480.s19.e0" charOffset="50-58"
            type="drug" text="clozapine"/>
        <entity id="DDI-DrugBank.d480.s19.e1" charOffset="91-101"
            type="drug" text="fluvoxamine"/>
        <entity id="DDI-DrugBank.d480.s19.e2" charOffset="106-115"
            type="drug" text="paroxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s20" text="After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.">
        <entity id="DDI-DrugBank.d480.s20.e0" charOffset="66-74"
            type="drug" text="clozapine"/>
        <entity id="DDI-DrugBank.d480.s20.e1" charOffset="97-116"
            type="drug_n" text="N-desmethylclozapine"/>
        <entity id="DDI-DrugBank.d480.s20.e2" charOffset="122-138"
            type="drug_n" text="clozapine N-oxide"/>
        <entity id="DDI-DrugBank.d480.s20.e3" charOffset="160-170"
            type="drug" text="fluvoxamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s21" text="Paroxetine produced only minor changes in the levels of clozapine and its metabolites.">
        <entity id="DDI-DrugBank.d480.s21.e0" charOffset="0-9"
            type="drug" text="Paroxetine"/>
        <entity id="DDI-DrugBank.d480.s21.e1" charOffset="56-64"
            type="drug" text="clozapine"/>
        <ddi id="DDI-DrugBank.d480.s21.d0" e1="DDI-DrugBank.d480.s21.e0"
            e2="DDI-DrugBank.d480.s21.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s22" text="However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.">
        <entity id="DDI-DrugBank.d480.s22.e0" charOffset="84-92"
            type="drug" text="clozapine"/>
        <entity id="DDI-DrugBank.d480.s22.e1" charOffset="129-137"
            type="drug" text="clozapine"/>
        <entity id="DDI-DrugBank.d480.s22.e2" charOffset="154-163"
            type="drug" text="paroxetine"/>
        <entity id="DDI-DrugBank.d480.s22.e3" charOffset="166-175"
            type="drug" text="fluoxetine"/>
        <entity id="DDI-DrugBank.d480.s22.e4" charOffset="182-191"
            type="drug" text="sertraline"/>
        <ddi id="DDI-DrugBank.d480.s22.d0" e1="DDI-DrugBank.d480.s22.e1"
            e2="DDI-DrugBank.d480.s22.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d480.s22.d1" e1="DDI-DrugBank.d480.s22.e1"
            e2="DDI-DrugBank.d480.s22.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d480.s22.d2" e1="DDI-DrugBank.d480.s22.e1"
            e2="DDI-DrugBank.d480.s22.e4" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s23" text="Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.">
        <entity id="DDI-DrugBank.d480.s23.e0" charOffset="115-123"
            type="drug" text="Clozapine"/>
        <entity id="DDI-DrugBank.d480.s23.e1" charOffset="173-183"
            type="drug" text="fluvoxamine"/>
        <ddi id="DDI-DrugBank.d480.s23.d0" e1="DDI-DrugBank.d480.s23.e0"
            e2="DDI-DrugBank.d480.s23.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s24" text="A reduced Clozapine dose should be considered.">
        <entity id="DDI-DrugBank.d480.s24.e0" charOffset="10-18"
            type="drug" text="Clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s25" text="A subset (3%-10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isozyme P450 2D6."/>
    <sentence id="DDI-DrugBank.d480.s26" text="Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, the tricyclic antidepressants, and clozapine.">
        <entity id="DDI-DrugBank.d480.s26.e0" charOffset="71-81"
            type="drug" text="debrisoquin"/>
        <entity id="DDI-DrugBank.d480.s26.e1" charOffset="84-99"
            type="drug" text="dextromethorphan"/>
        <entity id="DDI-DrugBank.d480.s26.e2" charOffset="106-130"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d480.s26.e3" charOffset="137-145"
            type="drug" text="clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s27" text="These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.">
        <entity id="DDI-DrugBank.d480.s27.e0" charOffset="76-84"
            type="drug" text="clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s28" text="In addition, certain drugs that are metabolized by this isozyme, including many antidepressants (clozapine, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isozyme, and thus may make normal metabolizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interaction.">
        <entity id="DDI-DrugBank.d480.s28.e0" charOffset="80-94"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d480.s28.e1" charOffset="97-105"
            type="drug" text="clozapine"/>
        <entity id="DDI-DrugBank.d480.s28.e2" charOffset="108-146"
            type="group" text="selective serotonin reuptake inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s29" text="Concomitant use of clozapine with other drugs metabolized by cytochrome P450 2D6 may require lower doses than usually prescribed for either clozapine or the other drug.">
        <entity id="DDI-DrugBank.d480.s29.e0" charOffset="19-27"
            type="drug" text="clozapine"/>
        <entity id="DDI-DrugBank.d480.s29.e1" charOffset="140-148"
            type="drug" text="clozapine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d480.s30" text="Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.">
        <entity id="DDI-DrugBank.d480.s30.e0" charOffset="32-40"
            type="drug" text="clozapine"/>
        <entity id="DDI-DrugBank.d480.s30.e1" charOffset="107-121"
            type="group" text="antidepressants"/>
        <entity id="DDI-DrugBank.d480.s30.e2" charOffset="124-137"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d480.s30.e3" charOffset="140-152"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d480.s30.e4" charOffset="159-181"
            type="group" text="Type 1C antiarrhythmics"/>
        <entity id="DDI-DrugBank.d480.s30.e5" charOffset="190-200"
            type="drug" text="propafenone"/>
        <entity id="DDI-DrugBank.d480.s30.e6" charOffset="203-212"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d480.s30.e7" charOffset="218-226"
            type="drug" text="encainide"/>
        <entity id="DDI-DrugBank.d480.s30.e8" charOffset="265-273"
            type="drug" text="quinidine"/>
        <ddi id="DDI-DrugBank.d480.s30.d0" e1="DDI-DrugBank.d480.s30.e0"
            e2="DDI-DrugBank.d480.s30.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d480.s30.d1" e1="DDI-DrugBank.d480.s30.e0"
            e2="DDI-DrugBank.d480.s30.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d480.s30.d2" e1="DDI-DrugBank.d480.s30.e0"
            e2="DDI-DrugBank.d480.s30.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d480.s30.d3" e1="DDI-DrugBank.d480.s30.e0"
            e2="DDI-DrugBank.d480.s30.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d480.s30.d4" e1="DDI-DrugBank.d480.s30.e0"
            e2="DDI-DrugBank.d480.s30.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d480.s30.d5" e1="DDI-DrugBank.d480.s30.e0"
            e2="DDI-DrugBank.d480.s30.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d480.s30.d6" e1="DDI-DrugBank.d480.s30.e0"
            e2="DDI-DrugBank.d480.s30.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d480.s30.d7" e1="DDI-DrugBank.d480.s30.e0"
            e2="DDI-DrugBank.d480.s30.e8" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d221.s0" text="The risk of a potential interaction between NovoSeven and coagulation factor concentrates has not been adequately evaluated in preclinical or clinical studies.">
        <entity id="DDI-DrugBank.d221.s0.e0" charOffset="44-52"
            type="brand" text="NovoSeven"/>
        <entity id="DDI-DrugBank.d221.s0.e1" charOffset="58-75"
            type="group" text="coagulation factor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d221.s1" text="Simultaneous use of activated prothrombin complex concentrates or prothrombin complex concentrates should be avoided.">
        <entity id="DDI-DrugBank.d221.s1.e0" charOffset="20-61"
            type="group" text="activated prothrombin complex concentrates"/>
        <entity id="DDI-DrugBank.d221.s1.e1" charOffset="66-97"
            type="group" text="prothrombin complex concentrates"/>
    </sentence>
    <sentence id="DDI-DrugBank.d221.s2" text="Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.">
        <entity id="DDI-DrugBank.d221.s2.e0" charOffset="170-184"
            type="drug" text="tranexamic acid"/>
        <entity id="DDI-DrugBank.d221.s2.e1" charOffset="187-203"
            type="drug" text="aminocaproic acid"/>
        <entity id="DDI-DrugBank.d221.s2.e2" charOffset="210-218"
            type="brand" text="NovoSeven"/>
    </sentence>
    <sentence id="DDI-DrugBank.d221.s3" text="NovoSeven should not be mixed with infusion solutions until clinical data are available to direct this use.">
        <entity id="DDI-DrugBank.d221.s3.e0" charOffset="0-8"
            type="brand" text="NovoSeven"/>
    </sentence>
    <sentence id="DDI-DrugBank.d464.s0" text="Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.">
        <entity id="DDI-DrugBank.d464.s0.e0" charOffset="0-6"
            type="drug" text="Codeine"/>
        <entity id="DDI-DrugBank.d464.s0.e1" charOffset="34-52"
            type="group" text="narcotic analgesics"/>
        <entity id="DDI-DrugBank.d464.s0.e2" charOffset="63-73"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d464.s0.e3" charOffset="76-89"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d464.s0.e4" charOffset="92-104"
            type="group" text="tranquilizers"/>
        <entity id="DDI-DrugBank.d464.s0.e5" charOffset="107-124"
            type="group" text="sedative-hypnotics"/>
        <entity id="DDI-DrugBank.d464.s0.e6" charOffset="136-150"
            type="group" text="CNS depressants"/>
        <entity id="DDI-DrugBank.d464.s0.e7" charOffset="163-169"
            type="drug" text="alcohol"/>
        <ddi id="DDI-DrugBank.d464.s0.d0" e1="DDI-DrugBank.d464.s0.e0"
            e2="DDI-DrugBank.d464.s0.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d464.s0.d1" e1="DDI-DrugBank.d464.s0.e0"
            e2="DDI-DrugBank.d464.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d464.s0.d2" e1="DDI-DrugBank.d464.s0.e0"
            e2="DDI-DrugBank.d464.s0.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d464.s0.d3" e1="DDI-DrugBank.d464.s0.e0"
            e2="DDI-DrugBank.d464.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d464.s0.d4" e1="DDI-DrugBank.d464.s0.e0"
            e2="DDI-DrugBank.d464.s0.e5" type="effect"/>
        <ddi id="DDI-DrugBank.d464.s0.d5" e1="DDI-DrugBank.d464.s0.e0"
            e2="DDI-DrugBank.d464.s0.e6" type="effect"/>
        <ddi id="DDI-DrugBank.d464.s0.d6" e1="DDI-DrugBank.d464.s0.e0"
            e2="DDI-DrugBank.d464.s0.e7" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d464.s1" text="When s.c."/>
    <sentence id="DDI-DrugBank.d464.s2" text="combination therapy is contemplated, the dosage of one or both agents should be reduced."/>
    <sentence id="DDI-DrugBank.d146.s0" text="Colchicine is inhibited by acidifying agents.">
        <entity id="DDI-DrugBank.d146.s0.e0" charOffset="0-9"
            type="drug" text="Colchicine"/>
        <entity id="DDI-DrugBank.d146.s0.e1" charOffset="27-43"
            type="group" text="acidifying agents"/>
        <ddi id="DDI-DrugBank.d146.s0.d0" e1="DDI-DrugBank.d146.s0.e0"
            e2="DDI-DrugBank.d146.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d146.s1" text="The action of colchicine is potentiated by alkalinizing agents.">
        <entity id="DDI-DrugBank.d146.s1.e0" charOffset="14-23"
            type="drug" text="colchicine"/>
        <entity id="DDI-DrugBank.d146.s1.e1" charOffset="43-61"
            type="group" text="alkalinizing agents"/>
        <ddi id="DDI-DrugBank.d146.s1.d0" e1="DDI-DrugBank.d146.s1.e0"
            e2="DDI-DrugBank.d146.s1.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d146.s2" text="Colchicine may increase sensitivity to the CNS depressants.">
        <entity id="DDI-DrugBank.d146.s2.e0" charOffset="0-9"
            type="drug" text="Colchicine"/>
        <entity id="DDI-DrugBank.d146.s2.e1" charOffset="43-57"
            type="group" text="CNS depressants"/>
        <ddi id="DDI-DrugBank.d146.s2.d0" e1="DDI-DrugBank.d146.s2.e0"
            e2="DDI-DrugBank.d146.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d146.s3" text="Response to sympathomimetic agents may be enhanced by colchicine.">
        <entity id="DDI-DrugBank.d146.s3.e0" charOffset="12-33"
            type="group" text="sympathomimetic agents"/>
        <entity id="DDI-DrugBank.d146.s3.e1" charOffset="54-63"
            type="drug" text="colchicine"/>
        <ddi id="DDI-DrugBank.d146.s3.d0" e1="DDI-DrugBank.d146.s3.e0"
            e2="DDI-DrugBank.d146.s3.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d551.s0" text="WelChol  has been studied in several human drug interaction studies in which it was administered with a meal and the test drug.">
        <entity id="DDI-DrugBank.d551.s0.e0" charOffset="0-6"
            type="brand" text="WelChol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d551.s1" text="WelChol  was found to have no significant effect on the bioavailability of digoxin, lovastatin, metoprolol, quinidine, valproic acid, and warfarin.">
        <entity id="DDI-DrugBank.d551.s1.e0" charOffset="0-6"
            type="brand" text="WelChol"/>
        <entity id="DDI-DrugBank.d551.s1.e1" charOffset="75-81"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d551.s1.e2" charOffset="84-93"
            type="drug" text="lovastatin"/>
        <entity id="DDI-DrugBank.d551.s1.e3" charOffset="96-105"
            type="drug" text="metoprolol"/>
        <entity id="DDI-DrugBank.d551.s1.e4" charOffset="108-116"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d551.s1.e5" charOffset="119-131"
            type="drug" text="valproic acid"/>
        <entity id="DDI-DrugBank.d551.s1.e6" charOffset="138-145"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d551.s2" text="WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.">
        <entity id="DDI-DrugBank.d551.s2.e0" charOffset="0-6"
            type="brand" text="WelChol"/>
        <entity id="DDI-DrugBank.d551.s2.e1" charOffset="57-65"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d551.s2.e2" charOffset="68-75"
            type="brand" text="Calan SR"/>
        <ddi id="DDI-DrugBank.d551.s2.d0" e1="DDI-DrugBank.d551.s2.e0"
            e2="DDI-DrugBank.d551.s2.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d551.s2.d1" e1="DDI-DrugBank.d551.s2.e0"
            e2="DDI-DrugBank.d551.s2.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d551.s3" text="Since there is a high degree of variability in the bioavailability of verapamil, the clinical significance of this finding is unclear.">
        <entity id="DDI-DrugBank.d551.s3.e0" charOffset="70-78"
            type="drug" text="verapamil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s5" text="INCREASED PHENYTOIN LEVELS SHOULD BE TREATED WITH APPROPRIATE DOSAGE ADJUSTMENT.">
        <entity id="DDI-DrugBank.d19.s5.e0" charOffset="10-18"
            type="drug" text="PHENYTOIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s6" text="It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.">
        <entity id="DDI-DrugBank.d19.s6.e0" charOffset="49-62"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d19.s6.e1" charOffset="91-100"
            type="drug" text="disulfiram"/>
        <entity id="DDI-DrugBank.d19.s6.e2" charOffset="109-118"
            type="drug" text="disulfiram"/>
        <ddi id="DDI-DrugBank.d19.s6.d0" e1="DDI-DrugBank.d19.s6.e0"
            e2="DDI-DrugBank.d19.s6.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s7" text="Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;">
        <entity id="DDI-DrugBank.d19.s7.e0" charOffset="16-24"
            type="drug" text="isoniazid"/>
        <entity id="DDI-DrugBank.d19.s7.e1" charOffset="31-40"
            type="drug" text="disulfiram"/>
        <ddi id="DDI-DrugBank.d19.s7.d0" e1="DDI-DrugBank.d19.s7.e0"
            e2="DDI-DrugBank.d19.s7.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s8" text="the disulfiram should be discontinued if such signs appear.">
        <entity id="DDI-DrugBank.d19.s8.e0" charOffset="4-13"
            type="drug" text="disulfiram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s9" text="In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.">
        <entity id="DDI-DrugBank.d19.s9.e0" charOffset="35-44"
            type="drug" text="disulfiram"/>
        <entity id="DDI-DrugBank.d19.s9.e1" charOffset="50-56"
            type="drug" text="nitrite"/>
        <entity id="DDI-DrugBank.d19.s9.e2" charOffset="149-158"
            type="drug" text="disulfiram"/>
        <entity id="DDI-DrugBank.d19.s9.e3" charOffset="175-182"
            type="group" text="nitrites"/>
        <ddi id="DDI-DrugBank.d19.s9.d0" e1="DDI-DrugBank.d19.s9.e0"
            e2="DDI-DrugBank.d19.s9.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d19.s9.d1" e1="DDI-DrugBank.d19.s9.e2"
            e2="DDI-DrugBank.d19.s9.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s10" text="Disulfiram alone in the rat s diet did not lead to such tumors.">
        <entity id="DDI-DrugBank.d19.s10.e0" charOffset="0-9"
            type="drug" text="Disulfiram"/>
    </sentence>
    <sentence id="DDI-DrugBank.d19.s11" text="The relevance of this finding to humans is not known at this time."/>
    <sentence id="DDI-DrugBank.d274.s0" text="Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.">
        <entity id="DDI-DrugBank.d274.s0.e0" charOffset="29-38"
            type="drug" text="dobutamine"/>
        <entity id="DDI-DrugBank.d274.s0.e1" charOffset="98-112"
            type="group" text="b-blocking drug"/>
        <ddi id="DDI-DrugBank.d274.s0.d0" e1="DDI-DrugBank.d274.s0.e0"
            e2="DDI-DrugBank.d274.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d274.s1" text="In such a case, the peripheral vascular resistance may increase."/>
    <sentence id="DDI-DrugBank.d274.s2" text="Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.">
        <entity id="DDI-DrugBank.d274.s2.e0" charOffset="57-66"
            type="drug" text="dobutamine"/>
        <entity id="DDI-DrugBank.d274.s2.e1" charOffset="72-84"
            type="drug" text="nitroprusside"/>
        <ddi id="DDI-DrugBank.d274.s2.d0" e1="DDI-DrugBank.d274.s2.e0"
            e2="DDI-DrugBank.d274.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d274.s3" text="There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.">
        <entity id="DDI-DrugBank.d274.s3.e0" charOffset="72-81"
            type="drug" text="dobutamine"/>
        <entity id="DDI-DrugBank.d274.s3.e1" charOffset="141-162"
            type="group" text="digitalis preparations"/>
        <entity id="DDI-DrugBank.d274.s3.e2" charOffset="165-174"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d274.s3.e3" charOffset="177-190"
            type="drug" text="spironolactone"/>
        <entity id="DDI-DrugBank.d274.s3.e4" charOffset="193-201"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d274.s3.e5" charOffset="204-222"
            type="drug" text="glyceryl trinitrate"/>
        <entity id="DDI-DrugBank.d274.s3.e6" charOffset="225-244"
            type="drug" text="isosorbide dinitrate"/>
        <entity id="DDI-DrugBank.d274.s3.e7" charOffset="247-254"
            type="drug" text="morphine"/>
        <entity id="DDI-DrugBank.d274.s3.e8" charOffset="257-264"
            type="drug" text="atropine"/>
        <entity id="DDI-DrugBank.d274.s3.e9" charOffset="267-273"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d274.s3.e10" charOffset="276-284"
            type="drug" text="protamine"/>
        <entity id="DDI-DrugBank.d274.s3.e11" charOffset="287-304"
            type="drug" text="potassium chloride"/>
        <entity id="DDI-DrugBank.d274.s3.e12" charOffset="307-316"
            type="drug" text="folic acid"/>
        <entity id="DDI-DrugBank.d274.s3.e13" charOffset="323-335"
            type="drug" text="acetaminophen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d371.s0" text="There have been no formal clinical studies to evaluate the drug interactions of TAXOTERE with other medications.">
        <entity id="DDI-DrugBank.d371.s0.e0" charOffset="80-87"
            type="brand" text="TAXOTERE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d371.s1" text="In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.">
        <entity id="DDI-DrugBank.d371.s1.e0" charOffset="51-59"
            type="drug" text="docetaxel"/>
        <entity id="DDI-DrugBank.d371.s1.e1" charOffset="197-208"
            type="drug" text="cyclosporine"/>
        <entity id="DDI-DrugBank.d371.s1.e2" charOffset="211-221"
            type="drug" text="terfenadine"/>
        <entity id="DDI-DrugBank.d371.s1.e3" charOffset="224-235"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d371.s1.e4" charOffset="238-249"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d371.s1.e5" charOffset="256-269"
            type="drug" text="troleandomycin"/>
        <ddi id="DDI-DrugBank.d371.s1.d0" e1="DDI-DrugBank.d371.s1.e0"
            e2="DDI-DrugBank.d371.s1.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d371.s1.d1" e1="DDI-DrugBank.d371.s1.e0"
            e2="DDI-DrugBank.d371.s1.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d371.s1.d2" e1="DDI-DrugBank.d371.s1.e0"
            e2="DDI-DrugBank.d371.s1.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d371.s1.d3" e1="DDI-DrugBank.d371.s1.e0"
            e2="DDI-DrugBank.d371.s1.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d371.s1.d4" e1="DDI-DrugBank.d371.s1.e0"
            e2="DDI-DrugBank.d371.s1.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d371.s2" text="Caution should be exercised with these drugs when treating patients receiving TAXOTERE as there is a potential for a significant interaction.">
        <entity id="DDI-DrugBank.d371.s2.e0" charOffset="78-85"
            type="brand" text="TAXOTERE"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s0" text="Drug/Laboratory Test Interactions None known."/>
    <sentence id="DDI-DrugBank.d558.s1" text="Drug-Drug Interactions Cimetidine: Concomitant use of cimetidine is contraindicated.">
        <entity id="DDI-DrugBank.d558.s1.e0" charOffset="23-32"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d558.s1.e1" charOffset="54-63"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s2" text="Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.">
        <entity id="DDI-DrugBank.d558.s2.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d558.s2.e1" charOffset="76-82"
            type="brand" text="TIKOSYN"/>
        <entity id="DDI-DrugBank.d558.s2.e2" charOffset="136-145"
            type="drug" text="dofetilide"/>
        <ddi id="DDI-DrugBank.d558.s2.d0" e1="DDI-DrugBank.d558.s2.e0"
            e2="DDI-DrugBank.d558.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s3" text="Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).">
        <entity id="DDI-DrugBank.d558.s3.e0" charOffset="0-9"
            type="drug" text="Cimetidine"/>
        <entity id="DDI-DrugBank.d558.s3.e1" charOffset="75-84"
            type="drug" text="dofetilide"/>
        <ddi id="DDI-DrugBank.d558.s3.d0" e1="DDI-DrugBank.d558.s3.e0"
            e2="DDI-DrugBank.d558.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s4" text="No studies have been conducted at intermediate doses of cimetidine.">
        <entity id="DDI-DrugBank.d558.s4.e0" charOffset="56-65"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s5" text="If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.">
        <entity id="DDI-DrugBank.d558.s5.e0" charOffset="22-28"
            type="brand" text="TIKOSYN"/>
        <entity id="DDI-DrugBank.d558.s5.e1" charOffset="34-43"
            type="group" text="anti-ulcer"/>
        <entity id="DDI-DrugBank.d558.s5.e2" charOffset="75-84"
            type="drug" text="omeprazole"/>
        <entity id="DDI-DrugBank.d558.s5.e3" charOffset="87-96"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d558.s5.e4" charOffset="102-109"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d558.s5.e5"
            charOffset="112-119;135-143" type="drug" text="aluminum hydroxide"/>
        <entity id="DDI-DrugBank.d558.s5.e6" charOffset="125-143"
            type="drug" text="magnesium hydroxide"/>
        <entity id="DDI-DrugBank.d558.s5.e7" charOffset="174-183"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d558.s5.e8" charOffset="251-257"
            type="brand" text="TIKOSYN"/>
        <ddi id="DDI-DrugBank.d558.s5.d0" e1="DDI-DrugBank.d558.s5.e0"
            e2="DDI-DrugBank.d558.s5.e7" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s6" text="Verapamil: Concomitant use of verapamil is contraindicated.">
        <entity id="DDI-DrugBank.d558.s6.e0" charOffset="0-8"
            type="drug" text="Verapamil"/>
        <entity id="DDI-DrugBank.d558.s6.e1" charOffset="30-38"
            type="drug" text="verapamil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s7" text="Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.">
        <entity id="DDI-DrugBank.d558.s7.e0" charOffset="21-27"
            type="brand" text="TIKOSYN"/>
        <entity id="DDI-DrugBank.d558.s7.e1" charOffset="34-42"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d558.s7.e2" charOffset="69-78"
            type="drug" text="dofetilide"/>
        <entity id="DDI-DrugBank.d558.s7.e3" charOffset="136-145"
            type="drug" text="dofetilide"/>
        <ddi id="DDI-DrugBank.d558.s7.d0" e1="DDI-DrugBank.d558.s7.e0"
            e2="DDI-DrugBank.d558.s7.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s8" text="In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.">
        <entity id="DDI-DrugBank.d558.s8.e0" charOffset="117-125"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d558.s8.e1" charOffset="132-141"
            type="drug" text="dofetilide"/>
        <ddi id="DDI-DrugBank.d558.s8.d0" e1="DDI-DrugBank.d558.s8.e0"
            e2="DDI-DrugBank.d558.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s9" text="Ketoconazole: Concomitant use of ketoconazole is contraindicated.">
        <entity id="DDI-DrugBank.d558.s9.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d558.s9.e1" charOffset="33-44"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s10" text="Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.">
        <entity id="DDI-DrugBank.d558.s10.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d558.s10.e1" charOffset="91-97"
            type="brand" text="TIKOSYN"/>
        <entity id="DDI-DrugBank.d558.s10.e2" charOffset="151-160"
            type="drug" text="dofetilide"/>
        <ddi id="DDI-DrugBank.d558.s10.d0" e1="DDI-DrugBank.d558.s10.e0"
            e2="DDI-DrugBank.d558.s10.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s11" text="Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.">
        <entity id="DDI-DrugBank.d558.s11.e0" charOffset="0-11"
            type="drug" text="Trimethoprim"/>
        <entity id="DDI-DrugBank.d558.s11.e1" charOffset="42-57"
            type="drug" text="Sulfamethoxazole"/>
        <entity id="DDI-DrugBank.d558.s11.e2" charOffset="79-90"
            type="drug" text="trimethoprim"/>
        <entity id="DDI-DrugBank.d558.s11.e3" charOffset="121-136"
            type="drug" text="sulfamethoxazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s12" text="Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.">
        <entity id="DDI-DrugBank.d558.s12.e0" charOffset="0-18"
            type="drug" text="Hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d558.s12.e1" charOffset="21-24"
            type="drug" text="HCTZ"/>
        <entity id="DDI-DrugBank.d558.s12.e2" charOffset="56-66"
            type="drug" text="Triamterene"/>
        <entity id="DDI-DrugBank.d558.s12.e3" charOffset="88-91"
            type="drug" text="HCTZ"/>
        <entity id="DDI-DrugBank.d558.s12.e4" charOffset="122-132"
            type="drug" text="triamterene"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s13" text="HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).">
        <entity id="DDI-DrugBank.d558.s13.e0" charOffset="0-3"
            type="drug" text="HCTZ"/>
        <entity id="DDI-DrugBank.d558.s13.e1" charOffset="17-20"
            type="drug" text="HCTZ"/>
        <entity id="DDI-DrugBank.d558.s13.e2" charOffset="22-32"
            type="drug" text="triamterene"/>
        <entity id="DDI-DrugBank.d558.s13.e3" charOffset="72-78"
            type="brand" text="TIKOSYN"/>
        <entity id="DDI-DrugBank.d558.s13.e4" charOffset="126-133"
            type="group" text="diuretic"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s14" text="In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.">
        <entity id="DDI-DrugBank.d558.s14.e0" charOffset="22-25"
            type="drug" text="HCTZ"/>
        <entity id="DDI-DrugBank.d558.s14.e1" charOffset="34-43"
            type="drug" text="dofetilide"/>
        <ddi id="DDI-DrugBank.d558.s14.d0" e1="DDI-DrugBank.d558.s14.e0"
            e2="DDI-DrugBank.d558.s14.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s15" text="However, the pharmacodynamic effect increased by 197% (QTc increase over time) and by 95% (maximum QTc increase)."/>
    <sentence id="DDI-DrugBank.d558.s16" text="However, the pharmacodynamic effect increased by 190% (QTc increase over time) and by 84% (Maximum QTc increase)."/>
    <sentence id="DDI-DrugBank.d558.s17" text="The pharmacodynamic effects can be explained by a combination of the increase in dofetilide exposure and the reductions in serum potassium.">
        <entity id="DDI-DrugBank.d558.s17.e0" charOffset="81-90"
            type="drug" text="dofetilide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s18" text="In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics.">
        <entity id="DDI-DrugBank.d558.s18.e0" charOffset="55-61"
            type="brand" text="TIKOSYN"/>
        <entity id="DDI-DrugBank.d558.s18.e1" charOffset="67-75"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d558.s18.e2" charOffset="177-185"
            type="group" text="diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s19" text="Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI 0.376, 1.230).">
        <entity id="DDI-DrugBank.d558.s19.e0" charOffset="28-56"
            type="group" text="potassium depleting diuretics"/>
        <entity id="DDI-DrugBank.d558.s19.e1" charOffset="136-142"
            type="brand" text="TIKOSYN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s20" text="Potential Drug Interactions Dofetilide is eliminated in the kidney by cationic secretion.">
        <entity id="DDI-DrugBank.d558.s20.e0" charOffset="28-37"
            type="drug" text="Dofetilide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s21" text="Inhibitors of renal cationic secretion are contraindicated with TIKOSYN.">
        <entity id="DDI-DrugBank.d558.s21.e0" charOffset="64-70"
            type="brand" text="TIKOSYN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s22" text="In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.">
        <entity id="DDI-DrugBank.d558.s22.e0" charOffset="68-78"
            type="drug" text="triamterene"/>
        <entity id="DDI-DrugBank.d558.s22.e1" charOffset="81-89"
            type="drug" text="metformin"/>
        <entity id="DDI-DrugBank.d558.s22.e2" charOffset="95-103"
            type="drug" text="amiloride"/>
        <entity id="DDI-DrugBank.d558.s22.e3" charOffset="165-174"
            type="drug" text="dofetilide"/>
        <ddi id="DDI-DrugBank.d558.s22.d0" e1="DDI-DrugBank.d558.s22.e0"
            e2="DDI-DrugBank.d558.s22.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s22.d1" e1="DDI-DrugBank.d558.s22.e1"
            e2="DDI-DrugBank.d558.s22.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s22.d2" e1="DDI-DrugBank.d558.s22.e2"
            e2="DDI-DrugBank.d558.s22.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s23" text="Dofetilide is metabolized to a small extent by the CYP3A4 isoenzyme of the cytochrome P450 system.">
        <entity id="DDI-DrugBank.d558.s23.e0" charOffset="0-9"
            type="drug" text="Dofetilide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s24" text="Inhibitors of the CYP3A4 isoenzyme could increase systemic dofetilide exposure.">
        <entity id="DDI-DrugBank.d558.s24.e0" charOffset="59-68"
            type="drug" text="dofetilide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s25" text="Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.">
        <entity id="DDI-DrugBank.d558.s25.e0" charOffset="36-56"
            type="group" text="macrolide antibiotics"/>
        <entity id="DDI-DrugBank.d558.s25.e1" charOffset="59-81"
            type="group" text="azole antifungal agents"/>
        <entity id="DDI-DrugBank.d558.s25.e2" charOffset="84-102"
            type="group" text="protease inhibitors"/>
        <entity id="DDI-DrugBank.d558.s25.e3" charOffset="105-133"
            type="group" text="serotonin reuptake inhibitors"/>
        <entity id="DDI-DrugBank.d558.s25.e4" charOffset="136-145"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d558.s25.e5" charOffset="148-159"
            type="group" text="cannabinoids"/>
        <entity id="DDI-DrugBank.d558.s25.e6" charOffset="162-170"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d558.s25.e7" charOffset="191-200"
            type="drug" text="nefazadone"/>
        <entity id="DDI-DrugBank.d558.s25.e8" charOffset="203-213"
            type="drug" text="norfloxacin"/>
        <entity id="DDI-DrugBank.d558.s25.e9" charOffset="216-222"
            type="drug" text="quinine"/>
        <entity id="DDI-DrugBank.d558.s25.e10" charOffset="225-235"
            type="drug" text="zafirlukast"/>
        <entity id="DDI-DrugBank.d558.s25.e11" charOffset="279-285"
            type="brand" text="TIKOSYN"/>
        <entity id="DDI-DrugBank.d558.s25.e12" charOffset="320-329"
            type="drug" text="dofetilide"/>
        <ddi id="DDI-DrugBank.d558.s25.d0" e1="DDI-DrugBank.d558.s25.e0"
            e2="DDI-DrugBank.d558.s25.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s25.d1" e1="DDI-DrugBank.d558.s25.e1"
            e2="DDI-DrugBank.d558.s25.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s25.d2" e1="DDI-DrugBank.d558.s25.e2"
            e2="DDI-DrugBank.d558.s25.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s25.d3" e1="DDI-DrugBank.d558.s25.e3"
            e2="DDI-DrugBank.d558.s25.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s25.d4" e1="DDI-DrugBank.d558.s25.e4"
            e2="DDI-DrugBank.d558.s25.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s25.d5" e1="DDI-DrugBank.d558.s25.e5"
            e2="DDI-DrugBank.d558.s25.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s25.d6" e1="DDI-DrugBank.d558.s25.e6"
            e2="DDI-DrugBank.d558.s25.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s25.d7" e1="DDI-DrugBank.d558.s25.e7"
            e2="DDI-DrugBank.d558.s25.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s25.d8" e1="DDI-DrugBank.d558.s25.e8"
            e2="DDI-DrugBank.d558.s25.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s25.d9" e1="DDI-DrugBank.d558.s25.e9"
            e2="DDI-DrugBank.d558.s25.e11" type="advise"/>
        <ddi id="DDI-DrugBank.d558.s25.d10"
            e1="DDI-DrugBank.d558.s25.e10"
            e2="DDI-DrugBank.d558.s25.e11" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s26" text="Dofetilide is not an inhibitor of CYP3A4 nor of other cytochrome P450 isoenzymes (e.g., CYP2C9, CYP2D6) and is not expected to increase levels of drugs metabolized by CYP3A4.">
        <entity id="DDI-DrugBank.d558.s26.e0" charOffset="0-9"
            type="drug" text="Dofetilide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s27" text="Other Drug Interaction Information Digoxin: Studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics of digoxin.">
        <entity id="DDI-DrugBank.d558.s27.e0" charOffset="35-41"
            type="drug" text="Digoxin"/>
        <entity id="DDI-DrugBank.d558.s27.e1" charOffset="90-96"
            type="brand" text="TIKOSYN"/>
        <entity id="DDI-DrugBank.d558.s27.e2" charOffset="138-144"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s28" text="In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.">
        <entity id="DDI-DrugBank.d558.s28.e0" charOffset="47-53"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d558.s28.e1" charOffset="60-69"
            type="drug" text="dofetilide"/>
        <ddi id="DDI-DrugBank.d558.s28.d0" e1="DDI-DrugBank.d558.s28.e0"
            e2="DDI-DrugBank.d558.s28.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s29" text="It is not clear whether this represents an interaction with TIKOSYN or the presence of more severe structural heart disease in patients on digoxin;">
        <entity id="DDI-DrugBank.d558.s29.e0" charOffset="60-66"
            type="brand" text="TIKOSYN"/>
        <entity id="DDI-DrugBank.d558.s29.e1" charOffset="139-145"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s30" text="structural heart disease is a known risk factor for arrhythmia."/>
    <sentence id="DDI-DrugBank.d558.s31" text="No increase in mortality was observed in patients taking digoxin as concomitant medication.">
        <entity id="DDI-DrugBank.d558.s31.e0" charOffset="57-63"
            type="drug" text="digoxin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s32" text="Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.">
        <entity id="DDI-DrugBank.d558.s32.e0" charOffset="36-45"
            type="drug" text="amlodipine"/>
        <entity id="DDI-DrugBank.d558.s32.e1" charOffset="48-56"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d558.s32.e2" charOffset="59-67"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d558.s32.e3" charOffset="70-79"
            type="drug" text="ranitidine"/>
        <entity id="DDI-DrugBank.d558.s32.e4" charOffset="82-91"
            type="drug" text="omeprazole"/>
        <entity id="DDI-DrugBank.d558.s32.e5" charOffset="151-159"
            type="group" text="estrogens"/>
        <entity id="DDI-DrugBank.d558.s32.e6" charOffset="165-183"
            type="drug" text="medroxyprogesterone"/>
        <entity id="DDI-DrugBank.d558.s32.e7" charOffset="187-193"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d558.s32.e8"
            charOffset="196-203;219-227" type="drug" text="aluminum hydroxide"/>
        <entity id="DDI-DrugBank.d558.s32.e9" charOffset="209-227"
            type="drug" text="magnesium hydroxide"/>
        <entity id="DDI-DrugBank.d558.s32.e10" charOffset="235-246"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d558.s32.e11" charOffset="287-293"
            type="brand" text="TIKOSYN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s33" text="In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.">
        <entity id="DDI-DrugBank.d558.s33.e0" charOffset="59-65"
            type="brand" text="TIKOSYN"/>
        <entity id="DDI-DrugBank.d558.s33.e1" charOffset="127-134"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d558.s33.e2" charOffset="164-174"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d558.s33.e3" charOffset="197-205"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d558.s33.e4" charOffset="208-219"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d558.s33.e5" charOffset="230-243"
            type="group" text="contraceptives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s34" text="Population pharmacokinetic analyses were conducted on plasma concentration data from 1445 patients in clinical trials to examine the effects of concomitant medications on clearance or volume of distribution of dofetilide.">
        <entity id="DDI-DrugBank.d558.s34.e0" charOffset="210-219"
            type="drug" text="dofetilide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s35" text="Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.">
        <entity id="DDI-DrugBank.d558.s35.e0" charOffset="40-53"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d558.s35.e1" charOffset="61-74"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d558.s35.e2" charOffset="77-100"
            type="group" text="calcium channel blockers"/>
        <entity id="DDI-DrugBank.d558.s35.e3" charOffset="103-115"
            type="group" text="beta blockers"/>
        <entity id="DDI-DrugBank.d558.s35.e4" charOffset="118-135"
            type="group" text="cardiac glycosides"/>
        <entity id="DDI-DrugBank.d558.s35.e5" charOffset="240-247"
            type="group" text="nitrates"/>
        <entity id="DDI-DrugBank.d558.s35.e6" charOffset="250-263"
            type="group" text="sulphonylureas"/>
        <entity id="DDI-DrugBank.d558.s35.e7" charOffset="266-279"
            type="group" text="loop diuretics"/>
        <entity id="DDI-DrugBank.d558.s35.e8" charOffset="282-308"
            type="group" text="potassium sparing diuretics"/>
        <entity id="DDI-DrugBank.d558.s35.e9" charOffset="311-328"
            type="group" text="thiazide diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d558.s36" text="Differences in clearance between patients on these medications (at any occasion in the study) and those off medications varied between -16% and +3%."/>
    <sentence id="DDI-DrugBank.d558.s37" text="The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.">
        <entity id="DDI-DrugBank.d558.s37.e0" charOffset="23-32"
            type="drug" text="dofetilide"/>
        <entity id="DDI-DrugBank.d558.s37.e1" charOffset="72-89"
            type="group" text="thiazide diuretics"/>
        <ddi id="DDI-DrugBank.d558.s37.d0" e1="DDI-DrugBank.d558.s37.e0"
            e2="DDI-DrugBank.d558.s37.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s0" text="The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.">
        <entity id="DDI-DrugBank.d42.s0.e0" charOffset="73-82"
            type="drug" text="dolasetron"/>
        <entity id="DDI-DrugBank.d42.s0.e1" charOffset="88-102"
            type="drug_n" text="hydrodolasetron"/>
        <entity id="DDI-DrugBank.d42.s0.e2" charOffset="182-196"
            type="drug_n" text="hydrodolasetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s1" text="Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.">
        <entity id="DDI-DrugBank.d42.s1.e0" charOffset="16-30"
            type="drug_n" text="hydrodolasetron"/>
        <entity id="DDI-DrugBank.d42.s1.e1" charOffset="51-60"
            type="drug" text="dolasetron"/>
        <entity id="DDI-DrugBank.d42.s1.e2" charOffset="86-95"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d42.s1.e3" charOffset="197-204"
            type="drug" text="rifampin"/>
        <ddi id="DDI-DrugBank.d42.s1.d0" e1="DDI-DrugBank.d42.s1.e1"
            e2="DDI-DrugBank.d42.s1.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d42.s1.d1" e1="DDI-DrugBank.d42.s1.e1"
            e2="DDI-DrugBank.d42.s1.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s2" text="Dolasetron has been safely coadministered with drugs used in chemotherapy and surgery.">
        <entity id="DDI-DrugBank.d42.s2.e0" charOffset="0-9" type="drug" text="Dolasetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s18" text="This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.">
        <entity id="DDI-DrugBank.d466.s18.e0" charOffset="49-60"
            type="drug" text="fexofenadine"/>
        <entity id="DDI-DrugBank.d466.s18.e1" charOffset="205-216"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d466.s18.e2" charOffset="228-239"
            type="drug" text="fexofenadine"/>
        <entity id="DDI-DrugBank.d466.s18.e3" charOffset="275-286"
            type="drug" text="erythromycin"/>
        <ddi id="DDI-DrugBank.d466.s18.d0" e1="DDI-DrugBank.d466.s18.e1"
            e2="DDI-DrugBank.d466.s18.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s19" text="Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.">
        <entity id="DDI-DrugBank.d466.s19.e0" charOffset="23-30"
            type="group" text="Antacids"/>
        <entity id="DDI-DrugBank.d466.s19.e1" charOffset="60-85"
            type="drug" text="fexofenadine hydrochloride"/>
        <entity id="DDI-DrugBank.d466.s19.e2" charOffset="131-138"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d466.s19.e3" charOffset="144-152"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d466.s19.e4" charOffset="165-171"
            type="group" text="antacid"/>
        <entity id="DDI-DrugBank.d466.s19.e5" charOffset="174-179"
            type="brand" text="Maalox"/>
        <entity id="DDI-DrugBank.d466.s19.e6" charOffset="193-204"
            type="drug" text="fexofenadine"/>
        <ddi id="DDI-DrugBank.d466.s19.d0" e1="DDI-DrugBank.d466.s19.e1"
            e2="DDI-DrugBank.d466.s19.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d466.s19.d1" e1="DDI-DrugBank.d466.s19.e1"
            e2="DDI-DrugBank.d466.s19.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d466.s19.d2" e1="DDI-DrugBank.d466.s19.e1"
            e2="DDI-DrugBank.d466.s19.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d466.s19.d3" e1="DDI-DrugBank.d466.s19.e1"
            e2="DDI-DrugBank.d466.s19.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s20" text="ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.">
        <entity id="DDI-DrugBank.d466.s20.e0" charOffset="0-6"
            type="brand" text="ALLEGRA"/>
        <entity id="DDI-DrugBank.d466.s20.e1" charOffset="49-56"
            type="drug" text="aluminum"/>
        <entity id="DDI-DrugBank.d466.s20.e2" charOffset="62-70"
            type="drug" text="magnesium"/>
        <entity id="DDI-DrugBank.d466.s20.e3" charOffset="83-90"
            type="group" text="antacids"/>
        <ddi id="DDI-DrugBank.d466.s20.d0" e1="DDI-DrugBank.d466.s20.e0"
            e2="DDI-DrugBank.d466.s20.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d466.s20.d1" e1="DDI-DrugBank.d466.s20.e0"
            e2="DDI-DrugBank.d466.s20.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s21" text="Interactions with Fruit Juices Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.">
        <entity id="DDI-DrugBank.d466.s21.e0" charOffset="128-139"
            type="drug" text="fexofenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s22" text="This is based on the results from 3 clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.">
        <entity id="DDI-DrugBank.d466.s22.e0" charOffset="59-67"
            type="drug" text="histamine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s23" text="The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.">
        <entity id="DDI-DrugBank.d466.s23.e0" charOffset="59-84"
            type="drug" text="fexofenadine hydrochloride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s24" text="Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice."/>
    <sentence id="DDI-DrugBank.d466.s25" text="The clinical significance of these observations is unknown."/>
    <sentence id="DDI-DrugBank.d466.s26" text="In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.">
        <entity id="DDI-DrugBank.d466.s26.e0" charOffset="192-203"
            type="drug" text="fexofenadine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s27" text="Therefore, to maximize the effects of fexofenadine, it is recommended that ALLEGRA should be taken with water">
        <entity id="DDI-DrugBank.d466.s27.e0" charOffset="38-49"
            type="drug" text="fexofenadine"/>
        <entity id="DDI-DrugBank.d466.s27.e1" charOffset="75-81"
            type="brand" text="ALLEGRA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d466.s28" text="."/>
    <sentence id="DDI-DrugBank.d466.s29" text=""/>
    <sentence id="DDI-DrugBank.d1.s0" text="Drug interactions between NEUPOGEN  and other drugs have not been fully evaluated.">
        <entity id="DDI-DrugBank.d1.s0.e0" charOffset="26-33"
            type="brand" text="NEUPOGEN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d1.s1" text="Drugs which may potentiate the release of neutrophils, such as lithium, should be used with caution.">
        <entity id="DDI-DrugBank.d1.s1.e0" charOffset="63-69"
            type="drug" text="lithium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d209.s0" text="No drug interactions of clinical importance have been identified."/>
    <sentence id="DDI-DrugBank.d209.s1" text="Finasteride does not appear to affect the cytochrome P450-linked drug-metabolizing enzyme system.">
        <entity id="DDI-DrugBank.d209.s1.e0" charOffset="0-10"
            type="drug" text="Finasteride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d209.s2" text="Compounds that have been tested in man include antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.">
        <entity id="DDI-DrugBank.d209.s2.e0" charOffset="47-56"
            type="drug" text="antipyrine"/>
        <entity id="DDI-DrugBank.d209.s2.e1" charOffset="59-65"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d209.s2.e2" charOffset="68-78"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d209.s2.e3" charOffset="81-92"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d209.s2.e4" charOffset="99-106"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d209.s3" text="Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.">
        <entity id="DDI-DrugBank.d209.s3.e0" charOffset="84-94"
            type="drug" text="finasteride"/>
        <entity id="DDI-DrugBank.d209.s3.e1" charOffset="167-179"
            type="drug" text="acetaminophen"/>
        <entity id="DDI-DrugBank.d209.s3.e2" charOffset="182-201"
            type="drug" text="acetylsalicylic acid"/>
        <entity id="DDI-DrugBank.d209.s3.e3" charOffset="216-225"
            type="group" text="analgesics"/>
        <entity id="DDI-DrugBank.d209.s3.e4" charOffset="228-273"
            type="group" text="angiotensin-converting enzyme (ACE) inhibitors"/>
        <entity id="DDI-DrugBank.d209.s3.e5" charOffset="276-290"
            type="group" text="anticonvulsants"/>
        <entity id="DDI-DrugBank.d209.s3.e6" charOffset="293-307"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d209.s3.e7" charOffset="310-322"
            type="group" text="beta blockers"/>
        <entity id="DDI-DrugBank.d209.s3.e8" charOffset="325-348"
            type="group" text="calcium-channel blockers"/>
        <entity id="DDI-DrugBank.d209.s3.e9" charOffset="359-366"
            type="group" text="nitrates"/>
        <entity id="DDI-DrugBank.d209.s3.e10" charOffset="369-377"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d209.s3.e11" charOffset="380-393"
            type="group" text="H2 antagonists"/>
        <entity id="DDI-DrugBank.d209.s3.e12" charOffset="396-423"
            type="group" text="HMG-CoA reductase inhibitors"/>
        <entity id="DDI-DrugBank.d209.s3.e13" charOffset="426-460"
            type="group" text="prostaglandin synthetase inhibitors"/>
        <entity id="DDI-DrugBank.d209.s3.e14" charOffset="483-488"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d209.s3.e15" charOffset="496-520"
            type="group" text="quinolone anti-infectives"/>
    </sentence>
    <sentence id="DDI-DrugBank.d209.s4" text="Drug/Laboratory Test Interactions Finasteride had no effect on circulating levels of cortisol, thyroid-stimulating hormone, or thyroxine, nor did it affect the plasma lipid profile (e.g., total cholesterol, low-density lipoproteins, high-density lipoproteins and triglycerides) or bone mineral density.">
        <entity id="DDI-DrugBank.d209.s4.e0" charOffset="34-44"
            type="drug" text="Finasteride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d209.s5" text="In studies with finasteride, no clinically meaningful changes in luteinizing hormone (LH), follicle-stimulating hormone (FSH) or prolactin were detected.">
        <entity id="DDI-DrugBank.d209.s5.e0" charOffset="16-26"
            type="drug" text="finasteride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d209.s6" text="In healthy volunteers, treatment with finasteride did not alter the response of LH and FSH to gonadotropin-releasing hormone indicating that the hypothalamic-pituitary-testicular axis was not affected.">
        <entity id="DDI-DrugBank.d209.s6.e0" charOffset="38-48"
            type="drug" text="finasteride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d209.s7" text="In clinical studies with PROPECIA (finasteride, 1 mg) in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12.">
        <entity id="DDI-DrugBank.d209.s7.e0" charOffset="25-32"
            type="brand" text="PROPECIA"/>
        <entity id="DDI-DrugBank.d209.s7.e1" charOffset="35-45"
            type="drug" text="finasteride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d209.s8" text="Further, in clinical studies with PROSCAR (finasteride, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%.">
        <entity id="DDI-DrugBank.d209.s8.e0" charOffset="34-40"
            type="brand" text="PROSCAR"/>
        <entity id="DDI-DrugBank.d209.s8.e1" charOffset="43-53"
            type="drug" text="finasteride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d209.s9" text="These findings should be taken into account for proper interpretation of serum PSA when evaluating men treated with finasteride.">
        <entity id="DDI-DrugBank.d209.s9.e0" charOffset="116-126"
            type="drug" text="finasteride"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s0" text="Drug Interactions."/>
    <sentence id="DDI-DrugBank.d87.s1" text="TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects.">
        <entity id="DDI-DrugBank.d87.s1.e0" charOffset="0-7"
            type="brand" text="TAMBOCOR"/>
        <entity id="DDI-DrugBank.d87.s1.e1" charOffset="53-74"
            type="group" text="digitalis preparations"/>
        <entity id="DDI-DrugBank.d87.s1.e2" charOffset="79-109"
            type="group" text="beta-adrenergic blocking agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s2" text="During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.">
        <entity id="DDI-DrugBank.d87.s2.e0" charOffset="48-55"
            type="brand" text="TAMBOCOR"/>
        <entity id="DDI-DrugBank.d87.s2.e1" charOffset="113-119"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d87.s2.e2" charOffset="151-157"
            type="drug" text="digoxin"/>
        <ddi id="DDI-DrugBank.d87.s2.d0" e1="DDI-DrugBank.d87.s2.e0"
            e2="DDI-DrugBank.d87.s2.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s3" text="In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.">
        <entity id="DDI-DrugBank.d87.s3.e0" charOffset="48-55"
            type="brand" text="TAMBOCOR"/>
        <entity id="DDI-DrugBank.d87.s3.e1" charOffset="61-71"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d87.s3.e2" charOffset="94-103"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d87.s3.e3" charOffset="141-151"
            type="drug" text="propranolol"/>
        <ddi id="DDI-DrugBank.d87.s3.d0" e1="DDI-DrugBank.d87.s3.e0"
            e2="DDI-DrugBank.d87.s3.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s4" text="In this formal interaction study, TAMBOCOR and propranolol were each found to have negative inotropic effects;">
        <entity id="DDI-DrugBank.d87.s4.e0" charOffset="34-41"
            type="brand" text="TAMBOCOR"/>
        <entity id="DDI-DrugBank.d87.s4.e1" charOffset="47-57"
            type="drug" text="propranolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s5" text="when the drugs were administered together, the effects were additive."/>
    <sentence id="DDI-DrugBank.d87.s6" text="The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.">
        <entity id="DDI-DrugBank.d87.s6.e0" charOffset="45-52"
            type="brand" text="TAMBOCOR"/>
        <entity id="DDI-DrugBank.d87.s6.e1" charOffset="58-68"
            type="drug" text="propranolol"/>
        <ddi id="DDI-DrugBank.d87.s6.d0" e1="DDI-DrugBank.d87.s6.e0"
            e2="DDI-DrugBank.d87.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s7" text="In TAMBOCOR clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects.">
        <entity id="DDI-DrugBank.d87.s7.e0" charOffset="3-10"
            type="brand" text="TAMBOCOR"/>
        <entity id="DDI-DrugBank.d87.s7.e1" charOffset="57-69"
            type="group" text="beta blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s8" text="Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.">
        <entity id="DDI-DrugBank.d87.s8.e0" charOffset="72-84"
            type="group" text="beta blockers"/>
        <entity id="DDI-DrugBank.d87.s8.e1" charOffset="90-99"
            type="drug" text="flecainide"/>
        <ddi id="DDI-DrugBank.d87.s8.d0" e1="DDI-DrugBank.d87.s8.e0"
            e2="DDI-DrugBank.d87.s8.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s9" text="Flecainide is not extensively bound to plasma proteins.">
        <entity id="DDI-DrugBank.d87.s9.e0" charOffset="0-9" type="drug" text="Flecainide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s10" text="In vitro studies with several drugs which may be administered concomitantly showed that the extent of flecainide binding to human plasma proteins is either unchanged or only slightly less.">
        <entity id="DDI-DrugBank.d87.s10.e0" charOffset="102-111"
            type="drug" text="flecainide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s11" text="Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected.">
        <entity id="DDI-DrugBank.d87.s11.e0" charOffset="82-95"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s12" text="TAMBOCOR has been used in a large number of patients receiving diuretics without apparent interaction.">
        <entity id="DDI-DrugBank.d87.s12.e0" charOffset="0-7"
            type="brand" text="TAMBOCOR"/>
        <entity id="DDI-DrugBank.d87.s12.e1" charOffset="63-71"
            type="group" text="diuretics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s13" text="Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.">
        <entity id="DDI-DrugBank.d87.s13.e0" charOffset="59-67"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d87.s13.e1" charOffset="70-82"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d87.s13.e2" charOffset="85-97"
            type="drug" text="carbamazepine"/>
        <entity id="DDI-DrugBank.d87.s13.e3" charOffset="145-154"
            type="drug" text="flecainide"/>
        <ddi id="DDI-DrugBank.d87.s13.d0" e1="DDI-DrugBank.d87.s13.e0"
            e2="DDI-DrugBank.d87.s13.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d87.s13.d1" e1="DDI-DrugBank.d87.s13.e1"
            e2="DDI-DrugBank.d87.s13.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d87.s13.d2" e1="DDI-DrugBank.d87.s13.e2"
            e2="DDI-DrugBank.d87.s13.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s14" text="In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.">
        <entity id="DDI-DrugBank.d87.s14.e0" charOffset="30-39"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d87.s14.e1" charOffset="75-84"
            type="drug" text="flecainide"/>
        <ddi id="DDI-DrugBank.d87.s14.d0" e1="DDI-DrugBank.d87.s14.e0"
            e2="DDI-DrugBank.d87.s14.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s15" text="When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.">
        <entity id="DDI-DrugBank.d87.s15.e0" charOffset="5-14"
            type="drug" text="amiodarone"/>
        <entity id="DDI-DrugBank.d87.s15.e1" charOffset="28-37"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d87.s15.e2" charOffset="55-64"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d87.s15.e3" charOffset="124-133"
            type="drug" text="flecainide"/>
        <ddi id="DDI-DrugBank.d87.s15.d0" e1="DDI-DrugBank.d87.s15.e0"
            e2="DDI-DrugBank.d87.s15.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s16" text="Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;">
        <entity id="DDI-DrugBank.d87.s16.e0" charOffset="48-56"
            type="drug" text="quinidine"/>
        <entity id="DDI-DrugBank.d87.s16.e1" charOffset="104-113"
            type="drug" text="flecainide"/>
        <entity id="DDI-DrugBank.d87.s16.e2" charOffset="147-156"
            type="drug" text="flecainide"/>
        <ddi id="DDI-DrugBank.d87.s16.d0" e1="DDI-DrugBank.d87.s16.e0"
            e2="DDI-DrugBank.d87.s16.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s17" text="especially if these patients are extensive metabolizers."/>
    <sentence id="DDI-DrugBank.d87.s18" text="There has been little experience with the coadministration of TAMBOCOR and either disopyramide or verapamil.">
        <entity id="DDI-DrugBank.d87.s18.e0" charOffset="62-69"
            type="brand" text="TAMBOCOR"/>
        <entity id="DDI-DrugBank.d87.s18.e1" charOffset="82-93"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d87.s18.e2" charOffset="98-106"
            type="drug" text="verapamil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s19" text="Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.">
        <entity id="DDI-DrugBank.d87.s19.e0" charOffset="104-111"
            type="brand" text="TAMBOCOR"/>
        <entity id="DDI-DrugBank.d87.s19.e1" charOffset="134-145"
            type="drug" text="disopyramide"/>
        <entity id="DDI-DrugBank.d87.s19.e2" charOffset="151-159"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d87.s19.e3" charOffset="202-209"
            type="brand" text="TAMBOCOR"/>
        <ddi id="DDI-DrugBank.d87.s19.d0" e1="DDI-DrugBank.d87.s19.e1"
            e2="DDI-DrugBank.d87.s19.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d87.s19.d1" e1="DDI-DrugBank.d87.s19.e2"
            e2="DDI-DrugBank.d87.s19.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d87.s20" text="There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.">
        <entity id="DDI-DrugBank.d87.s20.e0" charOffset="66-73"
            type="brand" text="TAMBOCOR"/>
        <entity id="DDI-DrugBank.d87.s20.e1" charOffset="80-89"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d87.s20.e2" charOffset="94-102"
            type="drug" text="diltiazem"/>
    </sentence>
    <sentence id="DDI-DrugBank.d361.s0" text="Combination Therapy: Any form of therapy which adds to the stress of the patient, interferes with nutrition or depresses bone marrow function will increase the toxicity of Floxuridine.">
        <entity id="DDI-DrugBank.d361.s0.e0" charOffset="172-182"
            type="drug" text="Floxuridine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d453.s0" text="Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.">
        <entity id="DDI-DrugBank.d453.s0.e0" charOffset="0-19"
            type="drug" text="Cytosine arabinoside"/>
        <entity id="DDI-DrugBank.d453.s0.e1" charOffset="24-39"
            type="group" text="cytostatic agent"/>
        <entity id="DDI-DrugBank.d453.s0.e2" charOffset="101-111"
            type="drug" text="flucytosine"/>
        <ddi id="DDI-DrugBank.d453.s0.d0" e1="DDI-DrugBank.d453.s0.e0"
            e2="DDI-DrugBank.d453.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d453.s1" text="Drugs which impair glomerular filtration may prolong the biological half-life of flucytosine.">
        <entity id="DDI-DrugBank.d453.s1.e0" charOffset="81-91"
            type="drug" text="flucytosine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d453.s2" text="Drug/Laboratory Test Interactions: Measurement of serum creatinine levels should be determined by the Jaffe reaction, since Ancobon does not interfere with the determination of creatinine values by this method.">
        <entity id="DDI-DrugBank.d453.s2.e0" charOffset="124-130"
            type="brand" text="Ancobon"/>
    </sentence>
    <sentence id="DDI-DrugBank.d453.s3" text="Most automated equipment for measurement of creatinine makes use of the Jaffe reaction."/>
    <sentence id="DDI-DrugBank.d444.s0" text="The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.">
        <entity id="DDI-DrugBank.d444.s0.e0" charOffset="11-17"
            type="brand" text="FLUDARA"/>
        <entity id="DDI-DrugBank.d444.s0.e1" charOffset="53-63"
            type="drug" text="pentostatin"/>
        <ddi id="DDI-DrugBank.d444.s0.d0" e1="DDI-DrugBank.d444.s0.e0"
            e2="DDI-DrugBank.d444.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s0" text="When administered concurrently, the following drugs may interact with adrenal corticosteroids.">
        <entity id="DDI-DrugBank.d526.s0.e0" charOffset="70-92"
            type="group" text="adrenal corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s1" text="Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.">
        <entity id="DDI-DrugBank.d526.s1.e0" charOffset="0-13"
            type="drug" text="Amphotericin B"/>
        <entity id="DDI-DrugBank.d526.s1.e1" charOffset="18-46"
            type="group" text="potassium-depleting diuretics"/>
        <entity id="DDI-DrugBank.d526.s1.e2" charOffset="49-65"
            type="group" text="benzothiadiazines"/>
        <entity id="DDI-DrugBank.d526.s1.e3" charOffset="86-100"
            type="drug" text="ethacrynic acid"/>
        <entity id="DDI-DrugBank.d526.s1.e4" charOffset="106-115"
            type="drug" text="furosemide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s2" text="Check serum potassium levels at frequent intervals;"/>
    <sentence id="DDI-DrugBank.d526.s3" text="use potassium supplements if necessary .">
        <entity id="DDI-DrugBank.d526.s3.e0" charOffset="4-12"
            type="drug" text="potassium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s4" text="Digitalis glycosides enhanced possibility of arrhythmias or digitalis toxicity associated with hypokalemia.">
        <entity id="DDI-DrugBank.d526.s4.e0" charOffset="0-19"
            type="group" text="Digitalis glycosides"/>
        <entity id="DDI-DrugBank.d526.s4.e1" charOffset="60-68"
            type="group" text="digitalis"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s5" text="Monitor serum potassium levels;"/>
    <sentence id="DDI-DrugBank.d526.s6" text="use potassium supplements if necessary.">
        <entity id="DDI-DrugBank.d526.s6.e0" charOffset="4-12"
            type="drug" text="potassium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s7" text="Oral anticoagulants decreased prothrombin time response.">
        <entity id="DDI-DrugBank.d526.s7.e0" charOffset="5-18"
            type="group" text="anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s8" text="Monitor prothrombin levels and adjust anticoagulant dosage accordingly.">
        <entity id="DDI-DrugBank.d526.s8.e0" charOffset="38-50"
            type="group" text="anticoagulant"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s9" text="Antidiabetic drugs (oral agents and insulin) diminished antidiabetic effect.">
        <entity id="DDI-DrugBank.d526.s9.e0" charOffset="0-17"
            type="group" text="Antidiabetic drugs"/>
        <entity id="DDI-DrugBank.d526.s9.e1" charOffset="36-42"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s10" text="Monitor for symptoms of hyperglycemia;"/>
    <sentence id="DDI-DrugBank.d526.s11" text="adjust dosage of antidiabetic drug upward if necessary.">
        <entity id="DDI-DrugBank.d526.s11.e0" charOffset="17-33"
            type="group" text="antidiabetic drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s12" text="Aspirin increased ulcerogenic effect;">
        <entity id="DDI-DrugBank.d526.s12.e0" charOffset="0-6"
            type="brand" text="Aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s13" text="decreased pharmacologic effect of aspirin.">
        <entity id="DDI-DrugBank.d526.s13.e0" charOffset="34-40"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s14" text="Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.">
        <entity id="DDI-DrugBank.d526.s14.e0" charOffset="7-16"
            type="group" text="salicylate"/>
        <entity id="DDI-DrugBank.d526.s14.e1" charOffset="65-72"
            type="group" text="steroids"/>
        <entity id="DDI-DrugBank.d526.s14.e2" charOffset="101-107"
            type="brand" text="aspirin"/>
        <ddi id="DDI-DrugBank.d526.s14.d0" e1="DDI-DrugBank.d526.s14.e1"
            e2="DDI-DrugBank.d526.s14.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s15" text="Monitor salicylate levels or the therapeutic effect for which aspirin is given;">
        <entity id="DDI-DrugBank.d526.s15.e0" charOffset="8-17"
            type="group" text="salicylate"/>
        <entity id="DDI-DrugBank.d526.s15.e1" charOffset="62-68"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s16" text="adjust salicylate dosage accordingly if effect is altered.">
        <entity id="DDI-DrugBank.d526.s16.e0" charOffset="7-16"
            type="group" text="salicylate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s17" text="Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.">
        <entity id="DDI-DrugBank.d526.s17.e0" charOffset="0-11"
            type="group" text="Barbiturates"/>
        <entity id="DDI-DrugBank.d526.s17.e1" charOffset="14-22"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d526.s17.e2" charOffset="28-35"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d526.s17.e3" charOffset="70-92"
            type="drug" text="fludrocortisone acetate"/>
        <ddi id="DDI-DrugBank.d526.s17.d0" e1="DDI-DrugBank.d526.s17.e0"
            e2="DDI-DrugBank.d526.s17.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d526.s17.d1" e1="DDI-DrugBank.d526.s17.e1"
            e2="DDI-DrugBank.d526.s17.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d526.s17.d2" e1="DDI-DrugBank.d526.s17.e2"
            e2="DDI-DrugBank.d526.s17.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s18" text="Observe the patient for possible diminished effect of steroid and increase the steroid dosage accordingly.">
        <entity id="DDI-DrugBank.d526.s18.e0" charOffset="54-60"
            type="group" text="steroid"/>
        <entity id="DDI-DrugBank.d526.s18.e1" charOffset="79-85"
            type="group" text="steroid"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s19" text="Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.">
        <entity id="DDI-DrugBank.d526.s19.e0" charOffset="0-16"
            type="group" text="Anabolic steroids"/>
        <entity id="DDI-DrugBank.d526.s19.e1" charOffset="47-55"
            type="group" text="androgens"/>
        <entity id="DDI-DrugBank.d526.s19.e2" charOffset="65-76"
            type="drug" text="oxymetholone"/>
        <entity id="DDI-DrugBank.d526.s19.e3" charOffset="79-96"
            type="drug" text="methandrostenolone"/>
        <entity id="DDI-DrugBank.d526.s19.e4" charOffset="99-113"
            type="drug" text="norethandrolone"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s20" text="Use caution when giving these drugs together, especially in patients with hepatic or cardiac disease."/>
    <sentence id="DDI-DrugBank.d526.s21" text="Vaccines neurological complications and lack of antibody response .">
        <entity id="DDI-DrugBank.d526.s21.e0" charOffset="0-7"
            type="group" text="Vaccines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s22" text="Estrogen increased levels of corticosteroid-binding globulin, thereby increasing the bound (inactive) fraction;">
        <entity id="DDI-DrugBank.d526.s22.e0" charOffset="0-7"
            type="group" text="Estrogen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s23" text="this effect is at least balanced by decreased metabolism of corticosteroids.">
        <entity id="DDI-DrugBank.d526.s23.e0" charOffset="60-74"
            type="group" text="corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s24" text="When estrogen therapy is initiated, a reduction in corticosteroid dosage may be required, and increased amounts may be required when estrogen is terminated.">
        <entity id="DDI-DrugBank.d526.s24.e0" charOffset="5-12"
            type="group" text="estrogen"/>
        <entity id="DDI-DrugBank.d526.s24.e1" charOffset="51-64"
            type="group" text="corticosteroid"/>
        <entity id="DDI-DrugBank.d526.s24.e2" charOffset="133-140"
            type="group" text="estrogen"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s25" text="Drug/Laboratory Test Interactions Corticosteroids may affect the nitrobluetetrazolium test for bacterial infection and produce false-negative results">
        <entity id="DDI-DrugBank.d526.s25.e0" charOffset="34-48"
            type="group" text="Corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d526.s26" text="."/>
    <sentence id="DDI-DrugBank.d526.s27" text=""/>
    <sentence id="DDI-DrugBank.d234.s0" text="Interaction with central nervous system depressants other than benzodiazepines has not been specifically studied;">
        <entity id="DDI-DrugBank.d234.s0.e0" charOffset="17-50"
            type="group" text="central nervous system depressants"/>
        <entity id="DDI-DrugBank.d234.s0.e1" charOffset="63-77"
            type="group" text="benzodiazepines"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s1" text="however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.">
        <entity id="DDI-DrugBank.d234.s1.e0" charOffset="52-60"
            type="brand" text="ROMAZICON"/>
        <entity id="DDI-DrugBank.d234.s1.e1" charOffset="85-93"
            type="group" text="narcotics"/>
        <entity id="DDI-DrugBank.d234.s1.e2" charOffset="109-119"
            type="group" text="anesthetics"/>
        <entity id="DDI-DrugBank.d234.s1.e3" charOffset="122-137"
            type="group" text="muscle relaxants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s2" text="Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.">
        <entity id="DDI-DrugBank.d234.s2.e0" charOffset="43-51"
            type="brand" text="ROMAZICON"/>
        <entity id="DDI-DrugBank.d234.s2.e1" charOffset="203-224"
            type="group" text="cyclic antidepressants"/>
        <entity id="DDI-DrugBank.d234.s2.e2" charOffset="263-276"
            type="group" text="benzodiazepine"/>
        <entity id="DDI-DrugBank.d234.s2.e3" charOffset="288-297"
            type="drug" text="flumazenil"/>
        <ddi id="DDI-DrugBank.d234.s2.d0" e1="DDI-DrugBank.d234.s2.e0"
            e2="DDI-DrugBank.d234.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s3" text="The use of ROMAZICON is not recommended in epileptic patients who have been receiving benzodiazepine treatment for a prolonged period.">
        <entity id="DDI-DrugBank.d234.s3.e0" charOffset="11-19"
            type="brand" text="ROMAZICON"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s4" text="Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.">
        <entity id="DDI-DrugBank.d234.s4.e0" charOffset="9-17"
            type="brand" text="ROMAZICON"/>
        <entity id="DDI-DrugBank.d234.s4.e1" charOffset="121-134"
            type="group" text="benzodiazepine"/>
        <ddi id="DDI-DrugBank.d234.s4.d0" e1="DDI-DrugBank.d234.s4.e0"
            e2="DDI-DrugBank.d234.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s5" text="ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.">
        <entity id="DDI-DrugBank.d234.s5.e0" charOffset="0-8"
            type="brand" text="ROMAZICON"/>
        <entity id="DDI-DrugBank.d234.s5.e1" charOffset="40-54"
            type="group" text="benzodiazepines"/>
        <ddi id="DDI-DrugBank.d234.s5.d0" e1="DDI-DrugBank.d234.s5.e0"
            e2="DDI-DrugBank.d234.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s6" text="The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.">
        <entity id="DDI-DrugBank.d234.s6.e0" charOffset="79-87"
            type="drug" text="zopiclone"/>
        <entity id="DDI-DrugBank.d234.s6.e1" charOffset="142-150"
            type="brand" text="ROMAZICON"/>
        <ddi id="DDI-DrugBank.d234.s6.d0" e1="DDI-DrugBank.d234.s6.e0"
            e2="DDI-DrugBank.d234.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s7" text="The pharmacokinetics of benzodiazepines are unaltered in the presence of flumazenil and vice versa.">
        <entity id="DDI-DrugBank.d234.s7.e0" charOffset="24-38"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d234.s7.e1" charOffset="73-82"
            type="drug" text="flumazenil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s8" text="There is no pharmacokinetic interaction between ethanol and flumazenil.">
        <entity id="DDI-DrugBank.d234.s8.e0" charOffset="48-54"
            type="drug" text="ethanol"/>
        <entity id="DDI-DrugBank.d234.s8.e1" charOffset="60-69"
            type="drug" text="flumazenil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s9" text="Use in Ambulatory Patients The effects of ROMAZICON may wear off before a long-acting benzodiazepine is completely cleared from the body.">
        <entity id="DDI-DrugBank.d234.s9.e0" charOffset="42-50"
            type="brand" text="ROMAZICON"/>
        <entity id="DDI-DrugBank.d234.s9.e1" charOffset="74-99"
            type="group" text="long-acting benzodiazepine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s10" text="In general, if a patient shows no signs of sedation within 2 hours after a 1-mg dose of flumazenil, serious resedation at a later time is unlikely.">
        <entity id="DDI-DrugBank.d234.s10.e0" charOffset="88-97"
            type="drug" text="flumazenil"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s11" text="An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as diazepam) or large doses of short-acting benzodiazepines (such as  10 mg of midazolam) have been used.">
        <entity id="DDI-DrugBank.d234.s11.e0" charOffset="82-108"
            type="group" text="long-acting benzodiazepines"/>
        <entity id="DDI-DrugBank.d234.s11.e1" charOffset="119-126"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d234.s11.e2" charOffset="147-174"
            type="group" text="short-acting benzodiazepines"/>
        <entity id="DDI-DrugBank.d234.s11.e3" charOffset="195-203"
            type="drug" text="midazolam"/>
    </sentence>
    <sentence id="DDI-DrugBank.d234.s12" text="Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.">
        <entity id="DDI-DrugBank.d234.s12.e0" charOffset="84-98"
            type="group" text="benzodiazepines"/>
        <entity id="DDI-DrugBank.d234.s12.e1" charOffset="215-228"
            type="group" text="benzodiazepine"/>
        <entity id="DDI-DrugBank.d234.s12.e2" charOffset="231-237"
            type="drug" text="alcohol"/>
        <entity id="DDI-DrugBank.d234.s12.e3" charOffset="243-250"
            type="group" text="sedative"/>
        <entity id="DDI-DrugBank.d234.s12.e4" charOffset="322-330"
            type="brand" text="ROMAZICON"/>
    </sentence>
    <sentence id="DDI-DrugBank.d214.s0" text="No information available."/>
    <sentence id="DDI-DrugBank.d482.s0" text="Do not take this medicine with thioridizine, or within 5 weeks of taking fluoxetine.">
        <entity id="DDI-DrugBank.d482.s0.e0" charOffset="73-82"
            type="drug" text="fluoxetine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s1" text="Talk to your doctor if you are taking certain antibiotics such as erythromycin, clarithromycin or azithromycin.">
        <entity id="DDI-DrugBank.d482.s1.e0" charOffset="46-56"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d482.s1.e1" charOffset="66-77"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d482.s1.e2" charOffset="80-93"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d482.s1.e3" charOffset="98-109"
            type="drug" text="azithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s2" text="This medicine should not be taken with MAO inhibitors.">
        <entity id="DDI-DrugBank.d482.s2.e0" charOffset="39-52"
            type="group" text="MAO inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s3" text="Caution should be exercised when taking this medicine certain antibiotics, such as erythromycin, clarithromycin, or azithromycin.">
        <entity id="DDI-DrugBank.d482.s3.e0" charOffset="62-72"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d482.s3.e1" charOffset="83-94"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d482.s3.e2" charOffset="97-110"
            type="drug" text="clarithromycin"/>
        <entity id="DDI-DrugBank.d482.s3.e3" charOffset="116-127"
            type="drug" text="azithromycin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s4" text="This medicine should not be taken with MAO inhibitors.">
        <entity id="DDI-DrugBank.d482.s4.e0" charOffset="39-52"
            type="group" text="MAO inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s5" text="If you think you are taking an MAO inhibitor talk to your doctor or pharmacist.">
        <entity id="DDI-DrugBank.d482.s5.e0" charOffset="31-43"
            type="group" text="MAO inhibitor"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s6" text="Do not take this medicine with St. Johns Wort because of the additive effects of sertonin."/>
    <sentence id="DDI-DrugBank.d482.s7" text="This medication should not be taken with MAO inhibitors.">
        <entity id="DDI-DrugBank.d482.s7.e0" charOffset="41-54"
            type="group" text="MAO inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s8" text="Your doctor or pharmacist can give you more information on MAO inhibitors.">
        <entity id="DDI-DrugBank.d482.s8.e0" charOffset="59-72"
            type="group" text="MAO inhibitors"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s9" text="Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.">
        <entity id="DDI-DrugBank.d482.s9.e0" charOffset="28-39"
            type="drug" text="escitalopram"/>
        <entity id="DDI-DrugBank.d482.s9.e1" charOffset="59-85"
            type="group" text="non-selective MAO inhibitor"/>
        <ddi id="DDI-DrugBank.d482.s9.d0" e1="DDI-DrugBank.d482.s9.e0"
            e2="DDI-DrugBank.d482.s9.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d482.s10" text="Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.">
        <entity id="DDI-DrugBank.d482.s10.e0" charOffset="31-43"
            type="group" text="MAO inhibitor"/>
        <entity id="DDI-DrugBank.d482.s10.e1" charOffset="61-72"
            type="drug" text="escitalopram"/>
        <ddi id="DDI-DrugBank.d482.s10.d0" e1="DDI-DrugBank.d482.s10.e0"
            e2="DDI-DrugBank.d482.s10.e1" type="advise"/>
    </sentence>
